marrakesh agreement establishing the world trade organ

No. 31874

Multilateral

Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994

Authentic texts: English, French and Spanish.Registered by the Director-General of the World Trade Organization, acting

on behalf of the Parties, on 1 June 1995.

Multilat ral

Accord de Marrakech instituant l'Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994

Textes authentiques : anglais, français et espagnol.Enregistré par le Directeur général de l'Organisation mondiale du com

merce, agissant au nom des Parties, le 1 er juin 1995.

Vol. 1867, 1-31874

4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995

Table of contents

Table des matières

Indice

[Volume 1867]

FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUNDOF MULTILATERAL TRADE NEGOTIATIONSACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONSCOMMERCIALES MULTILATERALES DU CYCLE D'URUGUAYACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOSDE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALESMULTILATERALES

SIGNATURES - SIGNATURES - FIRMAS

MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDINGDECISIONS, DECLARATIONS ET MEMORANDUMD'ACCORD MINISTERIELSDECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES

MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATIONACCORD DE MARRAKECH INSTITUANT L'ORGANISATION MONDIALE DUCOMMERCEACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI NMUND1AL DEL COMERCIO

ANNEX 1 ANNEXE 1 ANEXO 1

ANNEX 1A: MULTILATERAL AGREEMENTS ON TRADE IN GOODS ANNEXE 1A: ACCORDS MULTILATERAUX SUR LE COMMERCE DES

MARCHANDISES ANEXO 1A: ACUERDOS MULTILATERALES SOBRE EL COMERCIO DE

MERCANC AS

MARRAKESH PROTOCOL TO THE GENERAL AGREEMENT ONTARIFFS AND TRADE 1994PROTOCOLE DE MARRAKECH ANNEXE A L'ACCORD GENERALSUR LES TARIFS DOUANIERS ET LE COMMERCE DE 1994PROTOCOLO DE MARRAKECH ANEXO AL ACUERDOGENERAL SOBRE ARANCELES ADUANEROS Y COMERCIO DE 1994

TRADE IN PHARMACEUTICAL PRODUCTS COMMERCE DES PRODUITS PHARMACEUTIQUES COMERCIO DE PRODUCTOS FARMAC UTICOS

Vol. 1867, 1-31874

1995 United Nations — Treaty Series • Nations Unies — Recueil des Traités

SCHEDULES/LISTES/LISTAS

1 II!ÎV

VI VI!VIII

IXXI!XIIIXIVXV

AUSTRALIABRAZILMYANMAR

CANADA

SRI LANKACHILECHINA

CUBAINDIANEW ZEALANDNORWAYPAKISTAN

XVIII

XX

XXI XXIIIxxrvXXIXXXX

SOUTH AFRICA

UNITED STATES

INDONESIADOMINICAN REPUBLIC FINLAND NICARAGUA SWEDEN

XXXIXXXII XXXV XXXVII

URUGUAY AUSTRIA PERU TURKEY

XXXVIII - JAPAN

XXXIX XLII

XLIIIXLVIIXLIXLILULIVLIX

LX

LXIILxm LXIV

MALAYSIA ISRAEL

NIGERIAGABONSENEGALMADAGASCARC TE D'IVOIREZIMBABWESWITZERLAND-LIECHTENSTEIN

KOREA

ICELANDEGYPTARGENTINA

Vol. 1867, 1-31874

United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995

LXVLXVILXVII -LXIX

LXXILXXIII -LXX V -LXXV -

LXXVI -LXXVH -LXXVIII -LXXIX -

LXXX

LXXXI -LXXXII -LXXXIII -LXXXIV -LXXXV -LXXXVI -LXXXVII -LXXXVIH -LXXXDC -

xc

XCIXCII

XCIIIxcvXCVII -xcvra -XCIVc

CilcmCVIICVIIICIXCXICXIICXII cxrvCXVII -CXVIH -CXXICXXII

POLANDJAMAICATRINIDAD AND TOBAGOROMANIA

HUNGARYSINGAPORESURINAMEPHILIPPINES

COLOMBIAMEXICOZAMBIATHAILAND

EUROPEAN COMMUNITIES

MOROCCOHONG KONGTUNISIABOLIVIACOSTA RICAVENEZUELAEL SALVADORGUATEMALAMACAU

NAMIBIA

PARAGUAYCZECH REPUBLIC

SLOVAK REPUBLICHONDURASANTIGUA AND BARBUDABAHRAINBARBADOSBELIZE

BRUNEI DARUSSALAMCAMEROONCYPRUSDOMINICAFUIGHANAGUYANAKENYAKUWAITMALTAMAURITIUSST. LUCIAST. VINCENT AND THE GRENADINES

CXXIII SWAZILAND

Vol. 1867, 1-31874

1995 United Nations — Treaty Series • Nations Unies — Recueil des Traités

XLVIII - BENINL - MAURITANIALUI - NIGERLXX - BANGLADESHCVI - CONGOCXXIV - TANZANIACXXVI - UGANDA

MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATIONACCORD DE MARRAKECH INSTITUANT L'ORGANISATION MONDIALEDU COMMERCEACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LAORGANIZACI N MUNDIAL DEL COMERCIO

ANNEX 1A (cont.) ANNEXE 1A (suite) ANEXO 1A (cont.)

AGREEMENT ON AGRICULTURE ACCORD SUR L'AGRICULTURE ACUERDO SOBRE LA AGRICULTURA

AGREEMENT ON THE APPLICATION OF SANITARY ANDPHYTOSANITARY MEASURESACCORD SUR L'APPLICATION DES MESURES SANITAIRESET PHYTOSANITAIRESACUERDO SOBRE LA APLICACI N DE MED DAS SANITARIASY FITOSANITARIAS

[Volume 1868]AGREEMENT ON TEXTILES AND CLOTHING ACCORD SUR LES TEXTILES ET LES VETEMENTS ACUERDO SOBRE LOS TEXTILES Y EL VESTIDO

AGREEMENT ON TECHNICAL BARRIERS TO TRADE ACCORD SUR LES OBSTACLES TECHNIQUES AU COMMERCE ACUERDO SOBRE OBST CULOS T CNICOS AL COMERCIO

AGREEMENT ON TRADE-RELATED INVESTMENT MEASURES ACCORD SUR LES MESURES CONCERNANT LES INVESTISSEMENTS ET LIEES AU COMMERCEACUERDO SOBRE LAS MEDIDAS EN MATERIA DE INVERSIONES RELACIONADAS CON EL COMERCIO

AGREEMENT ON IMPLEMENTATION OF ARTICLE VI OF THEGENERAL AGREEMENT ON TARIFFS AND TRADE 1994ACCORD SUR LA MISE EN OEUVRE DE L'ARTICLE VIDE L'ACCORD GENERAL SUR LES TARIFS DOUANIERS ET LECOMMERCE DE 1994ACUERDO RELATIVO A LA APLICACI N DEL ART CULO VIDEL ACUERDO GENERAL SOBRE ARANCELES ADUANEROSY COMERCIO DE 1994

Vol. 1867, 1-31874

United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995

AGREEMENT ON IMPLEMENTATION OF ARTICLE VII OFTHE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994ACCORD SUR LA MISE EN OEUVRE DE L'ARTICLE VIIDE L'ACCORD GENERAL SUR LES TARIFS DOUANIERS ETLE COMMERCE DE 1994ACUERDO RELATIVO A LA APLICACI N DELART CULO VII DEL ACUERDO GENERAL SOBRE ARANCELESADUANEROS Y COMERCIO DE 1994

AGREEMENT ON PRESHIPMENT INSPECTION ACCORD SUR L'INSPECTION AVANT EXPEDITION ACUERDO SOBRE INSPECCI N PREV A A LA EXPEDICI N

AGREEMENT ON RULES OF ORIGIN ACCORD SUR LES REGLES D'ORIGINE ACUERDO SOBRE NORMAS DE ORIGEN

AGREEMENT ON IMPORT LICENSING PROCEDURES ACCORD SUR LES PROCEDURES DE LICENCES D'IMPORTATION ACUERDO SOBRE PROCEDIMIENTOS PARA EL TR MITE DE LICENCIAS DE IMPORTACI N

[Volume 1869]

AGREEMENT ON SUBSIDIES AND COUNTERVAILING MEASURES ACCORD SUR LES SUBVENTIONS ET LES MESURES COMPENSATOIRES ACUERDO SOBRE SUBVENCIONES Y MEDIDAS COMPENSATORS

AGREEMENT ON SAFEGUARDS ACCORD SUR LES SAUVEGARDES ACUERDO SOBRE SALVAGUARDIAS

MARRAKESH AGREEMENT ESTABLISHING THEWORLD TRADE ORGANIZATIONACCORD DE MARRAKECH INSTITUANT L'ORGANISATIONMONDIALE DU COMMERCEACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LAORGAN ZACI N MUNDIAL DEL COMERCIO

ANNEX I B: GENERAL AGREEMENT ON TRADE IN SERVICESANNEXE 1 B: ACCORD GENERAL SUR LE COMMERCE DES SERVICESANEXO 1 B: ACUERDO GENERAL SOBRE EL COMERCIO DE SERVICIOS

Vol. 1867, 1-31874

1995_______United Nations — Treaty Series » Nations Unies — Recueil des Traités________

SCHEDULES/LISTES/LISTAS

ALGERIE (LISTE)ANTIGUA AND BARBUDA (SCHEDULE)ARGENTINA (LISTA)AUSTRALIA (SCHEDULE)

(ART.II EXEMPTIONS) AUSTRIA (SCHEDULE)

(ART.II EXEMPTIONS) BAHRAIN (SCHEDULE) BANGLADESH (SCHEDULE) BARBADOS (SCHEDULE) BELIZE (SCHEDULE) BENIN (LISTE)

(EXEMPTIONS ART.II) BOLIVIA (LISTA)

(EXENCIONES ART.II) BRAZIL (SCHEDULE)

(ART.II EXEMPTIONS) BRUNEI DARUSSALAM (SCHEDULE)

(ART.II EXEMPTIONS) BURKINA FASO (LISTE) CAMEROUN (LISTE) CANADA (SCHEDULE)

(ART.II EXEMPTIONS) CHILE (LISTA)

(EXENCIONES ART.II) CHINA (SCHEDULE)

(ART.II EXEMPTIONS) COLOMBIA (LISTA)

(EXENCIONES ART.II) CONGO (LISTE)

(EXEMPTIONS ART.II) COSTA RICA (LISTA)

(EXENCIONES ART.II) C TE D'IVOIRE (LISTE)

(EXEMPTIONS ART.II) CUBA (LISTA)

(EXENCIONES ART.II) CYPRUS (SCHEDULE)

(ART.II EXEMPTIONS) CZECH REPUBLIC (SCHEDULE)

(ART.II EXEMPTIONS) DOMINICA (SCHEDULE) REP BLICA DOMINICANA (LISTA)

(EXENCIONES ART.II) EGYPT (SCHEDULE)

(ART.II EXEMPTIONS) EL SALVADOR (LISTA)

(EXENCIONES ART.II) EUROPEAN COMMUNITIES AND THEIR MEMBER STATES (SCHEDULE*

{ART.II EXEMPTIONS) FIJI (SCHEDULE)

Vol. 1867, 1-31874

10 United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995

FINLAND (SCHEDULE)(ART.II EXEMPTIONS)

FRANCE AU TITRE DELA NOUVELLE-CALEDONIE (LISTE.

GABON (LISTE)(EXEMPTIONS ART.ID

GHANA (SCHEDULE) GRENADA (SCHEDULE) GUATEMALA (LISTA;

(EXENC ONES ART.U) GUYANA (SCHEDULE) HONDURAS (LISTA)

(EXENC ONES ART. ) HONG KONG (SCHEDULE)

(ART.II EXEMPTIONS) HUNGARY (SCHEDULE)

(ART.II EXEMPTIONS) ICELAND (SCHEDULE)

(ART.H EXEMPTIONS) INDIA (SCHEDULE)

(ART.H EXEMPTIONS) INDONESIA (SCHEDULE)

(ART.II EXEMPTIONS) ISRAEL (SCHEDULE)

(ART.II EXEMPTIONS) JAMAICA (SCHEDULE)

(ART. II EXEMPTIONS) JAPAN (SCHEDULE) KENYA (SCHEDULE) KOREA, REP. OF (SCHEDULE)

(ART.II EXEMPTIONS) KUWAIT (SCHEDULE)

(ART.II EXEMPTIONS) LIECHTENSTEIN (SCHEDULE)

(ART.II EXEMPTIONS) MACAU (SCHEDULE) MADAGASCAR (LISTE) MALAYSIA (SCHEDULE)

(ART. II EXEMPTIONS) MALTA (SCHEDULE)

(ART.H EXEMPTIONS) MAROC (LISTE)

(EXEMPTIONS ART.II) MAURITIUS (SCHEDULE) MEXICO (LISTA)

(EXENCIONES ART.II) MOZAMBIQUE (SCHEDULE) MYANMAR (SCHEDULE) NAMIBIA (SCHEDULE) NETHERLANDS WITH RESPECT

TO ARUBA (SCHEDULE) NETHERLANDS WITH RESPECT

TO NETHERLANDS ANTILLES (SCHEDULE)

Vol. 1867, 1-31874


NEW ZEALAND (SCHEDULE)(ART. II EXEMPTIONS)

NICARAGUA (LISTA) NIGER (LISTE)

(EXEMPTIONS ART.II) NIGERIA (SCHEDULE) NORWAY (SCHEDULE)

(ART.II EXEMPTIONS) PAKISTAN (SCHEDULE)

(ART.II EXEMPTIONS) PARAGUAY (LISTA) PERU (LISTA)

(EXENCIONES ART.II) PHILIPPINES (SCHEDULE)

(ART.II EXEMPTIONS) POLAND (SCHEDULE)

(ART.II EXEMPTIONS) ROMANIA (SCHEDULE)

(ART.II EXEMPTIONS) ST. LUCIA (SCHEDULE) ST. VINCENT AND

THE GRENADINES (SCHEDULE) SENEGAL (LISTE)

(EXEMPTIONS ART.II) SINGAPORE (SCHEDULE)

(ART.II EXEMPTIONS) SLOVAK REPUBLIC (SCHEDULE)

(ART.n EXEMPTIONS) SOUTH AFRICA (SCHEDULE)

(ART.II EXEMPTIONS) SRI LANKA (SCHEDULE) SURINAME (SCHEDULE) SWAZILAND (SCHEDULE)

(ART.II EXEMPTIONS) SWEDEN (SCHEDULE)

(ART.H EXEMPTIONS) SWITZERLAND (SCHEDULE)

(ART.II EXEMPTIONS) TANZANIA (SCHEDULE) THAILAND (SCHEDULE)

(ART.II EXEMPTIONS) TRINIDAD AND TOBAGO (SCHEDULE)

(ART.II EXEMPTIONS) TUNISIE (LISTE)

(EXEMPTIONS ART.II) TURKEY (SCHEDULE)

(ART.II EXEMPTIONS) UGANDA (SCHEDULE) UNITED STATES (SCHEDULE)

(ART.II EXEMPTIONS) URUGUAY (LISTA)

(EXENCIONES ART.II) VENEZUELA (LISTA)

(EXENCIONES ART.II) ZAMBIA (SCHEDULE) ZIMBABWE (SCHEDULE)

Vol. 1867, 1-31874


MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L'ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUNDIAL DEL COMERCIO

ANNEX 1C: AGREEMENT ON TRADE-RELATEDASPECTS OF INTELLECTUAL PROPERTY RIGHTS

ANNEXE 1C: ACCORD SUR LES ASPECTS DESDROITS DE PROPRIETE INTELLECTUELLE QUI TOUCHENT AU COMMERCE

ANEXO 1C: ACUERDO SOBRE LOS ASPECTOS DELOS DERECHOS DE PROPIEDAD INTELECTUAL RELACIONADOS CON EL CQMERCIO

ANNEX 2: UNDERSTANDING ON RULES AND PROCEDURES GOVERNING THE SETTLEMENT OF DISPUTES

ANNEXE 2: MEMORANDUM D'ACCORD SURLES REGLES ET PROCEDURES REGISSANT LE REGLEMENT DES DIFFERENDS

ANEXO 2: ENTENDIMIENTO RELATIVO A LAS NORMAS Y PROCEDIMIENTOS POR LOS QUE SE RIGE LA SOLUCI N DE DIFERENCIAS

ANNEX 3:

ANNEXE 3:

ANEXO 3:

ANNEX 4:

TRADE POLICY REVIEW MECHANISM

MECANISME D'EXAMEN DES POLITIQUES COMMERCIALES

MECANISMO DE EXAMEN DE LAS POL TICAS COMERCIALES

PLURILATERAL TRADE AGREEMENTS

AGREEMENT ON TRADE IN CIVIL AIRCRAFT

AGREEMENT ON GOVERNMENT PROCUREMENT

INTERNATIONAL DAIRY AGREEMENT

INTERNATIONAL BOVINE MEAT AGREEMENT

Vol. 1867, 1-31874


ANNEXE 4: ACCORDS COMMERCIAUX PLURILATERAUX

ACCORD SUR LE COMMERCE DES AERONEFS CIVILS

ACCORD SUR LES MARCHES PUBLICS

ACCORD INTERNATIONAL SUR LE SECTEUR LAITIER

ACCORD INTERNATIONAL SUR LA VIANDE BOVINE

ANEXO 4: ACUERDOS COMERCIALES PLURILATERALES

ACUERDO SOBRE EL COMERCIO DE AERONAVES CIVILES

ACUERDO SOBRE CONTRATACI N P BLICA

ACUERDO INTERNACIONAL DE LOS PRODUCTOS L CTEOS

ACUERDO INTERNACIONAL DE LA CARNE DE BOVINO

Vol. 1867, 1-31874

14________United Nations — Treaty Series » Nations Unies — Recueil des Traités 1995

FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS

1. Having met in order to conclude the Uruguay Round of Multilateral Trade Negotiations, representatives of the governments and of the European Communities, members of the Trade Negotiations Committee, agree that the Agreement Establishing the World Trade Organization (referred to in this Final Act as the " WTO Agreement "), the Ministerial Declarations and Decisions, and the Understanding on Commitments hi Financial Services, as annexed hereto, embody the results of their negotiations and form an integral part of this Final Act.

2. By signing the present Final Act, the representatives agree

(a) to submit, as appropriate, the WTO Agreement for the consideration of their respective competent authorities with a view to seeking approval of the Agreement in accordance with their procedures; and

(b) to adopt the Ministerial Declarations and Decisions.

3. The representatives agree on the desirability of acceptance of the WTO Agreement by all participants in the Uruguay Round of Multilateral Trade Negotiations (hereinafter referred to as "participants") with a view to its entry into force by 1 January 1995, or as early as possible thereafter. Not later than late 1994, Ministers will meet, in accordance with the final paragraph of the Punta del Este Ministerial Declaration, to decide on the international implementation of the results, including the timing of their entry into force.

4. The representatives agree that the WTO Agreement shall be open for acceptance as a whole, by signature or otherwise, by all participants pursuant to Article XTV thereof. The acceptance and entry into force of a Plurilateral Trade Agreement included in Annex 4 of the WTO Agreement shall be governed by the provisions of that Plurilateral Trade Agreement.

5. Before accepting the WTO Agreement, participants which are not contracting parties to the General Agreement on Tariffs and Trade1 must first have concluded negotiations for their accession to the General Agreement and become contracting parties thereto. For participants which are not contracting parties to the General Agreement as of the date of the Final Act, the Schedules are not definitive and shall be subsequently completed for the purpose of their accession to the General Agreement and acceptance of the WTO Agreement.

6. This Final Act and the texts annexed hereto shall be deposited with the Director-General to the CONTRACTING PARTIES to the General Agreement on Tariffs and Trade who shall promptly furnish to each participant a certified copy thereof.

DONE at Marrakesh this fifteenth day of April one thousand nine hundred and ninety-four, in a single copy, in the English, French and Spanish languages, each text being authentic.

[For the signatures, see page 17 of this volume.}

1 United Nations, Treaty Series, vol. 55, p. 187.

Vol. 1867, 1-31874


For the People's Democratic Republic of Algeria:

Pour la République algérienne démocratique et populaire:

Mustapha Mokraoui

(Sous reserve de ratification) '

Por la Repûblica Argelina Democrâtica y Popular:

For the Republic of Angola: Pour la République d'Angola: Por la Repûblica de Angola:

J. Eduardo Pinnock

For Antigua and Barbuda: Pour Antigua et Barbuda:

J.A.E. Thomas

Por Antigua y Barbuda:

For thé Argentine Republic: Pour la République argentine: Por la Repûblica Argentina:

Guido Di Telia

For Australia: Pour l'Australie:

R. Francis McMullan

Por Australia:

For the Republic of Austria: Pour la République d'Autriche: Por la Repûblica de Austria:

Wolfgang Schlûssel

1 Subject to ratification.

Vol. 1867, 1-31874


For thé State of Bahrain: Pour l'Etat de Bahrain:

Habib A. Qassim

(Subject to ratification) 2

Por el Estado de Bahrein:

For the People's Republic of Bangladesh:

Pour la République populaire du Bangladesh:

Shamsul Islam

Por la Republica Popular de Bangladesh:

For Barbados: Pour la Barbade:

Warwick O. Franklin

Por Barbados:

For the Kingdom of Belgium, the French Community of Belgium, the Flemish Community of Belgium, the German-language Community of Belgium, the Walloon Region of Belgium, the Flemish Region of Belgium, and the Brussels-Capital Region of Belgium:

Pour le Royaume de Belgique, la Communauté française de Belgique, la Communauté flamande de Belgique, la Communauté germanophone de Belgique, la Région wallonne de Belgique, la Région flamande de Belgique et la Région Bruxelles-Capitale de Belgique:

R. Urbain(Subject to ratification)

Por el Reino de Bélgica, la Comunidad Francesa de Bélgica, la Comunidad Flamenca de Bélgica, la Comunidad Germanohablante de Bélgica, la Région Valona de Bélgica, la Région Flamenca de Bélgica y la Région de Bruselas Capital de Bélgica:

For Belize: Pour le Belize:

Jean Tamer

Por Belice:

2 Sous réserve de ratification.

Vol. 1867, 1-31874


For the Republic of Benin: Pour la République du Bénin: Por la Republica de Bénin:

Yacoubou A. Fassassi

For the Republic of Bolivia: Pour la République de Bolivie: Por la Republica de Bolivia:

M. Reyes Chavez

For the Republic of Botswana: Pour la République du Botswana: Por la Republica de Botswana:

P.H.K. Kedikilwe

For the Federative Republic of Brazil:

Pour la République federative du Brésil:

C.L.N. Amorim

Por la Republica Federativa del Brasil:

For Brunei Darussalam: Pour Brunei Darussalam:

P.D. Abdul-Rahman Taib

Por Brunei Darussalam:

For Burkina Faso: Pour le Burkina Faso: Por Burkina Faso:

Vol. 1867, 1-31874


For the Republic of Burundi: Pour la République du Burundi: Por la Repûblica de Burundi:

Claudine Matuturu

For the Republic of Cameroon:

Pour la République du Cameroun:

F.-Xavier Ngoubeyou

Por la Repûblica del Camerùn:

For Canada: Pour le Canada:

Roy MacLaren

Por el Canada:

For thé Central African Republic:

Pour la République centrafricaine:

L. Odoudou Ignabode

Por la Repûblica Centroafricana:

For the Republic of Chad: Pour la République du Tchad: Por la Repûblica del Chad:

For the Republic of Chile: Pour la République du Chili: Por la Repûblica de Chile:

Carlos Figueroa Serrano

Vol. 1867, 1-31874


For the People's Republic of China:

Pour la République populaire de Chine:

Gu Jongjiang

Por la Repûblica Popular de China:

For the Republic of Colombia: Pour la République de Colombie: Por la Repûblica de Colombia:

Juan M. Santos

For the Republic of the Congo: Pour la République du Congo:

Maurice Mouabenga

Por la Repûblica del Congo:

For the Republic of Costa Rica:

Pour la République du Costa Rica:

Roberto Rojas

Por la Repûblica de Costa Rica:

For the Republic of Côte d'Ivoire:

Pour la République de Côte d'ivoire:

Amara Essy

Por la Repûblica de Côte d'Ivoire:

For the Republic of Cuba: Pour la République de Cuba: Por la Repûblica de Cuba:

Cabrisas Ruiz

Vol. 1867, 1-31874


For the Republic of Cyprus: Pour la République de Chypre: Por la Repûblica de Chipre:

A.P. Michaeldies

For the Czech Republic: Pour la République tchèque:

Vladimir Dlouhy

Por la Repûblica Checa:

For the Kindgom of Denmark: Pour le Royaume du Danemark: Por el Reino de Dinamarca:

Niels L. Helveg Petersen

For the Commonwealth of Dominica:

Pour le Commonwealth de la Dominique:

Por el Commonwealth de Dominica:

For the Dominican Republic: Pour la République dominicaine: Por la Repûblica Dominicana:

Federico A. Cuello

For the Arab Republic of Egypt:

Pour la République arabe d'Egypte:

M. Mohamed Mahmoud

Por la Repûblica Arabe de Egipto:

Vol. 1867, 1-31874


For the Republic of El Salvador:

Pour la République d'El Salvador:

M.A. Salaverria

Por la Repûblica de El Salvador:

For the European Communities:

Pour les Communautés européennes:

G. Romaios

L. Brittan

Por las Comunidades Europeas:

For the Republic of Fiji: Pour la République des Fidji:

Kaliopate Tavola

Por la Repûblica de Fiji:

For the Republic of Finland: Pour la République de Finlande: Por la Repûblica de Finlandia:

Pertti Salolainen

For the French Republic: Pour la République française: Por la Repûblica Francesa:

G. Longuet

For the Gabonese Republic: Pour la République gabonaise: Por la Repûblica Gabonesa:

Patrice Nziengui

Vol. 1867, 1-31874


For the Republic of the Gambia:

Pour la République de Gambie:

Por la Repûblica de Gambia:

For the Federal Republic of Germany:

G. Rexrodt

Pour la République fédérale Por la Repûblica Federal d'Allemagne: de Alemania:

Alois Jelonek(Subject to ratification)

For the Republic of Ghana: Pour la République du Ghana: Por la Repûblica de Ghana:

Emma Mitchell

For the Hellenic Republic: Pour la République hellénique: Por la Repûblica Helénica:

Theodores Pangalos

For Grenada: Pour la Grenade: Por Granada:

For the Republic of Guatemala:

Marithza Ruiz de Vielman

Pour la République du Guatemala:

Por la Repûblica de Guatemala:

Manuel E. Gonzalez Castillo

Vol. 1867, 1-31874


For the Republic of Guinea-Bissau:

Pour la République du Guinée-Bissau:

Ansumane Mane

Por la Repûblica de Guinea-Bissau:

For the Republic of Guyana:

Pour la République de Guyana:

M. Shree Chand

Por la Repûblica de Guyana:

For the Republic of Haiti: Pour la République d'Haïti: Por la Repûblica de Haiti:

For the Republic of Honduras:

Pour la République du Honduras:

D. Urbizo Panting

Por la Repûblica de Honduras:

For Hong Kong: Pour Hong Kong:

T.H. Chau

Por Hong Kong:

For the Republic of Hungary: Pour la République de Hongrie: Por la Repûblica de Hungrîa:

Bêla Kâdâr

Vol. 1867, 1-31874


For the Republic of Iceland: Pour la République d'Islande: Por la Repûblica de Islandia:

Jon Baldvin Hannibalsson

For the Republic of India: Pour la République de l'Inde: Por la Repûblica de la India:

Pranab Mukherjee

For the Republic of Indonesia: Pour la République d'Indonésie: Por la Repûblica de Indonesia:

S.B. Joedono

For Ireland: Pour l'Irlande:

Charles McCreevy

Por Manda:

For thé State of Israel: Pour l'Etat d'Israël:

M. Harish

Por el Estado de Israël:

For the Italian Republic: Pour la République italienne: Por la Repûblica Italiana:

Paolo Baratta

Vol. 1867, 1-31874


For Jamaica: Pour la Jamaïque:

P. Robertson

Por Jamaica:

For Japan: Pour le Japon:

T. Hâta

Por el Japon:

For the Republic of Kenya: Pour la République du Kenya: Por la Repûblica de Kenya:

R. Laibon M'Munkindia

For the Republic of Korea: Pour la République de Corée: Por la Repûblica de Corea:

Chulsu Kim

For thé State of Kuwait: Pour l'Etat du Koweït:

Walid A. Al Wahib

Por el Estado de Kuwait:

For the Kingdom of Lesotho: Pour le Royaume du Lesotho: Por el Reino de Lesotho:

Vol. 1867, 1-31874


For the Principality of Liechtenstein:

Pour la Principauté de Liechtenstein:

Andréa Willi

Por el Principado de Liechtenstein:

For thé Grand Duchy of Luxembourg:

Pour le Grand-Duché de Luxembourg:

Georges Wohlfart

Por el Gran Ducado de Luxemburgo:

For Macau: Pour Macao

V. Rodriguez Pessoa

Por Macao:

For the Republic of Madagascar:

Pour la République de Madagascar:

Jacques Sylla

Por la Repûblica de Madagascar:

For the Republic of Malawi: Pour la République du Malawi: Por la Repûblica de Malawi:

M.W. Mbekeani

For Malaysia: Pour la Malaisie:

Rafïdah Aziz

Por Malasia:

Vol. 1867, 1-31874


For the Republic of Pour la République des Por la Repûblica de Maldives: Maldives: de Maldivas:

For the Republic of Mali: Pour la République du Mali: Por la Repûblica de Mali:

Ahmad Ag Hamani

For the Republic of Malta: Pour la République de Malte: Por la Repûblica de Malta:

Anthony E. Borg

For the Islamic Republic Pour la République islamique Por la Repûblica Islâmica of Mauritania: de Mauritanie: de Mauritania:

Ould Cheikh Melainine Chebih

For the Republic of Pour la République de Por la Repûblica de Mauritius: Maurice: Mauricio:

A.K. Bachoo

Vol. 1867, 1-31874

30 United Nations — Treaty Series » Nations Unies — Recueil des Traités 1995

For thé United Pour les Etats-Unis Por los Estados Unidos Mexican States: du Mexique: Mexicanos:

J. Serra Puche

For the Kingdom of Pour le Royaume du Por el Reino de Morocco: Maroc: Marruecos:

Abdellatif Filali

For the Republic of Pour la République du Por la Repûblica de Mozambique: Mozambique: Mozambique:

D.G. Tembe

For thé Union of Myanmar: Pour l'Union de Myanmar: Por la Union de Myanmar:

Brigadier D.O. Abel

For the Republic of Namibia: Pour la République de Namibie: Por la Repûblica de Namibia:

H. Hamutenya

Vol. 1867, 1-31874


For the Kingdom of the Netherlands:

Pour le Royaume des Pays-Bas:

Y. van Rooy

Por el Reino de los Paîses Bajos:

For New Zealand: Pour la Nouvelle-Zélande:

P. Burdon

Por Nueva Zelandia:

For the Republic of Nicaragua:

Pour ia République du Nicaragua:

E. Belli Pereira

Por la Repûblica de Nicaragua:

For the Republic of Niger: Pour la République du Niger: Por la Repûblica del Niger:

Maliki Barhouni

For the Federal Republic of Nigeria:

Pour la République fédérale du Por la Repûblica Federal de Nigeria: Nigeria:

Chief Melford Okilo

For the Kingdom of Norway: Pour le Royaume de Norvège: Por el Reino de Noruega:

Grete Knudsen

Vol. 1867, 1-31874


For the Islamic Republic of Pakistan:

Pour la République islamique du Pakistan:

Ahmad Mukhtar

Por la Repûblica Islâmica del Pakistan:

For the Republic of Paraguay: Pour la République du Paraguay: Por la Repûblica del Paraguay:

Luis M. Ramirez-Boettner

For the Republic of Peru: Pour la République du Pérou: Por la Repûblica del Peru:

Efrain Goldenberg

For the Republic of the Philippines:

Pour la République des Philippines:

Rizalino S. Navarro

Por la Repûblica de Filipinas:

For the Republic of Poland: Pour la République de Pologne: Por la Repûblica de Polonia:

Leslaw Podkanski

Vol. 1867, 1-31874


For the Portuguese Republic: Pour la République portugaise: Por la Repûblica Portuguesa:

José M. D. Barroso

For thé State of Qatar: Pour l'Etat du Qatar:

A. Ahmed Al-Suleiti

Por el Estado de Qatar:

For Romania: Pour la Roumanie:

M. Berinde

Por Rumania:

For the Rwandese Republic: Pour la République rwandaise: Por la Repûblica Rwandesa:

For Saint Kitts and Nevis: Pour Saint-Kitts-Nevis: Por Saint Kitts y Nevis:

For Saint Lucia: Pour Sainte-Lucie:

Edwin Laurent

Por Santa Lucia:

Vol. 1867, 1-31874


For Saint Vincent and Pour Saint-Vincent-et- Por San Vicente y las thé Grenadines: Grenadines: Granadinas:

For the Republic of Senegal: Pour la République du Sénégal: Por la Repûblica del Senegal:

Moustapha Niasse

For the Republic of Pour la République de Por la Repûblica de Sierra Leone: Sierra Leone: Sierra Leona:

For the Republic of Pour la République de Por la Repûblica de Singapore: Singapour: Singapur:

Yeo Cheow long

For the Slovak Republic: Pour la République slovaque: Por la Repûblica Eslovaca:

Peter Magvasi

Vol. 1867, 1-31874


For the Republic of South Africa:

Pour la République sud-africaine:

D-L. Keys

Por la Repûblica de Sudâfrica:

For the Kingdom of Spain: Pour le Royaume d'Espagne: Por el Reino de Espana:

J. Gomez-Navarro

For the Democratic Socialist Republic of Sri Lanka:

Pour la République socialiste démocratique de Sri Lanka:

A.R. Munsoor

Por la Repûblica Socialista Democrâtica de Sri Lanka:

For the Republic of Suriname:

Pour la République de Suriname:

R.B. Kalloe

Por la Repûblica de Suriname:

For the Kingdom of Swaziland:

Pour le Royaume du Swaziland:

Por el Reino de Swazilandia:

Vol. 1867, 1-31874


For the Kingdom of Sweden: Pour le Royaume de Suède: Por el Reino de Suecïa:

Ulf Dinkelspiel

(Subject to ratification)

For the Swiss Confederation: Pour la Confédération suisse: Por la Confederation Suiza:

J.-P. Delamuraz

For thé United Republic of Tanzania:

Pour la République Unie de Tanzanie:

C.D. Msuya

Por la Repûblica Unida de Tanzania:

For the Kingdom of Thailand: Pour le Royaume de Thaïlande: Por el Reino de Tailandia:

S. Panitchpakdi

For the Togolese Republic: Pour la République togolaise: Por la Repûblica Togolesa:

Vol. 1867, 1-31874


For the Republic of Trinidad and Tobago:

Pour la République de Trinité- et-Tobago:

Ralph Maraj

Por la Repûblica de Trinidad y Tabago:

For the Republic of Tunisia: Pour la République tunisienne: Por la Repûblica de Tûnez:

Habib B. Yahia

Subject to ratification

For the Republic of Turkey: Pour la République turque:

Yener Dinçmen

Por la Repûblica de Turquîa:

For the Republic of Uganda:

Pour la République de l'Ouganda:

Richard Kaijuka

Por la Repûblica de Uganda:

For thé United Arab Emirates:

Pour les Emirats arabes unis:

S.A. Ghobash

Por los Emiratos Arabes Unidos:

Vol. 1867, 1-31874


For thé United Kingdom of Great Britain and Northern Ireland:

Pour la Royaume-Uni de Grande-Bretagne et d'Irlande du Nord:

Timothy Sainsbury

Por el Reino Unido de Gran Bretana e Irlande del Norte:

For thé United States of America:

Pour ies Etats-Unis d'Amérique:

Michael Kaiitor

Por los Estados Unidos de America:

For the Eastern Republic of Uruguay:

Pour la République orientale de l'Uruguay:

Sergio A. Bonilla

Por la Repûblica Oriental del Uruguay:

For the Republic of Venezuela:

Pour la République du Venezuela:

Alberto Poletto

Por la Repûblica de Venezuela:

For the Republic of Zaire: Pour la République du Zaïre:

T.B. Tangale

Por la Repûblica del Zaire:

Vol. 1867, 1-31874

1995_______United Nations — Treaty Series • Nations Unies — Recueil des Traités 39

For the Republic of Zambia: Pour la République de Zambie: Por la Repûblica de Zambia:

D. Patel

For the Republic of Pour la République du Por la Repûblica de Zimbabwe: Zimbabwe: Zimbabwe:

H.M. Murerwa

Vol. 1867, 1-31874

40________United Nations — Treaty Series » Nations Unies — Recueil des Traités_______1995

MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING

DECISIONS, DECLARATIONS, ET MEMORANDUM D'ACCORD MINISTERIELS

DECISIONES, DECLARACIONES Y ENTENDMIENTO MINISTERIALES

Vol. 1867, 1-31874


DECISION ON MEASURES IN FAVOUR OF LEAST-DEVELOPED COUNTRIES

Ministers,

Recognizing the plight of the least-developed countries and the need to ensure their effective participation in the world trading system, and to take further measures to improve their trading opportunities;

Recognizing the specific needs of the least-developed countries in the area of market access where continued preferential access remains an essential means for improving their trading opportunities;

Reaffirming their commitment to implement fully the provisions concerning the least-developed countries contained in paragraphs 2(d), 6 and 8 of the Decision of 28 November 1979 on Differential and More Favourable Treatment, Reciprocity and Fuller Participation of Developing Countries;

Having regard to the commitment of the participants as set out in Section B (vii) of Part I of the Punta del Este Ministerial Declaration;

1. Decide that, if not already provided for in the instruments negotiated in the course of the Uruguay Round, notwithstanding their acceptance of these instruments, the least-developed countries, and for so long as they remain in that category, while complying with the general rules set out in the aforesaid instruments, will only be required to undertake commitments and concessions to the extent consistent with their individual development, financial and trade needs, or their administrative and institutional capabilities. The least-developed countries shall be given additional time of one year from 15 April 1994 to submit their schedules as required in Article XI of the Agreement Establishing the World Trade Organization.

2. Agree that:

(i) Expeditious implementation of all special and differential measures taken in favour of least-developed countries including those taken within the context of the Uruguay Round shall be ensured through, inter alia, regular reviews.

(ii) To the extent possible, MFN concessions on tariff and non-tariff measures agreed in the Uruguay Round on products of export interest to the least-developed countries may be implemented autonomously, in advance and without staging. Consideration shall be given to further improve GSP and other schemes for products of particular export interest to least-developed countries.

(iii) The rules set out in the various agreements and instruments and the transitional provisions in the Uruguay Round should be applied in a flexible and supportive manner for the least-developed countries. To this effect, sympathetic consideration shall be given to specific and motivated concerns raised by the least-developed countries in the appropriate Councils and Committees.

(iv) In the application of import relief measures and other measures referred to in paragraph 3(c) of Article XXXVII of GATT 1947 and the corresponding provision of GATT 1994, special consideration shall be given to the export interests of least-developed countries.

(v) Least-developed countries shall be accorded substantially increased technical assistance in the development, strengthening and diversification of their production and export bases including those of services, as well as in trade promotion, to enable them to maximize the benefits from liberalized access to markets.

3. Agree to keep under review the specific needs of the least-developed countries and to continue to seek the adoption of positive measures which facilitate the expansion of trading opportunities in favour of these countries.

Vol. 1867, 1-31874


DECLARATION ON THE CONTRIBUTION OF THEWORLD TRADE ORGANIZATION TO ACHIEVING GREATER

COHERENCE IN GLOBAL ECONOMIC POLICYMAKING

1. Ministers recognize that the giobalization of the world economy has led to ever-growing interactions between the economic policies pursued by individual countries, including interactions between the structural, macroeconomic, trade, financial and development aspects of economic policymaking. The task of achieving harmony between these policies falls primarily on governments at the national level, but their coherence internationally is an important and valuable element in increasing the effectiveness of these policies at national level. The Agreements reached in the Uruguay Round show that all the participating governments recognize the contribution that liberal trading policies can make to the healthy growth and development of their own economies and of the world economy as a whole.

2. Successful cooperation in each area of economic policy contributes to progress in other areas. Greater exchange rate stability, based on more orderly underlying economic and financial conditions, should contribute towards the expansion of trade, sustainable growth and development, and the correction of external imbalances. There is also a need for an adequate and timely flow of concessional and non-concessional financial and real investment resources to developing countries and for further efforts to address debt problems, to help ensure economic growth and development. Trade liberalization forms an increasingly important component in the success of the adjustment programmes that many countries are undertaking, often involving significant transitional social costs. In this connection, Ministers note the role of the World Bank and the IMF in supporting adjustment to trade liberalization, including support to net food-importing developing countries facing short-term costs arising from agricultural trade reforms.

3. The positive outcome of the Uruguay Round is a major contribution towards more coherent and complementary international economic policies. The results of the Uruguay Round ensure an expansion of market access to the benefit of all countries, as well as a framework of strengthened multilateral disciplines for trade. They also guarantee that trade policy will be conducted in a more transparent manner and with greater awareness of the benefits for domestic competitiveness of an open trading environment. The strengthened multilateral trading system emerging from the Uruguay Round has the capacity to provide an improved forum for liberalization, to contribute to more effective surveillance, and to ensure strict observance of multilaterally agreed rules and disciplines. These improvements mean that trade policy can in the future play a more substantial role in ensuring the coherence of global economic policymaking.

4. Ministers recognize, however, that difficulties the origins of which lie outside the trade field cannot be redressed through measures taken in the trade field alone. This underscores the importance of efforts to improve other elements of global economic policymaking to complement the effective implementation of the results achieved in the Uruguay Round.

5. The interlinkages between the different aspects of economic policy require that the international institutions with responsibilities in each of these areas follow consistent and mutually supportive policies. The World Trade Organization should therefore pursue and develop cooperation with the international organizations responsible for monetary and financial matters, while respecting the mandate, the confidentiality requirements and the necessary autonomy in decision-making procedures of each institution, and avoiding the imposition on governments of cross- conditionality or additional conditions. Ministers further invite the Director-General of the WTO to review with the Managing Director of the International Monetary Fund and the President of the World Bank, the implications of the WTO's responsibilities for its cooperation with the Bretton Woods institutions, as well as the forms such cooperation might take, with a view to achieving greater coherence in global economic policymaking.

Vol. 1867, 1-31874


DECISION ON NOTIFICATION PROCEDURES

Ministers decide to recommend adoption by the Ministerial Conference of the decision on improvement and review of notification procedures set out below.

Members,

Desiring to improve the operation of notification procedures under the Agreement Establishing the World Trade Organization (hereinafter referred to as the "WTO Agreement"), and thereby to contribute to the transparency of Members' trade policies and to the effectiveness of surveillance arrangements established to that end;

Recalling obligations under the WTO Agreement to publish and notify, including obligations assumed under the terms of specific protocols of accession, waivers, and other agreements entered into by Members;

Agree as follows:

I. General obligation to notify

Members affirm their commitment to obligations under the Multilateral Trade Agreements and, where applicable, the Plurilateral Trade Agreements, regarding publication and notification.

Members recall their undertakings set out in the Understanding Regarding Notification, Consultation, Dispute Settlement and Surveillance adopted on 28 November 1979 (BISD 26S/210). With regard to their undertaking therein to notify, to the maximum extent possible, their adoption of trade measures affecting the operation of GATT 1994, such notification itself being without prejudice to views on the consistency of measures with or their relevance to rights and obligations under the Multilateral Trade Agreements and, where applicable, the Plurilateral Trade Agreements, Members agree to be guided, as appropriate, by the annexed list of measures. Members therefore agree that the introduction or modification of such measures is subject to the notification requirements of the 1979 Understanding.

II. Central registry of notifications

A central registry of notifications shall be established under the responsibility of the Secretariat. While Members will continue to follow existing notification procedures, the Secretariat shall ensure that the central registry records such elements of the information provided on the measure by the Member concerned as its purpose, its trade coverage, and the requirement under which it has been notified. The central registry shall cross-reference its records of notifications by Member and obligation.

The central registry shall inform each Member annually of the regular notification obligations to which that Member will be expected to respond in the course of the following year.

The central registry shall draw the attention of individual Members to regular notification requirements which remain unfulfilled.

Information in the central registry regarding individual notifications shall be made available on request to any Member entitled to receive the notification concerned.

III. Review of notification obligations and procedures

The Council for Trade in Goods will undertake a review of notification obligations and procedures under the Agreements in Annex 1A of the WTO Agreement. The review will be carried out by a working group, membership in which will be open to all Members. The group will be established immediately after the date of entry into force of the WTO Agreement.

Vol. 1867, 1-31874


The terms of reference of the working group will be:

— to undertake a thorough review of all existing notification obligations of Members established under the Agreements in Annex 1A of the WTO Agreement, with a view to simplifying, standardizing and consolidating these obligations to the greatest extent practicable, as well as to improving compliance with these obligations, bearing in mind the overall objective of improving the transparency of the trade policies of Members and the effectiveness of surveillance arrangements established to this end, and also bearing in mind the possible need of some developing country Members for assistance in meeting their notification obligations;

— to make recommendations to the Council for Trade in Goods not later than two years after the entry into force of the WTO Agreement.

Vol. 1867, 1-31874

SO________United Nations — Treaty Series » Nations Unies — Recueil des Traités_______1995

ANNEX

INDICATIVE LIST1 OF NOTIFIABLE MEASURES

Tariffs (including range and scope of bindings, GSP provisions, rates applied to members of free-trade areas/customs unions, other preferences)

Tariff quotas and surcharges

Quantitative restrictions, including voluntary export restraints and orderly marketing arrangements affecting imports

Other non-tariff measures such as licensing and mixing requirements; variable levies

Customs valuation

Rules of origin

Government procurement

Technical barriers

Safeguard actions

Anti-dumping actions

Countervailing actions

Export taxes

Export subsidies, tax exemptions and concessionary export financing

Free-trade zones, including in-bond manufacturing

Export restrictions, including voluntary export restraints and orderly marketing arrangements

Other government assistance, including subsidies, tax exemptions

Role of state-trading enterprises

Foreign exchange controls related to imports and exports

Government-mandated countertrade

Any other measure covered by the Multilateral Trade Agreements in Annex 1A to the WTO Agreement

'This list does not alter existing notification requirements in the Multilateral Trade Agreements in Annex 1A to the WTO Agreement or, where applicable, the Plurilateral Trade Agreements in Annex 4 of the WTO Agreement.

Vol. 1867, 1-31874


DECLARATION ON THE RELATIONSHIP OF THEWORLD TRADE ORGANIZATION WITH THE

INTERNATIONAL MONETARY FUND

Ministers,

Noting the close relationship between the CONTRACTING PARTIES to the GATT 1947 and the International Monetary Fund, and the provisions of the GATT 1947 governing that relationship, in particular Article XV of the GATT 1947;

Recognizing the desire of participants to base the relationship of the World Trade Organization with the International Monetary Fund, with regard to the areas covered by the Multilateral Trade Agreements in Annex 1A of the WTO Agreement, on the provisions that have governed the relationship of the CONTRACTING PARTIES to the GATT 1947 with the International Monetary Fund;

Hereby reaffirm that, unless otherwise provided for in the Final Act, the relationship of the WTO with the International Monetary Fund, with regard to the areas covered by the Multilateral Trade Agreements in Annex 1A of the WTO Agreement, will be based on the provisions that have governed the relationship of the CONTRACTING PARTIES to the GATT 1947 with the International Monetary Fund.

Vol. 1867, 1-31874


DECISION ON MEASURES CONCERNINGTHE POSSIBLE NEGATIVE EFFECTS OF THE

REFORM PROGRAMME ON LEAST-DEVELOPED ANDNET FOOD-IMPORTING DEVELOPING COUNTRIES

1. Ministers recognize that the progressive implementation of the results of the Uruguay Round as a whole will generate increasing opportunities for trade expansion and economic growth to the benefit of all participants.

2. Ministers recognize that during the reform programme leading to greater liberalization of trade in agriculture least-developed and net food-importing developing countries may experience negative effects in terms of the availability of adequate supplies of basic foodstuffs from external sources on reasonable terms and conditions, including short-term difficulties in financing normal levels of commercial imports of basic foodstuffs.

3. Ministers accordingly agree to establish appropriate mechanisms to ensure that the implementation of the results of the Uruguay Round on trade in agriculture does not adversely affect the availability of food aid at a level which is sufficient to continue to provide assistance in meeting the food needs of developing countries, especially least-developed and net food-importing developing countries. To this end Ministers agree:

(i) to review the level of food aid established periodically by the Committee on Food Aid under the Food Aid Convention 1986 and to initiate negotiations in the appropriate forum to establish a level of food aid commitments sufficient to meet the legitimate needs of developing countries during the reform programme;

(ii) to adopt guidelines to ensure that an increasing proportion of basic foodstuffs is provided to least- developed and net food-importing developing countries in fully grant form and/or on appropriate concessional terms in line with Article IV of the Food Aid Convention 1986;

(iii) to give full consideration in the context of their aid programmes to requests for the provision of technical and financial assistance to least-developed and net food-importing developing countries to improve their agricultural productivity and infrastructure.

4. Ministers further agree to ensure that any agreement relating to agricultural export credits makes appropriate provision for differential treatment in favour of least-developed and net food-importing developing countries.

5. Ministers recognize that as a result of the Uruguay Round certain developing countries may experience short-term difficulties in financing normal levels of commercial imports and that these countries may be eligible to draw on the resources of international financial institutions under existing facilities, or such facilities as may be established, in the context of adjustment programmes, in order to address such financing difficulties. In this regard Ministers take note of paragraph 37 of the report of the Director-General to the CONTRACTING PARTIES to GATT 1947 on his consultations with the Managing Director of the International Monetary Fund and the President of the World Bank (MTN.GNG/NG14/W/35).

6. The provisions of this Decision will be subject to regular review by the Ministerial Conference, and the follow-up to this Decision shall be monitored, as appropriate, by the Committee on Agriculture.

Vol. 1867, 1-31874

1995_______United Nations — Treaty Series » Nations Unies — Recueil des Traités 63

DECISION ON NOTIFICATION 0F FIRST INTEGRATION UNDER ARTICLE 2.6 OF THE AGREEMENT ON TEXTILES AND CLOTHING

Ministers agree that the participants maintaining restrictions falling under paragraph 1 of Article 2 of the Agreement on Textiles and Clothing shall notify full details of the actions to be taken pursuant to paragraph 6 of Article 2 of that Agreement to the GATT Secretariat not later than 1 October 1994. The GATT Secretariat shall promptly circulate these notifications to the other participants for information. These notifications will be made available to the Textiles Monitoring Body, when established, for the purposes of paragraph 21 of Article 2 of the Agreement on Textiles and Clothing.

Vol. 1867, 1-31874


DECISION ON PROPOSED UNDERSTANDING ON WTO-ISO STANDARDS INFORMATION SYSTEM

Ministers decide to recommend that the Secretariat of the Worid Trade Organization reach an understanding with the Intemational Organization for Standardization ("ISO") to establish an information system under which:

1. ISONET members shall transmit to the ISO/IEC Information Centre in Geneva the notifications referred to in paragraphs C and J of the Code of Good Practice for the Preparation, Adoption and Application of Standards in Annex 3 to the Agreement on Technical Barriers to Trade, in the manner indicated there;

2. the following (alpha)numeric classification systems shall be used in the work programmes referred to in paragraph J:

( a ) a standards classification system which would allow standardizing bodies to give for each standard mentioned in the work programme an (alpha)mimeric indication of the subject matter;

( b ) a stage code system which would allow standardizing bodies to give for each standard mentioned in die work programme an (alpha)nurneric indication of the stage of development of the standard; for this purpose, at least five stages of development should be distinguished: (1) the stage at which the decision to develop a standard has been taken, but technical work has not yet begun; (2) the stage at which technical work has begun, but the period for the submission of comments has not yet started; (3) the stage at which the period for the submission of comments has started, but has not yet been completed; (4) the stage at which the period for the submission of comments has been completed, but the standard has not yet been adopted; and (5) the stage at which the standard has been adopted;

( c ) an identification system covering all international standards which would allow standardizing bodies to give for each standard mentioned in the work programme an (alpha)numeric indication of the international standard(s) used as a basis;

3. the ISO/IEC Information Centre shall promptly convey to the Secretariat copies of any notifications referred to in paragraph C of the Code of Good Practice;

4. the ISO/IEC Information Centre shall regularly publish the information received in the notifications made to it under paragraphs C and J of the Code of Good Practice; this publication, for which a reasonable fee may be charged, shall be available to ISONET members and through the Secretariat to the Members of the WTO,

Vol. 1867, 1-31874


DECISION ON REVIEW OF THE ISO/IEC INFORMATION CENTRE PUBLICATION

Ministers decide that in conformity with paragraph 1 of Article 13 of the Agreement on Technical Barriers to Trade in Annex 1A of the Agreement Establishing the World Trade Organization, the Committee on Technical Barriers to Trade established thereunder shall, without prejudice to provisions on consultation and dispute settlement, at least once a year review the publication provided by the ISO/IEC Information Centre on information received according to the Code of Good Practice for the Preparation, Adoption and Applicationof Standards in Annex 3 of the Agreement, for the purpose of affording Members opportunity of discussing any matters relating to the operation of that Code.

In order to facilitate this discussion, the Secretariat shall provide a list by Member of all standardizing bodies that have accepted the Code, as well as a list of those standardizing bodies that have accepted or withdrawn from the Code since the previous review.

The Secretariat shall also distribute promptly to the Members copies of the notifications it receives from the ISO/IEC Information Centre.

Vol. 1867, 1-31874


DECISION ON ANTI-CIRCUMVENTION

Ministers,

Noting that while the problem of circumvention of anti-dumping duty measures formed part of the negotiations which preceded the Agreement on Implementation of Article VI of GATT 1994, negotiators were unable to agree on specific text,

Mindful of the desirability of the applicability of uniform rules in this area as soon as possible,

Decide to refer this matter to the Committee on Anti-Dumping Practices established under that Agreement for resolution.

Vol. 1867, 1-31874

1995_______United Nations — Treaty Series » Nations Unies — Recueil des Traités________75

DECISION ON REVIEW OF ARTICLE 17.6 OF THEAGREEMENT ON IMPLEMENTATION OF ARTICLE VI OF THE

GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

Ministers decide as follows:

The standard of review in paragraph 6 of Article 17 of the Agreement on Implementation of Article VI of GATT 1994 shall be reviewed after a period of three years with a view to considering the question of whether it is capable of general application.

Vol. 1867, 1-31874


DECLARATION ON DISPUTE SETTLEMENT PURSUANT TO THE AGREEMENTON IMPLEMENTATION OF ARTICLE VI OF THE GENERAL AGREEMENT ON

TARIFFS AND TRADE 1994 OR PART V OF THE AGREEMENTON SUBSIDIES AND COUNTERVAILING MEASURES

Ministers recognize, with respect to dispute settlement pursuant to the Agreement on Implementation of Article VI of GATT 1994 or Part V of the Agreement on Subsidies and Countervailing Measures, the need for the consistent resolution of disputes arising from anti-dumping and countervailing duty measures.

Vol. 1867, 1-31874


DECISION REGARDING CASES WHERE CUSTOMSADMINISTRATIONS HAVE REASONS TO DOUBT THE TRUTH

OR ACCURACY OF THE DECLARED VALUE

Ministers invite the Committee on Customs Valuation established under the Agreement on Implementation of Article VII of GATT 1994 to take the following decision:

The Committee on Customs Valuation,

Reaffirming that the transaction value is the primary basis of valuation under the Agreement on Implementation of Article VII of GATT 1994 (hereinafter referred to as the "Agreement");

Recognizing that the customs administration may have to address cases where it has reason to doubt the truth or accuracy of the particulars or of documents produced by traders in support of a declared value;

Emphasizing that in so doing thecustoms administration should not prejudice the legitimate commercial interests of traders;

Taking into account Article 17 of the Agreement, paragraph 6 of Annex III to the Agreement, and the relevant decisions of the Technical Committee on Customs Valuation;

Decides as follows:

1. When a declaration has been presented and where the customs administration has reason to doubt the truth or accuracy of the particulars or of documents produced in support of this declaration, the customs administration may ask the importer to provide further explanation, including documents or other evidence, that the declared value represents the total amount actually paid or payable for the imported goods, adjusted in accordance with the provisions of Article 8. If, after receiving further information, or in the absence of a response, the customs administration still has reasonable doubts about the truth or accuracy of the declared value, it may, bearing in mind the provisions of Article 11, be deemed that the customs value of the imported goods cannot be determined under the provisions of Article 1. Before taking a final decision, the customs administration shall communicate to the importer, in writing if requested, its grounds for doubting the truth or accuracy of the particulars or documents produced and the importer shall be given a reasonable opportunity to respond. When a final decision is made, the customs administration shall communicate to the importer in writing its decision and the grounds therefor.

2. It is entirely appropriate in applying the Agreement for one Member to assist another Member on mutually agreed terms.

Vol. 1867, 1-31874


DECISION ON TEXTS RELATING TO MINIMUM VALUES AND IMPORTS BY SOLE AGENTS, SOLE DISTRIBUTORS AND SOLE CONCESSIONAIRES

Minisiers decide to refer the following texts to the Committee on Customs Valuation established under the Agreement on Implementation of Article VII of GATT 1994, for adoption.

Where a developing country makes a reservation to retain officially established minimum values within the terms of paragraph 2 of Annex 1IÏ and shows good cause, the Committee shall give the request for the reservation sympathetic consideration.

Where a reservation is consented to, the terms and conditions referred to in paragraph 2 of Annex III shall take full account of the development, financial and trade needs of the developing country concerned.

1. A number of developing countries have a concern that problems may exist in the valuation of imports by sole agents, sole distributors and sole concessionaires. Under paragraph 1 of Article 20, developing country Members have a period of delay of up to five years prior to the application of the Agreement. In this context, developing country Members availing themselves of this provision could use the period to conduct appropriate studies and to take such other actions as are necessary to facilitate application.

2. In consideration of this, the Committee recommends that the Customs Co-operation Council assist developing country Members, in accordance with the provisions of Annex II, to formulate and conduct studies in areas identified as being of potential concern, including those relating to importations by sole agents, sole distributors and sole concessionaires.

Vol. 1867, 1-31874


DECISION ON INSTITUTIONAL ARRANGEMENTS FOR THE GENERAL AGREEMENT ON TRADE IN SERVICES

Ministers decide to recommend that the Council for Trade in Services at its first meeting adopt the decision on subsidiary bodies set out below.

The Council for Trade in Services,

Acting pursuant to Article XXIV with a view to facilitating the operation and furthering the objectives of the General Agreement on Trade in Services,

Decides as follows:

1. Any subsidiary bodies that the Council may establish shall report to the Council annually or more often as necessary. Each such body shall establish its own rules of procedure, and may set up its own subsidiary bodies as appropriate.

2. Any sectoral committee shall carry out responsibilities as assigned to it by the Council, and shall afford Members the opportunity to consult on any matters relating to trade in services in the sector concerned and the operation of the sectoral annex to which it may pertain. Such responsibilities shall include:

(a) to keep under continuous review and surveillance the application of the Agreement with respect to the sector concerned;

(b) to formulate proposals or recommendations for consideration by the Council in connection with any matter relating to trade in the sector concerned;

(c) if there is an annex pertaining to the sector, to consider proposals for amendment of that sectoral annex, and to make appropriate recommendations to the Council;

(d) to provide a forum for technical discussions, to conduct studies on measures of Members and to conduct examinations of any other technical matters affecting trade in services in the sector concerned;

(e) to provide technical assistance to developing country Members and developing countries negotiating accession to the Agreement Establishing the World Trade Organization in respect of the application of obligations or other matters affecting trade in services in the sector concerned; and

(f) to cooperate with any other subsidiary bodies established under the General Agreement on Trade in Services or any international organizations active in any sector concerned.

3. There is hereby established a Committee on Trade in Financial Services which will have the responsibilities listed in paragraph 2.

Vol. 1867, 1-31874


DECISION ON CERTAIN DISPUTE SETTLEMENT PROCEDURES FOR THE GENERAL AGREEMENT ON TRADE IN SERVICES

Ministers decide to recommend that the Council for Trade in Services at its first meeting adopt the decision set out below.


Taking into account the specific nature of the obligations and specific commitments of the Agreement, and of trade in services, with respect to dispute settlement under Articles XXII and XXIII,

Decides as follows:

1. A roster of panelists shall be established to assist in the selection of panelists.

2. To this end, Members may suggest names of individuals possessing the qualifications referred to in paragraph 3 for inclusion on the roster, and shall provide a curriculum vitae of their qualifications including, if applicable, indication of sector-specific expertise.

3. Panels shall be composed of well-qualified governmental and/or non-governmental individuals who have experience in issues related to the General Agreement on Trade in Services and/or trade in services, including associated regulatory matters. Panelists shall serve in their individual capacities and not as representatives of any government or organisation.

4. Panels for disputes regarding sectoral matters shall have the necessary expertise relevant to the specific services sectors which the dispute concerns.

5. The Secretariat shall maintain the roster and shall develop procedures for its administration in consultation with the Chairman of the Council.

Vol. 1867, 1-31874


DECISION ON TRADE IN SERVICES AND THE ENVIRONMENT



Acknowledging that measures necessary to protect the environment may conflict with the provisions of the Agreement; and

Noting that since measures necessary to protect the environment typically have as their obj ecti ve the protection of human, animal or plant life or health, it is not clear that there is a need to provide for more than is contained in paragraph (b) of Article XIV;

Decides as follows:

1. In order to determine whether any modification of Article XIV of the Agreement is required to take account of such measures, to request the Committee on Trade and Environment to examine and report, with recommendations if any, on the relationship between services trade and the environment including the issue of sustainable development. The Committee shall also examine the relevance of inter-govemmental agreements on the environment and their relationship to the Agreement.

2. The Committee shall report the results of its work to the first biennial meeting of the Ministerial Conference after the entry into force of the Agreement Establishing the World Trade Organization.

Vol. 1867, 1-31874


DECISION ON NEGOTIATIONS ON MOVEMENT OF NATURAL PERSONS

Ministers,

Noting the commitments resulting from the Uruguay Round negotiations on the movement of natural persons for the purpose of supplying services;

Mindful of the objectives of the General Agreement on Trade in Services, including the increasing participation of developing countries in trade in services and the expansion of their service exports;

Recognizing the importance of achieving higher levels of commitments on the movement of natural persons, in order to provide for a balance of benefits under the General Agreement on Trade in Services;

Decide as follows:

1. Negotiations on further liberalization of movement of natural persons for the purpose of supplying services shall continue beyond the conclusion of the Uruguay Round, with a view to allowing the achievement of higher levels of commitments by participants under the General Agreement on Trade in Services.

2. A Negotiating Group on Movement of Natural Persons is established to carry out the negotiations. The group shall establish its own procedures and shall report periodically to the Council on Trade in Services.

3. The negotiating group shall hold its first negotiating session no later than 16 May 1994. It shall conclude these negotiations and produce a final report no later than six months after the entry into force of the Agreement Establishing the World Trade Organization.

4. Commitments resulting from these negotiations shall be inscribed in Members' Schedules of specific commitments.

Vol. 1867, 1-31874


DECISION ON FINANCIAL SERVICES

Ministers,

Noting that commitments scheduled by participants on financial services at the conclusion of the Uruguay Round shall enter into force on an MFN basis at the same time as the Agreement Establishing the World Trade Organization (hereinafter referred to as the "WTO Agreement"),

Decide as follows:

1. At the conclusion of a period ending no later than six months after the date of entry into force of the WTO Agreement, Members shall be free to improve, modify or withdraw all or part of their commitments in this sector without offering compensation, notwithstanding the provisions of Article XXI of the General Agreement on Trade in Services. At the same time Members shall finalize their positions relating to MFN exemptions in this sector, notwithstanding the provisions of the Annex on Article II Exemptions. From the date of entry into force of the WTO Agreement and until the end of the period referred to above, exemptions listed in the Annex on Article II Exemptions which are conditional upon the level of commitments undertaken by other participants or upon exemptions by other participants will not be applied.

2. The Committee on Trade in Financial Services shall monitor the progress of any negotiations undertaken under the terms of this Decision and shall report thereon to the Council for Trade in Services no later than four months after the date of entry into force of the WTO Agreement.

Vol. 1867, 1-31874

102_______United Nations — Treaty Series » Nations Unies — Recueil des Traités_______1995

DECISION ON NEGOTIATIONS ON MARITIME TRANSPORT SERVICES

Ministers,

Noting that commitments scheduled by participants on maritime transport services at the conclusion of the Uruguay Round shall enter into force on an MFN basis at the same time as the Agreement Establishing the World Trade Organization (hereinafter referred to as the "WTO Agreement"),

Decide as follows:

1. Negotiations shall be entered into on a voluntary basis in the sector of maritime transport services within the framework of the General Agreement on Trade in Services. The negotiations shall be comprehensive in scope, aiming at commitments in international shipping, auxiliary services and access to and use of port facilities, leading to the elimination of restrictions within a fixed time scale.

2. A Negotiating Group on Maritime Transport Services (hereinafter referred to as the "NGMTS") is established to carry out this mandate. The NGMTS shall report periodically on the progress of these negotiations.

3. The negotiations in the NGMTS shall be open to ail governments and the European Communities which announce their intention to participate. To date, the following have announced their intention to take part in the negotiations:

Argentina, Canada, European Communities and their member States, Finland, Hong Kong, Iceland, Indonesia, Korea, Malaysia, Mexico, New Zealand, Norway, Philippines, Poland, Romania, Singapore, Sweden, Switzerland, Thailand, Turkey, United States.

Further notifications of intention to participate shall be addressed to the depositary of the WTO Agreement.

4. The NGMTS shall hold its first negotiating session no later than 16 May 1994. It shall conclude these negotiations and make a final report no later than June 1996. The final report of the NGMTS shall include a date for the implementation of results of these negotiations.

5. Until the conclusion of the negotiations Article II and paragraphs 1 and 2 of the Annex on Article II Exemptions are suspended in their application to this sector, and it is not necessary to list MFN exemptions. At the conclusion of the negotiations, Members shall be free to improve, modify or withdraw any commitments made in this sector during the Uruguay Round without offering compensation, notwithstanding the provisions of Article XXI of the Agreement. At the same time Members shall finalize their positions relating to MFN exemptions in this sector, notwithstanding the provisions of the Annex on Article II Exemptions. Should negotiations not succeed, the Council for Trade in Services shall decide whether to continue the negotiations in accordance with this mandate.

6. Any commitments resulting from the negotiations, including the date of their entry into force, shall be inscribed in the Schedules annexed to the General Agreement on Trade in Services and be subject to all the provisions of the Agreement.

7. Commencing immediately and continuing until the implementation date to be determined under paragraph 4, it is understood that participants shall not apply any measure affecting trade in maritime transport services except in response to measures applied by other countries and with a view to maintaining or improving the freedom of provision of maritime transport services, nor in such a manner as would improve their negotiating position and leverage.

8. The implementation of paragraph 7 shall be subject to surveillance in the NGMTS. Any participant may bring to the attention of the NGMTS any action or omission which it believes to be relevant to the fulfilment of paragraph 7. Such notifications shall be deemed to have been submitted to the NGMTS upon their receipt by the Secretariat.

Vol. 1867, 1-31874


DECISION ON NEGOTIATIONS ON BASIC TELECOMMUNICATIONS

Ministers decide as follows:

1. Negotiations shall be entered into on a voluntary basis with a view to the progressive liberalization of trade in telecommunications transport networks and services (hereinafter referred to as "basic telecommunications") within the framework of the General Agreement on Trade in Services.

2. Without prejudice to their outcome, the negotiations shall be comprehensive in scope, with no basic telecommunications excluded a priori.

3. A Negotiating Group on Basic Telecommunications (hereinafter referred to as the "NGBT") is established to carry out this mandate. The NGBT shall report periodically on the progress of these negotiations.

4. The negotiations in the NGBT shall be open to all governments and the European Communities which announce their intention to participate. To date, the following have announced their intention to take part in the negotiations:

Australia, Austria, Canada, Chile, Cyprus, European Communities and their member States, Finland, Hong Kong, Hungary, Japan, Korea, Mexico, New Zealand, Norway, Slovak Republic, Sweden, Switzerland, Turkey, United States.

Further notifications of intention to participate shall be addressed to the depositary of the Agreement Establishing the World Trade Organization.

5. The NGBT shall hold its first negotiating session no later than 16May 1994. It shall conclude these negotiations and make a final report no later than 30 April 1996. The final report of the NGBT shall include a date for the implementation of results of these negotiations.

6. Any commitments resulting from the negotiations, including the date of their entry into force, shall be inscribed in the Schedules annexed to the General Agreement on Trade in Services and shall be subject to all the provisions of the Agreement.

7. Commencing immediately and continuing until the implementation date to be determined under paragraph 5, it is understood that no participant shall apply any measure affecting trade in basic telecommunications in such a manner as would improve its negotiating position and leverage. It is understood that this provision shall not prevent the pursuit of commercial and governmental arrangements regarding the provision of basic telecommunications services.

8. The implementation of paragraph 7 shall be subject to surveillance in the NGBT. Any participant may bring to the attention of the NGBT any action or omission which it believes to be relevant to the fulfilment of paragraph 7. Such notifications shall be deemed to have been submitted to the NGBT upon their receipt by the Secretariat.

Vol. 1867, 1-31874


DECISION ON PROFESSIONAL SERVICES



Recognizing the impact of regulatory measures relating to professional qualifications, technical standards and licensing on the expansion of trade in professional services;

Desiring to establish multilateral disciplines with a view to ensuring that, when specific commitments are undertaken, such regulatory measures do not constitute unnecessary barriers to the supply of professional services;

Decides as follows:

1. The work programme foreseen in paragraph 4 of Article VI on Domestic Regulation should be put into effect immediately. To this end, a Working Party on Professional Services shal! be established to examine and report, with recommendations, on the disciplines necessary to ensure that measures relating to qualification requirements and procedures, technical standards and licensing requirements in the field of professional services do not constitute unnecessary barriers to trade.

2. As a matter of priority, the Working Party shall make recommendations for the elaboration of multilateral disciplines in the accountancy sector, so as to give operational effect to specific commitments. In making these recommendations, the Working Party shall concentrate on:

(a) developing multilateral disciplines relating to market access so as to ensure that domestic regulatory requirements are: (i) based on objective and transparent criteria, such as competence and the ability to supply the service; (ii) not more burdensome than necessary to ensure the quality of the service, thereby facilitating the effective liberalization of accountancy services;

(b) the use of international standards and, in doing so, it shall encourage the cooperation with the relevant international organizations as defined under paragraph 5(b) of Article VI, so as to give full effect to paragraph 5 of Article VII;

(c) facilitating the effective application of paragraph 6 of Article VI of the Agreement by establishing guidelines for the recognition of qualifications.

In elaborating these disciplines, the Working Party shall take account of the importance of the governmental and non governmental bodies regulating professional services.

Vol. 1867, 1-31874


DECISION ON ACCESSION TO THE AGREEMENT ON GOVERNMENT PROCUREMENT

1. Ministers invite the Committee on Government Procurement established under the Agreement on Government Procurement in Annex 4(b) of the Agreement Establishing the World Trade Organization to clarify that:

(a) a Member interested in accession according to paragraph 2 of Article XXIV of the Agreement on Government Procurement would communicate its interest to the Director-General of the WTO, submitting relevant information, including a coverage offer for incorporation in Appendix I having regard to the relevant provisions of the Agreement, in particular Article I and, where appropriate, Article V;

(b) the communication would be circulated to Parties to the Agreement;

(c) the Member interested in accession would hold consultations with the Parties on the terms for its accession to the Agreement;

(d) with a view to facilitating accession, the Committee would establish a working party if the Member in question, or any of the Parties to the Agreement, so requests. The working party should examine: (/') the coverage offer made by the applicant Member; and (ii) relevant information pertaining to export opportunities in the markets of the Parties, taking into account the existing and potential export capabilities of the applicant Member and export opportunities for the Parties in the market of the applicant Member;

(e) upon a decision by the Committee agreeing to the terms of accession including the coverage lists of the acceding Member, the acceding Member would deposit with the Director-General of the WTO an instrument of accession which states the terms so agreed. The acceding Member's coverage lists in English, French and Spanish would be appended to the Agreement;

(f) prior to the date of entry into force of the WTO Agreement, the above procedures would apply mutatis mutandis to contracting parties to the GATT 1947 interested in accession, and the tasks assigned to the Director-General of the WTO would be carried out by the Director-General to the CONTRACTING PARTIES to the GATT 1947.

2. It is noted that Committee decisions are arrived at on the basis of consensus. It is also noted that the non- application clause of paragraph 11 of Article XXIV is available to any Party.

Vol. 1867, 1-31874


DECISION ON THE APPLICATION AND REVIEW OF THE UNDERSTANDING ON RULES AND PROCEDURES GOVERNING THE SETTLEMENT OF DISPUTES

Ministers,

Recalling the Decision of 22 February 1994 that existing rules and procedures of GATT 1947 in the field of dispute settlement shall remain in effect until the date of entry into force of the Agreement Establishing the World Trade Organization,

Invite the relevant Councils and Committees to decide that they shall remain in operation for the purpose of dealing with any dispute for which the request for consultation was made before that date;

Invite the Ministerial Conference to complete a rull review of dispute settlement rules and procedures under the World Trade Organization within four years after the entry into force of the Agreement Establishing the World Trade Organization, and to take a decision on the occasion of its first meeting after the completion of the review, whether to continue, modify or terminate such dispute settlement rules and procedures.

Vol. 1867, 1-31874


UNDERSTANDING ON COMMITMENTS IN FINANCIAL SERVICES

Participants in the Uruguay Round have been enabled to take on specific commitments with respect to financial services under the General Agreement on Trade in Services (hereinafter referred to as the "Agreement") on the basis of an alternative approach to that covered by the provisions of Part III of the Agreement. It was agreed that this approach could be applied subject to the following understanding:

(i) it does not conflict with the provisions of the Agreement;

(ii) it does not prejudice the right of any Member to schedule its specific commitments in accordance with the approach under Part III of the Agreement;

(iii) resulting specific commitments shall apply on a most-favoured-nation basis;

(iv) no presumption has been created as to the degree of liberalization to which a Member is committing itself under the Agreement.

Interested Members, on the basis of negotiations, and subject to conditions and qualifications where specified, have inscribed in their schedule specific commitments conforming to the approach set out below.

A. Standstill

Any conditions, limitations and qualifications to the commitments noted below shall be limited to existing non-conforming measures.

B. Market Access

Monopoly Rights

1. In addition to Article VIII of the Agreement, the following shall apply:

Each Member shall list in its schedule pertaining to financial services existing monopoly rights and shall endeavour to eliminate them or reduce their scope. Notwithstanding subparagraph l(b) of the Annex on Financial Services, this paragraph applies to the activities referred to in subparagraph l(b)(iii) of the Annex.

Financial Services purchased by Public Entities

2. Notwithstanding Article XIII of the Agreement, each Member shall ensure that financial service suppliers of any other Member established in its territory are accorded most-favoured-nation treatment and national treatment as regards the purchase or acquisition of financial services by public entities of the Member in its territory.

Cross-border Trade

3. Each Member shall permit non-resident suppliers of financial services to supply, as a principal, through an intermediary or as an intermediary, and under terms and conditions that accord national treatment, the following services:

(a) insurance of risks relating to:

(i) maritime shipping and commercial aviation and space launching and freight (including satellites), with such insurance to cover any or all of the following: the goods being transported, the vehicle transporting the goods and any liability arising therefrom; and

(ii) goods in international transit;

(b) reinsurance and retrocession and the services auxiliary to insurance as referred to in subparagraph 5(a)(iv) of the Annex;

(c) provision and transfer of financial information and financial data processing as referred to in subparagraph 5(a)(xv) of the Annex and advisory and other auxiliary services, excluding intermediation, relating to banking and other financial services as referred to in subparagraph 5(a)(xvi) of the Annex.

Vol. 1867, 1-31874


4. Each Member shall permit its residents to purchase in the territory of any other Member the financial services indicated in:

(a) subparagraph 3(a);

(b) subparagraph 3(b); and

(c) subparagraphs 5(a)(v) to (xvi) of the Annex.

Commercial Presence

5. Each Member shall grant financial service suppliers of any other Member the right to establish or expand within its territory, including through the acquisition of existing enterprises, a commercial presence.

6. A Member may impose terms, conditions and procedures for authorization of the establishment and expansion of a commercial presence in so far as they do not circumvent the Member's obligation under paragraph 5 and they are consistent with the other obligations of the Agreement.

New Financial Services

1. A Member shall permit financial service suppliers of any other Member established in its territory to offer in its territory any new financial service.

Transfers of Information and Processing of Information

8. No Member shall take measures that prevent transfers of information or the processing of financial information, including transfers of data by electronic means, or that, subject to importation rules consistent with international agreements, prevent transfers of equipment, where such transfers of information, processing of financial information or transfers of equipment are necessary for the conduct of the ordinary business of a financial service supplier. Nothing in this paragraph restricts the right of a Member to protect personal data, personal privacy and the confidentiality of individual records and accounts so long as such right is not used to circumvent the provisions of the Agreement.

Temporary Entry of Personnel

9. (a) Each Member shall permit temporary entry into its territory of the following personnel of a financial sen-ice supplier of any other Member that is establishing or has established a commercial presence in the territory of the Member:

(i) senior managerial personnel possessing proprietary information essential to the establishment, control and operation of the services of the financial service supplier; and

(ii) specialists in the operation of the financial service supplier.

(b) Each Member shall permit, subject to the availability of qualified personnel in its territory, temporary entry into its territory of the following personnel associated with a commercial presence of a financial service supplier of any other Member:

(i) specialists in computer services, telecommunication services and accounts of the financial service supplier; and

(ii) actuarial and legal specialists.

Non-discriminatory Measures

10. Each Member shall endeavour to remove or to limit any significant adverse effects on financial service suppliers of any other Member of:

(a) non-discriminatory measures that prevent financial service suppliers from offering in the Member's territory, in the form determined by the Member, all the financial services permitted by the Member;

(b) non-discriminatory measures that limit the expansion of the activities of financial service suppliers into the entire territory of the Member;

Vol. 1867, 1-31874


(c) measures of a Member, when such a Member applies the same measures to the supply of both banking and securities services, and a financial service supplier of any other Member concentrates its activities in the provision of securities services; and

(d) other measures that, although respecting the provisions of the Agreement, affect adversely the ability of financial service suppliers of any other Member to operate, compete or enter the Member's market;

provided that any action taken under this paragraph would not unfairly discriminate against financial service suppliers of the Member taking such action.

11. With respect to the non-discriminatory measures referred to in subparagraphs 10(a) and (b), a Member shall endeavour not to limit or restrict the present degree of market opportunities nor the benefits already enjoyed by financial service suppliers of all other Members as a class in the territory of the Member, provided that this commitment does not result in unfair discrimination against financial service suppliers of the Member applying such measures.

C. National Treatment

1. Under terms and conditions that accord national treatment, each Member shall grant to financial service suppliers of any other Member established in its territory access to payment and clearing systems operated by public entities, and to official funding and refinancing facilities available in the normal course of ordinary business. This paragraph is not intended to confer access to the Member's lender of last resort facilities.

2. When membership or participation in, or access to, any self-regulatory body, securities or futures exchange or market, clearing agency, or any other organization or association, is required by a Member in order for financial service suppliers of any other Member to supply financial services on an equal basis with financial service suppliers of the Member, or when the Member provides directly or indirectly such entities, privileges or advantages in supplying financial services, the Member shall ensure that such entities accord national treatment to financial service suppliers of any other Member resident in the territory of the Member.

D. Definitions

For the purposes of this approach:

1. A non-resident supplier of financial services is a financial service supplier of a Member which supplies a financial service into the territory of another Member from an establishment located in the territory of another Member, regardless of whether such a financial service supplier has or has not a commercial presence in the territory of the Member in which the financial service is supplied.

2. "Commercial presence" means an enterprise within a Member's territory for the supply of financial services and includes wholly- or partly-owned subsidiaries, joint ventures, partnerships, sole proprietorships, franchising operations, branches, agencies, representative offices or other organizations.

3. A new financial service is a service of a financial nature, including services related to existing and new products or the manner in which a product is delivered, that is not supplied by any financial service supplier in the territory of a particular Member but which is supplied in the territory of another Member.

Vol. 1867, 1-31874


ADDITIONAL DECISIONS AND DECLARATIONS ADOPTED AT THE MINISTERIAL MEETING AT MARRAKESH

DECISIONS ET DECLARATIONS ADDITIONELLES ADOPTEES A LA REUNION MINISTERIELLE DE MARRAKECH

DECISIONES Y DECLARACIONES ADICIONALES ADOPTADAS EN LA REUNION MINISTERIAL DE MARRAKECH

Vol. 1867, 1-31874


Acceptance of and Accession to the Agreement Establishing the World Trade Organization

Decision of 14 April 1994

Ministers,

Noting that Articles XI and XIV of the Agreement Establishing the World Trade Organization (hereinafter referred to as "WTO Agreement") provide that only contracting parties to the GATT 1947 as of the entry into force of the WTO Agreement for which schedules of concessions and commitments are annexed to GATT 1994 and for which schedules of specific commitments are annexed to the General Agreement on Trade in Services (hereinafter referred to as "GATS") may accept the WTO Agreement;

Noting further that paragraph 5 of the Final Act Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations (hereinafter referred to as "Final Act" and "Uruguay Round" respectively) provides that die schedules of participants which are not contracting parties to GATT 1947 as of the date of the Final Act are not definitive and shall be subsequently completed for the purpose of their accession to GATT 1947 and their acceptance of the WTO Agreement;

Having regard to paragraph 1 of the Decision on Measures in Favour of Least-Developed Countries which provides that the least-developed countries shall be given an additional time of one year from 15 April 1994 to submit their schedules as required in Article XI of the WTO Agreement;

Recognizing that certain participants in the Uruguay Round which had applied GATT 1947 on a de facto basis and became contracting parties under Article XXVI:5(c) of the GATT 1947 were not in a position to submit schedules to GATT 1994 and the GATS;

Recognizing further that some States or separate customs territories which were not participants in the Uruguay Round may become contracting parties to GATT 1947 before the entry into force of the WTO Agreement and that States or customs territories should be given the opportunity to negotiate schedules to GATT 1994 and the GATS so as to enable them to accept the WTO Agreement;

Talcing into account that some States or separate customs territories which cannot complete the process of accession to GATT 1947 before the entry into force of the WTO Agreement or which do not intend to become contracting parties to GATT 1947 may wish to initiate the process of their accession to the WTO before the entry into force of the WTO Agreement;

Recognizing that the WTO Agreement does not distinguish in any way between WTO Members which accepted that Agreement in accordance with its Articles XI and XIV and WTO Members which acceded to it in accordance with its Article XII and wishing to ensure that the procedures for accession of the States and separate customs territories which have not become contracting parties to the GATT 1947 as of the date of entry into force of the WTO Agreement are such as to avoid any unnecessary disadvantage or delay for these States and separate customs territories;

Decide that:

1. (a) Any Signatory of the Final Act

-to which paragraph 5 of the Final Act applies, or

to which paragraph 1 of the Decision on Measures in Favour of Least-Developed Countries applies, or

which became a contracting party under Article XXVI:5(c) of the GATT 1947 before 15 April 1994 and was not in a position to establish a schedule to GATT 1994 and the GATS for inclusion in the Final Act, and

any State or separate customs territory

Vol. 1867, 1-31874


which becomes a contracting party tc the GATT 1947 between 15 April 1994 and the date of entry into force of the WTO Agreement

may submit to the Preparatory Committee for its examination and approval a schedule of concessions and commitments to GATT 1994 and a schedule of specific commitments to the GATS.

(b) The WTO Agreement shall be open for acceptance in accordance with Article XIV of that Agreement by contracting parties to GATT 1947 the schedules of which have been so submitted and approved before the entry into force of the WTO Agreement.

(c) The provisions of subparagraphs (a) and (b) of this paragraph shall be without prejudice to the right of the least-developed countries to submit their schedules within one year from 15 April 1994.

2. (a) Any State or separate customs territory may request the Preparatory Committee to propose for approval by the Ministerial Conference of the WTO the terms of its accession to the WTO Agreement in accordance with Article XII of that Agreement. If such a request is made by a State or separate customs territory which is in the process of acceding to G ATT 1947, the Preparatory Committee shall, to the extent practicable, examine the request jointly with the Working Party established by the CONTRACTING PARTIES to GATT 1947 to examine the accession of that State or separate customs territory.

(b) The Preparatory Committee shall submit to the Ministerial Conference a report on its examination of the request. The report may include a protocol of accession, including a schedule of concessions and commitments to GATT 1994 and a schedule of specific commitments for the GATS, for approval by the Ministerial Conference. The report of the Preparatory Committee shall be taken into account by the Ministerial Conference in its consideration of any application by the State or separate customs territory concerned to accede to the WTO Agreement.

Vol. 1867, 1-31874


Trade and Environment


Ministers, meeting on the occasion of signing the Final Act embodying the results of the Uruguay Round of Multilateral Trade Negotiations at Marrakesh on 15 April 1994,

tfeca//m£thepreambleof the Agreement establishing the World Trade Organization (WTO), which states that members' "relations in the field of trade and economic endeavour should be conducted with a view to raising standards of living, ensuring full employment and a large and steadily growing volume of real income and effective demand, and expanding the production of and trade in goods and services, while allowing for the optimal use of the world's resources in accordance with the objective of sustainable development, seeking both to protect and preserve the environment and to enhance the means for doing so in a manner consistent with their respective needs and concerns at different levels of economic development,"

Noting:

— the Rio Declaration on Environment and Development, Agenda 21, and its follow-up in GATT, as reflected in the statement of the Chairman of the Council of Representatives to the CONTRACTING PARTIES at their 48th Session in December 1992, as well as the work of the Group on Environmental Measures and International Trade, the Committee on Trade and Development, and the Council of Representatives;

— the work programme envisaged in the Decision on Trade in Services and the Environment; and

— the relevant provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights,

Considering that there should not be, nor need be, any policy contradiction between upholding and safeguarding an open, non-discriminatory and equitable multilateral trading system on the one hand, and acting for the protection of the environment, and the promotion of sustainable development on the other,

Desiring to coordinate the policies in the field of trade and environment, and this without exceeding the competence of the multilateral trading system, which is limited to trade policies and those trade-related aspects of environmental policies which may result in significant trade effects for its members,

Decide:

— to direct the first meeting of the General Council of the WTO to establish a Committee on Trade and Environment open to all members of the WTO to report to the first biennial meeting of the Ministerial Conference after the entry into force of the WTO when the work and terms of reference of the Committee will be reviewed, in the light of recommendations of the Committee,

— that the TNC Decision of 15 December 1993 which reads, in part, as follows:

"(a) to identify the relationship between trade measures and environmental measures, in order to promote sustainable development;

(b) to make appropriate recommendations on whether any modifications of the provisions of the multilateral trading system are required, compatible with the open, equitable and non-discriminatory nature of the system, as regards, in particular:

— the need for rules to enhance positive interaction between trade and environmental measures, for the promotion of sustainable development, with special consideration to the needs of developing countries, in particular those of the least developed among them; and

Vol. 1867, 1-31874


— the avoidance of protectionist trade measures, and the adherence to effective multilateral disciplines to ensure responsiveness of the multilateral trading system to environmental objectives set forth in Agenda 21 and the Rio Declaration, in particular Principle 12; and

— surveillance of trade measures used for environmental purposes, of trade-related aspects of environmental measures which have significant trade effects, and of effective implementation of the multilateral disciplines governing those measures;"

constitutes, along with the preambular language above, the terms of reference of the Committee on Trade and Environment,

— that, within these terms of reference, and with the aim of making international trade and environmental policies mutually supportive, the Committee will initially address the following matters, in relation to which any relevant issue may be raised:

— the relationship between the provisions of the multilateral trading system and trade measures for environmental purposes, including those pursuant to multilateral environmental agreements;

— the relationship between environmental policies relevant to trade and environmental measures with significant trade effects and the provisions of the multilateral trading system;

— the relationship between the provisions of the multilateral trading system and:

(a) charges and taxes for environmental purposes

(b) requirements for environmental purposes relating to products, including standards and technical regulations, packaging, labelling and recycling;

— the provisions of the multilateral trading system with respect to the transparency of trade measures used for environmental purposes and environmental measures and requirements which have signi ficant trade effects;

— the relationship between the dispute settlement mechanisms in the multilateral trading system and those found in multilateral environmental agreements;

— theeffect of environmental measures on market access, especially in relation to developing countries, in particular to the least developed among them, and environmental benefits of removing trade restrictions and distortions;

— the issue of exports of domestically prohibited goods,

— that the Committee on Trade and Environment will consider the work programme envisaged in the Decision on Trade in Services and the Environment and the relevant provisions of the Agreement on Trade-Related Aspects of Intellectual Property Rights as an integral part of its work, within the above terms of reference,

— that, pending the first meeting of the General Council of the WTO, the work of the Committee on Trade and Environment should be carried out by a Sub-Committee of the Preparatory Committee of the World Trade Organization (PCWTO), open to all members of the PCWTO,

— to invite the Sub-Committee of the Preparatory Committee, and the Committee on Trade and Environment when it is established, to provide input to the relevant bodies in respect of appropriate arrangements for relations with inter-governmental and non-governmental organizations referred to in Article V of the WTO.

Vol. 1867, 1-31874


Organizational and Financial Consequences flowing fromImplementation of the Agreement Establishing

the World Trade Organization


Ministers,

Recognizing the importance of the rôle and contribution to international trade of the World Trade Organization (hereinafter referred to as the WTO),

Desiring to ensure the efficient functioning of the WTO Secretariat,

Recognizing that implementation of the results of the Uruguay Round will expand the scope and complexity of the duties of the Secretariat and that the resource implications thereof need to be studied,

Recalling the statements made by previous Chairmen of the GATT CONTRACTING PARTIES and the GATT Council drawing attention to the need to improve the terms and conditions of service, including salaries and pensions, for the professional staff of the Secretariat,

Mindful of the need for the WTO to be competitive in the conditions of service it will offer to its professional staff so as to attract the required expertise,

Noting the proposal of the Director-General that, in setting WTO staff conditions of services, including salaries and pensions, due account be taken of those of the International Monetary Fund and the World Bank,

Noting Article VI of the Agreement establishing the WTO, in particular paragraph 3 thereof empowering the Director-General to appoint the staff of the Secretariat to determine their duties and conditions of service in accordance with regulations adopted by the Ministerial Conference,

Recalling that the mandate of the Preparatory Committee requires it to perform such functions as may be necessary to ensure the efficient operation of the WTO immediately as of the date of its establishment, including the preparation of recommendations for the consideration of the competent body of the WTO, or to the extent necessary, the taking of decisions or, as appropriate, provisional decisions with respect to administrative, budgetary and financial matters assisted by proposals from the Secretariat,

Hereby agree that the Preparatory Committee shall consider the organizational changes, resource requirements and staff conditions of service proposed in connection with the establishment of the WTO and the implementation of the Uruguay Round agreements and prepare recommendations and take decisions, to the extent necessary, on the adjustments required.

Vol. 1867, 1-31874

142 United Nations — Treaty Series » Nations Unies — Recueil des Traités_______1995

Decision on the Establishment of the Preparatory Committee for the World Trade Organization


Ministers,

Having regard to the Agreement Establishing the World Trade Organization (hereinafter referred to as "WTO Agreement" and "WTO"), and

Mindful of the desirability of ensuring an orderly transition to the WTO and the efficient operation of the WTO as of the date of entry into force,

hereby agree as follows:

1. A Preparatory Committee for the WTO (hereinafter referred to as "Committee") is hereby established. Mr. P.D. Sutherland in his persona! capacity is appointed Chairman of the Committee.

2. The Committee shall be open for membership to all Signatories of the Final Act of the Uruguay Round of Multilateral Trade Negotiations and to any contracting party eligible to become an original member of the WTO in accordance with Article XI of the WTO Agreement.

3. A Sub-Committee on Budget, Finance and Administration, to be chaired by the Chairman of the GATT CONTRACTING PARTIES, and a Sub-Committee on Services responsible for preparatory work on GATS matters are also established. The Committee may establish additional sub-committees as appropriate. Membership of the Sub- Committees shall be open to all members of the Committee. The Committee shall establish its own procedures and those of its sub-committees.

4. The Committee will make all its decisions by consensus.

5. Only those members of the Committee that are G ATT contracting parties eligible to become original Members of the WTO in accordance with Articles XI and XIV of the WTO Agreement may participate in the decision-making of the Committee.

6. The Committee and its sub-committees shall be serviced by the GATT Secretariat.

7. The Committee shall cease to exist upon the entry into force of the WTO Agreement, at which time it will forward its records and recommendations to the WTO.

8. The Committee shall perform such functions as may be necessary to ensure the efficient operation of the WTO immediately as of the date of its establishment, including the functions set out below:

(a) Administrative, budgetary and financial matters:

To prepare recommendations for the consideration of the competent body of the WTO, or, to the extent necessary, take decisions or, as appropriate, provisional decisions in advance of the establishment of the WTO, with respect to the recommendations submitted to it by the Chairman of the Sub-Committee on Budget, Finance and Administration referred to in paragragh 3 above, in cooperation with the Chairman of the GATT Committee on Budget, Finance and Administration, assisted by proposals from the Secretariat on:

the headquarters agreement provided for in Article VIII:5 of the WTO Agreement;

financial regulations, including guidelines for theassessmentofWTOmembers'budget contributions, in accordance with the criteria set out in Article VII of the WTO Agreement;

(iii) the budget estimates for the first year of operation of the WTO;

Vol. 1867, 1-31874


the transfer of the property, including financial assets, of the ICITO/GATT to the WTO;

the transfer and the terms and conditions of the transfer of the GATT staff to the WTO Secretariat; and

(vi) the relationship between the International Trade Centre and the WTO.

(b) Institutional, procedural and legal matters:

(i) To carry out the examination of and approve the schedules submitted to it in accordance with the "Decision on Acceptance of and Accession to the Agreement Establishing the World Trade Organization" and to propose terms of accession in accordance with paragraph 2 of that Decision;

(ii) To make proposals concerning terms of reference for the bodies of the WTO, in particular those established in Article IV of the WTO Agreement, and the rules of procedure which they are called upon to establish for themselves, bearing in mind paragraph 1 of Article XVI;

(iii) To make recommendations to the General Council of the WTO concerning the appropriate arrangements with respect to relations with other organizations referred to in Article V of the WTO Agreement; and

(iv) To prepare and submit a report on its activities to the WTO.

(c) Matters related to the entry into force of the WTO Agreement and to the activities of the WTO within its scope and functions:

To convene and prepare the Implementation Conference;

To initiate the work programme arising from the Uruguay Round results as set out in the Final Act, such as overseeing, in the Sub-Committee on Services referred to in paragragh 3 above, negotiations in specific services sectors, and also to undertake work resulting from Decisions of the Marrakeshmeeting;

To discuss suggestions for the inclusion of additional items on the agenda of the WTO's work programme;

To make proposals concerning the composition of the Textiles Monitoring Body in accordance with the criteria set out in Article 8 of the Agreement on Textiles and Clothing; and

To convene the first meeting of the Ministerial Conference or the General Council of the WTO, whichever meets first, and to prepare the provisional agenda thereof.

Vol. 1867, 1-31874


Marrakesh Declaration of 15 April 1994

Ministers,

Representing the 124 Governments and the European Communities participating in the Uruguay Round of Multilateral Trade Negotiations, on the occasion of the final session of the Trade Negotiations Committee at Ministerial level held at Marrakesh, Morocco from 12 to 15 April 1994,

Recalling the Ministerial Declaration adopted at Punta del Este, Uruguay on 20 September 1986 to launch the Uruguay Round of Multilateral Trade Negotiations,

Recalling the progress achieved at the Ministerial meetings held at Montreal, Canada and Brussels, Belgium in December of 1988 and 1990 respectively,

Noting that the negotiations were substantially concluded on 15 December 1993,

Determined to build upon the success of the Uruguay Round through the participation of their economies in the world trading system, based upon open, market-oriented policies and the commitments set out in the Uruguay Round Agreements and Decisions,

Have today adopted the following:

DECLARATION:

16. Ministers salute the historic achievement represented by the conclusion of the Round, which they believe wili strengthen the world economy and lead to more trade, investment, employment and income growth throughout the world. In particular, they welcome:

— the stronger and clearer legal framework they have adopted for the conduct of international trade, including a more effective and reliable dispute settlement mechanism,

— the global reduction by 40 per cent of tariffs and wider market-opening agreements on goods, and the increased predictability and security represented by a major expansion in the scope of tariff commitments, and

— the establishment of a multilateral framework of disciplines for trade in services and for the protection of trade-related intellectual property rights, as well as the reinforced multilateral trade provisions in agriculture and in textiles and clothing.

17. Ministers affirm that the establishment of the World Trade Organization (WTO) ushers in a new era of global economic cooperation, reflecting the widespread desire to operate in a fairer and more open multilateral trading system for the benefit and welfare of their peoples. Ministers express their determination to resist protectionist pressures of all kinds. They believe that the trade liberalization and strengthened rules achieved in the Uruguay Round will lead to a progressively more open world trading environment. Ministers undertake, with immediate effect and until the entry into force of the WTO, not to take any trade measures that would undermine or adversely affect the results of the Uruguay Round negotiations or their implementation.

18. Ministers confirm their resolution to strive for greater global coherence of policies in the fields of trade, money and finance, including cooperation between the WTO, the IMF and the World Bank for that purpose.

19. Ministers welcome the fact that participation in the Uruguay Round was considerably wider than in any previous multilateral trade negotiation and, in particular, that developing countries played a notably active rôle in it. This has marked a historic step towards a more balanced and integrated global trade partnership. Ministers note that during the period these negotiations were underway significant measures of economic reform and autonomous trade liberalization were implemented in many developing countries and formerly centrally planned economies.

Vol. 1867, 1-31874


20. Ministers recall that the results of the negotiations embody provisions conferring differential and more favourable treatment for developing economies, including special attention to the particular situation of least-developed countries. Ministers recognize the importance of the implementation of these provisions for the least-developed countries and declare their intention to continue to assist and facilitate the expansion of their trade and investment opportunities. They agree to keep under regular review by the Ministerial Conference and the appropriate organs of the WTO the impact of the results of the Round on the least-developed countries as well as on the net-food importing developing countries, with a view to fostering positive measures to enable them to achieve their development objectives. Ministers recognize the need for strengthening the capability of the GATT and the WTO to provide increased technical assistance in their areas of competence, and in particular to substantially expand its provision to the least-developed countries.

21. Ministers declare that their signature of the "Final Act Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations " and their adoption of associated Ministerial Decisions initiates the transition from the GATT to the WTO. They have in particular established a Preparatory Committee to lay the ground for the entry into force of the WTO Agreement and commit themselves to seek to complete all steps necessary to ratify the WTO Agreement so that it can enter into force by 1 January 1995 or as early as possible thereafter. Ministers have furthermore adopted a Decision on Trade and Environment.

22. Ministers express their sincere gratitude to His Majesty King Hassaii II for his personal contribution to the success of this Ministerial Meeting, and to his Government and the people of Morocco for their warm hospitality and the excellent organization they have provided. The fact that this final Ministerial Meeting of the Uruguay Round has been held at Marrakesh is an additional manifestation of Morocco's commitment to an open world trading system and to its fullest integration to the global economy.

23. With the adoption and signature of the Final Act and the opening for acceptance of the WTO Agreement, Ministers declare the work of the Trade Negotiations Committee to be complete and the Uruguay Round formally concluded.

Vol. 1867, 1-31874


MARRAKESH AGREEMENT1 ESTABLISHING THE WORLD TRADE ORGANIZATION

The Ponies to this Agreement,

Recognizing that their relations in the field of trade and economic endeavour should be conducted with a view to raising standards of living, ensuring full employment and a large and steadily growing volume of real income and effective demand, and expanding the production of and trade in goods and services, while allowing for the optimal use of the world's resources in accordance with the objective of sustainable development, seeking both to protect and preserve the environment and to enhance the means for doing so in a manner consistent with their respective needs and concerns at different levels of economic development,

Recognizing further that there is need for positive efforts designed to ensure that developing countries, and especially the least developed among them, secure a share in the growth in international trade commensurate with the needs of their economic development,

Being desirous of contributing to these objectives by entering into reciprocal and mutually advantageous arrangements directed to the substantial reduction of tariffs and other barriers to trade and to the elimination of discriminatory treatment in international trade relations,

1 The above Agreement and the Multilateral Trade Agreements annexed hereto came into force in respect of the following Contracting Parties to the General Agreement on Tariffs and Trade of 1947 and the European Communities, which were eligible to become original Members of the World Trade Organization, on 1 January 1995, i.e., the date determined by the Ministers of all participants in the Uruguay Round of Multilateral Trade Negotiations, in accordance with article XIV (1):

ParticipantAntigua and Barbuda . Argentina ..........Australia* ..........Austria* ............Bahrain ............Bangladesh* ........Barbados ...........Belgium ............Belize ..............Brazil* .............Brunei Darussalam . . . Canada* ............Chile* ..............Costa Rica* ........Côte d'Ivoire* .......Czech Republic ......Denmark ...........Dominica ...........European Community Finland ............France .............Gabon* ............Germany ...........Ghana* ............Greece .............

Date of deposit of the instrumentof ratification,

-accession (a), acceptance (A),approval (AA) or date

of definitive signature (s). 15 April 1994s. 29 December 1994. 21 December 1994A. 6 December 1994. 27 July 1994. 15 April 1994s. 15 April 1994s. 30 December 1994. 15 April 1994s. 21 December 1994. 16 November 1994. 30 December 1994. 28 December 1994A. 26 December 1994A. 29 December 1994. 23 December 1994AA. 30 December 1994. 22 December 1994s. 30 December 1994AA. 30 December 1994. 30 December 1994. 15 April 1994s. 30 December 1994. 23 December 1994. 30 December 1994A

Participant

Date of deposit of the instrumentof ratification,

accession (a), acceptance (A),approval (AA) or date

of definitive signature (s)Guyana ..................... 15 April 1994sHonduras* .................. 16 December 1994Hong Kong .................. 3 October 1994AHungary .................... 28 December 1994Iceland ...................... 30 December 1994India ........................ 30 December 1994Indonesia* ................... 2 December 1994Ireland ...................... 30 December 1994Italy ........................ 30 December 1994Japan ....................... 27 December 1994AKenya* ..................... 23 December 1994Kuwait ...................... 15 April 1994sLuxembourg ................. 30 December 1994Macau ...................... 23 December 1994AMalaysia* ................... 6 September 1994AMalta* ...................... 22 December 1994Mauritius* ................... 15 April 1994sMexico ...................... 31 August 1994Morocco .................... 15 April 1994sMyanmar* ................... 29 November 1994ANamibia ..................... 15 April 1994sNetherlands ................. 30 December 1994A

(For the Kingdom in Europeand the Netherlands Antilles.)

New Zealand* ............... 7 December 1994 (Continued on page 155)

Vol. 1867, 1-31874


Resolved, therefore, to develop an integrated, more viable and durable multilateral trading system encompassing the General Agreement on Tariffs and Trade, the results of past trade liberalization efforts, and all of the results of the Uruguay Round of Multilateral Trade Negotiations,

Determined to preserve the basic principles and to further the objectives underlying this multilateral trading system,

Agree as follows:

Article I

Establishment of the Organization

The World Trade Organization (hereinafter referred to as "the WTO") is hereby established.

Article II

Scope of the WTO

1. The WTO shall provide the common institutional framework for the conduct of trade relations among its Members in matters related to the agreements and associated legal instruments included in the Annexes to this Agreement.

2. The agreements and associated legal instruments included in Annexes 1, 2 and 3 (hereinafter referred to as "Multilateral Trade Agreements") are integral parts of this Agreement, binding on all Members.

3. The agreements and associated legal instruments included in Annex 4 (hereinafter referred to as "Plurilateral Trade Agreements") are also part of this Agreement for those Members that have

(Footnote / continued from page 154)Date of deposit Date of deposit

of the instrument of the instrumentof ratification, of ratification,

accession (a), acceptance (A), accession (a), acceptance (A),approval (AA) or date approval (AA) or date

Participant of definitive signature (s) Participant of definitive signature ($)Nigeria ...................... 6 December 1994A Spain ....................... 30 December 1994Norway ..................... 7 December 1994 Sri Lanka* .................. 6 July 1994APakistan* .................... 30 December 1994 Suriname .................... 15 April 1994sParaguay* ................... 30 November 1994 Swaziland ................... 28 December 1994Peru ........................ 21 December 1994 Sweden ..................... 22 December 1994Philippines* ................. 19 December 1994 Thailand* ................... 28 December 1994Portugal ..................... 30 December 1994 Uganda ..................... 15 April 1994sRepublic of Korea ............ 30 December 1994A United Kingdom of Great BritainRomania .................... 23 December 1994 and Northern Ireland ........ 30 December 1994Saint Lucia .................. 30 December 1994 United Republic of Tanzania .. 6 September 1994aSaint Vincent and the Grenadines 28 December 1994A United States of America* .... 30 December 1994ASenegal* .................... 29 December 1994 Uruguay* ................... 29 December 1994Singapore* .................. 17 October 1994 Venezuela* .................. 30 December 1994Slovakia .................... 23 December 1994A Zambia ...................... 15 April 1994sSouth Africa ................. 2 December 1994A

* For the texts of the statements, communications, reservations and declarations made upon ratification, acceptance, or definitive signature, see page 511 of volume 1869.

Vol. 1867, 1-31874


accepted them, and are binding on those Members. The Plurilateral Trade Agreements do not create either obligations or rights for Members that have not accepted them.

4. The General Agreement on Tariffs and Trade 1994 as specified in Annex 1A (hereinafter referred to as "GATT 1994") is legally distinct from the General Agreement on Tariffs and Trade, dated 30 October 1947, annexed to die Final Act Adopted at the Conclusion of the Second Session of the Preparatory Committee of the United Nations Conference on Trade and Employment, as subsequently rectified, amended or modified (hereinafter referred to as "GATT 1947").

Article III

Functions of the WTO

1. The WTO shall facilitate the implementation, administration and operation, and further the objectives, of this Agreement and of the Multilateral Trade Agreements, and shall also provide the framework for the implementation, administration and operation of the Plurilateral Trade Agreements.

2. The WTO shall provide the forum for negotiations among its Members concerning their multilateral trade relations in matters dealt with under the agreements in the Annexes to this Agreement. The WTO may also provide a forum for further negotiations among its Members concerning their multilateral trade relations, and a framework for the implementation of the results of such negotiations, as may be decided by the Ministerial Conference.

3. The WTO shall administer the Understanding on Rules and Procedures Governing the Settlement of Disputes (hereinafter referred to as the "Dispute Settlement Understanding" or "DSU") in Annex 2 to this Agreement.

4. The WTO shall administer the Trade Policy Review Mechanism (hereinafter referred to as the "TPRM") provided for in Annex 3 to this Agreement.

5. With a view to achieving greater coherence in global economic policy-making, the WTO shall cooperate, as appropriate, with the International Monetary Fund and with the International Bank for Reconstruction and Development and its affiliated agencies.

Article IV

Structure of the WTO

1. There shall be a Ministerial Conference composed of representatives of all the Members, which shall meet at least once every two years. The Ministerial Conference shall carry out the functions of the WTO and take actions necessary to this effect. The Ministerial Conference shall have the authority to take decisions on all matters under any of the Multilateral Trade Agreements, if so requested by a Member, in accordance with the specific requirements for decision-making in this Agreement and in the relevant Multilateral Trade Agreement.

2. There shall be a General Council composed of representatives of all the Members, which shall meet as appropriate. In the intervals between meetings of the Ministerial Conference, its functions shall be conducted by the General Council. The General Council shall also carry out the functions assigned to it by this Agreement. The General Council shall establish its rules of procedure and approve the rules of procedure for the Committees provided for in paragraph 7.

Vol. 1867, 1-31874


3. The General Council shall convene as appropriate to discharge the responsibil ities of the Dispute Settlement Body provided for in the Dispute Settlement Understanding. The Dispute Settlement Body may have its own chairman and shall establish such rules of procedure as it deems necessary for the fulfilment of those responsibilities.

4. The General Council shall convene as appropriate to discharge the responsibilities of the Trade Policy Review Body provided for in the TPRM. The Trade Policy Review Body may have its own chairman and shall establish such rules of procedure as it deems necessary for the fulfilment of those responsibilities.

5. There shall be a Council for Trade in Goods, a Council for Trade in Services and a Council for Trade-Related Aspects of Intellectual Property Rights (hereinafter referred to as the "Council for TRIPS"), which shall operate under the general guidance of the General Council. The Council for Trade in Goods shall oversee the functioning of the Multilateral Trade Agreements in Annex 1A. The Council for Trade in Services shall oversee the functioning of the General Agreement on Trade in Services (hereinafter referred to as "GATS"). The Council for TRIPS shall oversee the functioning of the Agreement on Trade-Related Aspects of Intellectual Property Rights (hereinafter referred to as the "Agreement on TRIPS"). These Councils shall carry out the functions assigned to them by their respective agreements and by the General Council. They shall establish their respective rules of procedure subject to the approval of the General Council. Membership in these Councils shall be open to representatives of all Members. These Councils shall meet as necessary to carry out their functions.

6. The Council for Trade in Goods, the Council for Trade in Services and the Council for TRIPS shall establish subsidiary bodies as required. These subsidiary bodies shall establish their respective rules of procedure subject to the approval of their respective Councils.

7. The Ministerial Conference shall establish a Committee on Trade and Development, a Committee on Balance-of-Payments Restrictions and a Committee on Budget, Finance and Administration, which shall carry out the functions assigned to them by this Agreement and by the Multilateral Trade Agreements, and any additional functions assigned to them by the General Council, and may establish such additional Committees with such functions as it may deem appropriate. As part of its functions, the Committee on Trade and Development shall periodically review the special provisions in the Multilateral Trade Agreements in favour of the least-developed country Members and report to the General Council for appropriate action. Membership in these Committees shall be open to representatives of all Members.

8. The bodies provided for under the Plurilateral Trade Agreements shall carry out the functions assigned to them under those Agreements and shall operate within the institutional framework of the WTO. These bodies shall keep the General Council informed of their activities on a regular basis.

Article V

Relations with Other Organizations

1. The General Council shall make appropriate arrangements for effective cooperation with other intergovernmental organizations that have responsibilities related to those of the WTO.

2. The General Council may make appropriate arrangements for consultation and cooperation with non-governmental organizations concerned with matters related to those of the WTO.

Vol. 1867, 1-31874


Article VI

The Secrétariat

1. There shall be a Secretariat of the WTO (hereinafter referred to as "the Secretariat") headed by a Director-General.

2. The Ministerial Conference shall appoint the Director-General and adopt regulations setting out the powers, duties, conditions of service and term of office of the Director-General.

3. The Director-General shall appoint the members of the staff of the Secretariat and determine their duties and conditions of service in accordance with regulations adopted by the Ministerial Conference.

4. The responsibilities of the Director-General and of the staff of the Secretariat shall be exclusively international in character. In the discharge of their duties, the Director-Genera! and the staff of the Secretariat shall not seek or accept instructions from any government or any other authority external to the WTO. They shall refrain from any action which might adversely reflect on their position as international officials. The Members of the WTO shall respect the international character of the responsibilities of the Director-General and of the staff of the Secretariat and shall not seek to influence them in the discharge of their duties.

Article VII

Budget and Contributions

1. The Director-General shall present to the Committee on Budget, Finance and Administration the annual budget estimate and financial statement of the WTO. The Committee on Budget, Finance and Administration shall review the annual budget estimate and the financial statement presented by the Director-General and make recommendations thereon to the General Council. The annual budget estimate shall be subject to approval by the General Council.

2. The Committee on Budget, Finance and Administration shall propose to the General Council financial regulations which shall include provisions setting out:

(a) the scale of contributions apportioning the expenses of the WTO among its Members; and

(b) the measures to be taken in respect of Members in arrears.

The financial regulations shall be based, as far as practicable, on the regulations and practices of GATT 1947.

3. The General Council shall adopt the financial regulations and the annual budget estimate by a two-thirds majority comprising more than half of the Members of the WTO.

4. Each Member shall promptly contribute to the WTO its share in the expenses of the WTO in accordance with the financial regulations adopted by the General Council.

Vol. 1867, 1-31874


Article VIII

Status of the WTO

1. The WTO shall have legal personality, and shall be accorded by each of its Members such legal capacity as may be necessary for the exercise of its functions.

2. The WTO shall be accorded by each of its Members such privileges and immunities as are necessary for the exercise of its functions.

3. The officiais of the WTO and the representatives of the Members shall similarly be accorded by each of its Members such privileges and immunities as are necessary for the independent exercise of their functions in connection with the WTO.

4. The privileges and immunities to be accorded by a Member to the WTO, its officials, and the representatives of its Members shall be similar to the privileges and immunities stipulated in the Convention on the Privileges and Immunities of the Specialized Agencies, approved by the General Assembly of the United Nations on 21 November 1947*

5. The WTO may conclude a headquarters agreement.

Anlcle IX

Decision-Making

1. The WTO shall continue the practice of decision-making by consensus followed under GATT 1947.' Except as otherwise provided, where a decision cannot be arrived at by consensus, the matter at issue shall be decided by voting. At meetings of the Ministerial Conference and the General Council, each Member of the WTO shall have one vote. Where the European Communities exercise their right to vote, they shall have a number of votes equal to the number of their member States2 which are Members of the WTO. Decisions of the Ministerial Conference and the General Council shall be taken by a majority of the votes cast, unless otherwise provided in this Agreement or in the relevant Multilateral Trade Agreement.3

2. The Ministerial Conference and the General Council shall have the exclusive authority to adopt interpretations of this Agreement and of the Multilateral Trade Agreements. In the case of an interpretation of a Multilateral Trade Agreement in Annex 1, they shall exercise their authority on the basis of a recommendation by the Council overseeing the functioning of that Agreement. The decision to adopt an interpretation shall be taken by a three-fourths majority of the Members. This paragraph shall not be used in a manner that would undermine the amendment provisions in Article X.

3. In exceptional circumstances, the Ministerial Conference may decide to waive an obligation imposed on a Member by this Agreement or any of the Multilateral Trade Agreements, provided that

1 The body concerned shall be deemed to have decided by consensus on a matter submitted for its consideration, if no Member, present at the meeting when the decision is taken, formally objects to the proposed decision.

2 The number of votes of the European Communities and their member States shall in no case exceed the number of the member States of the European Communities.

3 Decisions by the General Council when convened as the Dispute Settlement Body shall be taken only in accordance with the provisions of paragraph 4 of Article 2 of the Dispute Settlement Understanding.

* United Nations, Treaty Series, vol. 33, p. 261. For the final and revised texts of annexes published subsequently, see vol. 71, p. 318; vol. 79, p. 326; vol. 117, p. 386; vol. 275, p. 298; vol. 314, p. 308; vol. 323, p. 364; vol. 327, p. 326; vol. 371, p. 266; vol. 423, p. 284; vol. 559, p. 348; vol. 645, p. 340; vol. 1057, p. 320 and vol. 1060, p. 337.

Vol. 1867, 1-31874


any such decision shall be taken by three fourths" of the Members unless otherwise provided for in this paragraph.

(a) A request for a waiver concerning this Agreement shall be submitted to the Ministerial Conference for consideration pursuant to the practice of decision-making by consensus. The Ministerial Conference shall establish a time-period, which shall not exceed 90 days, to consider the request. If consensus is not reached during the time-period, any decision to grant a waiver shall be taken by three fourths4 of the Members.

(b) A request for a waiver concerning the Multilateral Trade Agreements in Annexes 1A or IB or 1C and their annexes shall be submitted initially to the Council for Trade in Goods, the Council for Trade in Services or the Council for TRIPS, respectively, for consideration during a time-period which shall not exceed 90 days. At the end of the time-period, the relevant Council shall submit a report to the Ministerial Conference.

4. A decision by the Ministerial Conference granting a waiver shall state the exceptional circumstances justifying the decision, the terms and conditions governing the application of the waiver, and the date on which the waiver shall terminate. Any waiver granted for a period of more than one year shall be reviewed by the Ministerial Conference not later than one year after it is granted, and thereafter annually until the waiver terminates. In each review, the Ministerial Conference shall examine whether the exceptional circumstances justifying the waiver still exist and whether the terms and conditions attached to the waiver have been met. The Ministerial Conference, on the basis of the annual review, may extend, modify or terminate the waiver.

5. Decisions under a Plurilateral Trade Agreement, including any decisions on interpretations and waivers, shall be governed by the provisions of that Agreement.

Article X

Amendments

1. Any Member of the WTO may initiate a proposal to amend the provisions of this Agreement or the Multilateral Trade Agreements in Annex 1 by submitting such proposal to the Ministerial Conference. The Councils listed in paragraph 5 of Article IV may also submit to the Ministerial Conference proposals to amend the provisions of the corresponding Multilateral Trade Agreements in Annex 1 the functioning of which they oversee. Unless the Ministerial Conference decides on a longer period, for a period of 90 days after the proposal has been tabled formally at the Ministerial Conference any decision by the Ministerial Conference to submit the proposed amendment to the Members for acceptance shall be taken by consensus. Unless the provisions of paragraphs 2, 5 or 6 apply, that decision shall specify whether the provisions of paragraphs 3 or 4 shall apply. If consensus is reached, the Ministerial Conference shall forthwith submit the proposed amendment to the Members for acceptance. If consensus is not reached at a meeting of the Ministerial Conference within the established period, the Ministerial Conference shall decide by a two-thirds majority of the Members whether to submit the proposed amendment to the Members for acceptance. Except as provided in paragraphs 2, 5 and 6, the provisions of paragraph 3 shall apply to the proposed amendment, unless the Ministerial Conference decides by a three-fourths majority of the Members that the provisions of paragraph 4 shall apply.

4 A decision to grant a waiver in respect of any obligation subject to a transition period or a period for staged implementation that the requesting Member has not performed by the end of the relevant period shall be taken only by consensus.

Vol. 1867, 1-31874


2. Amendments to the provisions of this Article and to the provisions of the following Articles shall take effect only upon acceptance by all Members:

Article IX of this Agreement; Articles I and II of GATT 1994; Article II: lof GATS; Article 4 of the Agreement on TRIPS.

3. Amendments to provisions of this Agreement, or of the Multilateral Trade Agreements in Annexes 1A and 1C, other than those listed in paragraphs 2 and 6, of a nature that would alter the rights and obligations of the Members, shall take effect for the Members that have accepted them upon acceptance by two thirds of the Members and thereafter for each other Member upon acceptance by it. The Ministerial Conference may decide by a three-fourths majority of the Members that any amendment made effective under this paragraph is of such a nature that any Member which has not accepted it within a period specified by the Ministerial Conference in each case shall be free to withdraw from the WTO or to remain a Member with the consent of the Ministerial Conference.

4. Amendments to provisions of this Agreement or of the Multilateral Trade Agreements in Annexes 1A and 1C, other than those listed in paragraphs 2 and 6, of a nature that would not alter the rights and obligations of the Members, shall take effect for all Members upon acceptance by two thirds of the Members.

5. Except as provided in paragraph 2 above, amendments to Parts I, II and III of GATS and the respective annexes shall take effect for the Members that have accepted them upon acceptance by two thirds of the Members and thereafter for each Member upon acceptance by it. The Ministerial Conference may decide by a three-fourths majority of the Members that any amendment made effective under the preceding provision is of such a nature that any Member which has not accepted it within a period specified by the Ministerial Conference in each case shall be free to withdraw from the WTO or to remain a Member with the consent of the Ministerial Conference. Amendments to Parts IV, V and VI of GATS and the respective annexes shall take effect for all Members upon acceptance by two thirds of the Members.

6. Notwithstanding the other provisions of this Article, amendments to the Agreement on TRIPS meeting the requirements of paragraph 2 of Article 71 thereof may be adopted by the Ministerial Conference without further formal acceptance process.

7. Any Member accepting an amendment to this Agreement or to a Multilateral Trade Agreement in Annex 1 shall deposit an instrument of acceptance with the Director-General of the WTO within the period of acceptance specified by the Ministerial Conference.

8. Any Member of the WTO may initiate a proposal to amend the provisions of the Multilateral Trade Agreements in Annexes 2 and 3 by submitting such proposal to the Ministerial Conference. The decision to approve amendments to the Multilateral Trade Agreement in Annex 2 shall be made by consensus and these amendments shall take effect for all Members upon approval by the Ministerial Conference. Decisions to approve amendments to the Multilateral Trade Agreement in Annex 3 shall take effect for all Members upon approval by the Ministerial Conference.

9. The Ministerial Conference, upon the request of the Members parties to a trade agreement, may decide exclusively by consensus to add that agreement to Annex 4. The Ministerial Conference, upon the request of the Members parties to a Plurilateral Trade Agreement, may decide to delete that Agreement from Annex 4.

10. Amendments to a Plurilateral Trade Agreement shail be governed by the provisions of that Agreement.

Vol. 1867, 1-31874


Anicle XI

Original Membership

1. The contracting parties to GATT 1947 as of the date of entry into force of this Agreement, and the European Communities, which accept this Agreement and the Multilateral Trade Agreements and for which Schedules of Concessions and Commitments are annexed to GATT 1994 and for which Schedules of Specific Commitments are annexed to GATS shall become original Members of the WTO.

2. The least-developed countries recognized as such by the United Nations wiil only be required to undertake commitments and concessions to the extent consistent with their individual development, financial and trade needs or their administrative and institutional capabilities.

Article XII

Accession

1. Any State or separate customs territory possessing full autonomy in the conduct of its external commercial relations and of the other matters provided for in this Agreement and the Multilateral Trade Agreements may accede to this Agreement, on terms to be agreed between it and the WTO. Such accession shall apply to this Agreement and the Multilateral Trade Agreements annexed thereto.

2. Decisions on accession shall be taken by the Ministerial Conference. The Ministerial Conference shall approve the agreement on the terms of accession by a two-thirds majority of the Members of the WTO.

3. Accession to a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement.

Article XIII

Non-Application of Multilateral Trade Agreements between Particular Members

1. This Agreement and the Multilateral Trade Agreements in Annexes 1 and 2 shall not apply as between any Member and any other Member if either of the Members, at the time either becomes a Member, does not consent to such application.

2. Paragraph 1 may be invoked between original Members of the WTO which were contracting parties to GATT 1947 only where Article XXXV of that Agreement had been invoked earlier and was effective as between those contracting parties at the time of entry into force for them of this Agreement.

3. Paragraph 1 shall apply between a Member and another Member which has acceded under Article XII only if the Member not consenting to the application has so notified the Ministerial Conference before the approval of the agreement on the terms of accession by the Ministerial Conference.

4. The Ministerial Conference may review the operation of this Article in particular cases at the request of any Member and make appropriate recommendations.

5. Non-application of a Plurilateral Trade Agreement between parties to that Agreement shall be governed by the provisions of that Agreement.

Vol. 1867, 1-31874


Article XIV

Acceptance, Entry into Force and Deposit

1. This Agreement shall be open for acceptance, by signature or otherwise, by contracting parties to GATT 1947, and the European Communities, which are eligible to become original Members of the WTO in accordance with Article XI of this Agreement. Such acceptance shall apply to this Agreement and the Multilateral Trade Agreements annexed hereto. This Agreement and the Multilateral Trade Agreements annexed hereto shall enter into force on the date determined by Ministers in accordance with paragraph 3 of the Final Act Embodying the Results of the Uruguay Round of Multilateral Trade Negotiations and shall remain open for acceptance for a period of two years following that date unless the Ministers decide otherwise. An acceptance following the entry into force of this Agreement shall enter into force on the 30th day following the date of such acceptance.

2. A Member which accepts this Agreement after its entry into force shall implement those con cessions and obligations in the Multilateral Trade Agreements that are to be implemented over a period of time starting with the entry into force of this Agreement as if it had accepted this Agreement on the date of its entry into force.

3. Until the entry into force of this Agreement, the text of this Agreement and the Multilateral Trade Agreements shall be deposited with the Director-General to the CONTRACTING PARTIES to GATT 1947. The Director-General shall promptly furnish a certified true copy of this-Agreement and the Multilateral Trade Agreements, and a notification of each acceptance thereof, to each government and the European Communities having accepted this Agreement. This Agreement and the Multilateral Trade Agreements, and any amendments thereto, shall, upon the entry into force of this Agreement, be deposited with the Director-General of the WTO.

4. The acceptance and entry into force of a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement. Such Agreements shall be deposited with the Director-General to the CONTRACTING PARTIES to GATT 1947. Upon the entry into force of this Agreement, such Agreements shall be deposited with the Director-General of the WTO.

Article XV

Withdrawal

1. Any Member may withdraw from this Agreement. Such withdrawal shall apply both to this Agreement and the Multilateral Trade Agreements and shall take effect upon the expiration of six months from the date on which written notice of withdrawal is received by the Director-General of the WTO.

2. Withdrawal from a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement.

Article XVI

Miscellaneous Provisions

1. Except as otherwise provided under this Agreement or the Multilateral Trade Agreements, the WTO shall be guided by the decisions, procedures and customary practices followed by the CONTRACTING PARTIES to GATT 1947 and the bodies established in the framework of GATT 1947.

Vol. 1867, 1-31874


2. To the extent practicable, the Secretariat of GATT 1947 shall become the Secretariat of the WTO, and the Director-General to the CONTRACTING PARTIES to GATT 1947, until such time as the Ministerial Conference has appointed a Director-General in accordance with paragraph 2 of Article VI of this Agreement, shall serve as Director-General of the WTO.

3. In the event of a conflict between a provision of this Agreement and a provision of any of the Multilateral Trade Agreements, the provision of this Agreement shall prevail to the extent of the conflict.

4. Each Member shall ensure the conformity of its laws, regulations and administrative procedures with its obligations as provided in the annexed Agreements.

5. No reservations may be made in respect of any provision of this Agreement. Reservations in respect of any of the provisions of the Multilateral Trade Agreements may only be made to the extent provided for in those Agreements. Reservations in respect of a provision of a Plurilateral Trade Agreement shall be governed by the provisions of that Agreement.

6. This Agreement shall be registered in accordance with the provisions of Article 102 of the Charter of the United Nations.

DONE at Marrakesh this fifteenth day of April one thousand nine hundred and ninety-four, in a single copy, in the English, French and Spanish languages, each text being authentic.

[For the signatures, see page 489 of volume 1869. ]

Explanatory Notes:

The terms "country" or "countries" as used in this Agreement and the Multilateral Trade Agreements are to be understood to include any separate customs territory Member of the WTO.

In the case of a separate customs territory Member of the WTO, where an expression in this Agreement and the Multilateral Trade Agreements is qualified by the term "national", such expression shall be read as pertaining to that customs territory, unless otherwise specified.

Vol. 1867, 1-31874


ANNEX 1

ANNEX 1A

MULTILATERAL AGREEMENTS ON TRADE IN GOODS

General interpretative note to Annex 1A:

In the event of conflict between a provision of theGeneral Agreement on Tariffs andTrade 1994 and a provision of another agreement in Annex 1A to the Agreement Establishing the World Trade Organization (referred to in the agreements in Annex 1A as the "WTO Agreement"), the provision of the other agreement shall prevail to the extent of the conflict.

Vol. 1867, 1-31874


GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

1. The General Agreement on Tariffs and Trade 1994 ("GATT 1994") shall consist of:

(a) the provisions in the General Agreement on Tariffs and Trade, dated 30 October 1947, annexed to the Final Act Adopted at the Conclusion of the Second Session of the Preparatory Committee of the United Nations Conference on Trade and Employment (excluding the Protocol of Provisional Application), as rectified, amended or modified by the terms of legal instruments which have entered into force before the date of entry into force of the WTO Agreement;

(b) the provisions of the legal instruments set forth below that have entered into force under the GATT 1947 before the date of entry into force of the WTO Agreement:

(i) protocols and certifications relating to tariff concessions;

(ii) protocols of accession (excluding the provisions (a) concerning provisional application and withdrawal of provisional application and (b) providing that Part II of GATT 1947 shall be applied provisionally to the fullest extent not inconsistent with legislation existing on the date of the Protocol);

(iii) decisions on waivers granted under Article XXV of GATT 1947 and still in force on the date of entry into force of the WTO Agreement1 ;

(iv) other decisions of the CONTRACTING PARTIES to GATT 1947;

(c) the Understandings set forth below:

(i) Understanding on the Interpretation of Article 11:1 (b) of the General Agreement on Tariffs and Trade 1994;

(ii) Understanding on the Interpretation of Article XVII of the General Agreement on Tariffs and Trade 1994;

(iii) Understanding on Balance-of-Payments Provisions of the General Agreement on Tariffs and Trade 1994;

(iv) Understanding on the Interpretation of Article XXIV of the General Agreement on Tariffs and Trade 1994;

(v) Understanding in Respect of Waivers of Obligations under the General Agreement on Tariffs and Trade 1994;

(vi) Understanding on the Interpretation of Article XXVIII of the General Agreement on Tariffs and Trade 1994; and

(d) the Marrakesh Protocol to GATT 1994.

'The waivers covered by this provision are listed in footnote 7 on pages 11 and 12 in Part II of document MTN/FA of 15 December 1993 and in MTN/FA/Corr.6 of 21 March 1994. The Ministerial Conference shall establish at its first session a revised list of waivers covered by this provision that adds any waivers granted under GATT 1947 after 15 December 1993 and before the date of entry into force of the WTO Agreement, and deletes the waivers which will have expired by that time.

Vol. 1867, 1-31874


2. Explanatory Notes

(a) The references to "contracting party" in the provisions of GATT 1994 shall be deemed to read "Member". The references to "less-developed contracting party" and "developed contracting party" shall be deemed to read "developing country Member" and "developed country Member". The references to "Executive Secretary" shall be deemed to read "Director-General of the WTO".

(b) The references to the CONTRACTING PARTIES acting jointly in Articles XV: 1, XV:2, XV:8, XXXVin and the Notes Ad Article XII and XVIII; and in the provisions on special exchange agreements in Articles XV:2, XV:3, XV:6, XV:7 and XV:9 of GATT 1994 shall be deemed to be references to the WTO. The other functions that the provisions of GATT 1994 assign to the CONTRACTING PARTIES acting jointly shall be allocated by the Ministerial Conference.

(c) (i) The text of GATT 1994 shall be authentic in English, French and Spanish.

(ii) The text of GATT 1994 in the French language shall be subject to the rectifications of terms indicated in Annex A to document MTN.TNC/41.

(iii) The authentic text of GATT 1994 in the Spanish language shall be the text in Volume IV of the Basic Instruments and Selected Documents series, subject to the rectifications of terms indicated in Annex B to document MTN.TNC/41.

3. (a) The provisions of Part II of GATT 1994 shall not apply to measures taken by a Member under specific mandatory legislation, enacted by that Member before it became a contracting party to GATT 1947, that prohibits the use, sale or lease of foreign-built or foreign-reconstructed vessels in commercial applications between points in national waters or the waters of an exclusive economic zone. This exemption applies to: (a) the continuation or prompt renewal of a non-conforming provision of such legislation; and (b) the amendment to a non-conforming provision of such legislation to the extent that the amendment does not decrease the conformity of the provision with Part II of GATT 1947. This exemption is limited to measures taken under legislation described above that is notified and specified prior to the date of entry into force of the WTO Agreement. If such legislation is subsequently modified to decrease its conformity with Part II of GATT 1994, it will no longer qualify for coverage under this paragraph.

(b) The Ministerial Conference shall review this exemption not later than five years after the date of entry into force of the WTO Agreement and thereafter every two years for as long as the exemption is in force for the purpose of examining whether the conditions which created the need for the exemption still prevail.

(c) A Member whose measures are covered by this exemption shall annually submit a detailed statistical notification consisting of a five-year moving average of actual and expected deliveries of relevant vessels as well as additional information on the use, sale, lease or repair of relevant vessels covered by this exemption.

(d) A Member that considers that this exemption operates in such a manner as to justify a reciprocal and proportionate limitation on the use, sale, lease or repair of vessels constructed in the territory of the Member invoking the exemption shall be free to introduce such a limitation subject to prior notification to the Ministerial Conference.

(e) This exemption is without prejudice to solutions concerning specific aspects of the legislation covered by this exemption negotiated in sectoral agreements or in other fora.

Vol. 1867, 1-31874


UNDERSTANDING ON THE INTERPRETATION OF ARTICLE II:l(b) OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

Members hereby agree as follows:

1. In order to ensure transparency of the legal rights and obligations deriving from paragraph 1 (b) of Article II, the nature and level of any "other duties or charges" levied on bound tariff items, as referred to in that provision, shall be recorded in the Schedules of concessions annexed to GATT 1994 against the tariff item to which they apply. It is understood that such recording does not change the legal character of "other duties or charges".

2. The date as of which "other duties or charges" are bound, for the purposes of Article II, shall be 15 April 1994. "Other duties or charges" shall therefore be recorded in the Schedules at the levels applying on this date. At each subsequent renegotiation of a concession or negotiation of a new concession the applicable date for the tariff item in question shall become the date of the incorporation of the new concession in the appropriate Schedule. However, the date of the instrument by which a concession on any particular tariff item was first incorporated into GATT 1947 or GATT 1994 shall also continue to be recorded in column 6 of the Loose-Leaf Schedules.

3. "Other duties or charges" shall be recorded in respect of all tariff bindings.

4. Where a tariff item has previously been the subject of a concession, the level of "other duties or charges" recorded in the appropriate Schedule shall not be higher than the level obtaining at the time of the first incorporation of the concession in that Schedule. It will be open to any Member to challenge the existence of an "other duty or charge", on the ground that no such "other duty or charge" existed at the time of the original binding of the item in question, as well as the consistency of the recorded level of any "other duty or charge" with the previously bound level, for a period of three years after the date of entry into force of the WTO Agreement or three years after the date of deposit with the Director-General of the WTO of the instrument incorporating the Schedule in question into GATT 1994, if that is a later date.

5. The recording of "other duties or charges" in the Schedules is without prejudice to their consistency with rights and obligations under GATT 1994 other than those affected by paragraph 4. All Members retain the right to challenge, at any time, the consistency of any "other duty or charge" with such obligations.

6. For the purposes of this Understanding, the provisions of Articles XXII and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding shall apply.

7. "Other duties or charges" omitted from a Schedule at the time of deposit of the instrument incorporating the Schedule in question into GATT 1994 with, until the date of entry into force of the WTO Agreement, the Director-General to the CONTRACTING PARTIES to GATT 1947 or, thereafter, with the Director-General of the WTO, shall not subsequently be added to it and any "other duty or charge" recorded at a level lower than that prevailing on the applicable date shall not be restored to that level unless such additions or changes are made within six months of the date of deposit of the instrument.

8. The decision in paragraph 2 regarding the date applicable to each concession for the purposes of paragraph l(b) of Article II of GATT 1994 supersedes the decision regarding the applicable date taken on 26 March 1980 (BISD 27S/24).

Vol. 1867, 1-31874


UNDERSTANDING ON THE INTERPRETATION OF ARTICLE XVII OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

Members,

Noting that Article XVII provides for obligations on Members in respect of the activities of the state trading enterprises referred to in paragraph 1 of Article XVII, which are required to be consistent with the general principles of non-discriminatory treatment prescribed in GATT 1994 for governmental measures affecting imports or exports by private traders;

Noting further that Members are subject to their GATT 1994 obligations in respect of those governmental measures affecting state trading enterprises;

Recognizing that this Understanding is without prejudice to the substantive disciplines prescribed in Article XVII;

Hereby agree as follows:

1. In order to ensure the transparency of the activities of state trading enterprises, Members shall notify such enterprises to the Council for Trade in Goods, for review by the working party to be set up under paragraph 5, in accordance with the following working definition:

"Governmental and non-governmental enterprises, including marketing boards, which have been granted exclusive or special rights or privileges, including statutory or constitutional powers, in the exercise of which they influence through their purchases or sales the level or direction of imports or exports. "

This notification requirement does not apply to imports of products for immediate or ultimate consumption in governmental use or in use by an enterprise as specified above and not otherwise for resale or use in the production of goods for sale.

2. Each Member shall conduct a review of its policy with regard to the submission of notifications on state trading enterprises to the Council for Trade in Goods, taking account of the provisions of this Understanding. In carrying out such a review, each Member should have regard to die need to ensure the maximum transparency possible in its notifications so as to permit a clear appreciation of the manner of operation of the enterprises notified and the effect of their operations on international trade.

3. Notifications shall be made in accordance with the questionnaire on state trading adopted on 24 May 1960(BISD 9S/184-185), it being understood that Members shall notify the enterprises referred to in paragraph 1 whether or not imports or exports have in fact taken place.

4. Any Member which has reason to believe that another Member has not adequately met its notification obligation may raise the matter with the Member concerned. If the matter is not satisfactorily resolved it may make a counter-notification to the Council for Trade in Goods, for consideration by the working party set up under paragraph 5, simultaneously informing the Member concerned.

5. A working party shall be set up, on behalf of the Council for Trade in Goods, to review notifications and counter-notifications. In the light of this review and withoutprejudice to paragraph 4(c) of Article XVII, the Council for Trade in Goods may make recommendations with regard to the adequacy of notifications and the need for further information. The working party shall also review, in the light of the notifications received, the adequacy of the above-mentioned questionnaire on state trading and the coverage of state trading enterprises notified under paragraph 1. It shall also develop an illustrative list showing the kinds of relationships between governments and enterprises, and the kinds of activities,

Vol. 1867, 1-31874


engaged inbytheseenterprises, which may berelevantforthepurposes of Article XVII. It is understood that the Secretariat will provide a general background paper for the working party on the operations of state trading enterprises as they relate to international trade. Membership of the working party shall be open to all Members indicating their wish to serve on it. It shall meet within a year of the date of entry into force of the WTO Agreement and thereafter at least once a year. It shall report annually to the Council for Trade in Goods. 1

'The activities of this working party shall be coordinated with those of the working group provided for in Section III of the Ministerial Decision on Notification Procedures adopted on IS April 1994.

Vol. 1867, 1-31874


UNDERSTANDING ON THE BALANCE-OF-PAYMENTS PROVISIONS OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

Members,

Recognizing the provisions of Articles XII and XVIII :B of GATT 1994 and of the Declaration on Trade Measures Taken for Balance-of-Payments Purposes adopted on 28 November 1979 (BISD 26S/205-209, referred to in this Understanding as the " 1979 Declaration " ) and in order to clarify such provisions1 ;


Application of Measures

1. Members confirm their commitment to announce publicly, as soon as possible, time-schedules for the removal of restrictive import measures taken for balance-of-payments purposes. It is understood that such time-schedules may be modified as appropriate to take into account changes in the balance-of- payments situation. Whenever a time-schedule is not publicly announced by a Member, that Member shall provide justification as to the reasons therefor.

2. Members confirm their commitment to give preference to those measures which have the least disruptive effect on trade. Such measures (referred to in this Understanding as "price-based measures") shall be understood to include import surcharges, import deposit requirements or other equivalent trade measures with an impact on the price of imported goods. It is understood that, notwithstanding the provisions of Article II, price-based measures taken for balance-of-payments purposes may be applied by a Member in excess of the duties inscribed in the Schedule of that Member. Furthermore, that Member shall indicate the amount by which the price-based measure exceeds the bound duty clearly and separately under the notification procedures of this Understanding.

3. Members shall seek to avoid the imposition of new quantitative restrictions for balance-of- payments purposes unless, because of a critical balance-of-payments situation, price-based measures cannot arrest a sharp deterioration in the external payments position. In diose cases in which a Member applies quantitative restrictions, it shall provide justification as to the reasons why price-based measures are not an adequate instrument to deal with the balance-of-payments situation. A Member maintaining quantitative restrictions shall indicate in successive consultations the progress made in significantly reducing the incidence and restrictive effect of such measures. It is understood that not more than one type of restrictive import measure taken for balance-of-payments purposes may be applied on the same product.

4. Members confirm that restrictive import measures taken for balance-of-payments purposes may only be applied to control the general level of imports and may not exceed what is necessary to address the balance-of-payments situation. In order to minimize any incidental protective effects, a Member shall administer restrictions in a transparent manner. The authorities of the importing Member shall provide adequate justification as to the criteria used to determine which products are subject to restriction. As provided in paragraph 3 of Article XII and paragraph 10 of Article XVIII, Members may, in the

'Nothing in this Understanding is intended to modify the rights and obligations of Members under Articles XII or XVIII: B ofGATT 1994. The provisions of Articles XXII and XXIII of GATT 1994aselaboratedandappliedbytheDisputeSettlement Understanding may be invoked with respect to any matters arising from the application of restrictive import measures taken for balance-of-payments purposes.

Vol. 1867, 1-31874


case of certain essential products, exclude or limit the application of surcharges applied across the board or other measures applied for balance-of-payments purposes. The term "essential products" shall be understood to mean products which meet basic consumption needs or which contribute to the Member's effort to improve its balance-of-payments situation, such as capital goods or inputs needed for production. In the administration of quantitative restrictions, a Member shall use discretionary licensing only when unavoidable and shall phase it out progressively. Appropriate justification shall be provided as to the criteria used to determine allowable import quantities or values.

Procedures for Bcdance-of-Payments Consultations

5. The Committee on Balance-of-Payments Restrictions (referred to in this Understanding as the "Committee") shall carry out consultations in order to review all restrictive import measures taken for balance-of-payments purposes. Themembership of the Committee is open to all Members indicating their wish to serve on it. The Committee shall follow the procedures for consultations on balance-of- payments restrictions approved on 28 April 1970 (BISD 18S/48-53, referred to in this Understanding as "full consultation procedures"), subject to the provisions set out below.

6. A Member applying new restrictions or raising the general level of its existing restrictions by a substantial intensification of the measures shall enter into consultations with the Committee within four months of the adoption of such measures. The Member adopting such measures may request that a consultation be held under paragraph 4(a) of Article XII or paragraph 12(a) of Article XVIIÏ as appropriate. If no such request has been made, the Chairman of the Committee shall invite the Member to hold such a consultation. Factors that may be examined in the consultation would include, inter alia, the introduction of new types of restrictive measures for balance-of-payments purposes, or an increase in the level or product coverage of restrictions.

7. All restrictions applied for balance-of-payments purposes shall be subject to periodic review in the Committee under paragraph 4(b) of Article XII or under paragraph 12(b) of Article XVIII, subject to the possibility of altering the periodicity of consultations in agreement with the consulting Member or pursuant to any specific review procedure that may be recommended by the General Council.

8. Consultations may be held under the simplified procedures approved on 19 December 1972 (BISD 20S/47-49, referred to in this Understanding as "simplified consultation procedures") in the case of least-developed country Members or in the case of developing country Members which are pursuing liberalization efforts in conformity with the schedule presented to the Committee in previous consultations. Simplified consultation procedures may also be used when the Trade Policy Review of a developing country Member is scheduled for the same calendar year as the date fixed for the consultations. In such cases the decision as to whether full consultation procedures should be used will be made on the basis of the factors enumerated in paragraph 8 of the 1979 Declaration. Except in the case of least-developed country Members, no more than two successive consultations may be held under simplified consultation procedures.

Notification and Documentation

9. A Member shall notify to the General Council the introduction of or any changes in the application of restrictive import measures taken for balance-of-payments purposes, as well as any modifications in time-schedules for the removal of such measures as announced under paragraph 1. Significant changes shall be notified to the General Council prior to or not later than 30 days after their announcement. On a yearly basis, each Member shall make available to the Secretariat a consolidated notification, including all changes in laws, regulations, policy statements or public notices, for examination by Members. Notifications shall include full information, as far as possible, at the tariff-line level, on the type of measures applied, the criteria used for their administration, product coverage and trade flows affected.

Vol. 1867, 1-31874


10. At the request of any Member, notifications may be reviewed by the Committee. Such reviews would be limited to the clarification of specific issues raised by a notification or examination of whether a consultation under paragraph 4(a) of Article XII or paragraph 12(a) of Article XVIII is required. Members which have reasons to believe that a restrictive import measure applied by another Member was taken for balance-of-payments purposes may bring the matter to the attention of the Committee. The Chairman of the Committee shall request information on the measure and make it available to all Members. Without prejudice to the right of any member of the Committee to seek appropriate clarifications in the course of consultations, questions may be submitted in advance for consideration by the consulting Member.

11. The consulting Member shall prepare a Basic Document for the consultations which, in addition to any other information considered to be relevant, should include: (a) an overview of the balance-of- payments situation and prospects, including a consideration of the internal and external factors having a bearing on the balance-of-payments situation and the domestic policy measures taken in order to restore equilibrium on a sound and lasting basis; (b) a full description of the restrictions applied for balance-of- payments purposes, their legal basis and steps taken to reduce incidental protective effects; (c) measures taken since the last consultation to liberalize import restrictions, in the light of the conclusions of the Committee; (d) a plan for the elimination and progressive relaxation of remaining restrictions. References may be made, when relevant, to the information provided in other notifications or reports made to the WTO. Under simplified consultation procedures, the consulting Member shall submit a written statement containing essential information on the elements covered by the Basic Document.

12. The Secretariat shall, with a view to facilitating the consultations in the Committee, prepare a factual background paper dealing with the different aspects of the plan for consultations. In the case of developing country Members, the Secretariat document shall include relevant background and analytical material on the incidence of the external trading environment on the balance-of-payments situation and prospects of the consulting Member. The technical assistance services of the Secretariat shall, at the request of a developing country Member, assist in preparing the documentation for the consultations.

Conclusions of Balance-of-Payments Consultations

13. The Committee shall report on its consultations to the General Council. When full consultation procedures have been used, the report should indicate the Committee's conclusions on the different elements of the plan for consultations, as well as the facts and reasons on which they are based. The Committee shall endeavour to include in its conclusions proposals for recommendations aimed at promoting the implementation of Articles Xn and XVULB, the 1979 Declaration and this Understanding. In those cases in which a time-schedule has been presented for the removal of restrictive measures taken for balance-of-payments purposes, the General Council may recommend that, in adhering to such a time-schedule, a Member shall be deemed to be in compliance with its GATT 1994 obligations. Whenever the General Council has made specific recommendations, the rights and obligations of Members shall be assessed in the light of such recommendations. In the absence of specific proposals for recommendations by the General Council, the Committee's conclusions should record the different views expressed in the Committee. When simplified consultation procedures have been used, the report shall include a summary of the main elements discussed in the Committee and a decision on whether full consultation procedures are required.

Vol. 1867, 1-31874


UNDERSTANDING ON THE INTERPRETATION OF ARTICLE XXIV OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

Members,

Having regard to the provisions of Article XXIV of GATT 1994;

Recognizing that customs unions and free trade areas have greatly increased in number and importance since the establishment of GATT 1947 and today cover a significant proportion of world trade;

Recognizing the contribution to the expansion of world trade that may be made by closer integration between the economies of the parties to such agreements;

Recognizing also that such contribution is increased if the elimination between the constituent territories of duties and other restrictive regulations of commerce extends to all trade, and diminished if any major sector of trade is excluded;

Reaffirming that the purpose of such agreements should be to facilitate trade between the constituent territories and not to raise barriers to the trade of other Members with such territories; and that in their formation or enlargement the parties to them should to the greatest possible extent avoid creating adverse effects on the trade of other Members;

Convinced also of the need to reinforce the effectiveness of the role of the Council for Trade in Goods in reviewing agreements notified under Article XXIV, by clarifying the criteria and procedures for the assessment of new or enlarged agreements, and improving the transparency of all Article XXIV agreements;

Recognizing the need for a common understanding of the obligations of Members under paragraph 12 of Article XXIV;


1. Customs unions, free-trade areas, and interim agreements leading to the formation of a customs union or free-trade area, to be consistent with Article XXIV, must satisfy, inter alia, the provisions of paragraphs 5, 6, 7 and 8 of that Article.

Article XXIV.-5

2. The evaluation under paragraph 5(a) of Article XXIV of the general incidence of the duties and other regulations of commerce applicable before and after the formation of a customs union shall in respect of duties and charges be based upon an overall assessment of weighted average tariff rates and of customs duties collected. This assessment shall be based on import statistics for a previous representative period to be supplied by the customs union, on a tariff-line basis and in values and quantities, broken down by WTO country of origin. The Secretariat shall compute the weighted average tariff rates and customs duties collected in accordance with the methodology used in the assessment of tariff offers in the Uruguay Round of Multilateral Trade Negotiations. For this purpose, the duties and charges to be taken into consideration shall be the applied rates of duty. It is recognized that for the purpose of the overall assessment of the incidence of other regulations of commerce for which quantification and aggregation are difficult, the examination of individual measures, regulations, products covered and trade flows affected may be required.

Vol. 1867, 1-31874


3. The "reasonable length of time" referred to in paragraph 5(c) of Article XXIV should exceed 10 years only in exceptional cases. In cases where Members parties to an interim agreement believe that 10 years would be insufficient they shall provide a full explanation to the Council for Trade in Goods of the need for a longer period.

Article XXIV:6

4. Paragraph 6 of Article XXIV establishes the procedure to be followed when a Member forming a customs union proposes to increase a bound rate of duty. In this regard Members reaffirm that the procedure set forth in Article XXVIII, as elaborated in the guidelines adopted on 10 November 1980 (BISD 27S/26-28) and in the Understanding on the Interpretation of Article XXVIII of GATT 1994, must be commenced before tariff concessions are modified or withdrawn upon the formation of a customs union or an interim agreement leading to the formation of a customs union.

5. These negotiations will be entered into in good faith with a view to achieving mutually satisfactory compensatory adjustment. In such negotiations, as required by paragraph 6 of Article XXIV, due account shall be taken of reductions of duties on the same tariff line made by other constituents of the customs union upon its formation. Should such reductions not be sufficient to provide the necessary compensatory adjustment, the customs union would offer compensation, which may take the form of reductions of duties on other tariff lines. Such an offer shall be taken into consideration by the Members having negotiating rights in the binding being modified or withdrawn. Should the compensatory adjustment remain unacceptable, negotiations should be continued. Where, despite such efforts, agreement in negotiations on compensatory adjustment under Article XXVIII as elaborated by the Understanding on the Interpretation of Article XXVIII of GATT 1994 cannot be reached within a reasonable period from the initiation of negotiations, the customs union shall, nevertheless, be free to modify or withdraw the concessions; affected Members shall then be free to withdraw substantially equivalent concessions in accordance with Article XXVIII.

6. GATT 1994 imposes no obligation on Members benefiting from a reduction of duties consequent upon the formation of a customs union, or an interim agreement leading to the formation of a customs union, to provide compensatory adjustment to its constituents.

Review of Customs Unions and Free-Trade Areas

7. All notifications made under paragraph 7(a) of Article XXIV shall be examined by a working party in the light of the relevant provisions of GATT 1994 and of paragraph 1 of this Understanding. The working party shall submit a report to the Council for Trade in Goods on its findings in this regard. The Council for Trade in Goods may make such recommendations to Members as it deems appropriate.

8. In regard to interim agreements, the working party may in its report make appropriate recommendations on the proposed time-frame and on measures required to complete the formation of the customs union or free-trade area. It may if necessary provide for further review of the agreement.

9. Members parties to an interim agreement shall notify substantial changes in the plan and schedule included in that agreement to the Council for Trade in Goods and, if so requested, the Council shall examine the changes.

10. Should an interim agreement notified under paragraph 7(a) of Article XXIV not include a plan and schedule, contrary to paragraph 5(c) of Article XXIV, the working party shall in its report recommend such a plan and schedule. The parties shall not maintain or put into force, as the case may be, such agreement if they are not prepared to modify it in accordance with these recommendations. Provision shall be made for subsequent review of the implementation of the recommendations.

Vol. 1867, 1-31874


11. Customs unions and constituents of free-trade areas shall report periodically to the Council for Trade in Goods, as envisaged by the CONTRACTING PARTIES to GATT 1947 in their instruction to the GATT 1947 Council concerning reports on regional agreements (BISD 18S/38), on the operation of the relevant agreement. Any significant changes and/or developments in the agreements should be reported as they occur.

Dispute Settlement

12. The provisions of Articles XXII and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding may be invoked with respect to any matters arising from the application of those provisions of Article XXIV relating to customs unions, free-trade areas or interim agreements leading to the formation of a customs union or free-trade area.

Article XXIV:12

13. Each Member is fully responsible under GATT 1994 for the observance of all provisions of GATT 1994, and shall take such reasonable measures as may be available to it to ensure such observance by regional and local governments and authorities within its territory.

14. The provisions of Articles XXII and XXIH of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding may be invoked in respect of measures affecting its observance taken by regional or local governments or authorities within the territory of a Member. When the Dispute Settlement Body has ruled that a provision of GATT 1994 has not been observed, the responsible Member shall take such reasonable measures as may be available to it to ensure its observance. The provisions relating to compensation and suspension of concessions or other obligations apply in cases where it has not been possible to secure such observance.

15. Each Member undertakes to accord sympathetic consideration to and afford adequate opportunity for consultation regarding any representations made by another Member concerning measures affecting the operation of GATT 1994 taken within the territory of the former.

Vol. 1867, 1-31874


UNDERSTANDING IN RESPECT OF WAIVERS OF OBLIGATIONS UNDER THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994


1. A request for a waiver or for an extension of an existing waiver shall describe the measures which the Member proposes to take, the specific policy objectives which the Member seeks to pursue and the reasons which prevent the Member from achieving its policy objectives by measures consistent with its obligations under GATT 1994.

2. Any waiver in effect on the date of entry into force of the WTO Agreement shall terminate, unless extended in accordance with the procedures above and those of Article IX of the WTO Agreement, on the date of its expiry or two years from the date of entry into force of the WTO Agreement, whichever is earlier.

3. Any Member considering that a benefit accruing to it under GATT 1994 is being nullified or impaired as a result of:

(a) the failure of the Member to whom a waiver was granted to observe the terms or conditions of the waiver, or

(b) the application of a measure consistent with the terms and conditions of the waiver

may invoke the provisions of Article XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding.

Vol. 1867, 1-31874


UNDERSTANDING ON THE INTERPRETATION OF ARTICLE XXVIII OF THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994


1. For the purposes of modification or withdrawal of a concession, the Member which has the highest ratio of exports affected by the concession (i.e. exports of the product to the market of the Member modifying or withdrawing the concession) to its total exports shall be deemed to have a principal supplying interest if it does not already have an initial negotiating right or a principal supplying interest as provided for in paragraph 1 of Article XXVIII. It is however agreed that this paragraph will be reviewed by the Council for Trade in Goods five years from the date of entry into force of the WTO Agreement with a view to deciding whether this criterion has worked satisfactorily in securing a redistribution of negotiating rights in favour of small and medium-sized exporting Members. If this is not the case, consideration will be given to possible improvements, including, in the light of the availability of adequate data, the adoption of a criterion based on the ratio of exports affected by the concession to exports to all markets of the product in question.

2. Where a Member considers that it has a principal supplying interest in terms of paragraph 1, it should communicate its claim in writing, with supporting evidence, to the Member proposing to modify or withdraw a concession, and at the same time inform the Secretariat. Paragraph 4 of the "Procedures for Negotiations under Article XXVHI" adopted on 10 November 1980 (BISD 27S/26-28) shall apply in these cases.

3. In the determination of which Members have a principal supplying interest (whether as provided for in paragraph 1 above or in paragraph 1 of Article XXVIII) or substantial interest, only trade in the affected product which has taken place on an MFN basis shall be taken into consideration. However, trade in the affected product which has taken place under non-contractual preferences shall also be taken into account if the trade in question has ceased to benefit from such preferential treatment, thus becoming MFN trade, at the time of the negotiation for the modification or withdrawal of the concession, or will do so by the conclusion of that negotiation.

4. When a tariff concession is modified or withdrawn on a new product (i.e. a product for which three years' trade statistics are not available) the Member possessing initial negotiating rights on the tariff line where the product is or was formerly classified shall be deemed to have an initial negotiating right in the concession in question. The determination of principal supplying and substantial interests and the calculation of compensation shall take into account, inter alia, production capacity and investment in the affected product in the exporting Member and estimates of export growth, as well as forecasts of demand for the product in the importing Member. For the purposes of this paragraph, "new product" is understood to include a tariff item created by means of a breakout from an existing tariff line.

5. Where a Member considers that it has a principal supplying or a substantial interest in terms of paragraph 4, it should communicate its claim in writing, with supporting evidence, to the Member proposing to modify or withdraw a concession, and at the same time inform the Secretariat. Paragraph 4 of the above-mentioned "Procedures for Negotiations under Article XXVIII" shall apply in these cases.

6. When an unlimited tariff concession is replaced by a tariff rate quota, the amount of compensation provided should exceed the amount of the trade actually affected by the modification of the concession. The basis for the calculation of compensation should be the amount by which future trade prospects exceed the level of the quota. It is understood that the calculation of future trade prospects should be based on the greater of:

Vol. 1867, 1-31874


(a) the average annual trade in the most recent representative three-year period, increased by the average annual growth rate of imports in that same period, or by 10 per cent, whichever is the greater; or

(b) trade in the most recent year increased by 10 per cent.

In no case shall a Member's liability for compensation exceed that which would be entailed by complete withdrawal of the concession.

7. Any Member having a principal supplying interest, whether as provided for in paragraph 1 above or in paragraph 1 of Article XXVIII, in a concession which is modified or withdrawn shall be accorded an initial negotiating right in the compensatory concessions, unless another form of compensation is agreed by the Members concerned.

Vol. 1867, 1-31874


MARRAKESH PROTOCOL TO THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

Members,

Having carried out negotiations within the framework of GATT 1947, pursuant to the Ministerial Declaration on the Uruguay Round,


1. The schedule annexed to this Protocol relating to a Member shall become a Schedule to GATT 1994 relating to that Member on the day on which the WTO Agreement enters into force for that Member. Any schedule submitted in accordance with the Ministerial Decision on measures in favour of least-developed countries shall be deemed to be annexed to this Protocol.

2. The tariff reductions agreed upon by each Member shall be implemented in five equal rate reductions, except as may be otherwise specified in a Member's Schedule. The first such reduction shall be made effective on the date of entry into force of the WTO Agreement, each successive reduction shall be made effective on 1 January of each of the following years, and the final rate shall become effective no later than the date four years after the date of entry into force of the WTO Agreement, except as may be otherwise specified in that Member's Schedule. Unless otherwise specified in its Schedule, a Member that accepts the WTO Agreement after its entry into force shall, on the date that Agreement enters into force for it, make effective all rate reductions that have already taken place together with the reductions which it would under the preceding sentence have been obligated to make effective on 1 January of the year following, and shall make effective all remaining rate reductions on the schedule specified in the previous sentence. The reduced rate should in each stage be rounded off to the first decimal. For agricultural products, as defined in Article 2 of the Agreement on Agriculture, the staging of reductions shall be implemented as specified in the relevant parts of the schedules.

3. The implementation of the concessions and commitments contained in the schedules annexed to this Protocol shall, upon request, be subject to multilateral examination by the Members. This would be without prejudice to the rights and obligations of Members under Agreements in Annex 1A of the WTO Agreement.

4. After the schedule annexed to this Protocol relating to a Member has become a Schedule to GATT 1994 pursuant to the provisions of paragraph 1, such Member shall be free at any time to withhold or to withdraw in whole or in part the concession in such Schedule with respect to any product for which the principal supplier is any other Uruguay Round participant the schedule of which has not yet become a Schedule to GATT 1994. Such action can, however, only be taken after written notice of any such withholding or withdrawal of a concession has been given to die Council for Trade in Goods and after consultations have been held, upon request, with any Member, the relevant schedule relating to which has become a Schedule to GATT 1994 and which has a substantial interest in the product involved. Any concessions so withheld or withdrawn shall be applied on and after the day on which the schedule of the Member which has the principal supplying interest becomes a Schedule to GATT 1994.

5. (a) Without prejudice to the provisions of paragraph 2 of Article 4 of the Agreement on Agriculture, for the purpose of the reference in paragraphs 1 :(b) and 1 (c) of Article II of GATT 1994 to the date of that Agreement, the applicable date in respect of each product which is the subject of a concession provided for in a schedule of concessions annexed to this Protocol shall be the date of this Protocol.

Vol. 1867, 1-31874


(b) For the purpose of the reference in paragraph 6(a) of Article II of GATT 1994 to the date of that Agreement, the applicable date in respect of a schedule of concessions annexed to this Protocol shall be the date of this Protocol.

6. In cases of modification or withdrawal of concessions relating to non-tariff measures as contained in Part III of the schedules, the provisions of Article XXVffl of GATT 1994 and the "Procedures for Negotiations under Article XXVIII" adopted on 10 November 1980 (BISD 27S/26-28) shall apply. This would be without prejudice to the rights and obligations of Members under GATT 1994.

7. In each case in which a schedule annexed to this Protocol results for any product in treatment less favourable than was provided for such product in the Schedules of GATT 1947 prior to the entry into force of the WTO Agreement, the Member to whom the schedule relates shall be deemed to have taken appropriate action as would have been otherwise necessary under the relevant provisions of Article XXVIII of GATT 1947 or 1994. The provisions of this paragraph shall apply only to Egypt, Peru, South Africa and Uruguay.

8. The Schedules annexed hereto are authentic in the English, French or Spanish language as specified in each Schedule.

9. The date of this Protocol is 15 April 1994.

Vol. 1867, 1-31874


MARRAKESH PROTOCOL TO THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994

SCHEDULES

PROTOCOLE DE MARRAKECH ANNEXE A L'ACCORD GENERAL SUR LES TARIFS DOUANIERS ET LE COMMERCE DE 1994

LISTES

PROTOCOLO DE MARRAKECH ANEXO AL ACUERDO GENERAL SOBRE ARANCELES ADUANEROS Y COMERCIO DE 1994

LISTAS

Vol. 1867, 1-31874


SCHEDULES/LISTES/LISTAS l

Vol. 2

Vol. 3 (a + b)

Vol. 4

Vol. 5

Vol. 6

Vol. 7

Vol. 8 (a + b)

Vol. 9

Vol. 10

Vol. 11

Vol. 12

Vol. 13

IIIIIV

V

VIVIIVill

IXXII -XIII

XIVXV

XVIII

XX

XXIXXIIIxxrvXXIXXXX

XXXIXXXIIXXXV -XXXVII -

XXXVIII -

XXXIX -XLII

XLIIIXLVII -XLIXLILULFVLIX

AUSTRALIABRAZILMYANMAR

CANADA

SRI LANKACHILECHINA

CUBAINDLANEW ZEALAND

NORWAYPAKISTAN

SOUTH AFRICA

UNITED STATES

INDONESIADOMINICAN REPUBLICFINLANDNICARAGUASWEDEN

URUGUAYAUSTRIAPERUTURKEY

JAPAN

MALAYSIAISRAEL

NIGERIAGABONSENEGALMADAGASCARCÔTE D'IVOIREZIMBABWESWITZERLAND-LIECHTENSTEIN

1 For the schedules, see World Trade Organization publication VI-1994-600, volumes 2 to 26 — Pour les listes, voir la publication de l'Organisation mondiale du commerce VI-1994-600, volumes 2 à 26.

Vol. 1867, 1-31874


Vol. 14

Vol. 15

LX

LXII LXHILxrv

KOREA

ICELANDEGYPTARGENTINA

Vol. 16 LXV LXVI LXVII LXIX

POLANDJAMAICATRINIDAD AND TOBAGOROMANIA

Vol. 17 LXX1LxxmLXXIV LXXV

HUNGARY SINGAPORE SURINAME PHILIPPINES 2

Vol. 18

Vol. 19

Vol. 20

Vol. 21

Vol. 22

LXXVI - COLOMBIALXXVII - MEXICOLXXVIII - ZAMBIALXXIX - THAILAND

LXXX - EUROPEAN COMMUNITIES

LXXXI - MOROCCOLXXXII - HONG KONGLXXXIII - TUNISIALXXXIV - BOLIVIALXXXV - COSTARICALXXXVI - VENEZUELALXXXVII - EL SALVADORLXXXVIII GUATEMALALXXXIX - MACAU

XC - NAMIBIA

XCI - PARAGUAYXCII - CZECH REPUBLIC

Vol. 23 XCIIIxcvXCVII XCVIIIxcrv c

SLOVAK REPUBLICHONDURASANTIGUA AND BARBUDABAHRAINBARBADOSBELIZE

2 With procès-verbal of rectification of 30 November 1994 (GLI/303) — Avec procès-verbal de rectification du 30 novembre 1994 (GLI/303).

Vol. 1867, 1-31874


Vol. 24 CilcmCVIICVIIICIXCXICXII -CXIIICXIVCXVIICXVIII -CXXICXXII

BRUNEI DARUSSALAMCAMEROONCYPRUSDOMINICAFIJIGHANAGUYANAKENYAKUWAITMALTAMAURITIUSST. LUCIAST. VINCENT AND THE GRENADINES

Vol. 25

Vol. 26

CXXIII

XLVIIILLUILXXCVIcxxrv cxxvi

SWAZILAND

BENINMAURITANIANIGERBANGLADESHCONGOTANZANIAUGANDA

Vol. 1867, 1-31874


TRADE IN PHARMACEUTICAL PRODUCTS

The following communication concerning trade in phannaceutical products has been received from the delegations listed below:

RECORD OF DISCUSSION

In the course of the Uruguay Round negotiations, representatives of the following governments discussed the treatment of pharmaceutical products and came to the following conclusions:

AustraliaAustriaCanadaCzech RepublicEuropean CommunitiesFinlandJapanNorwaySlovak RepublicSwedenSwitzerlandUnited States

Each government will eliminate customs duties on pharmaceutical products, as defined below, recognizing the objective of tariff elimination should not be frustrated by trade restrictive or trade distorting measures. Other governments are encouraged to do the same.

1. With respect to pharmaceutical products (as defined below), they will eliminate customs duties and all other duties and charges, as defined within the meaning of Article II. 1 (b) of the General Agreement on Tariffs and Trade (1994), on ALL items in the following categories:

(i) items classified (or classifiable) in Harmonized System Chapter 30;

(ii) items classified (or classifiable) in HS headings 2936, 2937, 2939, and 2941, with the exception of dihydrostreptomycin and salts, esters, and hydrates thereof;

(iii)* pharmaceutical active ingredients as designated in Annex I and that bear an "international non-proprietary name," (INN) from the World Health Organization;

(iv) salts, esters, and hydrates of pharmaceutical products which are described by the combination of an INN active ingredient contained in Annex I with a prefix or suffix as designated in Annex II to this record, as long as such salt, ester, or hydrate is classified in the same HS 6-digit heading as the INN active ingredient;

Vol. 1867, 1-31874


(v) salts, esters, and hydrates of INN active ingredients that are separately contained in Annex III to this record and that are not classified in the same HS 6-digit heading as the INN active ingredient;

(vi) additional products used for theproduction and manufacture of finished pharmaceuticals as designated in Annex IV to this record.

In addition, to ensure transparency, each government will incorporate these measures into that government's schedule to the General Agreement on Tariffs and Trade (1994), and, in addition, at either its national tariff line level or the Harmonized System 6-digit level in either its national tariff or any other published versions of the tariff schedule, whichever is ordinarily used by importers and exporters.

Each government will fully implement the duty elimination on the date of entry into force of the World Trade Organization (WTO) agreement, for that government.

In incorporating the results described above, duty elimination can be achieved either by creating sub-headings at the national tariff line level, or attaching an Annex to the national tariff listing all products concerned or by a combination of the above methods, whereby duty-free treatment is provided for at national tariff line level for certain products.

In cases where it is not possible to designate an entire national tariff line for duty-free treatment, EACH GOVERNMENT will list the pharmaceutical products covered in an Annex to its national tariff, with a full concordance to the products listed in Annexes I, III, and IV at either the national tariff line level or the Harmonized System 6-digit level. Where some or all of the products are incorporated in such an Annex, each government will include appropriate footnotes (or other means of cross- referencing at the national tariffline level or the Harmonized System 6-digit level) either in the national tariff or in any other published version of the national tariff to indicate that bound duty-free treatment is provided for the products listed in the Annex.

2. In implementing these measures, each government's national customs authorities may require importers to provide one or more of the following types of information to certify that the imported chemical is included in this record:

(i) Harmonized System 6-digit heading of the chemical;

(ii) Chemical Description;

(iii) International Non-proprietary Name (INN);

(iv) Chemical Abstracts Service (CAS) Registry Number (RN);

(v) Prefix or suffix of the salt/ester/hydrate (if applicable).

3. Representatives of the governments listed above will meet under the auspices of the Council for Trade in Goods of the WTO — normally at least once every three years - to review the product coverage with a view to including, by consensus, additional pharmaceutical products for tariff elimination. They agreed to encourage autonomous elimination of duties prior to agreement to eliminate duties on a permanent and reciprocal basis, in accordance with their national procedures.

4. The positive list of products covered by these annexes has been deposited with the GATT Secretariat.

Vol. 1867, 1-31874


"Paracetamol, ibuprofen, dihydrostreptomycin, monosodium glutamate, and levomenthol have been excluded from the coverage of this record of discussion.

Vol. 1867, 1-31874


ANNEX I - DESIGNATED PHARMACEUTICAL ACTIVE INGREDIENTS (INN).

HS6

281830

283322

284110

284210

284210

284290

284290

284290

284290

284330

284330

284330

284330

284390

284390

284390

284390

284390

284390

284390

284390

284390

284390

284390

284390

284390

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

CAS*

1330-44-5

61115-28-4

41342-54-5

71205-22-6

12408-47-8

60239-66-9

66827-12-1

12304-65-3

74978-16-8

34031-32-8

16925-51-2

12244-57-4

10210-36-3

41575-94-4

15663-27-1

96392-96-0

111523-41-2

62928-11-4

135558-11-1

103775-75-3

95734-82-0

62816-98-2

61825-94-3

110172-45-7

74790-08-2

111490-36-90-00-0

15690-63-8

10375-56-1

13115-03-2

18195-32-9

13422-53-2

8016-07-7

54063-42-2-00-0

105851-17-0

Description Alternative Classification

algeldrate (INN)alusulf(INN)carbaldrate (INN)almasilate (INN)simaldrate (INN)almadrate sulfate (INN)almagate (INN)hydrotalcite (INN)

magaldrate (INN)

auranofin (INN)

aurothioglycanide (INN)

sodium aurothiomalate (INN)sodium aurotiosulfate (INN)carboplatm (INN)cisplatin (INN)dexormaplatin (INN)enloplatin (INN)iproplatm (INN)lobaplatin (INN)miboplatin (INN)nedaplatin (INN)ormaplatin (INN)oxaliplatin (INN)sebnplatin (INN)spiroplatin (INN)

zempiatin (INN)

altumomab (INN) 3002

cesium (131 Cs) chloride (INN)

chlormerodnn (197 Hg) (INN)

cyanocobalamin (57 Co) (INN)

cyanocobaiamin (58 Co) (INN)

cyanocobalamin (60 Co) (INN)

ethiodizedoil(131 I) (INN)

ferric (59 Fe) citrate injection (INN)

fibrinogen (125 I) (INN)

fludeoxyglucose (18 F) (INN)

Vol. 1867, 1-31874


HS6

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

2B4440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284440

284590

284590

284590

284690

284690

284690

284690

284690

CAS*

92812-82-3

41183-64-6

10043-49-9

77679-27-7

9048-49-1

9048-49-1

54510-20-2

42220-21-3

75917-92-9

127396-36-5

17033-82-8

17033-83-9

54182-63-7

54277-47-3

5579-94-2

15251-14-6

144058-40-2

1187-56-0

10039-53-9

24359-64-6

7790-26-3881-17-4

17692-74-9

15845-98-4

8027-28-9

121281-41-2

109581-73-9

106417-28-1

104716-22-5

54182-60-4

14932-42-4

35523-45-6

103831-41-0

122431-96-3

113662-23-0

138071-82-6

122795-43-1

117827-80-2

80529-93-7


fluorodopa 18F (INN)gallium (67 Ga) citrate (INN)gold (198 Au), colloidal (INN)iobenguane(131 I) (!NN)iodinated (125 I) human serum albumin (INN)iodinated (131 I) human serum albumin (INN)iodocetilic acid (123 I) (INN)iodocholesterol (131 I) (INN)iofetamine (123 1) (INN)iomazenil (123 I) (INN)

iometin (125 I) (INN)iometin (131 I) (INN)macrosalb(131 I) (INN)macrosalb (99m Tc) (INN)merisoprol(197Hg)(INN)rose bengal (131 I) sodium (INN)

satumomab (INN) 3002selenomethionine (75 Se) (INN)sodium chromate (51 Cr) (INN)sodium iodide (125 I) (INN)sodium iodide (131 I) (INN)sodium iodohippurate (131 I) (INN)sodium iotalamate (125 I) (INN)sodium iotalamate (131 I) (INN)sodium phosphate (32 P) (INN)technetium (99m Tc) bicisate (INN)technetium (99m Tc) sestamibi (INN)technetium (99m Tc) siboroxime (INN)technetium (99m Tc) teboroxime (INN)tolpovidone (131 I) (INN)xenon (133 Xe) (INN)fludalanine (INN)sodium borocaptate (10 B) (INN)zilascorb (2 H) (INN)gadobenic acid (INN)gadobutrol (INN)gadodiamide (INN)gadopenamide (INN)gadopentetic acid (INN)

Vol. 1867, 1-31874


HS6

284690

284690

290219

290290

290322

290330

290340

290340

290340

290340

290351

290359

290359

290362

290369

290369

290369

290369

290410

290410

290410

290410

290490

290490

290529

290539

290539

290549

290550

290550

290550

290550

290550

290550

290550

290550

290550

290611

290619

CAS»

72573-82-1

120066-54-875-19-4

75078-91-079-01-6

811-97-2

76-14-2

151-67-7

423-55-2

124-72-1

58-89-9

1715-40-8306-94-5

50-29-3

479-68-5

34106-48-4

56917-29-453-19-0

99287-30-6

5560-69-0

14992-59-7

6223-35-4124-88-9

126-31-8

77-75-8

35449-36-6

64218-02-6

7518-35-652-51-7

55-98-1

57-15-8

24403-04-1113-18-8

2209-86-1

488-41 -5

10318-26-0299-75-2

15356-70-4

19793-20-5


gadoteric acid (INN)

gadoteridol (INN)

cyclopropane (INN)

temarotene (INN)

trichloroethylene (INN)

norflurane (INN)

cryofluorane (INN)

halothane (INN)

perflubron (INN)

teflurane (INN)

lindane (ISO) (INN)

bromocyclen (ISO) (INN)

perflunafene (INN)

clofenotane (INN)

broparestrol (INN)

femodium chloride (INN)

fiuretofen (INN)

mitotane (INN)

egualen (INN)

ethyl dibunate (INN)

sodium dibunate (INN)

sodium gualenate (INN)

dimethiodal sodium (INN)

methiodal sodium (INN)

methylpentynol (INN)

gemcadiol (INN)

plaunotol (INN)

mannosulfan (INN)

bronopol (INN)

busulfan (INN)

chlorobutanol (INN)

debropol (INN)

ethchlorvynol (INN)

loprodiol (INN)

mrtobronitol (INN)

mitolactol (INN)

treosulfan (INN)

racementhol (INN)

bolandiol(INN)

Vol. 1867, 1-31874


HS6

290619

290619

290619

290619

290621

290629

290629

290629

290629

290629

290629

290629

290719

290719

290719

290719

290729

290729

290729

290729

290729

290729

290729

290810

290810

290810

290810

290810

290810

290810

290810

290810

290810

290810

290810

290810

290810

290810

290820

CAS*

.112828-00-9

29474-12-267-96-9

23089-26-1100-51-6

104561-36-6583-03-9

15687-18-0

56430-99-0

13980-94-479-93-6

14088-71-2

1300-94-3

5591-47-9

2078-54-8

13741-18-985-95-0

84-17-3

56-53-1

10457-66-6

5635-50-7

27686-84-6130-73-4

6915-57-7

15686-33-6

34633-34-659-50-7

88-04-0

10572-34-6

37693-01-9145-94-8

120-32-1

97-23-4

133-53-9

127035-60-370-30-4

65634-39-1

64396-09-4

20123-80-2


calcipotriol (INN)

cimepanol (INN)

dihydrotachysterol (INN)

ievomenol (INN)

benzyl alcohol (INN)

doretmel (INN)

fenipentol (INN)

fenpentadiol (INN)

flumecinol (INN)

metaglycodol (INN)

phenaglycodol (INN)

proclonol (INN)

amylmetacresol (INN)

cyclomenol (INN)

propofol (INN)

xibomol (INN)

benzestrol (INN)

dienestrol (INN)

diethylstilbestrol (INN)

geroqumol (INN)

hexestrol (INN)

masoprocol (INN)

methestrol (INN)

bibrocathol (INN)

biclotymol (INN)

bifluranol (INN)

chlorocresol (INN)

ctiloroxylenol (INN)

cicliomenol (INN)

clofoctol (INN)

clonndanol (INN)

clorofene (INN)

dichlorophen (ISO) (INN)

dichloroxytenol (INN)

enofelast (INN)

hexachlorophene (INN)

pentafluranol (INN)

terfluranol (INN)

calcium dobesilate (INN)

Vol. 1867, 1-31874


HS6

290820

290820

290820

290890

290890

290919

290919

290919

290919

290919

290919

290919

290919

290920

290930

290930

290930

290930

290930

290949

290949

290949

290949

290949

290949

290949

290949

290949

290949

290949

290949

290949

290949

290949

290950

290950

290950

290950

290950

CAS*

. 78480-14-5

4444-23-9

57775-26-5

10331-57-4

39224-48-1

57041-67-5

13838-16-9333-36-8

406-90-6

26675-46-776-38-0

679-90-3

28523-86-6

56689-41-9569-57-3

55837-16-6

80844-07-1

777-1 1-7

39219-28-8544-62-7

3563-58-4104-29-0

2216-77-5

3102-00-9

3671-05^

27318-86-1

63834-83-393-14-1

59-47-2

26159-36-4

39791-20-378-12-6

13021-53-9

6055-48-7

2174-64-3150-76-5

103-16-2

1321-14-8

3380-34-5


dicresulene (INN)

persilic acid (INN)

sultosilic acid (INN)

niclofolan (INN)

nitroclofene (INN)

desflurane (INN)

enflurane (INN)

flurotyl (INN)

fluroxene (INN)

isoflurane (INN)

methoxyflurane (INN)

roflurane (INN)

sevoflurane (INN)

aliflurane (INN)

chlorotnamsene (INN)

entsufon (INN)

etofenprox (INN)

haloprogin (INN)

promestnene (INN)

batilol (INN)

chloralodol (INN)

chlorphenesin (INN)

dibuprol (INN)

febuprol (INN)

fenocinol (INN)

floverine (INN)

guaietolin (INN)

guaifenesin (INN)

mephenesin (INN)

naproxol (INN)

nilestnol (INN)

petnchloral (INN)

terbuprol (INN)

toloxychlonnol (INN)

flamenol (INN)

mequmol (INN)

monobenzone (INN)

sulfogaiacol (INN)

tnclosan (INN)

Vol. 1867, 1-31874


HS6

291090

291090

291219

291419

291429

291429

291429

291430

291430

291430

291430

291430

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291449

291450

291450

291450

291450

291450

CAS*

60-57-1

1954-28-5111-30-8

6809-52-5

2226-11-1

63014-96-0

77016-85-4

58298-92-382-66-6

6723-40-683-12-5

55845-78-8

14107-37-0

23930-19-0

30781-27-2

3570-10-3

85969-07-9

5251-34-3

50673-97-7152-58-9

465-53-2

21208-26-4128-20-1

35100-44-8566-48-3

14340-01-3

17332-61-5

58691-88-6

33765-68-3

18118-80-4565-99-1

77287-05-9

10161-33-8

2673-23-6117-37-3

70356-09-1

75464-11-8

89672-11-7

3030-53-3


dieidrin (ISO) (INN)

etoglucid (INN)

glutaral (INN)

teprenone (INN)

bomelone (INN)

delanterone (INN)

plomestane (INN)

colimecycline (INN)

diphacinone (ISO) diphenadione (INN)

fiuindarol (INN)

phenindione (INN)

xenipentone (INN)

alfadolone (INN)

alfaxalone (INN)

amadinone (INN)

benorterone (INN)

budotitane (INN)

cloprednol (INN)

colestolone (INN)

cortodoxone (INN)

cyclopregnol (INN)

dimepregnen (INN)

eltanolone (INN)

endrisone (INN)

fonmestane (INN)

gestadienol (INN)

isoprednidene (INN)

nomegestrol (INN)

oxendolone (INN)

oxisopred (INN)

renanolone (INN)

noprostil (INN)

trenbolone (INN)

xenygloxal (INN)

anisindione (INN)

avobenzone (INN)butantrone (INN)cioteronel (INN)

clofenoxyde (INN)

Vol. 1867, 1-31874


HS6

291450

291450

291450

291450

291450

291450

291450

291450

291450

291450

291450

291450

291450

291450

291450

291450

291469

291469

291469

291469

291469

291469

291469

291469

291469

291469

291470

291470

291470

291470

291470

291470

291470

291470

291470

291470

291470

291470

291470

CAS*

.579-23-7131-53-3

480-22-8

52479-85-3

2295-58-1

27762-78-3

18493-30-6

1641-17-4

42924-53-8

7114-11-6

1843-05-6

69648-40-4131-57-7

70-70-2

2487-63-0

112018-00-5

88426-33-9117-10-2

114-43-2

80809-81-0

58186-27-9863-61-6

14561-42-3

4042-30-2319-89-1

303-98-0

56219-57-9

95233-18-4

1146-98-1

1146-99-2

1879-77-2957-56-2

15687-21-5

24320-27-2

16469-74-2

1470-35-5130-37-0

116313-94-1

49561-92-4


cyclovalone (INN)dioxybenzone (INN)dithranol (INN)

exifone (INN)fiopropione (INN)ketoxal (INN)metochalcone (INN)mexenone (INN)nabumetone (INN)naphthonone (INN)octabenzone (INN)oxoprostol (INN)oxybenzone (INN)paroxypropione (INN)quinbolone (INN)tebufelone (INN)buparvaquone (INN)dantron (INN)desaspidin (INN)docebenone (INN)idebenone (INN)menatetrenone (INN)menoctone (INN)parvaquone (INN)tetroquinone (INN)ubidecarenone (INN)arildone (INN)atovaquone (INN)bromindione (INN)clorindione (INN)doxibetasol (INN)fluindione (INN)flumedroxone (INN)halocortolone (INN)hydromadinone (INN)isobromindione (INN)menadione sodium bisulfite (INN)nitecapone (INN)nivimedone (INN)

Vol. 1867, 1-31874


HS6

291470

291470

291529

291539

291539

291539

291539

291539

291539

291539

291550

291570

291570

291590

291590

291590

291590

291590

291615

291619

291619

291619

291619

291619

291620

291620

291620

291620

291620

291639

291639

291639

291639

291639

291639

291639

291639

291639

291639

CAS*

4065-45-6

134308-13-7

82279-57-0514-50-1

80595-73-9

99107-52-5

2624-43-3

5984-83-8

91431-42^t102-76-1

13885-31-9555^44-2

555-44-2

7008-02-8124-07-2

77372-61-3

76584-70-899-66-1

26266-58-0

6217-54-5506-26-3

51-77-4

10417-94-4

83689-23-0

25229-42-9

75867-00-4

69915-62-4

52645-53-1

26002-80-2

55837-18-8

36950-96-6

34148-01-1

33159-27-2

51543-39-6

5728-52-9

36616-52-1

15301-67-4

7698-97-7

17692-38-5


sulisobenzone (INN)tolcapone (INN)zinc acetate, basic (INN)acebrochol (INN)acefluranol (INN)bunaprolast (INN)

cyciofenil (INN)

fenabutene (INN)

lonapalene (INN)tnacetin (INN)orestrate (INN)tnpalmitm (INN)tripalmitin (INN)lodetryl (INN)octanoic acid (INN)valproate pivoxil (INN)valproate semisodium (INN)valproic acid (INN)

sorbitan trioleate (INN)

doconexent (INN)

gamolenic acid (INN)

gefamate (INN)

icosapent (INN)

molfarnate (INN)

cicrotoic acid (INN)

fenfluthrin (INN)

loxanast (INN)permethrin (ISO) (INN)phenothrin (INN)butibufen (INN)cicloprofen (INN)clidanac (INN)ecabet (INN)esflurbiprofen (INN)felbinac (INN)fenclorac (INN)fenentrol (INN)fenestrel (INN)fluprofen (INN)

Vol. 1867, 1-31874


HS6

291639

291639

291639

291639

291639

291639

291639

291639

291639

291639

291639

291639

291713

291719

291719

291720

291734

291811

291816

291817

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

CAS*

5104-49-4

24645-20-3

1553-60-299-79-6

57144-56-6

37529-08-1

1085-91-2

91587-01-8

28168-10-7

84392-17-6959-10-4

964-82-9

123-99-9

577-11-7

53-10-1

5634-42-4131-67-9

15145-14-9

1317-30-2456-59-7

26976-72-7

74176-31-1

83997-19-7

17140-60-2

5793-88-4

34150-62-4

35700-23-3474-25-9

57808-63-6

81845-44-5

88931-51-5

17692-20-5512-16-3

68635-50-7551-11-1

5977-10-6

31221-85-9

73873-87-7

130209-82-4


flurbiprofen (INN)hexaprofen (INN)ibufenac (INN)iofendylate (INN)isoprofen (INN)mexoprofen (INN)nafcaproic acid (INN)pelretin (INN)tetriprofen (INN)xenalipm (INN)xenbucin (INN)xenyhexenic acid (INN)azelaic acid (INN)docusate sodium (INN)

hydroxydione sodium succinate (INN)

tocamphyl (INN)

ftalofyne (INN)ciclactate (INN)potassium glucaldrate (INN)cyctandelate (INN)aceburic acid (INN)alfaprostol (INN)ataprost (INN)

calcium glucoheptonate (INN)

calcium saccharate (INN)

calcium sodium fernclate (INN)

carboprost (INN)

chenodeoxycholic acid (INN)

cicloxilic acid (INN)

ciprostene (INN)

clmprost (INN)

cyclobutoic acid (INN)

cyclobutyrol (INN)

deloxolone (INN)

dinoprost (INN)

fencibutirol (INN)

ibuvenne (INN)

itoprost (INN)

latanoprost (INN)

Vol. 1867, 1-31874


HS6

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291819

291822

291822

291823

291823

291823

291829

291829

291829

291829

291829

291829

291829

291829

291829

291829

291829

291829

291830

291830

291830

291830

291830

291830

291830

291830

291830

291830

CAS*

93105-81-8503-49-1

61263-35-2

87269-59-8

79360-43-3125-65-5

81093-37-0

54120-61-5

56695-65-9

7009-49-6

7007-81-0128-13-2

55482-89-8

64496-66-8118-56-9

552-94-3

58703-77-8153-43-5

1884-24-8

22494-42-4486-79-3

22494-27-5490-79-9

83^*0-9

96-84-4

7009-60-1

4955-90-2

15534-92-6322-79-2

32808-51-881-23-2

36330-85-5519-95-9

892-01-3

58182-63-1

22071-15-4

41387-02-4

68767-14-6

3562-99-0


lodelaben (INN)

megluto! (INN)

meteneprost (INN)

naxaprostene (INN)nocloprast (INN)

pleuromulin (INN)

pravastatin (INN)

prostalene (INN)

rosaprostol (INN)

sodium hexacyclonate (INN)

trethocanic acid (INN)

ursodeoxycholic acid (INN)

guacetisal (INN)

salafibrate (INN)

homosalate (INN)

salsaiate (INN)

sulprosal (INN)

clorindanic acid (INN)

cynarine (INN)

diflunisal (INN)

dipyrocetyl (INN)

flufenisal (INN)

gentisic acid (INN)

hydroxytoluic acid (INN)

lophenoic acid (INN)

pheniodol sodium (INN)

sodium genlisate (INN)

terbuficin (INN)

tnflusal (INN)

bucloxic acid (INN)

dehydrocholic acid (INN)

fenbufen (INN)

florantyrone (INN)

hexacypronc (INN)

itanoxone (INN)

ketoprofen (INN)

lexofenac (INN)

loxoprofen (INN)

menbutone (INN)

Vol. 1867, 1-31874


HS6

291830

291830

291830

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

CAS*

63472-04-8

2522-81-8

145^1-5

2260-08^»

55079-83-9

106685-40-9

22131-79-9745-65-3

24818-79-9

5129-14-6

55028-70-1

117819-25-7

84386-11-8

55937-99-0

5711-40-0

69648-38-0

39087-48-4

4138-96-9

5697-56-3

95722-07-9

52247-86-6

35703-32-3

66984-59-6104-28-9

31581-02-9

52214-84-3

30299-08-2

22494-47-9637-07-0

882-09-7

88431-47-4

40665-92-7

62524-99-6

33813-84-2

13739-02-1

7706-67-4

90243-98^1363-24-6

51953-95-8


metbufen (INN)

pibecarb (INN)

sodium dehydrocholate (INN)

acetiromate (INN)

acitretin (INN)

adapalene (INN)

alclofenac (INN)

alprostadil (INN)

aluminium clofibrale (INN)

anisacri! (INN)

arbaprostil (INN)

bakeprofen (INN)

baxitozine (INN)

beclobrate (INN)

bromebric acid (INN)

butaprost (INN)

calcium clofibrate (INN)

canrenoic acid (INN)

carbenoxolone (INN)

cicaprost (INN)

cicloxolone (INN)

cinametic acid (INN)

cinfenoac (INN)

cinoxate (INN)

cinoxolone (INN)

ciprofibrate (INN)

clinofibrate (INN)

clobuzarit (INN)

clofibrate (INN)

cloflbnc acid (INN)

clomoxir (INN)

cloprostenol (INN)

delprostenate (INN)

deprostil (INN)

diacerem (INN)

dcmecrotic acid (INN)

dimoxaprost (INN)

dtnoprostone (INN)

doxaprost (INN)

Vol. 1867, 1-31874


HS6

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

CAS*

61887-16-9

81026-63-3471-53-4

73121-56-9

90693-76-858-54-8

124083-20-1

54350-48-0

26281-69-6

34645-84-6

54419-31-7

49562-28-9

31879-05-7

69381-94-8

17243-33-3

86348-98-3

33124-50-4

40666-16-8

62559-74-4

64318-79-2

25812-30-0

57296-63-6

2217-44-9

96609-16-4

88852-12-4

41791-49-5

74168-08^

14613-30-0579-94-2

517-18-0

40596-69-8

88980-20-5

59122-46-2

3771-19-5

22204-53-1

70667-26-4

68548-99-2

76676-34-1

68170-97-8


dulofibrate (INN)

enisoprost (INN)

enoxolone (INN)

enprostil (INN)

eptaloprost (INN)

etacrynic acid (INN)

etomoxir (INN)

etretinate (INN)

exiproben (INN)

fenclofenac (INN)

fenirofibrate (INN)

fenofibrate (INN)

fenoprofen (INN)

fenprostalene (INN)

fepentolic acid (INN)

flunoprost (INN)

fluocortin (INN)

fluprostenol (INN)

froxiprost (INN)

gemeprost (INN)

gemfibrozil (INN)

indacrinone (INN)

iodophthalein sodium (INN)

hfibrol (INN)

limaprost (INN)

lonaprofen (INN)

losmiprofen (INN)

magnesium clofibrate (INN)

menglytate (INN)

methallenesthl (INN)

methoprene (INN)

mexiprostil (INN)

misoprostol (INN)

nafenopin (INN)

naproxen (INN)

omoprostil (INN)

oxindanac (INN)

oxprenoate potassium (INN)

palmoxiric acid (INN)

Vol. 1867, 1-31874


HS6

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291890

291900

291900

291900

291900

291900

291900

291900

291900

291900

291900

292010

292010

292090

292090

292090

292090

292090

292090

292090

292090

292090

292090

CAS*

61557-12-8554-24-5

2181-04-6

110845-89-1

14929-11-4

55902-94-8

12214-50-5

64506-49-6

56488-59-651-26-3

51-24-1

41826-92-0

69900-72-7

84290-27-7

120373-36-6

77858-21-0

73647-73-1

28841-62-5

21466-07-9470-90-6

62-73-7

65708-37-4522-40-7

6064-83-183-86-3

306-52-5

17196-88-2

2104-96-3299-84-3

2612-33-1

5634-37-7

7297-25-8

15825-70-4

1612-30-278-11-5

1607-17-6

2921-92-8126-92-1

139-88-8


penprostene (INN)phenobutiodil (INN)potassium canrenoate (INN)remiprostol (INN)simfibrate (INN)sitofibrate (INN)sodium glucaspaldrate (INN)sofalcone (INN)

terbufibrol (INN)

thyropropic acid (INN)

tiratncol (INN)

trepibutone (INN)

trimoprostil (INN)

tucaresol (INN)

unoprostone (INN)

velaresol (INN)

viprostol (INN)

atrinositol (INN)

bromofenofos (INN)

chlorfenvinphos (ISO) clofenvinfos (INN)

dichlorvos (ISO) (INN)

flufosal (INN)

fosfestrol (INN)

fosfosal (INN)

fytic acid (INN)

triclofos (INN)

vincofos (INN)

bromophos (ISO) bromofos (INN)

fenchlorphos (ISO) fenclofos (INN)

clonitrate (INN)

cloretate (INN)

eritrityl tetranrtrate (INN)

mannrtol hexanitrate (INN)

menadiol sodium sulfate (INN)

pentaerithrityl tetranitrate (INN)

pentrinitrol (INN)

propatylnitrate (INN)

sodium etasulfate (INN)

sodium tetradecyl sulfate (INN)

Vol. 1867, 1-31874


HS6

292090

292112

292119

292119

292119

292119

292119

292119

292119

292119

292119

292119

292119

292119

292119

292129

292129

292129

292130

292130

292130

292130

292130

292130

292130

292130

292130

292145

292145

292145

292149

292149

292149

292149

292149

292149

292149

292149

292149

CAS*

88426-32-8

2624-44-4

3735-65-751-75-2

36505-83-6124-28-7

61822-36-4

3151-59-5

13946-02-6503-01-5

502-59-0

543-82-8

338-83-0

107-35-7

123-82-0

9011-04-5555-77-1

112-24-3

768-94-5

102-45-4

3570-07-8

6192-97-860-40-2

19982-08-2

3595-11-7

13392-28-4

79594-24-4494-03-1

79617-96-2

52795-02-5

4255-23-6150-59-4

15686-27-8300-62-9

50-48-6

156-08-1

17243-39-9

101828-21-1

19992-80-4


ursulcholic acid (INN)etamsylate (INN)butynamine (INN)

chlormethine (INN)

dectaflur (INN)

dimantine (INN)

diprobutine (INN)

hetaflur (INN)

iproheptme (INN)

isometheptene (INN)

octamylamine (INN)

octodrine (INN)

perfluamine (INN)

taurine (INN)

tuammoheptane (INN)

hexadimethnne bromide (INN)

trichlormethine (INN)

tnentme (INN)

amantadine (INN)

cyclopentamine (INN)

dimecamine (INN)

levopropylhexednne (INN)

mecamylamine (INN)

memantme (INN)

propylhexedrine (INN)

rimantadine (INN)

somantadine (INN)

chlomaphazine (INN)

sertraline (INN)

tametralme (INN)

alfetamine (INN)

alvenne (INN)

amfepentorex (INN)

amfetamine (INN)

amitriptyline (INN)

benzfetamine (INN)

benzoctamine (INN)

butenafine (INN)

butixirate (INN)

Vol. 1867, 1-31874


HS6

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

CAS*

.35941-65-2461-78-9

13364-32-4

10389-73-8303-53-7

15301-54-9

13977-33-851-64-9

3239-44-9102-05-6

5966-41-6

5581-40-8

17279-39-9

57653-27-7

2201-15-2341-00-4

457-87-4

1209-98-9

13042-18-7458-24-2

35764-73-9

7273-99-6

54063-48-8

140850-73-3

86939-10-8

7395-90-6

27466-27-9

7262-75-1156-34-3

37577-24-5

5118-30-9

10262-69-8

17243-57-1

5118-29-6100-92-5

119386-96-8

65472-88-072-69-5

47166-67-6


butriptyiine (INN)

chlorphentermine (INN)

clobenzorex (INN)

clortermine (INN)

cyclobenzaprine (INN)

cypenamine (INN)

demelverine (INN)

dexamphetamine (INN)

dexfenfluramine (INN)

dibemethine (INN)

diisopromine (INN)

dimefadane (INN)

dimetamfetamine (INN)

droprenilamine (INN)

eticyclidine (INN)

etifelmine (INN)

etilamfetamme (INN)

fencamfamin (INN)

fendiline (INN)

fenfiuramine (INN)

fluotracen (INN)

gamfexine (INN)

heptavenne (INN)

igmesine (INN)

indatralme (INN)

indriline (INN)

mtnptyline (INN)

lefetamine(INN)

levamfetamme (INN)

tevofenfluramine (INN)

Irtracen (INN)

maprotiline (INN)

mefenorex (INN)

melitracen (INN)

mephentermine (INN)

mofegihne (INN)

naftifine (INN)

nortriptyline (INN)

octriptyline (INN)

Vol. 1867, 1-31874


HS6

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292149

292159

292159

292159

292159

292211

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

CAS*

5580-32-5555-57-7

434-43-5

93-88-9

122-09-8

14334-40-8390-64-7

438-60-8

14611-51-9

106650-56-0

78628-80-5

15793-40-5

5632^4-0155-09-9

58757-61-2

77518-07-1

37640-71-4

3572-43-8

3590-16-7

2272-11-9509-74-0

82168-26-164-95-9

52742-40-2

17199-58-5

17199-54-1

18683-91-5

54063-24-0

54063-25-1

3563-01-7

87129-71-3

35607-20-6313-05-3

302-40-9

22487-42-9

2179-37-5

23602-78-0

17199-59-6

17199-55-2


ortetamine (INN)pargyline (INN)pentorex (INN)phenpromethamine (INN)phentermine (INN)pramiverine (INN)prenylamine (INN)protriptyline (INN)selegiline (INN)sibutramine (INN)terbinafine (INN)terodiline (INN)tolpropamine (INN)tranylcypromine (INN)trimexiline (INN)amifiamine (INN)apnndme (INN)bromhexine (INN)feclemine (INN)monoethanolamine oleate (INN)acetylmethadol (INN)adafenoxate (INN)adiphenine (INN)alimadol (INN)alphacetylmethadol (INN)alphamethadol (INN)ambroxol (INN)amiflovehne (INN)amiterol (INN)aprofene (INN)amolol (INN)avridine (INN)azacosterol (INN)benactyzine (INN)benaprizine (INN)bencyclane (INN)benfluorex (INN)betacetylmethadol (INN)betamethadol (INN)

Vol. 1867, 1-31874


HS6

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

CAS*

90293-01-9

20448-86-6118-23-0

604-74-0

14007-64-8

7433-10-5

55769-65-877-22-5

112922-55-177-38-3

69429-84-1

54141-87-6

1679-75-090-86-8

71827-56-0

37148-27-9

14860-49-2791-35-5

5632-52-0511-46-6

911-45-5

17780-72-2

3811-25-4

96389-68-3

15585-86-1

119356-77-3

120444-71-5

47419-52-3

15687-08-8469-62-5

77-19-0

545-90-4

53657-16-258-73-1

58473-73-7

1679-76-1102-60-3

25314-87-8

3565-72-8


bifemelane (INN)bomaprine (INN)bromazine (INN)bufenadrine (INN)butetamate (INN)butidrine (INN)butobendine (INN)caramiphen (INN)cericlamine (INN)chlorphenoxamine (INN)cilobamine (INN)cinfenine (INN)cinnamavenne (INN)cinnamednne (INN)clemeprol (INN)clenbuterol (INN)

clobutinol (INN)

clofedanol(INN)

clofenciclan (INN)

clofenetamine (INN)

clomifene (INN)

clorgiline (INN)

clorprenaline (INN)

cnsnatol (INN)

cyprodenate (INN)

dapoxetme (INN)

deramciclane (INN)

dexproxibutene (INN)

dextrofemine (INN)

dextropropoxyphene (INN)

dicyclovenne(INN)

dimepheptanol (INN)

dimepranol (INN)

diphenhydramine (INN)

drobuline (INN)

drofenine (INN)

edetol (INN)

elucaine (INN)

embramine (INN)

Vol. 1867, 1-31874


HS6

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

CAS»

15690-57-074-55-5

54063-36-4

1157-87-5

63075-47-8

82101-10-8

15221-81-5

50366-32-0

54910-89-3

69756-53-2

50583-06-7372-66-7

15599-37-8532-77-4

13425-98-4

16112-96-2

13445-63-1

7617-74-5

34433-66-4

2338-37-6

76496-68-9

56341-08-3576-68-1

51-68-3

5668-06-4

6284-40-8495-70-5

31828-71-4

53076-26-9

3572-74-5

15518-87-3

7712-50-7

1234-71-5

53716-48-6

7413-36-7

53179-07-0

1477-39-0

6818-37-783-98-7


enclomifene (INN)ethambutol (INN)etolorex (INN)etoloxamine (INN)fepradinol (INN)flerobuterol (INN)fludorex (INN)flunamme (INN)

fluoxetine (INN)

halofantnne (INN)

halonamine (INN)

heptammol (INN)

hexapradol (INN)

hexyicaine (INN)

improsulfan (INN)

indanorex (INN)

itramin tosilate (INN)

launxamine (INN)

levacetylmethadol (INN)

levopropoxyphene (INN)

levoprotiline (INN)

mabuterol (INN)

mannomustine (INN)

meclofenoxate (INN)

mecloxamine (INN)

meglumme (INN)

meprylcaine (INN)

mexiletine (INN)

moxapnndine (INN)

moxastine (INN)

myralact (INN)

myrtecaine (INN)

namoxyrate (INN)

nexeridme (INN)

nifenalol (INN)

nisoxetine (INN)

noracymethadol (INN)

olaflur (INN)

orphenadrine (INN)

Vol. 1867, 1-31874


HS6

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292219

292229

292229

292229

292229

292229

292229

292229

292229

292229

292229

292229

292229

CAS*

56433-44wt59-96-1

92-12-6

65236-29-5302-33-0

54-80-8

493-76-5

14089-84-0

22232-57-1

96743-96-3

4148-16-7

15639-50-6

126924-38-7

56481-43-7

6535-03-1

10540-29-1

15301-93-6

83015-26-3

89778-26-7

90845-56-0

58313-74-9

7077-34-1

53783-83-877-86-1

41570-61-0

83480-29-9

15690-55-8

112891-97-1

5585-64-8493-75-4

64638-07-9

53648-55-8

34368-04-251-61-6

86197-47-9

18840-47-6

1518-86-1

66195-31-1

61661-06-1


oxaprotiline (INN)

phenoxybenzamine (INN)

phenyltoloxamine (INN)

prenoverine (INN)

proadifen (INN)

pronetalo! (INN)

propanocaine (INN)

proxibutene (INN)

racefemine (INN)

ramciclane (INN)

ntrosulfan (INN)

safingol (INN)

seproxetme (INN)

setazindol (INN)

stevaladil (INN)

tamoxifen (INN)

tofenacin (INN)

tomoxetine (INN)

toremifene (INN)

trecadrme (INN)

treptilamine (INN)

trolnitrate (INN)

tromantadine (INN)

trometamol (INN)

tulobuterol (INN)

voglibose (INN)

zuclomifene (INN)

alentemol (INN)

aminoxytnphene (INN)

bialamicol (INN)

brolamfetamine (INN)

dezocine (INN)

dobutamine (INN)

dopamine (INN)

dopexamine (INN)

gepefrme (INN)

hydroxyamphetamine (INN)

ibopamme (INN)

levdobutamine (INN)

Vol. 1867, 1-31874


HS6

292229

292229

292229

292229

292229

292229

292229

292229

292229

292230

292230

292230

292230

292230

292230

292230

292230

292230

292230

292230

292230

292230

292241

292242

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

CAS*

39951-65-093-30-1

17692-54-5

1199-18-4370-14-9

15599-45-8

124937-51-5

15686-23-4

3735-^5-3

34911-55-290-84-6

71031-15-7

34662-67^

92629-87-3

53394-92-6466-40-0

6740-88-1125-58-6

15351-09-476-99-3

92615-20-8467-85-6

56-87-1

56-86-0

89796-99-656-41-7

60719-82-6

39718-89-3

57574-09-160-32-2

553-65-1

15250-13-256-84-8

1134-47-094-09-7

104-31-4

3818-62-0149-16-6

12111-24-9


lometrahne (INN)methoxyphenamine (INN)mitoclomine (INN)oxidopamine (INN)pholedrine (INN)symetine (INN)tolterodine (INN)trimoxamine (INN)vetrabutine (INN)amfebutamone (INN)

amfepramone (INN)cathmone (INN)cotriptyline (INN)dexnafenodone (INN)dhnidene (INN)isomethadone (INN)ketamine (INN)levomethadone (INN)metamfepramone (INN)methadone (INN)nafenodone (INN)normethadone (INN)lysine (INN)giutamic acid (INN) excluding rnonosodium glutaaceclofenac (INN)aianine (INN)alaproclate (INN)alminoprofen (INN)amineptine (INN)aminocaproïc acid (INN)amoxecaine (INN)araprofen (INN)aspartic acid (INN)baclofen (INN)benzocaine (INN)benzonatate (INN)betoxycaine (INN)butacaine (INN)calcium trisodium pentetate (INN)

Vol. 1867, 1-31874


HS6

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

292249

CAS*

54-30-8

55986-43-1

34675-84-8305-03-3

133-16-4

4295-55-0

13930-34-2

32447-90-8

15307-86-5

36499-65-760-00-4

67037-37-0

23049-93-6

7424-00-2530-78-9

60142-96-356-40-6

96-83-3

94-14-4

73-32-5

61-90-5

92-23-9

63329-53-3644-62-2

61-68-7

148-82-3

1088-80-870-26-8

21245-01-267-43-6

63-91-2

57775-28-759-46-1

94-12-2

531-76-0

62-33-9

15708-41-594-24-6

20380-58-9


camylofin (INN)cetaben (INN)cetraxate (INN)chlorambucil (INN)chloroprocaine (INN)clofenamic acid (INN)clormecame (INN)

dextilidine (INN)

diclofenac (INN)

dice-bait edetate (INN)

edetic acid (INN)

eflomithine (INN)

enfenamic acid (INN)

fenclomne (INN)

flufenamic acid (INN)

gabapentm (INN)

glycine (INN)

iopanoic acid (INN)

isobutamben (INN)

isoleucine (INN)

leucine (INN)

leucinocaine (INN)

lobenzarit (INN)

meclofenamic acid (INN)

mefenamic acid (INN)

metphalan (INN)

metamelfalan (INN)

omithine (INN)

padimate (INN)

pentetic acid (INN)

phenylalanine (INN)

prefenamate (INN)

procame (INN)

nsocaine (INN)

sarcolysin (INN)

sodium calcium edetate (INN)

sodium feredetate (INN)

tetracame (INN)

tilidine (INN)

Vol. 1867, 1-31874


HS6

292249

292249

292249

2S2249

292249

292249

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

CAS*

13710-19-5

1197-18-8

67330-25-072-18-4

60643-86-9

59209-97-1

101479-70-399-45-6

78756-61-3

124316-02-5

13655-52-2

50588^*7-1119-29-9

64862-96-0

51579-82-9646-02-6

4317-14-0

15350-99-9

128470-16-6

75219-46-4

3703-79-5

18965-97-4

63659-18-7

59170-23-9

66722-44-9

30392-40-6

66451-06-7

91714-94-2

22103-14-6

27591-01-1447-41-6

14556^*6-8

18109-80-3

2922-20-5

64552-17-6

66734-12-1

63659-12-1

39099-98-4

63269-31-8


tolfenamic acid (INN)

tranexamic acid (INN)

ufenamate (INN)

valine (INN)

vigabatrin (INN)

zafuleptine (INN)

adaprolol (INN)

adrenalone (INN)

alifedhne (INN)

alprafenone (INN)

aiprenolol (INN)

amafolone (INN)

ambucaine (INN)

ametantrone (INN)

amfenac (INN)

ammoethyl nitrate (INN)

amrtriptylinoxide (INN)

amoxydramine camsilate (INN)

arbutamme (INN)

atrimustine (INN)

bamethan (INN)

bertafenone (INN)

betaxolol (INN)

bevantolol (INN)

bisoprolol (INN)

bitolterol (INN)

bomaprolol (INN)

bromfenac (INN)

bufeniode (INN)

bunolol (INN)

buphenme (INN)

bupranolol (INN)

butamirate (INN)

butaxamine (INN)

butofilolol (INN)

butopamine (INN)

cicloprolol (INN)

cinamolol (INN)

ciramadol (INN)

Vol. 1867, 1-31874


HS6

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

CAS*

109525-44-2

97642-74-5

39563-28-5

18866-78-9829-74-3

512-15-2

60812-35-3

83200-09-3

3579-62-2

71771-90-9

23573-66-2

3506-31-8

5714-08-9407-41-0

407-41-0

5051-22-9

90237-04-0137-53-1

3686-78-0

80387-96-8

14587-50-9509-78-4

22950-29-4497-75-6

10329-60-9

52365-63-681447-80-5

54592-27-7

82413-20-5

23651-95-8

64552-16-567-42-5

85320-67-8

103598-03-490-54-0

93047-39-3709-55-7

85750-39-6

17365-01-4


cliropamine (INN)

clomifenoxide (INN)

cloranolol (INN)

colterol (INN)

corbadrine (INN)

cyclopentolate (INN)

decominol (INN)

dembrexine (INN)

denaverine (INN)

denopamine (INN)

detanosal (INN)

deterenol (INN)

detrothyronine (INN)

dexfosfosenne (INN)

dexfosfoserine (INN)

dexpropranolol (INN)

dexsecoverine (INN)

dextrothyroxine sodium (INN)

dietifen (INN)

difemerine (INN)

difeterol (INN)

drmenoxadol (INN)

dimetofrine (INN)

dioxethedrin (INN)

dioxifednne (INN)

dipivefrine (INN)

diprafenone (INN)

divabuterol (INN)

droloxifene (INN)

droxidopa (INN)

ecipramidil (INN)

egtazic acid (INN)

ehcolol (INN)

esmolol (INN)

etafenone (INN)

etanterol (INN)

etilefnne (INN)

etilefhne pnvalate (INN)

etiroxate (INN)

Vol. 1867, 1-31874


HS6

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

CAS*

30544-47-9

55837-19-9

123618-00-8

34616-39-2133-11-9

13392-18-2

84057-96-5

72973-11-6

103878-96-2299-61-6

36199-78-7

15687-23-754-03-5

3215-70-1487-53-6

490-98-2

53034-85-8

27581-02-8

60607-68-3

52403-19-7530-08-5

7683-59-2395-28-8

1092-46-2

7488-92-B51-31-0

93221-48-8

47141-42-459-92-7

77164-20-6

97747-88-1136^*4-7

3625-06-7

32359-34-5524-99-2

23891-60-389-57-6

3571-71-9390-28-3


etofenamate (INN)exapralol (INN)fedotozine (INN)fenalcomine (INN)fenamisal (INN)fenoterol (INN)flusoxolol (INN)fbrfenimex (INN)fosopamine (INN)ganglefene (INN)guafecainol (INN)guaiactamine (INN)hexobendine (INN)hexoprenaline (INN)hydroxyprocaine (INN)hydroxytetracaine (INN)ibuterol (INN)idropranolol (INN)indenolol (INN)iproxamme (INN)isoetarine (INN)isoprenaline (INN)isoxsupnne (INN)ketocaine (INN)ketocainol (INN)tevisoprenaline (INN)tevobetaxoiol (INN)tevobunolol (INN)tevodopa (INN)tevomoprolol (INN)lilopristone (INN)lisadimate (INN)mebevenne (INN)medifoxamine (INN)medrylamine (INN)mepramidil (INN)nnesalazine (INN)metaterol (INN)methoxamine (INN)

Vol. 1867, 1-31874


HS6

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

CAS*

. 555-30-6

22664-55-7

1212-03-9672-87-7

37350-58-6

62571-87-3

13877-99-1

65271-80-9

5741-22-054-32-0

42200-33-9

42050-23-7

93047-40-6

60734-87-4

15686-81-4536-21-0

96346-61-1

96346-61-1586-06-1

65415-42-1468-61-1

32462-30-9

4075-88-1365-26-4

6452-71-799-43^»

5633-20-5

15687-41-9

65655-59-6

77599-17-894-23-5

13479-13-5

47082-97-3

38363-40-577-23-6

59-42-7

67577-23-5

57526-81-5

27325-36-6


methyldopa (INN)

metipranolol (INN)

metiprenalme (INN)

metirosine (INN)

metoproiol (INN)

minaxolone (INN)

minepentate (INN)

mitoxantrone (INN)

moprolol (INN)

moxisylyte (INN)

nadolol (INN)

nafetolol (INN)

namintero! (INN)

nisbuterol (INN)

norbudnne (INN)

norfenefrine (INN)

onapnstone (INN)

onapnstone (INN) 293799

orciprenaline (INN)

oxabrexine (INN)

oxeladrn (INN)

oxfenicine (INN)

oxifentorex (INN)

oxilofrine (INN)

oxprenolol (INN)

oxybuprocame (INN)

oxybutynin (INN)

oxyfedrine (INN)

pacrmolol (INN)

panomifene (INN)

parethoxycame (INN)

pargeverine (INN)

pargolol (INN)

penbutoiol (INN)

pentoxyverine (INN)

phenylephnne (INN)

pivenfnne (INN)

prenalterol (1NN)

procinolol (INN)

Vol. 1867, 1-31874


HS6

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292250

292310

292310

292310

CAS*

.54063-53-586-43-1

525-66-6

499-67-2

620-30-4

97825-25-7

26652-09-5

53716-44-2

92071-51-7

58882-17-0

18559-94-9

18910-65-1

89365-50-4

125926-17-2

57558-44-856-45-1

68567-30-6

65429-87-0

23031-25-6

29098-15-572-19-5

27591-97-5

75626-99-2

2933-94-0

27203-92-5

39133-31-878^11-1

15301-96-960-18-4

93413-69-5

1174-11-4

3572-52-9

81584-06-7

19179-78-3

1600-19-7

68876-74-4

28319-77-967-48-1

507-30-2


propafenone (INN)

propoxycaine (INN)

propranolol (INN)

proxymetacaine (INN)

racemetirosine (INN)

ractopamine (INN)

ritodrine (INN)

rociverine (INN)

rotraxate (INN)

roxadimate (INN)

salbutamol (INN)

salmefamol (INN)

salmeterol (INN)

sarpogrelate (INN)

secoverine (INN)

serine (INN)

solpecainol (INN)

spirendolol (INN)

tertoutaline (INN)

terofenamate (INN)

threonine (INN)

tilorone (INN)

tobuterol (INN)

toliprolol (INN)

tramadol (INN)

trimebutine (INN)

tnparanol (INN)

tyromedan (INN)

tyrosine (INN)

venlafaxine (INN)

xenazoic acid (INN)

xenysalate (INN)

xibenolol (INN)

xipranolol (INN)

xyloxemine (INN)

zocainone (INN)

choline alfoscerate (INN)

choline chloride (INN)

choline gluconate (INN)

Vol. 1867, 1-31874


HS6

292310

292310

292310

292320

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

CAS*

2016-36-6

1336-80-7

28038-04-263-89-8

60-31-1

55077-30-0

58158-77-3306-53-6

121-54-0

139-07-1

19379-90-9

3818-50-6

15585-70-361-75-6

51-83-2

461-06-3

13254-33-6122-18-9

58703-78-957-09-0

7168-18-5

29546-59-6

68379-03-3

2218-68-0541-22-0

2401-56-1

2001-81-2

15687-13-5538-71-6

70641-51-9116-38-1

3614-30-0

30716-01-965-29-2

7008-13-1317-52-2

55-97-0

19486-61-4541-15-1


choline salicylate (INN)ferrocholinate (INN)salcolex (INN)colfosceril palmitate (INN)acetylcholirte chloride (INN)aclatonium napadisilate (INN)amantamum bromide (INN)azamethonium bromide (INN)benzethonium chloride (INN)benzododecimum chloride (INN)benzoxonium chloride (INN)bephenium hydroxynaphthoate (INN)bibenzonium bromide (INN)bretylium tosilate (INN)carbachol (INN)carnitine (INN)carpronium chloride (INN)cetalkomum chloride (INN)cethexonium chloride (INN)cetnmomum bromide (INN)chlorphenoctium amsonate (INN)ciclonium bromide (INN)clofilium phosphate (INN)clorai betaine (INN)decamethonium bromide (INN)deditonium bromide (INN)diponium bromide (INN)dodeclonium bromide (INN)domiphen bromrde (INN)edelfosine (INN)edrophonium chloride (INN)emepromum bromide (INN)emilium tosilate (INN)gallamme tneth iodide (INN)halopenium chloride (INN)hexafluromum bromide (INN)hexamethonium bromide (INN)lauralkonium chloride (INN)levocamitine (INN)

Vol. 1867, 1-31874


HS6

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292390

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

CAS*

7681-78-9

3006-10-8

4858-60-062-51-1

3166-62-9

25155-18-4

2424-71-7

58066-85-6139-08-2

7009-91-8

15687-40-8

7002-65-5

7174-23-450-10-2

17088-72-1541-20-8

42879-47-0

3690-61-7123-47-7

77257-42-271-27-2

54063-57-9

1119-97-771-91-0

552-92-1

79-90-3

125-99-5

391-70-8

4304-01-2

77337-76-977-66-7

2490-97-3131-48-6

99-15-0

57-08-9

39825-23-5

4213-51-8496-67-3

32838-26-9


mebezonium iodide (INN)mecetronium etilsulfate (INN)mefenidramium metilsulfate (INN)

methacholine chloride (INN)methylbenactyzium bromide (INN)methylbenzethonium chloride (INN)metocimum iodide (INN)miltefosine (INN)miristalkonium chloride (INN)nitricholine perchlorate (INN)

octafonium chloride (INN)oxibetame (INN)oxydipentonium chloride (INN)oxyphenonium bromide (INN)penoctonium bromide (INN)pentamethonium bromide (INN)pranolium chloride (INN)prodeconium bromide (INN)prolonium iodide (INN)stilonium iodide (INN)suxamethonium chloride (INN)suxethomum chloride (INN)tetradonium bromide (INN)tetrylammonium bromide (INN)tolocomum metilsulfate (INN)tnclobisomum chloride (INN)tridihexethy! iodide (INN)troxonium tosilate (INN)truxicunum iodide (INN)acamprosate (INN)acecartromal (INN)aceglutamide (INN)aceneuramic acid (INN)acetylleucme (INN)acexamic acid (INN)bisorcic (INN)bromacrylide (INN)bromisoval (INN)butoctamide (INN)

Vol. 1867, 1-31874


HS6

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

292410

CAS»

128326-81-8

5579-13-5541-79-7

77-65-6

78-44^i

154-93-8

35301-24-7633-47-6

6168-76-9

3342-61-8116-52-9

95-04-5

60784-46-578-28-4

56488-60-9306-41-2

18679-90-8466-14-8

3106-85-256-85-9

64-55-1

1954-79-657-53-4

76990-56-2

73105-03-0

25269-04-9544-31-0

32954-43-1

5667-70-9

26305-03-3

78512-63-7

69542-93-4

4910-46-7

78088-46-7

4268-36-451-79-6

512-48-1

52061-73-1

4171-13-5


caldiamide (INN)capuride (INN)carbocloral (INN)carbromal (INN)cansoprodol (INN)carmustine (INN)cedefingol (INN)cropropamide (INN)crotetamide (INN)deanol aceglumate (INN)dicloralurea (INN)ectylurea (INN)elmustine (INN)emylcamate (INN)glutaurine (INN)hexcarbachoiine bromide (INN)hopantenic acid (INN)ibrotamide (INN)isospaglumic acid (INN)levoglutamide (INN)mebutamate (INN)mecloralurea (INN)meprobamate (INN)milacemide (INN)neptamustine (INN)msobamate (INN)palmidrol (INN)pendecamaine (INN)pentabamate (INN)pepstatm (INN)pimelautide (INN)pivagabine (INN)spaglumic acid (INN)tabilautide (INN)tybamate (INN)urethane (INN)valdetamide (INN)valdipromide (INN)valnoctamide (INN)

Vol. 1867, 1-31874


HS6

292410

292421

292421

292421

292421

292421

292421

292421

292421

292421

292421

292421

292421

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

CAS*

2430-27-5

34866-47-2

56980-93-9

51213-99-1

87721-62-8369-77-7

13010-47-4

71475-35-9

103055-07-8

74738-24-2

13909-09-6

57460-41-0101-20-2

37517-30-9

32795-44-1556-08-1

118-57-0

18699-02-0

54785-02-3606-17-7

2901-75-9

3011-89-0

139402-18-9

26750-81-2

5486-77-1

88321-09-9115-79-7

519-88-0

787-93-9

5591-49-1

87071-16-7

22839^7-0

29122-68-7

16231-75-7

65617-86-9

81732-65-2

102670-46-2501-68-8

5003^8-5


valpromide (INN)

carbuterol (INN)

celiprolol (INN)

clanfenur (INN)

flestolol (INN)

halocarban (INN)

lomustine (INN)

lozilurea (INN)

lufenuron (INN)

recainam (INN)

semustine (INN)

talinolol (INN)

triclocarban (INN)

acebutolol (INN)

acecainide (INN)

acedoben (INN)

acetaminosalol (INN)

actant (INN)

adamexine (INN)

adiptodone (INN)

afalanine (INN)

aklomide (INN)

alestramustine (INN)

ahbendol (INN)

alloclamide (INN)

aloxistatin (INN)

ambenonium chloride (INN)

ambucetamide (INN)

ameltolide (INN)

anilamate (INN)

arclofenm (INN)

aspartame (INN)

atenolol (INN)

atolide (INN)

avizafone (INN)

bambuterol (INN)

batanopnde (INN)

beclamide (INN)

benonlate (INN)

Vol. 1867, 1-31874


HS6

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

CAS*

15686-76-7

37106-97-1148-07-2

3440-28-6

41859-67-0

70976-76-0

67579-24-2332-69-4

4093-35-0

41113-86-4

40912-73-0

54340-61-3

86216-41-3

1083-57-4575-74-6

32421-46-8

1233-53-0

4663-83-6

3785-21-5

66292-52-2528-96-1

123122-55-4

123122-54-3

21434-91-363-25-2

5749-67-7

15687-16-8

1042-42-8

3567-38-2

98815-38-4

34919-98-7735-52-4

97-27-8

64379-93-7

58473-74-8

5588-21-6

75616-03-4

10423-37-7

6170-69-0


bensalan (INN)bentiromide (INN)benzmalecene (INN)betamipron (INN)bezafibrate (INN)bifepramide (INN)bromadoline (INN)bromamide (INN)bromopride (INN)bromoxanide (INN)

brosotamide (INN)brovanexine (INN)broxitalamic acid (INN)bucetin (INN)buclosamide (INN)bunaftine (INN)bunamiodyl (INN)buramate (INN)butanilicaine (INN)butilfenin (INN)calcium benzamidosalicylate (INN)candoxatril (INN)candoxatnlat (INN)capobenic acid (INN)carbaryl (ISO) carbanl (INN)carbasalate calcium (INN)carbifene (INN)carcainium chloride (INN)carfimate (INN)casokefamide (INN)cetamolol (INN)cetofenicol (INN)chlorbetamide (INN)cinfiumide (INN)cinromide (INN)cmtramide (INN)ciprazafone (INN)citenamide (INN)clamidoxic acid (INN)

Vol. 1867, 1-31874


HS6

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

CAS»

.30544-61-7

3576-64-5

3207-50-9

14437-41-3

18966-32-0

5626-25-5

1223-36-5

26717-47-5

14261-75-7

15301-50-5

15687-05-5

65569-29-1

30531-86-3

14008-60-7483-63-6

5779-54-4

7199-29-3

14817-09-5

83435-66-956-94-0

3734-33-6

119817-90-2

2623-33-8

28197-69-5

36141-82-9552-25-0

87-12-7

24353-45-5

15585-88-3

17243-49-1134-62-3

75659-07-3579-38-4

60-46-8

58338-59-3

71119-12-5148-01-6

101-71-3

65717-97-7


clanobutin (INN)

clefamide (INN)

clmolamide (INN)

clioxanide (INN)

clocanfamide (INN)

clodacaine (INN)

clofexamide (INN)

clofibride (INN)

cloforex (INN)

cloponone (INN)

cloracetadol (INN)

cloxacepnde (INN)

colfenamate (INN)

cresotamide (1NN)

crotamiton (INN)

cyclarbamate (INN)

cyheptamide (INN)

decimemide (INN)

delapril (INN)

demecarium bromide (INN)

denatonium benzoate (INN)

dexloxiglumide (INN)

diacetamate (INN)

diacetolol (INN)

diamfenetide (INN)

diampromide (INN)

dibromsalan (INN)

dibusadol (INN)

dicarfen (INN)

diclometide (INN)

diethyltoluamide (INN)

dilevalol (INN)

diloxanide (INN)

dimevamide (INN)

dinalin (INN)

dinazafone (INN)

dinitolmide (INN)

diphenan (INN)

disofenin (INN)

Vol. 1867, 1-31874

2SS United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995

HS6

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

CAS*

54063-35-3

39907-68-1

75616-02-3

104775-36-2

71027-13-9

15687-14-6

2521-01-9

4582-18-7

10087-89-5

2998-57-4304-84-7

62992-61-4938-73-8

126-52-3

5714-09-0

36637-18-0

63245-28-3

25287-60-9

15302-15-5

53370-90-4

25451-15-4

4665-04-7306-20-7

27736-80-7

4551-59-1

54063-40-0

65646-68-6

5107-49-3847-20-1

40256-99-3

30533-89-2

4776-06-1

13311-84-7

15302-18-8

73573-87-2

19368-18-4

106719-74-8

26718-25-2358-52-1


dofamium chloride (INN)dopamantine (INN)dulozafone (INN)ecabapide (INN)eclanamine (INN)embutramide (INN)encyprate (INN)

endomide (INN)

enpromate (INN)

estramustme (INN)

etamivan (INN)

etersalate (INN)

ethenzamide (INN)

ethinamate (INN)

ethyl cartrizoate (INN)

etidocaine (INN)

etifenin (INN)

etofamide (INN)

etosalamide (INN)

exalamide (INN)

felbamate (INN)

fenacetmol (INN)

fenaclon (INN)

fenaftic acid (INN)

fenalamide (INN)

fenoxedil (INN)

fenretimde (INN)

flualamide (INN)

flubanilate (INN)

flucetorex (INN)

flurantel (INN)

flusalan (INN)

flutamide (INN)

fomnetorex (INN)

formoterol (INN)

ftaxilide (INN)

galtifenin (INN)

halofenate (INN)

hexapropymate (INN)

Vol. 1867, 1-31874


HS6

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

CAS*

.6961-46-2

74517-78-5

3115-05-7

136949-58-1

10397-75-8

16034-77-8440-58-4

81045-33-2

92339-11-2

31127-82-9

141660-63-1

49755-67-1

63941-73-1

63941-74-2

56562-79-9

2618-25-9

66108-95-0

22730-86-5

25827-76-3

78649-41-9

62883-00-5

89797-00-2

1456-52-6

73334-07-3

37723-78-7

97702-82-4

5591-33-3

51876-99-4

79211-10-2

37863-70-0

2276-90-6

60019-19-4

26887-04-7

79211-34-0

16024-67-2

79770-24-4

51022-74-3

87771^*0-2-00-0


idrocilamide (INN)indecamide (INN)iobenzamic acid (INN)iobitridol (INN)iocarmic acid (INN)iocetamic acid (INN)

iodamide (INN)

iodecimol (INN)

iodixanol (INN)

lodoxamic acid (INN)

lotratoi (INN)

ioglicic acid (INN)

loglucol (INN)

ioglucomide (INN)

ioglunide (INN)

ioglycamic acid (INN)

iohexol (INN)

iolixanic acid (INN)

lomeglamic acid (INN)

iomeprol (INN)

iopamidol (INN)

iopentol (INN)

loprocemic acid (INN)

iopromide (INN)

lopronic acid (INN)

iosarcol (INN)

losefamic acid (INN)toseric acid (INN)losimide (INN)iosumetic acid (INN)lotalamic acid (INN)lotetnc acid (INN)

lOtranic acid (INN)

iotriside (INN)

iotrizoic acid (INN)

iotrolan (INN)

iotroxic acid (INN)

ioversol (INN)

ioxabrolic acid (INN)

Vol. 1867, 1-31874


HS6

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

CAS*

.59017-64-0

107793-72-6

28179-44-4

19863-06-0

31598-07-971-81-8

122898-67-3

36894-69-6137-58-6

59160-29-1

24353-88-6

97964-56-2

59179-95-2

107097-80-3

82821 -47-4

78266-06-5

1227-61-8

54870-28-9

14417-88-0

2577-72-2621-42-1

100-95-8

532-03-6

364-62-5

42794-76-3

92623-85-3

29619-86-1

56281-36-8

1505-95-9114-80-7

50-65-7

2444-46-4

13912-77-1

58493-49-5526-18-1

26095-59-0

70009-66-4126-93-2

70541-17-2


ioxaglic acid (INN)ioxilan (INN)ioxitalamic acid (INN)ioxotrizoic acid (INN)iozomic acid (INN)isopropamide iodide (INN)itopride (INN)

labetalol (INN)

lidocame (INN)

lidofenin (INN)

lorbamate (INN)

lorglumide (INN)

lorzafone (INN)

loxiglumide (INN)

mabuprofen (INN)

mebrofenin (INN)

mefexamide (INN)

meglitinide (INN)

melmamide (INN)

metabromsalan (INN)

metacetamol (INN)

metalkomum chloride (INN)

methocarbamol (INN)

metoclopramide (INN)

midodrine (INN)

rniinacipran (INN)

moctamide (INN)

motretinide (INN)

naftypramide (INN)

neostigmme bromide (INN)

niclosamide (ISO) (INN)

nonivamide (INN)

octacaine (INN)

olvanil (INN)

osalmid (INN)

otilonium bromide (INN)

oxalinast (INN)

oxanamide (INN)

oxazafone (INN)

Vol. 1867, 1-31874


HS6

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

CAS»

126-27-2

29541-85-3

2277-92-150-19-1

75949-61-0

59110-35-9

1693-37-4

30653-83-9

5579-05-5

5579-06-663-98-9

62-44-2

90-49-3

673-31-4

6673-35-4721-50-6

51-06-9

13931-64-1

62666-20-0

6620-60-6

66532-85-2

1421-14-3730-07-4

5579-08-8

17692-45-4

22662-39-1

128298-28-2

20788-07-2

90895-85-5487-48-9

36093-47-7

46803-81-0587-49-5

65-45-2

6376-26-7

57227-17-5129-63-5

737-31-5

129-57-7


oxetacaine (INN)

oxitriptyline (INN)

oxyclozanide (INN)

oxyfenamate (INN)

pafenolol (INN)

pamatoloi (INN)

parapropamol (INN)

parsalmide (INN)

paxamate (INN)

pentalamide (INN)

phenacemide (INN)

phenacetin (INN)

pheneturide (INN)

phenprobamate (INN)

practolol (INN)

prilocaine (INN)

procainamide (INN)

procymate (INN)

progabide (INN)

proglumide (INN)

propacetamol (INN)

propanidid (INN)

propetamide (INN)

propyl docetrizoate (INN)

quatacaine (INN)

rafoxanide (INN)

remacemide (INN)

resorantel (INN)

ronactolol (INN)

salacetamide (INN)

salantel (INN)

saletamide (INN)

salfluvenne (INN)

salicylamide (INN)

salverine (INN)

sevopramide (INN)

sodium acetrizoate (INN)

sodium amidotrizoate (INN)

sodium diprotrizoate (INN)

Vol. 1867, 1-31874


HS6

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292429

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

292519

CAS*

7225-61-8

7246-21-194-35-9

129-46-4

5560-78-1

51012-32-9

55837-29-1

41708-72-9

38103-61-6

3686-58-6

97964-54-0

53902-12-887-10-5

6340-87-0

76812-98-1616-68-2

138-56-7

58970-76-6

38647-79-9

2897-83-8

51411-04-2125-84-8

69408-81-7

1673-06-964-65-3

22855-57-8

15518-76-077-67-8

60-45-7

77-21-4

77^)1-8

10403-51-7

54824-17-8

6319-06-8

1156-05-486-34-0

14166-26-8

21925-88-2

35423-09-7


sodium metrizoate (INN)sodium tyropanoate (INN)styramate (INN)suramin sodium (INN)teclozan (INN)tiapride (INN)tiropramide (INN)

tocainide (INN)

tolamolol (INN)

tolycaine (INN)

tomoglumide (INN)tranilast (INN)tribromsalan (INN)trictacetamol (INN)trigevolol (INN)

trimecaine (INN)

trimethobenzamide (INN)

ubemmex (INN)

urefibrate (INN)

alonimid (INN)

alrestatm (INN)

ammoglutethimide (INN)

amonafide (INN)

amphotalide (INN)

bemegride (INN)

brosuximide (INN)

ciproximide (INN)

ethosuximide (INN)

femmide (INN)

glutethimide (INN)

mesuximide (INN)

mitindomide (INN)

mitonafide (INN)

noreximide (INN)

phenglutanmide (INN)

phensuximide (INN)

taglutimide (INN)

tesicam (INN)tesimide (INN)

Vol. 1867, 1-31874


HS6

292519

292519

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

CAS*

7696-12-050-35-1

22573-93-9

5581 -35-1

3459-96-9

49745-00-8

33089-61-174-79-3

4320-30-3

81907-78-0

78718-52-255-73-2

85125-49-1692-13-7

3748-77-4

59721-28-7

22790-84-755-56-1

537-21-3

6903-79-3496-00-4

45086-03-1

80018-06-0

39492-01-8

55926-23-3

29110-47-2

3658-25-1

13050-83-4

104317-84-2

3811-75-4495-99-8

135^3-3

66871-56-5

46464-11-3657-24-9

459-86-9

81525-10-2

76631-45-3886-08-8


tetramethrin (ISO) (INN)

thaiidomide (INN)

alexidine (INN)

amfecloral (INN)

amicarbalide (INN)

amidantel (INN}

amîtraz (ISO) (INN)

argmine (INN)

arginine L-glutamate (INN)

batebulast (INN)

benexate (INN)

betanidine (INN)

biclodil (INN)

buformin (INN)

bunamidine (INN)

camostat (INN)

carbantel (INN)

chiorhexidme (INN)

chlorproguanil (INN)

creatinolfosfate (INN)

dibrompropamidine (INN)

etoformin (INN)

fengabine (INN)

gabexate (INN)

guanclofine (INN)

guanfacine (INN)

guanoctine (INN)

guanoxyfen (INN)

guspenmus (INN)

hexamidine (INN)

hydroxystilbamidine (INN)

lauroguadme (INN)

lidamidine (INN)

meobentme (INN)

metformin (INN)

mitoguazone (INN)

nafamostat (INN)

napactadine (INN)

norletimol (INN)

Vol. 1867, 1-31874


HS6

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292520

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

292690

CAS*

.5879-67-4

7232-51-1100-33-4

101-93-9

114-86-3

500-92-5

104-32-5

1729-61-9

1221-56-3140-59-0

85465-82-3

4210-97-3

86914-11-6

6443-40-9

65899-72-1

17590-01-1

83200-10-6

1069-55-2

34915-68-9

54239-37-1

21702-93-2

57808-65-8

85247-76-3

92302-55-1

38321-02-7

78370-13-5

6606-65-1

130929-57-6

86880-51-5

80471-63-2

15599-27-6

5232-99-5

15686-61-0

23023-91-8

16662-47-8

1113-10-677-51-0

101238-51-1

53882-12-5


oletimol (INN)pararosaniline embonate (INN)pentamidine (INN)phenacaine (INN)phenformin (INN)proguanil (INN)propamidine (INN)renytoiine (INN)sodium iopodate (INN)stilbamidine isetionate (INN)thymotrinan (INN)tiformin (INN)tolgabide (INN)xylamidine tosilate (INN)aiozafone (INN)amfetaminil (INN)anipamil (INN)bucrilate (INN)bunitrolol (INN)cimaterol (INN)cloguanamil (INN)closantel (INN)

dagapamil (INN)devapamil (INN)dexverapamil (INN)emopamil (INN)enbucrilate (INN)entacapone (INN)epanolol (INN)epostane (INN)etaminile (INN)etocrilene (INN)fenproporex (INN)flucnlate (INN)gallopamil (INN)guancidine (INN)isoaminile (INN)levemopamil (INN)lodoxamide (INN)

Vol. 1867, 1-31874


HS6

292690

292690

292690

292690

292690

292690

292690

292690

292690

292700

292700

292700

292700

292700

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

CAS*

.137-05-3

136033-49-3

1689-89-0

6701-17-3

6197-30-4

58503-83-6

85247-77-4

111753-73-252-53-9

80573-04-2502-98-7

536-71-0

94-10-0

80573-03-1546-88-3

5854-93-3

34297-34-2

15256-58-3

7654-03-7322-35-0

38274-54-3

4267-81-6555-65-7

2438-72-4

3583-64-0

53078-44-7

81424-67-1

3240-20-8

28860-95-9

25394-78-9

3788-16-7

54739-19-4

58832-68-1140-87-4

70-51-9

24701-51-7511-41-1

85750-38-5

105613-48-7


mecrilate (INN)nexopamil (INN)

nitroxinil (INN)

ocrilate (INN)

octocrilene (INN)

penirolol (INN)

ronipamil (INN)

satigrel (INN)

verapamii (INN)

balsalazide (INN)

chlorazodin (INN)

diminazene (INN)

etoxazene (INN)

ipsalazide (INN)

acetohydroxamic acid (INN)

alanoslne (INN)

anidoxime (INN)

beloxamide (INN)

benmoxin (INN)

benserazide (INN)

benurestat (INN)

bolazme (INN)

brocresine (INN)

bufexamac (INN)

bumadizone (INN)

caproxamine (INN)

caracemide (INN)

carbenzide (INN)

carbidopa (INN)

cetoxime (INN)

cimemoxin (INN)

clovoxamme (INN)

cloximate (INN)

cyacetacide (INN)

deferoxamme (INN)

demexiptiline (INN)

diphoxazide (INN)

erocamide (INN)

exametazime (INN)

Vol. 1867, 1-31874


HS6

292BOO

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292800

292990

292990

292990

292990

292990

292990

292990

292990

292990

CAS»

90581-63-8

3818-37-9

54739-18-3

5051-62-7

5001-32-1

7473-70-3127-07-1

53648-05-8

127420-24-0

3544-35-2

60070-14-665-64-5

54063-51-3

46263-35-8

15687-37-3

57925-64-1

51354-32-6

3362-45-6

4684-87-151-71-8

103-03-7

55-52-7

14816-18-379-17-4

671-16-9

25875-51-8

20228-27-7

5579-27-1

78372-27-7

56187-89-4

52658-53-4

52758-02-8299-86-5

3733-81-1

15339-50-1

70788-28-2

1491-41-4139-05-9

70788-29-3


falintolol (INN)

fenoxypropazine (INN)

fluvoxamine (INN)

guanabenz (INN)

guanoclor (INN)

guanoxabenz (INN)

hydroxycarbamide (INN)

ibuproxam (INN)

idrapri! (INN)

iprociozide (INN)

manptiline (INN)

mebanazine (INN)

nadoxolol (INN)

nafomine (INN)

naftazone (INN)

naprodoxime (INN)

nistenme (INN)

noxiptiline (INN)

octamoxin (INN)

phenelzine (INN)

phenicarbazide (INN)

pheniprazine (INN)

phoxim (ISO) (INN)

pimaged/ïne/ (INN)

procarbazine (INN)

robemdine (INN)

ruvazone (INN)

simtrazene (INN)

stirocainide (INN)

ximoprofen (INN)

benfosformm (INN)

benzapnnoxide (INN)

crufomate (ISO) (INN)

defosfamide (INN)

ferrotrenine (INN)

flurofamide (INN)

naftalofos (INN)

sodium cy clama te (INN)

tolfamide (INN)

Vol. 1867, 1-31874


HS6

293020

293020

293030

293030

293030

293040

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

CAS*

148-18-5

3735-90-897-77-8

95-05-6

137-26-8

63-68-3

77-46-3

127-60-6

616-91-1

63547-13-7

5667-98-1144-75-2

5965-40-2109-57-9

123955-10-2

85754-59-2539-21-9

3569-77-5

20537-88-6

26328-53-0305-97-5

106854-46-0

42293-72-1

103725-47-9

79467-22-497-18-7

844-26-8

4044-65-9

23233-88-7

65002-17-7108-02-1

486-17-9

638-23-3

786-19-6

473-32-5

82009-34-5

1166-34-3

89163-44-0

86042-50-4


ditiocarb sodium (INN)fencarbamide (INN)disulfiram (INN)sulfiram (INN)thiram (ISO) (INN)methionine (INN)acedapsone (INN)acediasulfone sodium (INN)

acetylcysteine (INN)

adrafinil (INN)

aldesulfone sodium (INN)

aldesulfone sodium (INN)

allocupreide sodium (INN)

allylthiourea (INN)

almokalant (INN)

ambamustine (INN)

ambazone (INN)

amidapsone (INN)

amifostine (INN)

amoscanate (INN)

anthiolimme (INN)

argimesna (INN)

bencisteme (INN)

betiatide (INN)

bipenamol (INN)

bithionol (INN)

brthionoloxide (INN)

bitoscanate (INN)

brotianide (INN)

bucillamine (INN)

captamine (INN)

captodiame (INN)

carbocisteme (INN)

carbophenothion (ISO) carbofenotion (INN)

chaulmosulfone (INN)

cilastatin (INN)

cmansenn (INN)

cinaproxen (INN)

cistinexine (INN)

Vol. 1867, 1-31874


HS6

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

CAS*

. 87556-66-952-90-4

18725-37-6

4938-00-580-08-0

5964-62-559-52-9

16208-51-867-68-5

5835-72-3

82599-22-2584-69-0

502-55-6

74639-40-0

112573-73-6513-10-0

87719-32-2

1234-30-6

58306-30-297-24-5

76639-94-6

113593-34-3

2924-67-6

90566-53-3

2507-91-7554-18-7

3569-59-3

83519-04-4

66608-32-0

23205-04-1

71767-13-0

88041-40-1

127304-28-3790-69-2

67110-79-6

2485-62-360-23-1

66516-09-4

19767-45-4


cloticasone (INN)cysteine (INN)dacisteme (INN)danosteine (INN)dapsone (INN)diathymosulfone (INN)dimercaprol (INN)dimesna (INN}dimethyl sulfoxide (INN)diprofene (INN)ditiomustine (INN)ditophal (INN)dixanthogen (INN)docarpamine (INN)ecadotnl (INN)ecothiopate iodide (INN)etarotene (INN)etocartide (INN)febantel (INN)fenticlor (INN)florfenicol (INN) 294140

flosatidil (INN)

fiuoresone (INN)

fluticasone (INN)

gloxazone (INN)

glucosulfone (INN)

hexasonium iodide (INN)

ilmofosine (INN)

imcarbofos (INN)

losulamide (INN)

iotasul (INN)

lemidosul (INN)

linarotene (INN)

loflucarban (INN)

luprostiol (INN)

mecysteine (INN)

mercaptamine (INN)

mertiatide (INN)

mesna (INN)

Vol. 1867, 1-31874


HS6

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

CAS*

926-93-2

66960-34-7

68693-11-8

122575-28-4

88255-01-0

19881-18-6

15599-39-0

35727-72-1

27450-21-1

27025-41-8

3569-58-2

1 14568-26-252-67-5

81045-50-3

5287-46-7

23288-49-5

34914-39-1

89767-59-9

54657-98-6

6385-58-6133-65-3

121-55-1

304-55-2

5934-14-5

66264-77-5

42461-79-0

38194-50-2

54063-56-8

25827-12-7

69217-67-0

105687-93-2

94055-76-2

85053-46-9

3383-96-8500-89-0

104-06-3

111-48-8

6964-20-1

55837-28-0


metallibure (INN)metkefamide (INN)

modafinil (INN)

naglivan (INN)

netobirnin (INN)

nrtroscanate (INN)noxytiolin (INN)

ontianil (INN)osmadizone (INN)oxiglutatione (INN)

oxysonium iodide (INN)

patamostat (INN)penicillamine (INN)

pivopril (INN)

prenisteine (INN)

probucol (INN)

ritiometan (INN)salmisteine (INN)serfibrate (INN)sodium bitionolate (INN)

solasulfone (INN)

subathizone (INN)

succimer (INN)

succisulfone (INN)

sulfinalol (INN)

sulfonterol (INN)

sulindac (INN)

suloctidil (INN)

suloxifen (INN)

sumacetamol (INN)

sumarotene (INN)

suplatast tosilate (INN)

suricainide (INN)

temephos (ISO) temefos (INN)

thiambutosine (INN)

thioacetazone (INN)

thiodiglycol (INN)

tiadenol (INN)

tiafibrate (INN)

Vol. 1867, 1-31874


HS6

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293090

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

CAS*

.10433-71-3

129731-11-9

13402-51-282-99-5

53993-67-2

89987-06^910-86-1

10489-23-3

1953-02-2

39516-21-7

15686-78-9

26481-51-6

70895-45-3

67040-53-3

50838-36-3

27877-51-6

38452-29-8

2398-96-1

82964-04-3

7009-79-2

22012-72-297.44-9

60668-24-8

66376-36-198-50-0

103486-79-9

17316-67-5

51395-42-7126-22-7

121-59-5

62-37-3

10596-23-3455-83-»

65606-61-3

3639-19-8

68959-20-6

2809-21-4

73514-87-1

63585-09-1


tiametonium iodide (INN)tibeglisene (INN)tibenzate (INN)tifenamil (INN)tiflorex (INN)tiludromc acid (INN)tiocarlide (INN)tioctilate (INN)tiopronm (INN)

tiopropamine (INN)

tiosalan (INN)

tiprenoiol (INN)

tipropidil (INN)

tiprostanide (INN)

tolciclate (INN)

tolindate (INN)

tolmesoxide (INN)

tolnaftate (INN)

toirestat (INN)xenthiorate (INN)zilantel (INN)

acetarsol (INN)

alafosfaltn (INN)alendronic acid (INN)

arsanihc acid (INN)

belfosdil (INN)

butafosfan (INN)

butedronic acid (INN)

butonate (ISO) (INN)

carbarsone (INN)

chlotmerodnn (INN)

clodronic acid (INN)

dichlorophenarsme (INN)

diciferron (INN)

difetarsone (INN)

disiquonium chlonde (INN)

etidromc acid (INN)

fosanlate (INN)

foscarnet sodium (INN)

Vol. 1867, 1-31874


HS6

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293100

293219

293219

CAS*

2398-95-0

16543-10-5

54870-27-8

13237-70-2

92118-27-9116-49-4

14235-86-0

1984-15-2

20223-84-1525-30-4

498-73-7

492-18-2

76541-72-5457-60-3

79778-41-998-72-6

15468-10-7306-12-7

40391-99-9535-51-3

8017-88-7

33204-76-1121-19-7

5964-24-9

51321-79-0

1344-34-9

5959-10-4618-82-6

75018-71-2

127502-06-1

14433-82-054-64-8

2430-46-8

57808-64-7

19028-28-552-68-6

554-72-3

72420-38-3

75748-50-4


foscolic acid (INN)

fosenazide (INN)

fosfonet sodium (INN)

fosmenic acid (INN)

fotemustine (INN)

glycobiarsol (INN)

hydrargaphen (INN)

medronic acid (INN)

mercaptomenn (INN)

mercuderamide (INN)

mercurobutol (INN)

mersalyl (INN)

mifobate (INN)

neoarsphenamine (INN)

neridronic acid (INN)

nitarsone (INN)

oxidronic acid (INN)

oxophenarsme (INN)

pamidronic acid (INN)

phenarsone sulfoxylate (INN)

phenylmercunc borate (INN)

quadrosilan (INN)

roxarsone (INN)

sodium timerfonate (INN)

spartosic acid (INN)Stibamme glucoside (INN)

stibosamine (INN)

sulfarsphenamme (INN)

taurosetchohc acid (INN)

tetrofosmm (INN)

thiacetarsamide sodium (INN)

thiomersat (INN)

tolboxane (INN)

toldimfos (INN)

toliodium chloride (INN)

tnchlorfon (ISO) metrrfonate (INN)

tryparsamide (INN)

acifran (INN)

ancaroiol (INN)

Vol. 1867, 1-31874


HS6

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293219

293229

293229

293229

293229

293229

293229

CAS*

28434-01-7

53684-49-4

29899-95-4

64743-08-4735-64-8

3690-58-2

3776-93-0

4662-17-3549-40-6

15686-77-8541-64-0

55902-93-7

31329-57-4405-22-1

3270-71-1

19561-70-7

5580-25-6

5579-95-3965-52-6

6236-05-1

5579-89-5

16915-70-167-28-7

84845-75-0

64743-09-559-87-0

60653-25-0

66357-35-5

33779-37-2

6673-97-8

10310-32-4

93064-63-2

3563-92-6642-83-1

152-72-7

67696-82-6

65776-67-276-65-3

3447-95-8


bioresmethrin (ISO) (INN)bufetolol (INN)clobenoside (INN)dtclofurime (INN)

fenamifuril (INN)

fubrogonium iodide (INN)

furfenorex (INN)

fundarone (INN)

furostilbestrol (INN)

fursalan (INN)

furtrethonium iodide (INN)

mebenoside (INN)

naftidrofuryl (INN)

nidroxyzone (INN)

nifuraldezone (INN)

nifuratrone (INN)

nifurethazone (INN)

nifurmerone (INN)

nifuroxazide (INN)

nifuroxime (INN)

nifursemizone (INN)

nifursol (INN)

nihydrazone (INN)

niperotidine (INN)

nitrafudam (INN)

nitrofural (INN)

orpanoxin (INN)

ranitidme (INN)

salprotoside (INN)

spiroxasone(INN)

tnbenoside (INN)

venntidine (INN)

zylofuramme (INN)

aceglatone (INN)

acenocoumarol (INN)

acnhellm (INN)

afurolol (INN)

amolanone (INN)

benfurodil hemisuccmate (INN)

Vol. 1867, 1-31874


HS6

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

CAS*

58409-59-9465-39-4

976-71-6

804-10-4

35838-63-2

60986-89-2

68206-94-056-72-4

4366-18-1

132100-55-1

1233-70-166-76-2

67392-87-4476-66-4

2908-75-0

91406-11-0548-00-5

480-49-9

87810-56-8

67268-43-3

32449-92-6321-55-1

90-33-5

81478-25-3

112856-44-7

75330-75-5

87952-98-5

52814-39-8

73573-88-3

75992-53-9

96829-58-2

15301-80-177-09-8

435-97-2

57-57-8

33156-28-4

79902-63-952-01-7

74220-07-8


bucumolol (INN)

bufbgenin (INN)

canrenone (INN)

carbocromen (INN)

clocoumarol (INN)

clofurac (INN)

cloricromen (INN)

coumaphos (ISO) coumafos (INN)

coumetarol (INN)

dalvastatin (INN)

diarbarone (INN)

dicoumarol (INN)

drospirenone (INN)

ellagic acid (INN)

esculamme (INN)

esuprone (INN)

ethyl biscoumacetate (INN)

filipm (INN)

fostriecin (INN)

giparmen (INN)

giucurolactone (INN)

haloxon (INN)

hymecromone (INN)

lomevactone (INN)

losigamone (INN)

lovastatm (INN)

mespirenone (INN)

metesculeloi (INN)

mevastatin (INN)moxadolen (INN)orlistat (INN)oxamann (INN)

phenolphthalem (INN)

phenprocoumon (INN)

propiolactone (INN)

ramnodigin (INN)

simvastatm (INN)

spironolactone (INN)

spirorenone (INN)

Vol. 1867, 1-31874


HS6

293229

293229

293229

293229

293229

293229

293229

293229

293229

293229

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

CAS*

29334-07-4

42422-68-4

66898-60-0

75139-06-9

3902-71-4

3258-51-3477-32-7

81-81-2

15301-97-0

26538-44-3

96566-25-5

56180-94-0

25161-41-5

2455-84-7

58805-38-2

4439-67-2

1951-25-3

79130-64-6

123072-45-7

71963-77-4

63968-64-9

88495-63-0

39552-01-7

27661-27-4

85443-48-7

81703-42-6

1477-19-6

3562-84-368-90-6

13157-90-9

88430-50-6

72619-34-2

58546-54-6

55102^4-8

78371-66-1

54340-62-4

4442-60-8

59733-86-7

55165-22-5


sulmarin (INN)talerano! (INN)talosalate (INN)tetronasin (INN)trioxysaien (INN)valofane (INN)visnadine (INN)warfarin (ISO) (INN)xylocoumarol (INN)zeranol (INN)ablukast (INN)acarbose (INN)acevaltrate (INN)ambenoxan (INN)ambicromil (INN)amikhellme (INN)amiodarone (INN)ansoxetine (INN)aprosulate sodium (INN)artemether (INN)artemisinin (INN)artesunate (INN)befunolol (INN)benaxibine (INN)bencianol (INN)bendacalol (INN)benzarone (INN)benzbromarone (INN)benziodarone (INN)benzquercin (INN)beraprost (INN)bermoprofen (INN)besigomsin (INN)bofumustine (INN)bucromarone (INN)bufuralol (INN)

butamoxane (INN)

butikacm (INN)

butocrolol (INN)

Vol. 1867, 1-31874


HS6

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

CAS*

12569-38-9

56689-43-1521-35-7

15879-93-3

4940-39-0154-23-4

19705-61-4

3607-18-9

34753-46-3

59729-33-8

3611-72-1

66575-29-9

16110-51-3

66211-92-5

18296-45-2

1165-48-6

6538-22-3

80743-08-4

3567-40-678-34-2

18467-77-1

114977-28-5

61869-07-661-74-5

122312-55-4

55286-56-1

1668-19-5

1972-08-3

98383-18-7

90733-40-7119-41-5

35121-78-9

15686-63-2

16509-23-2

59619-81-7

77416-65-0

34887-52-0

29041-71-2

15686-60-9


calcium glubionate (INN)

canbisol (INN)

cannabinol (INN)

chloralose (INN)

chromocarb (INN)

cianidanol (INN)

cicortonide (INN)

cîdoxepin (INN)

ciheptolane (INN)

citatopram (INN)

clondarol (INN)

colforsin (INN)

cromoglicic acid (INN)

detorubicin (INN)

didrovaltrate (INN)

dimeflme (INN)

dimeprozan (INN)

dioxadilol (INN)

dioxamate (INN)

dioxathion (ISO) dioxation (INN)

diprogulic acid (INN)

docetaxel (INN)

domiodol (INN)

domoxtn (INN)

dosmalfate (INN)

doxaminoi (INN)

doxeprn (INN)

dronabinol (INN)

ecomustine (INN)edifolone (INN)efloxate (INN)epoprostenol (INN)

etabenzarone (INN)

ethomoxane (INN)

etiproston (INN)

exepanol (INN)

fenisorex (INN)

feme fructose (INN)

flavamine (INN)

Vol. 1867, 1-31874


HS6

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

CAS*

37470-13-6

79619-31-1

71316-84-2

23580-33-8

67700-30-5

58012-63-8

38873-55-1

56983-13-2

105618-02-8

3416-24-8

61914-43-0

19889-45-3

81674-79-5

40580-59-4

2165-19-7451-77-4

35212-22-7

37855-80-4

116818-99-6

57009-15-1652-67-5

87-33-2

16051-77-7

55453-87-782-02-0

585-86-4

480-17-1

65350-86-9

26225-59-2

56290-94-9

4386-35-0129-16-8

53-46-3

B5-90-5

31112-62-6

87626-55-9

1508-45-8

74817-61-1

51022-71-0


flavodic acid (INN)

flavodiiol (INN)

fluradoline (INN)

furacrinic acid (INN)

furaprofen (INN)

furcloprofen (INN)

furobufen (INN)

furofenac (INN)

galamustine (INN)

glucosamme (INN)

glucuronamide (INN)

guabenxan (INN)

guaimesal (INN)

guanadrel (INN)

guanoxan (INN)

homarylamine (INN)

ipriflavone (INN)

iprocrolol (INN)

isalsteine (INN)

isocromil (INN)

isosorbide (INN)

isosorbide dinitrate (INN)

isosorbide mononitrate (INN)

isoxepac (INN)

khellin (INN)

lactitol (INN)

leucocianidol (INN)

meciadanol (INN)

mecinarone (INN)

medroxalol (INN)

meralem sodium (INN)

merbromin (INN)

methanthelmium bromide (INN)

methylchromone (INN)

metrizamide (INN)

mitoflaxone (INN)

mitopodozide (INN)

murabutide (INN)

nabilone (INN)

Vol. 1867, 1-31874


HS6

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

CAS*

74912-19-9

52934-83-5

99200-09-6

53983-00-9

71097-83-1

81486-22-8

22693-65-8541-66-2

55689-65-1

26020-55-3

33069-62-4

87549-36-8

4730-07-8

5684-90-2

67102-87-8

42408-79-7

68298-00-0

53341-49-4

23873-85-0470-43-9

50-34-0

136-70-9

60400-92-2

58994-96-0

128232-14-4

78113-36-7

22888-70-6

33889-69-9

29782-68-1474-58-8

47254-05-7

72492-12-7

49763-96-4

18883-66-4

58761-87-8

7182-51-6

108945-35-3

66112-59-2

51497-09-7


naboctate (INN)nanafrocin (INN)nebivolol (INN)

nibroxane (INN)

nileprost (INN)

nipraditol (INN)

olmidine (INN)

oxapropamum iodide (INN)

oxepinac (INN)

oxetorone (INN)

paclitaxel (INN)

parcetasal (INN)

pentamoxane (INN)

penthrichloral (INN)

pentomone (INN)

pirandamine (INN)

pimabin (INN)

ponfibrate (INN)

proligestone (INN)

promoxoiane (INN)

propantheline bromide (INN)

protokylol (INN)

proxicromil (INN)

ranimustine (INN)

raxofelast (INN)

romurtide (INN)

Silibinin (INN)

Silicnstin (INN)

silidianm (INN)

sitogluside (INN)

spiroxepin (INN)

spizofurone (INN)

sttnpentol (INN)

streptozocm (INN)

sudexanox (INN)

talopram (INN)

taprostene (INN)

temurtide (INN)

tenamfetamme (INN)

Vol. 1867, 1-31874


HS6

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293290

293311

293311

293311

293311

293311

293311

293311

293311

293311

293311

293311

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

CAS»

37456-21-6

77005-28-8602-41-5

97483-17-5

76301-19-4

40691-50-7

50465-39-9

97240-79-4

23915-73-3

30910-27-1

18296-44-1

33459-27-758-15-1

747-30-8

55837-24-6

7077-30-7

1046-17-9

22881-35-268-89-3

2139-47-160-80-0

479-92-5

3615-24-5105-20-4

50270-32-1

60104-29-2

81528-80-5

70181-03-2

20170-20-1

23111-34-4

30748-29-9

80410-36-2

7554-65-6

115436-73-2

50270-33-2853-34-9

53808-88-1

119322-27-9

7125-67-9


terbucromil (INN)texacromil (INN)thiocolchicoside (INN)tifurac (INN)timefurone (INN)tixanox (INN)tocofibrate (INN)topiramate (INN)trebenzomine (INN)treloxinate (INN)valtrate (INN)xanoxic acid (INN)aminophenazone (INN)ammophenazone cyclamate (INN)bisfenazone (INN)butopyrammonium iodide (INN)dibupyrone (INN)famprofazone (INN)metamizole sodium (INN)nifenazone (INN)phenazone (INN)propyphenazone (INN)ramifenazone (INN)betazole (INN)bufezolac (INN)clofezone (INN)dalbrammol (INN)dazopnde (INN)difenamizole (INN)feclobuzone (INN)feprazone (INN)fezolamme (INN)fomepizole (INN)tpazilide (INN)isofezolac (INN)kebuzone (INN)lonazolac (INN)menbendan (INN)metoquizine (INN)

Vol. 1867, 1-31874


HS6

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293319

293321

293321

293321

293321

293321

293321

293321

293321

293321

293321

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

CAS*

.2210-63-1

55294-15-0

59040-30-1129-20-4

50-33-9

71002-09-0

4023-00-1

34427-79-757-96-5

27470-51-5

103475-41-8

13221-27-7

32710-91-1

40828-44-2

5588-20-586-35-1

93390-81-9

89391-50-450-12-4

63612-50-057-41-0

122946-42-3

56605-16-4

91017-58-2830-89-7

1317-25-5

5579-81-7

63824-12-4

33178-86-8

4474-91-353-73-6

91-75-8

66711-21-5

60173-73-1

104054-27-5

40828-45-3

31478-45-2

57647-79-7

63927-95-7


mofebutazone (INN)

muzolimine (INN)

nafazatrom (INN)

oxyphenbutazone (INN)

phenylbutazone (INN)

pirazolac (INN)

praxadine (INN)

proxrfezone (INN)

sulfinpyrazone (INN)

suxibuzone (INN)

tepoxalin (INN)

tribuzone (INN)

trifezolac (INN)

clazolimme (INN)

clodantom (INN)

ethotoin (INN)

fosphenytoin (INN)

imirestat (INN)

mephenytoin (INN)

nilutamide (INN)

phenytoin (INN)

spinprostil (INN)

spiromustine (INN)

abumdazole (INN)

albutom (INN)

alcloxa (INN)

aldioxa (INN)

aliconazole (INN)

alinidine (INN)

angiotensin II (INN)

angiotensinamide (INN)

antazoline (INN)

apraclonidme (INN)

arfalasin (INN)

atipamezole (INN)

azolimine (INN)

bamnidazole (INN)

benctonidme (INN)

bentemazole (INN)

Vol. 1867, 1-31874


HS6

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

CAS»

.22994-85-0

60628-96-8

78186-34-2

96153-56-9

59803-98-4

108894-40-2

64872-76-0

105920-77-2

22232-54-8

42116-76-7

53267-01-9

120635-74-7

104902-08-1

51481-61-9

59939-16-1

38083-17-9

17692-28-3

4205-90-7

23593-75-1

77175-51-0

4342-03-4

76894-77-4

78218-09-4

70161-09-0

73931-96-1

122830-14-2

76631-46-4

81447-79-2

113775-47-6551-92-8

6043-01-2

3254-93-1

128326-82-9

27220-47-9

99500-54-6

113082-98-7

73790-28-0

77671-31-9

22668-01-5


benznidazole (INN)

bifonazote (INN)

bisantrene (INN)

bisfentidme (INN)

brimonidine (INN)

brolaconazole (INN)

butoconazole (INN)

camonagrel (INN)

carbimazole (INN)

carnidazole (INN)

cibenzoline (INN)

cilansetron (INN)

cilutazoline (INN)

cimetidine (INN)

cirazoline (INN)

climbazole (INN)

clonazoline (INN)

clomdme (INN)

clotnmazole (INN)

croconazole (INN)

dacarbazine (INN)

dazmegrel (INN)

dazoxiben (INN)

democonazole (INN)

denzimol (INN)

denglidole (INN)

detomidine (INN)

dexlofexidine (INN)

dexmedetomidine (INN)

dimetridazole (INN)

domazoline (INN)

doxenitoin (INN)

eberconazole (INN)

econazole (INN)

efetozole (INN)

enalkiren (INN)

enilconazole (INN)

enoximone (INN)

etanidazole (INN)

Vol. 1867, 1-31874


HS6

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

CAS*

.69539-53-3

33125-97-2

15037^*4-2

73445-46-2

41473-09-0

57653-26-6

4846-91-7

72479-26-6

38234-21-8

59729-37-2

53597-28-7

36740-73-5

4548-15-6

84962-75-4

28125-87-3

119006-77-8

5786-71-0

110883-46-0

25859-76-1

33515-09-271-00-1

57653-28-8

95668-38-5

84243-58-3

89371-37-9

36364-49-5

27885-92-3

7303-78-8

55273-05-7

40507-78-6

85392-79-6

14885-29-1

115574-30-6

110605-64-6

27523-40-6

1 16795-97-2

81447-78-1

115575-11-6

107429-63-0


etintidine (INN)

etomidate (INN)

etonam(INN)

fenflumizol (INN)

fenmetozole (INN)

fenobam (INN)

fenoxazoline (INN)

fenticonazole (INN)

fertireltn (INN)

fexinidazole (INN)

fludazonium chloride (INN)

flumizole (INN)

flunidazole (INN)

flutomidate (INN)

flutomdine (INN)

flutrimazole (INN)

fosfocreatinine (INN)

giracodazole (INN)

glibutimine (INN)

gonadorelin (INN)

histidine (INN)

ibazocine (INN)

idralfidine (INN)

imazodan (INN)

imidapril (INN)

imidazole salicylate (INN)

imidocarb (INN)

imidoline (INN)

impromidine (INN)

indanazolme (INN)

indanidine (INN)

ipronidazole (INN)

irtemazole (INN)

isaglidole (INN)

isoconazole (INN)

ledazerol (INN)

levlofexidine (INN)

liarozole (INN)

lintopride (INN)

Vol. 1867, 1-31874


HS6

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

CAS*

65571-68-8

31036-80-3

60628-98-0

114798-26-4

86347-14-0

58261-91-9

14058-90-3

5696-06-0

34839-70-8

5377-20-8

38349-38-1443-48-1

22916-47-8

23757-42-8

80614-27-3

83184-43-4

20406-60-4

13551-87-6

125472-02-8

97901-21-8

64212-22-2

91524-14-0835-31-4

130759-56-7

130726-68-0

17230-89-6

21721-92-6

54533-85-6

89838-96-0

137460-88-9

74512-12-2

1 16002-70-1

66778-37-8

16773-42-5

64211-45-6

1491-59-4

82571-53-7501-62-2

50-60-2


lofemizole (INN)lofexidine (INN)lombazole (INN)losartan (INN)medetomidine (INN)

mefenidil (INN)

metazamide (INN)

metetom (INN)

metiamide (INN)

metomidate (INN)

metrafazoline (INN)

metronidazole (INN)

mtconazole (INN)

midaflur (INN)

midazogrel (INN)

mifentidine (INN)

mipimazole (INN)

misonidazole (INN)

mivazerol (INN)

nafagrel (INN)

nafimidone (INN)

napamezole (INN)

naphazoitne (INN)

nemazoline (INN)

neticonazole (INN)

nimazone (INN)

nitrefazole (INN)

nizofenone (INN)

octimibate (INN)

odalprofen (INN)

omoconazole (INN)

ondansetron (INN)

orconazole (INN)

omidazole (INN)

oxiconazole (INN)

oxymetazoline (INN)

ozagrel (INN)

phenamazolme (INN)

phentolamme (INN)

Vol. 1867, 1-31874


HS6

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293329

293339

293339

293339

293339

293339

CAS»

.130120-57-9

76448-31-2

7036-58-0

126222-34-2

89781-55-5

65896-16-4

7681-76-7

34273-10-4

3366-95-8

54143-54-3

103926-64-3

79313-75-0

30529-16-9

61318-90-9

51022-76-5

1082-56-0

52232-67^

1077-93-684-22-0

60-56-0

62894-89-7

62882-99-9

19387-91-859-98-3

4201-22-3

1082-57-156-28-0

84203-09-8

62087-96-1

56097-80-4526-36-3

51940-78-4

90697-56-6

71097-23-9827-61-2

807-31-8

13410-86-1

87848-99-5

66564-15-6


prezatide copper acetate (INN)

propenidazole (INN)

propoxate (INN)

remikiren (INN)

rolafagrel (INN)

romifidine (INN)

ronidazole (INN)

saralasm (INN)

secnidazole (INN)

sepazonium chloride (INN)

sepimostat (INN)

sopromidine (INN)

stirimazole (INN)

sulconazole (INN)

sulnidazole (INN)

tefazoline (INN)

teriparatide (INN)

temidazole (INN)

tetryzoline (INN)

thiamazole (INN)

tiflamizole (INN)

tinazolme (INN)

tmidazole (INN)

tolazoline (INN)

tolonidine (INN)

tramazolme (INN)

triclodazol (INN)

thfenagrel (INN)

tnletide (INN)

valconazole (INN)

xylometazolme (INN)

zetidoline (INN)

zimidoben (INN)

zoficonazole (INN)

aceclidine (INN)

aceperone (INN)

aconiazide (INN)

acnvastine (INN)

alepride (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

71195-58-9

25384-17-2468-51-9

77-20-3

93277-96-4

83991-25-7

1580-71-8

88150-42-9

15378-99-1144-14-9

98330-05-3

86780-90-7

106669-71-0

68844-77-9115-46-8

3964-81-6

123524-52-7

4945-47-5

104713-75-9

105979-17-7

2062-84-2

2156-27-6

24671-26-9

3691-78-9

119391-55-8

16571-59-8

16852-81-653-89-4

587-46-2

126825-36-3

5638-76-6468-50-8

468-59-7

5205-82-3

15301-48-1

71195-57-8

116078-65-0479-81-2

69047-39-8


alfentanil (INN)

allylprodine (INN)

alphameprodine (INN)

alphaprodine (INN)

altapizone (INN)

ambasilide (INN)

amiperone (INN)

amlodipine (INN)

anazocine (INN)

anitendine (INN)

anpirtoline (INN)

aramdipine (INN)

arpromidine (INN)

astemizole (INN)

azacyclonol (INN)

azatadine (INN)

azelnidipine (INN)

bamipine (INN)

barnidipine (INN)

benidipme (INN)

benperidol (INN)

benproperine (INN)

bennxate (INN)

benzethidine (INN)

benzetimide (INN)

benzindopyrine (INN)

benzoclidine (INN)

benzpiperylone (INN)

benzpyrinium bromide (INN)

bertosamil (INN)

betahistme (INN)

betameprodme (INN)

betaprodme (INN)

bevonium metilsulfate (INN)

bezitramide (INN)

bicifadine(INN)

bidisomide (INN)

bietamivenne (INN)

binifibrate (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

.514-65-8603-50-9

89194-77-4

13456-08-1

71990-00-6

101345-71-5

71195-56-7

1812-30-2

10457-90-686-22-6

33144-79-5

57982-78-2

22632-06-0

2180-92-9

55285-35-3

55837-14^1

93821-75-1

55837-15-5

15302-05-3

79449-98-2

4876-45-3

70724-25-3486-16-8

90729-J2-3

59708-52-0

98323-83-2

7528-13-4

20977-50-8

5942-95-0

107266-08-0123-03-5

59-32-5

132-22-9

75985-31-8

53449-58-4

85166-20-7

132203-70-4

66564-14-5

14796-24-8


biperiden (INN)

bisacodyl (INN)

bisaramil (INN)

bitipazone (INN)

bremazocine (INN)

bnfentanil (INN)

broclepride (INN)

oromazepam (INN)

bromperidol (INN)

brompheniramine (INN)

broperamole (INN)

budipine (INN)

bupicomide (INN)

bupivacaine (INN)

butanixm (INN)

butavenne (INN)

butinazocine (INN)

butopiprine (INN)

butoxylate (INN)

cabastine (INN)

camphotamide (INN)

carbazeran (INN)

carbmoxamine (INN)

carebastine (INN)

carfentanil (INN)

carmoxirole (INN)

carperidine (INN)

carperone (INN)

catpipramine (INN)

carvotroline (INN)

cetylpyridinium chloride (INN)

chloropyramme (INN)

chlorphenamine (INN)

ctamexon (INN)

ciclontcate (INN)

ciclotropium bromide (INN)

cilnidipme (INN)

cinitapnde (INN)

cinperene (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS»

. 81098-60-4

55905-53-8

15302-10-0

3485-62-9

47739-98-0

10457-91-7

21829-22-1

17737-65-4

3703-76-2

2971-90-6

53179-12-7

61764-61-2

57653-29-9

7007-96-7

3572-80-3

47128-12-1139-62-8

77-39-4

129-03-3

4904-00-1

27115-86-2

31232-26-5

47029-84-5

63388-37-4

30652-11-0

99518-29-3132-21-8

25523-97-1

21888-98-2

24358-84-7

120054-86-6

27112-37-4

17737-68-7382-82-1

13862-07-2972-02-1

47806-92-8

28782^12-5561-77-3


cisapnde (INN)

clebopnde (INN)

clibucaine (INN)

clidinium bromide (INN)

clocapramine (INN)

clofluperol (INN)

clonixeril (INN)

clomxin (INN)

cloperastine (INN)

clopidol (INN)

clopimozide (INN)

cloroperone (INN)

cogazocine (INN)

crotoniazide (INN)

cyclazocme (INN)

cycltramine (INN)

cyclomethycaine (INN)

cycrimine (INN)

cyproheptadine (INN)

cyprolidol (INN)

dacuronium bromide (INN)

danitracen (INN)

dazadrol (INN)

declenperone (INN)

deferiprone (INN)

derpanicate (INN)

dexbrompheniramine (INN)

dexchlorpheniramine (INN)

dexetimide (INN)

dexivacaine (INN)

dexniguldipine (INN)

diamocaine (INN)

diclomxtn (INN)

dicolinium iodide (INN)

difemetorex (INN)

difenido! (INN)

difenoxrmide (INN)

difenoxm (INN)

dihexyverine (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

37398-31-5

3425-97-6

5636-83-9300-37-8

101-08-6

62-97-5

915-30-0

147-20-6

467-83-4

117-30-6

3696-28-4

68284-69-5

3737-09-5

15876-67-2

99499-40-8

103336-05-6

74517w»2-3

115956-12-2

57808-66-9

21228-13-7469-21-6

29125-56-2

34703-49-6548-73-2

78421-12-2

15599-26-5586-60-7

90729-43-4

119431-25-3

80879-63-6

37612-13-8

93181-85-2

67765-04-2

60662-18-2

66364-73-6

64840-90-0

132829-83-5

4140-20-9536-33-4


dilmefone (INN)dimecolomum iodide (INN)dimetindene (INN)diodone (INN)diperodon (INN)diphemanil metilsulfate (INN)diphenoxylate (INN)

diphenylpyraline (INN)

dipipanone (INN)

dipiproverine (INN)

dipyrithione (INN)

disobutamide (INN)

disopyramide (INN)distigmine bromide (INN)disuprazole (INN)ditekiren (INN)

ditercaiinium chloride (INN)

dolasetron (INN)

dompendone (INN)

dorastine (INN)

doxylamine (INN)

droclidinium bromide (INN)

dropempine (INN)

droperidol (INN)

droxicainide (INN)

droxypropine (INN)

dyclonine (INN)

ebastme (INN)

eliprodil (INN)

emiglitate (INN)

encainide (INN)

endixaphne (INN)

enefexine (INN)

entclobrate (INN)

enpirolme (INN)

epensone (INN)

espatropate (INN)

estrapronicate (INN)

ethionamide (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

. 31637-97-5469-82-9

100-91-4

86189-69-7

59859-58-4

30817-43-7

69365-65-7

55837-26-877-01-0

3540-95-2125-60-0

437-38-7

553-69-5

53415-46-6

138708-32-4

54063-45-5

21221-18-1

54143-55-4

86811-58-7

75444-64-3

38677-85-9

53179-10-5

56995-20-1

21686-10-2

54965-22-9

5598-52-7149-17-7

1539-39-5

106686-40-2

54063-47-7

107266-06-8

132553-86-7

109889-09-0852-42-6

1463-28-1

59831-65-152-86-8

7237-81-2

1096-72-6


etofibrate (INN)

etoxeridine (INN)

eucatropine (INN)

felodipme (INN)

femoxetme (INN)

fenclexonium metilsulfate (INN)

fenoctimine (INN)

fenperate (INN)

fenpipramide (INN)

fenpiprane (INN)

fenpiverinium bromide (INN)

fentanyl (INN)

fenyramidol (INN)

fepitrizol (INN)

ferpifosate sodium (INN)

fetoxilate (INN)

fiazalone (INN)

flecainide (INN)

fluazuron (INN)

flumendone (INN)

flunixm (INN)

fluperamide (INN)

flupirtine (INN)

flupranone (INN)

fluspiperone (INN)

tospirate (INN)

ftivazide (INN)

gapicomine (INN)

gapromidtne (INN)

gemazocme (INN)

gevotroline (INN)

glemansenn (INN)

granisetron (INN)

guaiapate (INN)

guanaclme (INN)

halopem.de (INN)

halopendol (INN)

hepromcate (INN)

hepzidine (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

.3626-67-3468-56-4

7008-17-5

100927-13-7

23210-56-2

66208-11-5

63758-79-2

3569-26-4

26844-12-2

6556-11-2

5579-92-0

5579-93-1

22150-28-354-92-2

89667-40-354-85-3

57021-61-1

36292-69-0469-79-4

103890-78-4

73278-54-3

103577-45-3

6272-74-8

76956-02-0

103878-84-8

125729-29-5

24678-13-5

5005-72-1

100427-26-7

79516-68-0634-08-2

22204-91-7

88678-31-3

86811-09-8

93181-81-8

61380-40-3

53179-11-6

106900-12-3

79794-75-5


hexadiline (INN)hydroxypethidine (INN)hydroxypyridine tartrate (INN)idavenne (INN)

ifenprodil (INN)

ifoxetine (INN)

indalpine (INN)

indopine (INN)

indoramin (INN)

inositol nicotinate (INN)

iopydol (INN)

iopydone (INN)

ipragratine (INN)

iproniazid (INN)

isbogrel (INN)

isoniazid (INN)

isonixm (INN)

ketazocine (INN)

ketobemidone (INN)

lacidipme (INN)

lamtidme (INN)

lansoprazole (INN)

lapinum chloride (INN)

lavoltidine (INN)

lazabemide (INN)

lemildipme (INN)

lenperone (INN)

leptacline (INN)

lercanidtpine (INN)

levocabastme (INN)

levofacetoperane (INN)

hfibrate (INN)

hranaftate (INN)litoxetine (INN)lodaxapnne (INN)lofentanil (INN)

loperamide (INN)

loperamide oxide (INN)

loratadme (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

.59729-31-6

128075-79-6

14745-50-7

3575-80-276-90-4

6968-72-5

22801-44-191-84-9

62658-88-2

4394-04-1

1707-15-9

3734-52-9

13447-95-5113-45-1

29342-02-754-36-4

114-91-0

89613-77-4

39537-99-0

66529-17-7

72432-03-2

59831-64-0

78415-72-2

75437-14-8

70260-53-6

52157-83-2

2748-88-1

2856-74-8

81329-71-7

122957-06-6

1050-79-9

89419-40-9

58239-89-7

4575-34-2

124858-35-1504-03-0

22443-11-451-12-7

3099-52-3


lorcaimde (INN)lufironil (INN)meletimide (INN)melperone (INN)mepenzolate bromide (INN)mepiroxol (INN)mepivacame (INN)mepyramine (INN)mesudipine (INN)metanixin (INN)metazide (INN)metazocine (INN)methaniazide (INN)methylphenidate (INN)metipirox (INN)metyrapone (INN)metyndine (INN)mezacopnde (INN)micimcate (INN)midaglizole (INN)miglitol (INN)milenperone (INN)milrinone (INN)milverine (INN)mindodilol (INN)mindoperone (INN)miripirium chloride (INN)modaline (INN)modecainide (INN)modipafant (INN)moperone(INN)mosapramme (INN)moxazocine (INN)myfadol (INN)nadifloxacin (INN)nanofin (INN)nepinalone (INN)nialamide (INN)nicametate (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

79455-30-4

55985-32-5

5868-05-3

13912-80-6

10571-59-2

31980-29-7

80614-21-7

27959-26-8

65141-46-0555-90-8

5657-61-4

36504-64-0

21829-25-4

4394-00-7

113165-32-559-26-7

22609-73-0

75530-68-6

66085-59-4

16426-83-8

15387-10-7

63675-72-9

39562-70-4

4394-05-2

60324-59-6561-48-8

96487-37-5

1 14-90-9

101343-69-5

71138-71-1

71251-02-0

87784-12-1

73590-58-6

2779-55-7

100158-38-1

2398-81-4

5322-53-2

13958-40-2

27302-90-5


nicaraven (INN)

nicardipine (INN)

niceritrol (INN)

nicoboxil (INN)

nicoclonate (INN)

nicofibrate (INN)

mcogrelate (INN)

nicomol (INN)

nicorandil (INN)

nicothiazone (INN)

nicoxamat (INN)

nictindole (INN)

nifedipine (INN)

niflumic acid (INN)

niguldipme (INN)

nikethamide (INN)

niludipine (INN)

nilvadipine (INN)

mmodipine (INN)

niometacm (INN)

niprofazone (INN)

nisoldipine (INN)

nrtrendipine (INN)

nixylic acid (INN)

nomelidme (INN)

norpipanone (INN)

nuvenzepine (INN)

obidoxime chloride (INN)

ocfentaml (INN)

octapinol (INN)

octenidme (INN)

ofomine (INN)

omeprazole (INN)

opmiazide (INN)

otenzepad (INN)

oxiniacic acid (INN)

oxiperomide (INN)

oxiramide (INN)

oxisuran (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

546-32-7

4354-45-4

96515-73-0

121650-80-4

15500-66-0

13752-33-5

96922-80-4

102625-70-7

80349-58-2

5634-41-3

7162-37-0

2066-89-9

50432-78-579-55-0

26864-56-2

7009-54-3

7681-80-3359-83-1

96513-83-6

4960-10-5

92268-40-1

6621-47-257-42-1

129-83-9

127-35-5

94-78-0

77-10-1

469-80-7

86-21-5

562-26-5

82227-39-2

57548-79-5

79201-85-7

51832-87-2

17692-43-2

3731-52-0586-98-1

21755-66-8

78090-11-6


oxpheneridine (INN)

oxyclipme (INN)

palonidipine (INN)

pancopride (INN)

pancuronium bromide (INN)

panidazole (INN)

pantemcate (INN)

pantoprazole (INN)

panuramme (INN)

parapenzotate bromide (INN)

pandocaine (INN)

pasimazid (INN)

pemerid (INN)

pempidine (INN)

penfluridol (INN)

pentapiperide(INN)

pentapiperium metilsuifate (INN)

pentazocine (INN)

pentisomide (INN)

perastine (INN)

perfomedil (INN)

pertiexiline (INN)

pethidine (INN)

phenampromide (INN)

phenazocine (INN)

phenazopyndtne (INN)

phencyclidine (INN)

phenendme (INN)

pheniramine (INN)

phenopendine (INN)

pibaxizine (INN)

picafibrate (INN)

picenadol (INN)

picobenzide (INN)

picodralazme (INN)

picolamme (INN)

piconol (INN)

picopenne (INN)

picoprazole (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

64063-57-6

130641-36-0

15686-87-0

31224-92-7

60576-13-8534-84-9

79992-71-5

3565-03-5578-89-2

13495-09-5

70132-50-2

2062-78-4

60560-33-0

28240-18-8

1893-33-0125-51-9

82-98-4

136-82-3

2531-04-6

4546-39-8

18841-58-2

55837-21-3

68797-29-5467-60-7

55313-67-2

3562-55-8

38677-81-5

35620-67-887-21-8

24340-35-0

75755-07-6

55285-45-5

55432-15-0

33605-94-6302-41-0

68252-19-7

124436-59-5

84490-12-0

54110-25-7


picotrin (INN)

picumeterol (INN)

pifenate (INN)

pifoxime (INN)

piketoprofen (INN)

pimeclone (INN)

pimetacin (INN)

pimetine (INN)

pimetremide (INN)

piminodine (INN)

pimonidazole (INN)

pimozide (INN)

pinacidil (INN)

pinolcaine (INN)

pipamperone (INN)

pipenzolate bromide (INN)

pipendolate (INN)

piperocaine (INN)

piperylone (INN)

pipe thanate (INN)

pipoctanone (INN)

pipoxizine (INN)

pipradimado! (INN)

pipradrol (INN)

pipramadol (INN)

piprocurarium iodide (INN)

pirbuterol (INN)

pirdonium bromide (INN)

piridocame (INN)

pindoxilate (INN)

piridronic acid (INN)

pinfibrate (INN)

pirintdazole (INN)

pirisudanol (INN)

pintramide (INN)

pirmenol (INN)

pirodavir (INN)

piroximone (INN)

pirozadil (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

103923-27-9

54063-52-4

39123-1 1-094-63-3

99522-79-9

85966-89-8

55837-22-4

95374-52-0511-45-5

1219-35-8

78997-40-7

31314-38-2561-76-2

3811-53-8

3670-68-6

15686-91-6

60569-19-9587-61-1

3781-28-0

14222-60-7

1882-26-4101-26-8

1740-22-3

13463-41-7

1098-97-1

15301-88-9

71276-43-2

10447-39-9

64755-06-2

31721-17-2

117976-89-3

132875-61-7

112727-80-7

135062-02-1

110140-89-1

104153-37-9

32953-89-2

71653-63-9

105462-24-6


pirtenidine (INN)pitofenone (INN)pituxate (INN)pralidoxime iodide (INN)pranidipine (INN)

preclamol (INN)pribecaine (INN)prideperone (INN)pridinol (INN)primaperone (INN)prisotinol (INN)prodipine (INN)properidine (INN)propinetidine (INN)

propipocaine (INN)

propiram (INN)

propiverine (INN)

propyliodone (INN)

propyperone (INN)

protionamide (INN)

pyricartate (INN)

pyndostigmme bromide (INN)

pynnolme (INN)

pyrithione zinc (INN)

pyritinol (INN)

pytamine (INN)

quadazocme (INN)

quifenadine (INN)

quinuclium bromide (INN)

quinupramine (INN)

rabeprazole (INN)

remifentanil (INN)

renzapride (INN)

repaglintde (INN)

ridogrel (INN)

nlopirox (INN)

nmiteral (INN)nodipine (INN)

nsedronic acid (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

CAS*

96449-05-7

78092-65-6

121840-95-7

42597-57-9

56079-81-3

84057-95-4

5560-77-0

78273-80-0

112192-04-8

2804-00-4

134377-69-8495-84-1

143257-97-0

115911-28-9

110347-85-8

57734-69-7

106516-24-9

122955-18-4

36175-05-0

10040-45-6

6184-06-1749-02-0

510-74-7

144-45-6

357-66-4

3784-99-4

80343-63-1

47662-15-7

59429-50-4

90961-53-8

77342-26-8

108687-08-7

72808-81-2

50679-08-8

37087-94-8

31932-09-9

57648-21-2

57237-97-5

77502-27-3


rispenzepine (INN)

ristianol (INN)

rogletimide (INN)

ronifibrate (INN)

ropitoin (INN)

ropivacaine (INN)

rotoxamine (INN)

roxatidine (INN)

roxindole (INN)

roxoperone (INN)

safironil (INN)

salinazid (INN)

sameridine (INN)

sampirtine (INN)

selfotel (INN)

sequifenadine (INN)

sertindole (INN)

sibopirdine (INN)

sodium picofosfate (INN)

sodium picosulfate (INN)

sorbmicate (INN)

spiperone (INN)

spiramide (INN)

spirgetme (INN)

spinlene (INN)

stilbazium iodide (INN)

sufotidme (INN)

suxemerid (INN)

tamitinol (INN)

tedisamil (INN)

tefenperate (INN)

teludipine (INN)

tepirindole (INN)

terfenadine (INN)

tibnc acid (INN)

ticarbodine (INN)

timiperone (INN)

timoprazole (INN)

tolpadol (INN)

Vol. 1867, 1-31874


HS6

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293339

293340

293340

293340

293340

293340

293340

293340

293340

293340

CAS»

728-88-1

97-57-4

71461-18-2

88296-62-2

86365-92-6

120656-74-8

13422-16-7749-13-3

144-11-6

56-97-3

64-39-1

5789-72-0

7009-82-791-81-6

486-12-4

1508-75-4

30751-05-4

35515-77-6

73590-85-9

72005-58-4

132373-81-0

85505-64-2

50700-72-693-47-0

15686-68-7

83059-56-7

90103-92-7

90182-92-6

56775-68-3

56383-05-2

90402-40-7

42465-20-3

15301-40-3

10023-54-8

3811-56-1

13425-92-886-42-0

550-81-2

17230-85-2


tolpensone (INN)

tolpromne (INN)

tonazocine (INN)

transcainide (INN)

trazolopnde (INN)

trefentanil (INN)

triflocin (INN)

trifluperidol (INN)

trihexyphenidyl (INN)

trimedoxime bromide (INN)

trimeperidine (INN)

tnmetamide (INN)

tnmethidinium methosulfate (INN)

tripelennamine (INN)

tnprohdine (INN)

tropicamide(INN)

troxipide (INN)

truxipicurium iodide (INN)

ufiprazole (INN)

vadocaine (INN)

vamicamide (INN)

vapiprost (INN)

vecuronium bromide (INN)

verazide (INN)

volazocine (INN)

zabicipril (INN)

zabiciprilat (INN)

zacopride (INN)

zimeldine (INN)

ztndotrine (INN)

abanoquil (INN)

acequinolme (INN)

actmoquinol (INN)

aminoquinol (INN)

aminoQuinunde (INN)

amiquinsin (INN)

amodiaquine (INN)

amopyroquine (INN)

amquinate (INN)

Vol. 1867, 1-31874


HS6

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

CAS»

64228-81-586-75-9

108437-28-1

22407-74-5

96187-53-0

15599-52-7

3684-46-6521-74-4

5486-03-3

42408-82-2

15686-38-1

141725-88^»54-05-7

72-80-0

54063-29-585-79-0

132-60-5

59889-36-0

19485-08-6

2545-39-3

4298-15-1

55150-67-9

105956-97-6130-26-7

54340-63-5

7270-12-4130-16-5

13007-93-7

1131-64-2

18507-89-6522-51-0

125-71-3

125-73-5

67165-56-483-73-8

147-27-3

77086-21-6

106819-53-8

14009-24-6


atracunum besilate (INN)benzoxiquine (INN)binfloxacin (INN)

bisobnn (INN)

brequmar(INN)

broqumaldol (INN)

broxaldine (INN)

broxyquinolme (INN)

buquinolate (INN)

butorphanol (INN)

carbazocine (INN)

cetefloxacm (INN)

chloroquine (INN)

chlorquînaldol (INN)

cicarperone (INN)

cinchocaine (INN)

cinchophen (INN)

ciprefadol (INN)

ciproquinate (INN)

clamoxyquine (INN)

cletoqutne (INN)

climiqualine (INN)

clinafioxacm (INN)

clioqumol (INN)

clofeverme (INN)

cloquinate(INN)

cloxiquine (INN)

cuproxoline (INN)

debnsoqume (INN)

decoqumate (INN)

dequalinium chloride (INN)

dextromethorphan (INN)

dextrorphan (INN)

diclofensme (INN)

diiodohydroxyqumoline (INN)

dimoxyline (INN)

dizocilpine (INN)

doxacunum chloride (INN)

drotavenne (INN)

Vol. 1867, 1-31874


HS6

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

CAS*

3176-03-2

37517-33-2486-47-5

18429-78-2

23779-99-9

83863-79-0

76568-02-0

3820-67-5154-73-4

4310-89-8118-42-3

55299-11-1

91524-15-1

56717-18-1

90828-99-2

72714-75-1

79798-39-3

3253-60-9146-37-2

10351-50-5152-02-3

125-70-2

10061-32-277-07-6

23910-07-8

53230-10-7

18429-69-1

110013-21-3

2154-02-1

106861-44-3

103775-10-6

103775-14-0

10539-19-2485-34-7

13997-19-8

64039-88-9

76252-06-7

2545-24-6

4008-48-4


drotebanol (INN)

esproquine (INN)

ethavenne (INN)

famotine (INN)

ftoctafenine (INN)

florifenine (INN)

flosequinan (INN)

glafenine (INN)

guanisoquine (INN)

hedaquinium chloride (INN)

hydroxychloroquine (INN)

iqumdamine (INN)

irloxacin (INN)

isotiquimide (INN)

itrocainide (INN)

ivoqualine (INN)

ketorfanol (INN)

laudexium metilsuifate (INN)

laurohnium acetate (INN)

leniquinsin (INN)

levallorphan (INN)

levomethorphan (INN)

levophenacylmorphan (INN)

levorphanol (INN)

mebiquine (INN)

mefloquine (INN)

memotine (INN)

meraftoxacin (INN)

metofolme (INN)

mivacunum chlonde (INN)

moexipnl (INN)

moexipnlat (INN)

moxavenne (INN)

neocinchophen (INN)

nequinate (INN)

nicafenine (INN)

nicamoprol (INN)

mcevenne (INN)

nitroxolme (INN)

Vol. 1867, 1-31874


HS6

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

293340

CAS*

24526-64-5

1531-12-0549-68-8

21738-42-1485-89-2

635-05-2

574-77-6

86-78-2

468-07-5

77472-98-190-34-6

1698-95-9548-84-5

86024-64-8

2768-90-3

85441-61-8

85441-60-7

19056-26-9

5714-76-186-80-6

525-61-1

13757-97-6

1776-83-6510-53-2

297-90-5

40034-42-2

127779-20-8

61563-18-6

74129-03-6

113079-82-6

7175-09-9

5541-67-3

53400-67-2

40692-37-3

1748-43-2

30418-38-3

79201-80-2

120443-16-5

72714-74-0


nomifensine (INN)

norlevorphanol (INN)

octavenne (INN)

oxamniqume (INN)

oxycinchophen (INN)

pamaquine (INN)

papaveroline (INN)

pentaqume (INN)

phenomorphan (INN)

pipequaline (INN)

pnmaquine (INN)

proquinolate (INN)

pyrvinium chloride (INN)

quinacainol (INN)

qumaldine blue (INN)

quinapril (INN)

quinaprilat (INN)

quindecamine (INN)

qumetalate (INN)

quinisocaine (INN)

qumocide (INN)

quinprenaline (INN)

quintiofos (ISO) (INN)

racemethorphan (INN)

racemorphan (INN)

rosoxacin (INN)

saquinavir (INN)

soquinolol (INN)

tebuquine (INN)

terbequinil (INN)

tilbroquinol (INN)

tiliqumol (INN)

tiqumamide (INN)

tisoquone (INN)

trethinium tosilate (INN)

tretoquinol (INN)

veradoline (INN)

vertukast (INN)

viquatine (INN)

Vol. 1867, 1-31874


HS6

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293351

293359

293359

CAS*

52-43-7

57-43-2

77-02-1

4388-82-357-44-3

144-02-5

744-80-9

561-86-4

841-73-6

77-26-9

960-05-4

52-31-3

15687-09-9

27511-99-5509-86-4

56-29-1

50-11-3

467-43-6

151-83-7

115-38-8

561-83-1

76-74-4

50-06-6

57-30-7

357-67-5

2409-26-9143-82-8

2537-29-3125-40-6

76-73-3

115-44-6

76-23-3

467-36-7

71-73-8

467-38-9

125-42-8

2430-49-1

55485-20-6299-89-8


allobarbrtal (INN)amobarbital (INN)aprobarbital (INN)barbexaclone (INN)barbital (INN)

barbitai sodium (INN)

benzobartaital (INN)brallobarbital (INN)bucolome (INN)butalbital (INN)cartoubarb (INN)cyclobarbital (INN)difebarbamate (INN)eterobarb (INN)heptabarb (INN)hexobarbital (INN)

metharbital (INN)

methitural (INN)

methohexita! (INN)

methylphenobarbital (INN)

nealbarbital (INN)

pentobarbital (INN)

phénobarbital (INN)

phénobarbital sodium (INN)

phetharbita! (INN)

prazitone (INN)

probarbital sodium (INN)

proxibarbal (INN)

secbutabarbital (INN)

secobarbital (INN)

talbutal (INN)

tetrabarbital (INN)

tnialbarbital (INN)

thiopental sodium (INN)

thiotetrabarbital (INN)

virtbartMtal (INN)

vmylbital (INN)

acaprazine (INN)

acetiamine (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

CAS»

.59277-89-3

101197-99-3

96914-39-5

56066-19-4

56066-63-8

56287-74-2315-30-0

27076-46-6

76330-71-7

86393-37-5642-44-4

58602-66-7550-28-7

36590-19-9

75558-90-6121-25-5

5587-93-9

68475-42-3442-03-5

55300-29-3

71576-40-4

86627-15-8

55779-18-5

136816-75-6

89303-63-9

2856-81-7

62973-76-6

1649-18-9448-34-0

5234-86-6446-86-6

102280-35-3

95634-82-5

52395-99-0

92210-43-0

88133-11-3

59752-23-7

22457-89-2299-88-7


aciclovir (INN)

acitemate (INN)

actisomide (INN)

aditeren (INN)

aditoprime (INN)

afloqualone (INN)

allopunnol (INN)

alpertine (INN)

altansehn (INN)

amifloxacin (INN)

aminometradme (INN)

aminoptenn sodium (INN)

amisometradine (INN)

amocarzine (INN)

amperozide (INN)

amprolium (INN)

ampynmine (INN)

anagrelide (INN)

anisopirol (INN)

antrafenine (INN)

aptazapme (INN)

aronixil (INN)

arprinocid (INN)

atevirdine (INN)

atiprosin (INN)

azabuperone (INN)

azanidazole (INN)

azaperone (INN)

azaprocm (INN)

azaquinzole (INN)

azathioprine (INN)

baquilopnm (INN)

batelapine (INN)

belanzme (INN)

bemannone (INN)

bemitradine (INN)

benderizine (INN)

benfotiamine (INN)

bentiamine (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

CAS*

17692-23-8

108210-73-7

86662-54-6

2667-89-2

55837-17-7

56518-41-3

56741-95-8

51481-62-0

86304-28-182-95-1

62052-97-5

80755-51-7

59184-78-0

76536-74-8

36505-84-7

87051-46-5

68741-18-4510-90-7

80433-71-2

61422-45-5

125363-87-3

83881-51-0522-18-9

82-93-9

53131-74-1

37751-39-6

80109-27-9

54063-30-8

23887-41-4

54063-23-9

23887-46-9298-57-7

60763-49-7

51493-19-7

23887-47-0

82117-51-9

85721-33-1

33453-23-5298-55-5


bentipimme (INN)

bifeprofen (INN)

binizolast (INN)

bisbentiamine (INN)

bnndoxime (INN)

brodimoprim (INN)

bropirimine (INN)

bucainide (INN)

buciclovir (INN)

buclizine (INN)

bumepidil (INN)

bunazosin (INN)

buquineran (INN)

buquitenne (INN)

buspirone (INN)

butansenn (INN)

buterizine (INN)

buthalital sodium (INN)

calcium levofolinate (INN)

carmofur (INN)

carsatrm (INN)

cetinzine (INN)

chlorbenzoxamine (INN)

chlorcyclizine (INN)

ciapilome (INN)

ciclazmdol (INN)

ciladopa (INN)

ciltoprazine (INN)

cmepazet (INN)

cinepazic acid (INN)

cinepazide (INN)

cinnarizine (INN)

cinnarizine clofibrate (INN)

cinprazole (INN)

cinpropazide (INN)

cinuperone (INN)

ciprofloxacm (INN)

ciproquazone (INN)

clocinizme (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

CAS»

4052-13-5

25509-07-3

5786-21-082-92-8

112398-08-0

72822-12-9

3733-63-9

117827-81-3

84408-37-7

24584-09-6

5355-16-8333-41-5

86641-76-190-89-1

98106-17-3

5522-39-4

7008-00-6

36518-02-258-32-2

90808-12-1

64019-03-0

120770-34-5

17692-31-8

80576-83-6

110629-41-9

95520-81-3

110690-43-2

107361-33-1

68576-86-3

74011-58-8

31729-24-5

93106-60-6

18694-40-1

73090-70-7

10402-90-1

32665-36-4

98123-83-2

64204-55-3

7432-25-9


cloperidone (INN)

cloroqualone (INN)

clozapine (INN)

cyclizine (INN)

danofloxacm (INN)

dapiprazole (INN)

decloxtzine (INN)

delfaprazme (INN)

desciclovir (INN)

dexrazoxane (INN)

dtavendine (INN)

diazinon (ISO) dimpylate (INN)

dibrospidium chloride (INN)

diethylcarbamazme (INN)

diftoxacin (INN)

difluanazine (INN)

dimetholizine (INN)

diproqualone (INN)

dipyndamote (INN)

divaplon (INN)

doqualast (INN)

draflazme (INN)

dropropizme (INN)

edatrexate (INN)

elbaniztne (INN)

elzivenne (INN)

emitefur(INN)

enazadrem (INN)

enciprazine (INN)

enoxaan (INN)

enpiprazole (INN)

enrofloxaan (INN)

epinzole (INN)

epiropnm (INN)

eprazinone (INN)

eprozinol (INN)

epsiprantel (INN)

esaprazole (INN)

etaqualone (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

CAS*

17692-34-1

52942-31-1

104227-87^»

13246-02-1

7077-33-0

54063-38-6

54063-39-7

75184-94-0

3607-24-7

79660-72-3

82190-92-9

1480-19-9

54340-64-6

2022-85-7

52468-60-751-21-8

67121-76-0

76716-60-4

40507-23-1

37554-40-8

86696-88-0

82410-32-0

83928-76-1

119914-60-2

55837-20-2141-94-6

115-63-9

21560-59-868-88-2

108674-88-0

75689-93-9

7008-18-6

41340-39-0

5984-97-4

69017-89-6

55477-19-5

96478-43-2

4214-72-6

74050-98-9


etodroxizine (INN)etoperidone (INN)famciclovir (INN)febarbamate (INN)febuverine (INN)fenaperone (INN)fenetradil (INN)fenprinast (INN)fenyripol (INN)fieroxacin (INN)flotrenizine (INN)fluanisone (INN)fluciprazine (INN)flucytosine (INN)

flunanzine (INN)

fluorouracil (INN)

fluperiapine (INN)

fluprazine (INN)

fluproquazone (INN)

fiuquazone (INN)

frabuprofen (INN)

ganciciovir (INN)

gepîrone (INN)

grepafloxacm (INN)

halofuginone (INN)

hexetidme (INN)

hexocychum metilsulfate (INN)

hoquizil (INN)

hydroxyztne (INN)

idenast (INN)

imanixil (INN)

iminophenimide (INN)

impacarzine (INN)

iodothiouracil (INN)

ipexidme (INN)

iprozilamme (INN)

inndalone (INN)

isaxonine (INN)

ketansenn (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

CAS*

.52196-22-2

143257-98-1

132449-46-8

99291-25-5

3416-26-0

119514-66-8

94192-59-3-00-0

86627-50-1

98079-51-7

101477-55-8

106400-81-1

61197-73-7

104719-71-3

108785-69-9

72141-57-2

80428-29-1

120092-68-4340-57-8

569-65-3

1243-33-0

87611-28-7

20326-12-950-44-2

72^4-659-05-2

56-04-2

68902-57-8

81043-56-3

50335-55-224219-97-4

24360-55-2

38304-91-5

79467-23-5

61337-67-5

108612-45-9

65329-79-5

56693-13-1

13665-88-8


ketotrexate (INN)

lerisetron (INN)

lesopitron (INN)

levodropropizine (INN)

lidoflazine (INN)

lifarizine (INN)

lixazinone (INN)

lobuprofen (INN)

lodinixil (INN)

lomefloxacin (INN)

lomenzine (INN)

lometrexol (INN)

loprazolam (INN)

lorcmadol (INN)

lorpiprazole (INN)

losulazine (INN)

mafoprazme (INN)

manidipine (INN)

mecloqualone (INN)

meciozine (INN)

mefeclorazine (INN)

melquinast (INN)

mepiprazole (INN)

mercaptopurine (INN)

methagualone (INN)

methotrexate (INN)

methylthiouracil (INN)

metiopnm (INN)

metren péroné (INN)

mezilamme (INN)

miansehn (INN)

milipertine (INN)

minoxidil (INN)

mioflazine (INN)

mirtazapine (INN)

mizolastcne (INN)

mobenzoxamine (INN)

mociprazine (INN)

mopidamol (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

CAS*

23790-08-1

75438-57-2

5061-22-3

57149-07-2

83366-66-9

109713-79-3

27367-90-4

60662-19-3

42471-28-3

56739-21-0

5626-36-8

70458-96-7

100587-52-8

76600-30-1315-72-0

60104-30-5

113617-63-3

6981-18-665-86-1

62305-86-6

36531-26-7

60607-34-3

2465-59-0153-87-7

125-53-1

70458-92-3

2208-51-7

94386-65-9

69372-19-6

39809-25-1-00-0

67254-81-3

72444-62-3

35265-50-0

1977-11-3

10001-13-5

39640-15-8

55837-13-3

5636-92-0


moxipraquine (INN)

moxonidine (INN)

nafivenne (INN)

naftopidil (INN)

nefazodone (INN)

neldazosin (INN)

niaprazine (INN)

nilprazole (INN)

mmustine (INN)

mtraquazone (INN)

nonapynmine (INN)

norfloxacm (INN)

norfloxacm succmil (INN)

nosantine (INN)

opipramol (INN)

orazamide (INN)

orbifioxacin (INN)

ormetoprim (INN)

orotic acid (INN)

orotirelm (INN)

oxantel (INN)

oxatomide (INN)

oxlpunnol (INN)

oxypertine (INN)

oxyphencyclimme (INN)

pefloxacin (INN)

pelansehn (INN)

pelrinone (INN)

pemirolast (INN)

penciclovir (INN)

peraclopone (INN)

peradoxime (INN)

perafensine (INN)

peraquinsm (INN)

perlapine (INN)

pexantel (INN)

piberaline (INN)

piclopastme (INN)

picloxydine (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

CAS*

27315-91-9

68399-57-5

51940-44-4

299-48-9

12002-30-1

54-91-1

2608-24-4

15534-05-1

21560-58-7

75444-65-4

28797-61-7

69479-26-1

50892-23-*

65089-17-0

1897-89-8

72732-56-0

60762-57-4

55149-05-8

39186-49-7

19562-30-2

65950-99-4

55268-74-1

67227-55-8

111786-07-3

57132-53-3

51-52-5

22760-18-5

23476-83-7

42061-52-9

58-14-0

5221-49-8

14222-46-9

70018-51-8

4015-32-1

15793-38-1

97466-90-5

77197-48-9

4774-24-7

95635-55-5


pipebuzone (INN)pipecuronium bromide (INN)pipemidic acid (INN)piperamide (INN)piperazme calcium edetate (INN)pipobroman (INN)piposulfan (INN)pipratecol (INN)piquizil (INN)pirenperone (INN)pirenzepme (INN)pirepolol (INN)pirinixic acid (INN)pirinixil (INN)piriqualone (INN)piritrexim (INN)pirtindole (INN)pirolate (INN)pirolazamide (INN)piromidtc acid (INN)pirqumozol (INN)

praziquantel (INN)primidolol (INN)prinoxodan (INN)proglumetacin (INN)propylthiouracil (INN)proquazone (INN)prospidium chlonde (INN)pumitepa (INN)pynmethamme (INN)pynmitate (INN)pyntidium bromide (INN)quazinone (INN)quazodme (INN)quinazosin (INN)quinelorane (INN)qumezamide (INN)quipazine (INN)ranolazine (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

CAS*

.21416-87-5

85673-87-6

133718-29-3

8063-28-3

79781-95-6

28610-84-6

75859-04-0

37750-83-7

108436-80-2

76696-97-4

1866-43-9

3601-19-2

629S9-33-7

98105-99-8

87729-89-3

115313-22-9

131635-06-8154-82-5

98631-95-9

110871-86-8

3286-46-2

85418-85-5

66093-35-4

128229-52-7

87760-53-0

88579-39-9

80680-06-4

108319-06-8

86181-42-2

56693-15-3

14728-33-7

53808-87-091-85-0

78299-53-3

5581-52-2154-42-7

52618-67-4

110101-66-1

5334-23-6


razoxane (INN)

revenast (INN)

revizinone (INN)

ribamrnol (INN)

riiapine (INN)

rimazolium metilsulfate (INN)

nmcazole (INN)

rimoprogin (INN)

rociclovir(INN)

rofelodine (INN)

roiodine (INN)

ropizine (INN)

sapropterin (INN)

sarafloxacin (INN)

segansehn (INN)

serazapine (INN)

sifaprazine (INN)

simetride (INN)

sobuzoxane (INN)

sparfloxacin (INN)

sulbutiamine (INN)

sunagrel (INN)

talmetoprim (INN)

tamolarizine (INN)

tandospirone (INN)

tâsuldine (INN)

tefludazine (INN)

temafloxacm (INN)

temelastme (INN)

terciprazine (INN)

teroxalene (INN)

tetroxoprim (INN)

thonzylamine (INN)

tiacnlast (INN)

tiamiprine (INN)

tioguanine (INN)

tiopendone (INN)

tirilazad (INN)

iisopurine (INN)

Vol. 1867, 1-31874


HS6

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293359

293369

293369

293369

293369

293369

CAS*

41964-07-2

70312-00-4

20326-13-0553-08-2

54063-58-0

15421-84-8

26070-23-5

19794-93-5

123205-52-7

82190-93-0

79855-88-2

6503-95-3396-01-0

5714-82-9

35795-16-5

5011-34-7738-70-5

52128-35-5

107736-98-166-75-1

34661-75-1

124832-26-4

81523-49-1

67469-69-6

79644-90-9

66172-75-6

26242-33-1

114298-18-9

37762-06-S

112733-05-9

34758-83-3

78208-13-6

4004-94-8

43200-80-2

27469-53-0645-05-6

537-17-7

63119-27-7500-42-5


tolimidone (INN)

tolnapersine (INN)

tolpiprazole (INN)

tonzonium bromide (iNN)

toprilidine (INN)

trapidil (INN)

trazitiline (iNN)

trazodone (INN)

trelnarizine (INN)

trenizine (INN)

trequinsin (INN)

triampyzine (INN)

tnamterene (INN)

triclofenol piperazine (iNN)

trimazosin (INN)

îrimetazidine (INN)

trimethoprim (INN)

tnmetrexate (INN)

umespirone (INN)

uramustme (INN)

urapidil (INN)

valaciclovir (INN)

vaneprim (INN)

vanoxenne (INN)

vebufioxacin (INN)

verofylline (iNN)

vintiamol (INN)

zalospirone (INN)

zapnnast (INN)

zenarestat(INN)

zipeprol (INN)

zolenzepine (INN)

zolertme (INN)

2opiclone(INN)

almitrme (INN)

alîretamme (iNN)

amanozine (INN)

anitrazafen (INN)

chlorazantl (INN)

Vol. 1867, 1-31874


HS6

293369

293369

293369

293369

293369

293369

293369

293369

293369

293369

293369

293369

29336S

293369

293369

293369

293369

293369

293369

293369

293369

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

29337g

293379

293379

293379

293379

CAS*

.101831-36-1

3378-93-6609-78-9

66215-27-8

101831-37-2

92257-40-4

57381-26-7

84057-84-1

103337-74-2

13957-36-3

128470-15-5

68289-14-5

5580-22-3

98410-36-7

15599-44-7

108258-89-587-90-1

35319-70-1

69004-03-151-18-3

2244-21-5

100510-33-6

88124-26-9

122852-42-0

22136-26-1134-37-2

60719-84-8

72432-10-1

86541-75-5

86541-78-8

65008-93-7

104051-20-9

51781-06-7

113957-09-8

29342-05-0

109859-50-968550-75-4

73963-72-1

22316^7-8


clazuril (!NN)ciociguanil (INN)cycioguani! embonate (INN)cyromazine (INN)diclazuril (INN)dizatrifone (INN)irsogladme (INN)lamotngine (!NN)

letrazurit (INN)

meladrazine (INNi)

melarsomine (INN)metrazïfone (INN)oxonazine (INN)palatrigine (INN)spîrazine (INN)sulazurii (INN)symclosene(INN)tiazuril (INN)toltrazuril (!NN)tretamme (INN)trociosene potassium (INN)adibendan (INN)adosopine (INN)alosetron (INN)amedalin (INN)amphenidone (iNN)smnnons (!NN)aniracetam (INN)benazepril (INN)benazephlat (INN)bometoloi (INN)brefonaiol (INN)carteoloi (SNN)cebaracetam (INN)ciclopirox (INN)aiobradina (INN)eilestamide (iNN)cilostazo! (INN)oiobazam (INN)

Vol. 1867, 1-31874


HS6

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

CAS*

54063-34-2

120551-59-9

67199-66-0

84629-61-8

53086-13-8

41729-52-6

126100-97-8

84901-45-1

67793-71-9

59776-90-8

88124-27-0467-90-3

33996-58-6

21590-92-1

77862-92-1

17692-37-4

1980-49-0

98319-26-7

2261-94-1

67542^1-0

63610-08-2

100643-96-7

31842-01-0

2176S-53-0

59227-89-3

102767-28-2

97878-35-8

73725-85-6

105431-72-9

128486-54-4

88296-61-1125-64-4

1910-68-5

102791-47-9

116041-13-5

77191-36-7

128326-80-7

50516-43-3

63958-90-7


cofisatrn (!NN)

crilvastatin (INN)

daniquidone (INN)

darenzepine (INN)

dexindoprofen (!NN)

dezaguanine (INN)

dimiracetam (INN)

doliracetam (INN)

draquînolol (INN)

dupracetam (INN)

atazepine (INN)

ethypicone (INN)

etiraeetam (INN)

etomidoline (!NN)

falipamil (INN)

fantndone (INN)

felipynne (INN)

finastende (INN!

fiucarbril (INN)

imuraceîam (INN)

indobufen (INN)

indolidan (INN)

indoprofen (INN)

ioltdonic acid (!NN)

iaurocapram (!NN)

fewetiracetam (INN)

iibenzapril (INN)

lidansenn (INN)

linopirdine (INN)

lurosetron (INN)

medorinone (ÎNN)

methyprylon (!NN)

metisazone (INN)

nantennone(INN)

nebracetam (INN)

nefiracetam (INN)

nicoracetam (INN)

nofecaimde (INN)

nonathymulin (INN)

Vol. 1867, 1-31874


HS6

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293379

293390

293390

293390

293390

CAS*

21590-91-0

62613-82-5125-13-3

13850&45-3

114485-92-698-79-3

7491-74-9

82209-39-0

53179-13-8

50650-76-5

108310-20-9

68497-62-1125-33-7

72332-33-377-04-3

101193-40-2

78466-98-5

111911-87-6

2829-19-8

61413-54-5

18356-28-0

91374-21-9

84088-42-6

102669-89-6

81377-02-8

103997-59-7

54935-03-4

35115-60-7

85136-71-6

22365-40-8

137099-09-3

26070-78-0

81840-15-5

85175-67-3

78466-70-3

111841-85-1

53164-05-9

3551-18-6

51037-30-0


omidoline (iNN)oxiracetam (INN)

oxyphenisatine (INN)

pidobenzone (iNN)pidolaœtamol (INN)pidolic acid (INN)piracetam (iNN)piraxeiate (INN)pirfenidone (INN)piroctone (INN)pirodomast (INN)pramiracetam (INN)primidone (INN)procaterol (INN)pyrithyldione (INN)quinotolast (INN)

razobazam (INN)

rebamipide (INN)

roiicyprine (INN)

roiipram (INN)

rolziracetam (INN)

ropinirole (INN)

roquinimex (iNN)

satennone (INN)

seglitide (INN)

selprazme (INN)

sulisatin (INN)

teprotide (INN)

tilisolol (INN)

tnfiubazam (INN)

turosteride (INN)

ubrsmdme (INN)

vesnannone (INN)

zatebradrne (INN)

zomebazam (INN)

abecamil (INN)

acemetacin (INN)

acetryptine (INN)

acipimox (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS»

79152-85-5

47487-22-9

7527-91-5

78459-19-5

37115-32-5

86696-87-9

74258-86-9

54965-21-8

54029-12-8

59338-93-1

119610-26-3

82626-01-5

28981-97-7

93479-96-0

60575-32-8

30573-37-1

15180-02-6

23271-63-8

2609-46-3

31386-24-090-45-9

69635-63-8

71675-85-9

24622-72-8

16870-37-4

5214-29-9

87344-06-7

132640-22-3

53716-46-4

66635-85-6

19281-29-9

37669-57-1113-79-1

113-80-4

77400-65-8

76530-44-4

13539-59-8

58581-89-8

26304-61-0


acodazole (INN)acridorex (INN)acrisorcin (INN)adimolol (INN)

adinazolam (INN)aganodine (INN)alacepril (INN)albendazote (INN)albendazole oxide (INN)alizapnde (INN)aloraeetam (INN)alpidem (INN)

alprazolam (INN)

alteconazole (INN)

amezepine (INN)

amezinium metilsulfate (INN)

amfonelic acid (INN)

amicibone (INN)

amiloride (INN)

amindocate (INN)

aminoacridine (INN)

amipizone (INN)

amisulpride (INN)

amixetrine (INN)

amogastrin (INN)

ampyzine (INN)

amtolmetin guacii (INN)

andolast (INN)

amiopam (INN)

anirolac (INN)

aptocaine (INN)

arfendazam (INN)

argipressin (INN)

argiprestocin (INN)

asocainol (INN)

azamulin(INN)

azapropazone (INN)

azelastine (INN)

azepindole (INN)

Vol. 1867, 1-31874


HSS

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS*

64118-86-1

1830-32-6

58503-82-5

87034-87-5

35135-01-4

16506-27-7

20187-55-7621-72-7

363-13-3

61864-30-0

1050-48-2

1980-45-6

13696-15-6

39544-74-663-12-7

642-72-8

49571-04-2

54063-27-3

130641-38-2

60662-16-0

41510-23-0

32195-33-8

129655-21-6

62658-63-3

4774-53-2

10355-14-3

84379-13-5

89622-90-2

15585-71-4

71119-11-4316-15-4

36798-79-5

55837-25-7

54867-56-0

30103-44-7

3896-11-5

36121-13-8

51152-91-1968-63-8


azimexon (INN)

aziniamide (INN)

azipramine (INN)

bamaiuzote (INN)

benafentrine (INN)

bendamustme (INN)

bendazac (INN)

bendazol (INN)

benhepazone (INN)

benolizime (INN)

benzilomum bromide (INN)

benzodepa (INN)

benzopyrronium bromide (INN)

benzotript (INN)

benzquinamide (INN)

benzydamine (INN)

bephdil (INN)

biclofibrate (INN)

bindarit (INN)

binedaline (INN)

biriperone (INN)

bisbendazole (INN)

bizelesm (INN)

bopindolol (INN)

botiacnne (INN)

boxidme (INN)

bretazenil (INN)

bnnazarone (INN)

brometenamine (INN)

bucmdolol (INN)

bucricaine (INN)

budralazine (INN)

bufiomedil (INN)

bufrolin (INN)

bumecame (INN)

bumetnzole (INN)

burodilme (INN)

butaelamol (INN)

butinoline (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS»

82228-20-0

15351-05-0

64241-34-5

132722-73-7

36104-80-0

54063-28-4

62571-86-2

57775-29-8

6804-07-5

298-46^69-81-8

51460-26-5

24279-91-2

59009-93-7

33605-67-3

38081-67-3

23465-76-1

39731-05-0

53716-49-7

34966-41-1

72956-09-3

111223-26-8

17650-98-5

7007-92-358-25-3

69-27-2

3689-76-7

65884-46-0

66834-24-0

32211-97-5

31431-43-3

33545-56-1

59865-13-3

88768-40-5

90139-06-3

20168-99^»

2056-56-6

28598-08-5

75696-02-5


butoprozine (INN)

buzepide mettodide (INN)

cadralazine (INN)

caltendo! (iNN)

camazepam (INN)

camiverine (INN)

captopril (INN)

carazoïo! (INN)

carbadox (INN)

carbamazepine (INN)

carbazochrome (INN)

carbazochrome sodium sulfonate (INN)

carboquone (INN)

carburazepam (iNN)

eargutocin (INN)

carmantadine (INN)

caroverine (INN)

carpindoJoi (INN)

carprofen (INN)

cartazolate (INN)

carvedilol (INN)

ceronapn! (INN)

ceruletide (INN)

cetohexazme (INN)

chlordiazepoxide (INN)

chlorisondamme chloride (INN)

chlormidazole (iNN}

ciadox (INN)

cianopramme (INN)

ciclindole (INN)

oclobendazole (INN)

ciclopramirie (INN)

cielosponn (INN)

ciiazapnl (INN)

cilazaprilat(INN)

cinmetacin (INN)

cinnopentazone (INN)

cinoctramide (iNN)

cinolazepam (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

GAS*

64557-97-7

35452-73-4

10171-69-4

15686-51-8442-52-4

27050-41-5

59467-77-5

1159-93-9

4755-59-3

2030-63-9

5310-55-4

25803-14-9303-49-1

1622-61-3

3861-76-5

42779-82-8

5220-68-8

47135-88-6

50801-44-0

1110-40-3

28069-65-0

15599-22-1

15687-07-7

22136-27-2

71680-63-2

105118-14-7

75991-50-3

75522-73-5

76002-75-0

34024-41-4

16401-80-2

2894-67-9963-39-3

42438-73-3303-54-8

51987-65-650-47-5

103420-77-5

52340-25-7

Description Alternative Ciassifieaitoii

cinoquidox (INN)Ciprafamtde (INN)clazolam (INN)clemastine (INN)clemizole (INN)clenpirin (INN)climazolam (INN)elobenzepam (INN)ctodazon (INN)clofazimine (INN)clomacran (INN)clometacin (INN)clomipramine (INN)clonazepam (INN)clonitazene (INN)clopirac (INN)

cloquinozine (INN)

closiramine (INN)

cortisuzol (!NN)

cortivazoi (INN)

cuprimyxin (INN)

cyciopyrronium bromide (INN)

cyprazepam (INN)

daledalin (INN)

dametralast (INN)

datelliptium chloride (INN)

dazepinil (INN)

dazidamine (INN)dazoquinast (iNN)

deboxamet (INN)

deimetacin (INN)

delorazepam (INN)

demoxepam (INN)

denpidazone (INN)

depramme (INN)

desglugastnn (INN)

desipramine (INN)

devazepide (INN)

dexclamoi (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS*

60719-87-1

91077-32-6439-14-5

57998-68-2

4498-32-2

17411-19-7

21626-89-1484-23-1

35898-87-4

36309-01-0

4757-55-5

51047-24-6

57109-90-7

95355-10-5

79700-61-1

90104-48-6

40762-15-0

76953-65-6

27314-77-8

63667-16-3

2440-22-4

25771-23-7

70977-46-7

1232-85-5

6196-08-369-25-0

52042-01-0

87233-61-2

75847-73-3

76420-72-9

39715-02-1

47206-15-5

80883-55-2

72301-79-2

66304-03-8

80012-43-7

83200-08-2

101246-68-8

72522-13-5


deximafen (INN)

dezinamide (INN)

diazepam (INN)

diaziquone (INN)

dibenzepin (INN)

dicarbine (INN)

diftalone (INN)

dihydralazine (INN)

dilazep (INN)

dimemorfan (INN)

dimetacrine (INN)

dimetipirium bromide (INN)

dipotassium clorazepate (INN)

domipizone (INN)

dopropidil (INN)

doreptide (INN)

doxefazepam (INN)

dramedilol (INN)

drazidox (INN)

dribendazote (INN)

drometnzole (INN)

duometacin (INN)

eflumast (INN)

elantrine (INN)

elanzepirte (INN)

eledoisîn (INN)

elfazepam (INN)

emedastine (INN)

enalapnl (INN)

enalaprilat (INN)

ertdralazine (INN)

enprazeptne (!NN)

enviradene (INN)

enviroxime (INN)

epicamide (INN)

epinastine (INN)

eproxindine (INN)

epîastigmme (INN)

eptazoane (iNN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS*

96645-87-3

79286-77-4

29975-16-4

68788-56-7

51022-77-6442-16-0

77-15-6

65400-85-3

23980-14-5

29177-84-2

84226-12-0

3478-15-7911-65-9

54063-37-5

2235-90-7

102676-47-1

108894-41-3

114432-13-2

49564-56-9

5467-78-7

43210-67-9

53597-27-6

15301-68-5

67227-56-954063-41-1

54063-46-6

34482-99-0

135381-77-0

53966-34-0

31430-15-6

40594-09-0

86386-73-4

3900-31-0

78755-81-4

42835-25-6

1622-62-4

17617-23-1

1841-19-6

52391-89-6


erizepine (INN)

esafioxaein (INN)

estazolam (INN)

etacepride (INN)

etazolate (INN)

ethacridine (INN)

ethoheptazine (INN)

ettiy! carfluzepate (INN)

ethyl dirazepate (INN)

ethyl loflazepate (INN)

eticiopride (INN)

etipirium iodide (INN)

etonitazene (INN)

etoprindole (INN)

etryptamine (INN)

fadrozole (INN)

famirapnnium chloride (INN)

fantofarone (INN)

fazadinium bromide (INN)

fenamole (INN)

fenbendazole (INN)

fendosal (INN)

fenharmane (INN)

fenoldopam (INN)

fepromide (INN)

fexicaine (INN)

fletazepam (INN)

fiezelastine (INN)

floxacrine (INN)

fiubendazole (INN)

flucindote (INN)

fluconazole (INN)

ftudiazepam (INN)

flumazenil (INN)

flumequine (INN)

flunitrazepam (INN)

flurazepam (INN)

fluspirilene (!NN)

flutemazepam (!NN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS»

.25967-29-7

70801-02-4

93957-54-1

76263-13-3

35322-07-7

97825-24-6

95399-71-6

114517-02-1

79700-63-3

109623-97-4

82230-53-3

17127-48-9

52443-21-7596-51-0

59252-59-455-65-2

23092-17-3

5980-31^}

3734-12-1493-80-1

1239-45-8848-53-3

35142-68-8

3614-J7-986-54-4

7008-14-2

7008-15-3

19120-01-5

91618-36-9

50847-11-5

57916-70-8

79449-99-3

116057-75-1

60719-86-0

59643-91-350-49-7

6829-98-7

99011-02-6

88578-07-8


flutoprazepam (INN)

flutroline (INN)

fluvastatin (INN)

fluzinamide (INN)

fosazepam (INN)

fosinoprii (INN)

fosinopriiat (INN)

fosqutdone (INN)

fronepidil (INN)

gedocarnii (!NN)

girisopam (INN)

gtaziovine (INN)

glucametacin (!NN)

glycopyrronium bromide (INN)

guanazodine (INN)

guanethidine (INN)

halazepam (INN)

hexedine (INN)

hexopyrronium bromide (INN)

histapyrrodine(IMN)

riomidium bromide (INN)

homochlorcyelizine (INN)

homopipramol (INN)

hydracarbazine (INN)

hydratazine (INN)

hydroxindasate (INN)

riydroxindasol (INN)

hydroxystenozole (INN)

ibafloxacin (INN)

ibudilast (INN)

iclazepam (INN)

icospiramide (INN)

idoxifene (INN)

imafen (INN)

imexon (INN)

imipramme (INN)

imipraminoxide (INN)

imiquimod (INN)

imoxiterol (INN)

Vol. 1867, 1-31874


HS6

293390

2S3390

293390

293390

293390

293390

293390

293390

293390

293390

293390

2S3390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS*

99323-21-4

3138S-25-1

80876-01-353-86-1

69907-17-1

73758-06-2

5034-76-4436-40-8

125974-72-3

15992-13-9

7248-21-7

5560-72-5

64779-98-2

55902-02-8

116861-00-8

86315-52-8

34301-55-8

56463-68-4487-79-6

796-29-2

74103-06-3

5633-16-9

104340-86-5

36945-03-6

71048-87-8

141505-33-1

105102-20-3

76547-98-3

6306-71-4

87646-83-1

29176-29-2

23047-25-8

50264-69-2

42863-81-0846-49-1

117857-45-1848-75-9

69175-77-5

88303-60-0


inaperisone (INN)

indocate (INN)

indolapril (INN)

indometacin (INN)

indopanolol (INN)

mdorenate (INN)

indoxote (INN)

inproquone (!NN)

intoplicine (INN)

intrazole (INN)

iprazochrome (INN)

iprindole (INN)

irolapride (INN)

isamfazone (INN)

isamoltan (INN)

isomazole (INN)

isometamidium chloride (INN)

isoprazone (INN)

kainic acid (INN)

ketimipramine (INN)

ketorolac (INN)

leiopyrrole (INN)

ieminoprazole (INN)

lergotrile (INN)

levonantradol (INN)

levosimendan (INN)

liroldine (INN)

lisinophl (INN)

lobendazole (INN)

lodazecar (INN)

lofendazam (INN)

lofepramine (INN)

lonidamine (INN)

lopirazepam (INN)

iorazepam (INN)

loreclezole (INN)

lormetazepam (INN)

losindole (INN)

losoxantrone (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS*

66535-86-2

52304-85-5

90509-02-7

22232-71-9

31431-39-7524-81-2

15574^*9-9

58662-84-3

2898-12-6300-22-1

3735-85-1

26921-72-2

28781-64-883-89-6

23694-81-7

54340-58-8

16915-79-0

65517-27-3

54063^9-9

21730-16-5

17692-51-2509-84-2

100-97-0

469-78-3

15687-33-9

54188-38-4

1661-29-6

27432-00-4496-38-8

59467-70-8

3277-59-6

55843-86-2

91753-07-0

85622-95-3

27737-38-8

4757-49-7

29442-58-8

85856-54-8

1845-11-0


lotnfen (INN)

iotucaine (INN)

luxabendazole (INN)

mazindol (INN)

meberidazoie (INN)

mebhydroiin (INN)

mecarfainate (INN)

meclonazepam (INN)

medazepam (INN)

medazomide (INN)

mefeserpine (INN)

melizame (INN)

menitrazepam (INN)

mepacrine (INN)

mepindolol (INN)

meptazinol (INN)

mequidox (INN)

metaclazepam (INN)

metamfazone (INN)

metapramine (INN)

metergoline (INN)

metethoheptazine (INN)

methenamme (INN)

metheptazine (INN)

metindizate (INN)

metralmdole (INN)

meturedepa (INN)

mezepine (INN)

midamaline (INN)

midazolam (INN)

mimbane (INN)

miroprofen (INN)

mitoquidone (INN)

mitozolomide (INN)

mixidine(INN)

monometacrine (INN)

motrazepam (INN)

moveltipril (INN)

nafoxidine (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS*

.389-08-2

65511-41-3

70696-66-1

73865-18-6

55248-23-2

103844-77-5

69624-50-8

93664-94-9

86140-10-5

102771-12-0

129618-40-2

2011-67-8

130610-93^8

4533-39-5146-22-5

10448-84-7

24358-76-7

40759-33-9

15997-76-9

1088-11-5

10379-11-0

59767-12-3

3147-75-9

23696-28-8

115972-78-6

108391-88-4

33996-33-7

56611-65-5

27035-30-9

99258-56-7

35578-20-2604-75-1

28721-07-5

17259-75-5

53716-50-0

20559-55-1

S4057-48-3

4350-09-8561-43-3


nalidixic acid (INN)nantradol (INN)napirimus (!NN)nardetero! (INN)nebidrazine (INN)necopidem (INN)nelezaprine (INN)

nemonapride (INN)

neraminol (INN)

nerisopam (INN)

nevirapine (!NN)

nimetazepam (INN)

niravoline (INN)

nitracrine (INN)

nitrazepam (INN)

nitromifene (!NN)

nivacortol (!NN)

noiinium bromide (INN)

nonaperone (INN)

nordazepam (INN)

nortetrazepam (INN)

octastine (INN)octnzole (INN)olaquindox (INN)olradipine (INN)orbutopril (INN)

oxaceprol (INN)

oxagrelate (INN)

oxametacin (INN)

oxamisote (INN)

oxarbazole (INN)

oxazepam (INN)

oxcartoazepine (INN)

oxdralazme (INN)

oxfendazole (INN)

oxtbendazole (!NN)

oxifungin (INN)

oxitnptan (INN)

oxypyrromum bromide (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS»

14255-87-9

61484-38-6

103238-56-8

65222-35-7

5534-95-254-95-5

62087-72-352-62-0

82924-03-6

82834-16-0

95153-31-484-12-8

82-88-2

62510-56-9

64000-73-3

88069-67-4

74150-27-9

54824-20-3

52463-83-9

83471-41-4

13523-86-9

78541-97-6

79672-88-1

85691-74-3

S2625-18-7

16378-21-5

91441-23-5

31793-07-4

17243-65-1

55299-10-0545-80-2

72702-95-5

5571-84-6

17716-89-1

2955-38-673-07-4

S7435-86-6

5370-41-2

4630-95-9


parbendazoie (INN)

pareptide (INN)

parodilol (INN)

pazelliptine (!NN)

pentagastrin (INN)

pentetrazol (INN)

pentigetide (INN)

pentolonium tartrate (iNN)

pentopril (INN)

perindcprii (INN)

penndoprilat (iNN)

phanquinone (INN)

phenindamine (!NN)

picilorex (INN)

pildralazine (INN)

pilsicainide (INN)

pimobendan (ÎNN)

pinafide (INN)

pinazepam (INN)

pincainide (iNN)

pindoiol (INN)

piquindone (INN)

piriprost (INN)

pirmagref (INN)

pirogliride (iNN)

piroheptine (INN)

piroxantrone (INN)

pirprofen (INN)

pirralkonium bromide (INN)

pivoxazepam (INN)

poidine metitsulfate (INN)

ponalrestat (INN)

potassium nitrazepate (INN)

pranosal (INN)

prazepam (!NN)

prazepine (INN)

premazepam (INN)

pndefine (INN)

prifinium bromide (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS»

77639-66-8

59010-44-5

23249-97-077-37-2

3734-17-6428-37-5

92-62-6

52829-30-877-14-5

147-85-3

493-92-5

10321-12-7

77650-95-4

3426-08-298-96-4

7009-69-0

3563-49-3

7009-68-9

2210-77-7

15636-97-2

36735-22-5

15301-89-0

87056-78-8130-81-4

2423-66-7

85760-74-3

84225-95-6

87333-19-5

87269-97-4

80125-14-0

73573-42-9

72238-02-9

83395-21-5

99593-25-6

79282-39-6

26308-28-1

53808-86-9

38821-80-6

10078-46-3


prinomide (INN)

prizidiiol (INN)

proeodazole (INN)

procydidine (INN)

prodHidine (INN)

profadoJ (INN)

profiavine (INN)

proflazepam (INN)

proheptazine (INN)

proiine (INN)

proiintane (INN)

propizepine (INN)

proterguride (INN)

prozapine (INN)

pyrazinamide (INN)

pyrophendane (INN)

pyrovalerone (INN)

pyroxamine (INN)

pyrrocaine (INN)

pyrrolifene (INN)

quazepam (INN)

quillifolme (INN)

quinagolide (INN)

quindonium bromide (INN)

quindoxln (INN)

quinpirole (INN)

raclopride (INN)

ramipril (INN)

ramiprilat (INN)

remoxipride (INN)

rescimetol (INN)

retelliptine (INN)

ndazolo! (INN)

rilmazafone (INN)

rilozarone (INN)

ripazepam (INN)

ritropirronium bromide (INN)

rodocame (INN)

roietamide (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS*

.66608-04-6

2201-39-0

53862-80-9

103884-86-6

78771-13-8

57645-05-3

64294-95-7

57262-94-9

99591-83-0

98374-54-0

131741-08-7

25126-32-3

30033-10-4

39862-58-3

2898-13-7

73384-60-8

53583-79-2

98116-53-1

110623-33-1

104675-35-6

34061-33-1321-64-2

16188-61-7

115308-98-0

17243-68-4

83166-17-0

141374-81-4

84812-85-1

87936-75-2

82989-25-1

91441-48-4

846-50-4

34499-96-2

85622-93-1

37686-84-3

58-46-8

10379-14-3

95104-27-1

17289-49-5


roigamidme (INN)rolicyciidine (INN)roxolonium metilsulfate (INN)saripidem (INN)sarmazenil (INN)sermetacin (INN)setastine (INN)setiptiime (INN)siguazodan (JNN)siltenzepine (INN)simendan (INN)sincalide (INN)stercuroniurti iodide (INN)strinoline (INN)sulazepam (INN)sulmazoie (INN)sultopride (INN)sulukast (INN)suntozole (INN)suronacrine (INN)îaciamme (INN)tacnne (INN)talastme (INN)tallimustme (INN)taloximine (INN)tampramine (INN)tarazepide (INN)tazadolene (INN)tazadolene (INN)tazanolast(INN)teloxantrone (INN)temazepam (INN)temodox (INN)temozolomide (INN)tergunde (INN)

tetrabenazme (INN)

tetrazepam (INN)

tetrazolast (!NN)tetridamine (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

CAS*

52-24-4

107489-37-2

54663-47-7

80225-28-1

83275-56-3

27314-97-2

14679-73-3

40173-75-9

22345-47-7

26171-23-3

50454-68-7

6187-50-4

86273-92-9

88107-10-2

76145-76-1

108138-46-1

41094-88-6

87679-37-6

87679-71-8

104485-01-0

97110-59-3

56030-50-3

1018-34-4

55242-77-868-76-8

28911-01-5

96258-13-8

68786-66-3

7009-76-9

3818-88-0739-71-9

63619-84-1

35710-57-7

14368-24-2

97546-74-23612-98-473-22-3

51037-88-8

28546-58-9


thiotepa(ÏNN)îhymoctonan (INN)tibezonium iodide (INN)tilsuprosî (INN)tiracizine (!NN)tirapazamine (INN)todralazine (iNN)tofetridine (INN)tofisopam (INN)tolmetin (1NN)tolnidamine (INN)tolquinzole (iNN)toiufazepam (INN)tomeluKast (INN)tomoxiprole (INN)tosufloxacin (INN)tracazolate (INN)trandolapnl (INN)trandoiapnlat (INN)trapencame (INN)trazium esilate (INN)trepipam (INN)trepinum iodide (INN)tnafungin (INN)thaziauone (INN)tnazolam (INN)tnbendilol (INN)tnciabendazole (INN)tnclazate (INN)tncyclamol chlonde (INN)tnmipramine (INN)tnoxifene(INN)tnzoxime (INN)

trocimine (INN)

troxoiamide (INN)troxypyrrolium tosiiate (INN)

Iryptophan (INN)

tuciazepam(INN)

uidazepam (INN)

Vol. 1867, 1-31874


HS6

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390

293390293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

CAS*

302^9-8

137862-53^1

112964-98-4

68318-20-7

21363-18-8

70704-03-9

106498-99-1

72301-78-1

129731-10-8

50528-97-7

50264-78-3

64098-32^1

101975-10-4

62851-43-8

117827-79-9

86111-26-4

72301-78-1

81872-10-8

75176-37-3

31352-82-6

1222-57-7

82626-48-0

33369-31-2

105292-70-1

82114-19-0

140-40-9

96-50-4

490-55-1

25422-75-7

88377-92-4

104777-03-9

13471-78-8

61990-92-9

21817-73-2

1 7969-45-8

26097-80-3

74772-77-3533-45-9

6469-36-9


uredepa (INN)

valsartan (INN)

velnacnne (!NN)

vehlopam (!NN)

viminoi (!NN)

vinconate (INN)

vintoperol (INN)

viroxime (INN)

vorozoie (INN)

xilobam (INN)

xinidamme (INN)

zapizolam ()NN)

zardavenne (INN)

zidometacin (INN)

zilpatero! (!NN)

zmdoxifene (INN)

zm viroxime (INN)

zofenopnl (INN)

zofenoprilat (INN)

zoiazepam (INN)

zolimictine(INN)

zolpidem (INN)

zomeptrac (1NN)

alonacic (INN)

amflutizole (INN)

aminrtrozole (INN)

ammotfiiazole (INN)

amiphenazole (1NN)

antazonite (INN)

arotinolol (INN)

asobamast (INN)

beclotiamine(lNN)

benpenoiism (INN)

bidimazium iodide (INN)

brofezil (INN)

eambendazole (INN)

ciglitazone (INN)clomethiazole (INN)

cloprothiazoie (INN)

Vol. 1867, 1-31874


HS6

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

CAS*

77519-25-6

109229-58-5

74604-76-5

82159-09-973-09-6

76824-35-6

79069-94-6

17969-20-9

18046-21-4

15387-18-5500-08-3

103181-72-2

138511-81-6

70529-35-0

53943-88-7

27826-45-5

71119-10-3

71125-38-7

119637-67-1

84233-61-4

54657-96-4

3570-75-061-57-4

55981-09-4962-02-7

76963-41-2

56784-39-5

68247-85-8

68247-85-8

29952-1 3-4

121808-62-6

111025-46-8

17243-64-0

13409-53-5

24840-59-393738-40-0

80830-42-8

39832-48-9

54147-28-3


dexetozoline (INN)englttazone (INN)enoxamast (INN)epairestat (INN)etozolm (iNN)famotidine (INN)

fanetizole (INN)

fenciozic acid (INN)

fentiazac (INN)

fezatione (INN)formmitrazote (!NN)guaisteme (INN)icoduhne (INN)

itazigrel (INN)

letosteine (INN)

libeciihde (INN)

lotifazole (INN)

meloxicam (INN)

moguisteine (INN)

nesosteine (INN)

nifuraiide (INN)

nifurthiazole (INN)

niridazole (INN)

nitazoxanide (INN)

nitrocan (INN)

nizatid:ne (INN)

ozolinone (INN)

peplomycin (INN)

peplomycin (INN) 294190

paratizole (INN)

pidotimod (INN)

piogbtazone (INN)

piprozolm (INN)

podilfen (INN)

pretamazium iodide (INN)rahtoime (INN)

rentiapni (INN)

tazolol (INN)

tebatizole (INN)

Vol. 1867, 1-31874


HS6

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293410

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293420

293430

CAS*

122946-43-4

3810-35-3148-79-8

473-30-3

60084-10-8

30097-06-4

71079-19-1

100417-09-2

54 179-54-0444-27-9

69014-14-8

74531-88-7

105523-37-3

30709-69-4

97322-87-1

91257-14-6

85604-00-8553-13-9

56355-17-095-27-2

514-73-8

70590-58-8

100035-75-4

75889-62-2

26130-02-9

1 5599-36-7

95847-70^

77528-67-7

104632-26-0

95847-87-3

1 744-22-5

104153-38-0

49785-74-2

79071-15-1

85702-89-2

32527-55-2

61570-90-9

110703-94-161-00-7


telmesteine (INN) tenonitrozoie (INN)miabendazole (ISO) tiâbendazole (INN)thiazosuifone (INN)tiazofurine (INN)tidiacic (INN)timegadine (INN)timirdine (INN)îimofibrate (INN)timonacic (INN)

tiotidine (INN)tioxamast (INN)tiprotimod (INN)tizoprolic acid (INN)îroglitazone (INN)tuvatidine (INN)zaitidme (INN)zolamme (!NN)zoliprofen (INN)dimazole (INN)dithiazanme iodide (INN)etrabamtne (INN)evandarrnne (INN)fostedil (INN)frentizole(INN)haletazoie (INN)ipsaprrone (INN)manozodil (INN)

prarnipexole (INN)

revospirone (INN)

nluzole (INN)

sabeluzoie (INN)

supidimide (INN)

lazasubrase (INN)

tazeprofen (INN)

tiaramide (INN)

tioxidazole (INN)

zopolrestat (INN)

acaprcmazine (INN)

Vol. 1867, 1-31874


HS6

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

CAS*

13461-01-3

2751-68-084-96-8

58-37-7

49864-70-2

54063-26-2653-03-2

2622-30-2800-22-6

84-01-5

50-53-3

17692-26-1

3546-03-0518-61-6

60-91-3

15302-12-2477-93-0

62030-88-0523-54-6

522-24-7

37561-27-6

30223-48-469-23-8

47682-41-7

7220-56-6

33414-30-1

33414-36-7

28532-90-3

3833-99-6

7224-08-060-99-1

1759-09-7

101396-42-3

29216-28-2

5588-33-0

1982-37-2

7009-43-061-01-8

61-73-4


aceprometazine (INN)

acetophenazine (INN)

alimemazine (INN)

aminopromazine (INN)

azadorzine (INN)

azaftozine (INN)

butaperazine (INN)

carfenazine (INN)

chtoracyzine (INN)

chlorproethazine (INN)

chlorpromazine (INN)

aclofenazme (INN)

cyamemazine (INN)

daeemazme (INN)

diethazine (INN)

dimetazine (INN)

dimethoxanate (INN)

duoperone (INN)

etymemazine (!NN)

fenetfiazine (INN)

fenovenne (INN)

fluacizme(INN)

fluphenazme (INN)

fiupimazine (INN)

flutiazm (INN)

ftormetazme (INN)

ftorpropazine (INN)

furomazme (INN)

homofenazme (INN)

imiciopazme(iNN)

levomepromazine (INN)

levometiomeprazine (INN)

mequitamium iodide (INN)

mequitazine (INN)

mesondazine (INN)

methdilazme (INN)

methiomeprazine (INN)

methopromazme (INN)

methylthionimum chlonde (iNN)

Vol. 1867, 1-31874


HS6

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293430

293490

293490

293490

293490

293490

293490

CAS»

13993-65-2388-51-2

14008-44-7

31883-05-3

16498-21-8

3689-50-7

14759-04-7

84-08-2

60-89-9

2622-26-6

13093-88-4

58-39-9

92-84-2

84-04-8

3819-00-958-38-8

522-00-9

58-40-2

SO-87-7

17693-51-5362-29-8

145-54-0

13799-03-6

23492-69-5

24527-27-3

14759-06-9

58-34-4

1420-55-9

84-06-0

50-52-2

2622-37-9

117-89-5

146-54-3

2627-69-2

10072-48-7

33665-90-6

42228-92-2

39633-62-0

748-44-7


mettaztnic acid (INN)metofenazate (INN)metopimazine (INN)moracizine (INN)oxaflunriazine (INN)oxomemazine (INN)oxyridazine (INN)parathiazine (INN)pecazme (INN)periciazine (INN)penmetazine (INN)perphenazine (INN)phenothiazine (INN)pipamazine (INN)piperacetazme (INN)prochlorperazme (INN)profenamine (INN)promazme (INN)prometfiazine (INN)promethazine teoclate (INN)propiomazine (INN)propyramazine bromide (INN)protizmic acid (INN)sopitazme (INN)spiciomazine (INN)sulfohdazme (INN)thiazmamium metilsulfate (JNN)thiethylperazine (INN)thiopropazate (INN)thiondazine (INN)trifluomeprazine (INN)trifluoperazine (INN)triflupromazine (INN)acadesine (INN)acefurtiamine (INN)acesulfame (INN)acivicin (INN)aciantate (iNN)acoxatnne (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

2S3490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS»

7008-42-6

17176-17-961-19-8

110314-48-2

81403-80-7526-35-2

84145-89-1

25526-93-6

121029-11-6

2207-50-3

111393-84-1

68302-57-8

22661-76-3

78613-35-1

14028-44-5

99464-64-9

95896-08-5

77658-97-0

31698-14-3

15301-45-8

5029-05-0

105219-56-5

92569-65-8

9004-04-0

19885-51-9

1 19-96-0

23964-58-1

90779-69-4

85076-06-8320-67-2

60207-31-0

72822-56-1

37855-92-8

2169-64-4

123040-69-7

34959-30-3

13074-00-5125-45-1

35067-73-9


acronine (INN)ademetionine (INN)adenostne phosphate (INN)adozeiesin (!NN)alfuzosin (INN)allomethadione (INN)almoxatone (INN)alovudme (INN)altoqualine (INN)aminorex (INN)amitivir (INN)amlexanox (INN)amoproxan (INN)amorolfine (INN)amoxapine (INN)ampiroxicam (INN)anaritide (INN)anaxirone (INN)ancltabme (INN)antafenite (INN)antienite (INN)apafant (INN)apnkalim (INN)aprotinin (INN)aranotm (INN)arsthinol (INN)articaine (INN)

atosiban (INN)

axamozide (INN)

azacitidine(INN)

azaconazole (INN)

azaloxan (INN)

azanator (INN)

azanbine (INN)

azasetron (INN)

azaspinum chlonde (INN)

azastene (INN)

azatepa (INN)

azepexoie (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

.64748-79-4

99156-66-8

79784-22-8

105685-11-8

94011-82-2

15351-04-9

130782-54-6

112893-26-2

100927-14-8

134564-82-2

41717-30-0

112018-01-6

16759-59-4

51234-28-7

1219-77-8

29462-18-8

1 14776-28-2

86434-57-3

10189-94-3

105567-83-7

120410-24-4

117545-11-6

102908-59-8

17692-24-9

69304-47-8

72481-99-3

63638-91-5

21440-97-1

5579-85-1

57801-81-7

76596-57-159-14-3

362-74-3

22131-35-7

54400-59-8127214-23-7

66203-00-7

18464-39-6

89213-87-6


azumolene (INN)

barmastine (INN)

barucainide (INN)

batoprazine (INN)

bazinapnne (INN)

becantone (INN)

beciparcil (INN)

becliconazole (INN)

befipende (INN)

befioxatone (INN)

befuralme (INN)

bemoradan (INN)

benoxafos (INN)

benoxaprofen (INN)

bensuldazic acid (INN)

bentazepam (INN)

bepafant (INN)

beperidium iodide (INN)

bepiastme (INN)

berefrine (INN)

biapenem (INN) 294190

bimakalim (INN)

binospirone (INN)

bisoxatin (INN)

bnvudine (INN)

brocnnat (INN)

brofaromine (INN)

• brofoxme (INN)

bromchlorenone (INN)

brotizolam (INN)

broxatero! (INN)

broxundme (INN)

budadesme (INN)

butalamme (INN)

butamisole (INN)

camiglibose (INN)

carocainide (INN)

caroxazone (INN)

carpentide (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS»

68020-77-9

2037-95-8

119813-10-4

14176-10-4494-14-4

80-77-3

148-65-2

113-59-7

132-89-8

95-25-0

55694-98-9

89943-82-8

66564-16-7

58765-21-2633-90-9

73815-11-9

62380-23-8

69118-25-8477-80-5

28657-80-9

88053-05-8

143631-62-3

104456-79-3

65509-66-2

21512-15-2987-78-0

1195-16-0

4291-63-8

16562-98-4

58001-*4-8

96125-53-033588-20-4

51022-75-4

14796-28-2

71923-34-7

3876-10-6982-24-1

113665-84-2

60085-78-1


carprazidil (INN)carsalam (!NN)carzeiesin (INN)cetiedil (JNN)chlordimonns (!NN)chtomnezanone (INN)chloropyrilene (INN)chlorprothixene (INN)chlorthenoxazine (INN)chlorzoxazone (INN)

cidafnne (INN)cicletanme (INN)ciclosidomine (INN)ciclotizolam (INN)cifostodine (INN)cimoxatone (INN)cinecromen (INN)cmepaxadil (INN)cinnofuradione (INN)cinoxacin (INN)cmoxopazide (INN)ciprokiren (INN)cisconazole (INN)citatepine (INN)citenazone (INN)citicoline (INN)Citiolone (INN)cladnbme (INN)clantifen (INN)ciavulanic acid (INN)ctentiazem (INN)clidafidine (INN)cliprofen (INN)clodanolene (INN)clodoxopone (INNtclommorex (INN)clopenthixol (INN)clopidogrel(INN)clopipazan (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

13448-22-1

2058-52-8

33671-46-4

1856-34-4

4177-58-6

24166-13-0

15311-77-0

37681-00-8

94470-67-4

53736-51-9

113759-50-5

14461-91-7

15301-52-750-18-0

147-94-4

125372-33-0

112362-50-21469-07-4

7261-97^5

141200-24-0

72803-02-2

61477-97-2

2353-33-5

79874-76-3

106972-33-2

1767-88-0

14769-74-5

4741-41-7357-56-2

364-98-7

5571-97-1

69655-05-6702-54-5

86-14-6

5617-26-542399-41-7695-53-4

524-84-5

6495-46-1


ciorotepine (INN)ciotiapine (INN)clotiazepam (INN)clotioxone (INN)ciotixamide (INN)cloxazolam (INN)cloxypendyl (INN)coumazoline (INN)cromakalirn (INN)cramitrile (INN)cronidipine (INN)cyclazodone (iNN)cyclexanone (INN)cyclophosphamide (INN)eytarabtne (INN)dacopafant (INN)dalfophstin (INN)damotepme (1NN)dantrolene (INN)darglitazone(INN) 293410darodipine (INN)dazolicme (INN)deeitabme (INN)delmopinol (INN)dempnde(lNN)desmethylmoramide (!NN)dexamisole (INN)dexoxadrol (INN)dextromoramide (INN)diazoxide (INN)dichlormezanone (INN)didanosine (INN)diethadione (INN)diethylthiambutene (INN)difencloxazme (INN)diltiazem (INN)dimethadione (INN)dimethylthiambutene (INN)dioxadrol (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

467-86-7

52042-24-7

87495-31-6

18471-20-0

106707-51-1

59831-63-9

99248-32-5113-53-1

84625-59-2

26058-50-4309-29-5

74191-85-8

3094-09-5

62904-71-6

35067^»7-1

90101-16-9

116539-59-4

60940-34-3

77695-52-4

80263-73-6

15176-29-1

89197-32-0

111011-63-3

119413-55-7

103946-15-2

72895-88-6

98224-03-4

129729-66^1

38957-41-4

124378-77-4

59798-73-1

55726-47-1

59755-82-7

60136-25-6

5696-17-3

2363-58-8

87940-60-1

101335-99-3

84611-23^4


dioxapiietyi butyrate (ÎNN)diproxadol (INN)disoxaril (INN)ditazole (INN)dobupnde (INN)doconazole (INN)donetidine (INN)dosulepin (INN)dotarizine (INN)dotefonium bromide (INN)doxapram (INN)doxazosin (INN)doxifluridine (INN)doxpicomme (INN)droxactn (INN)droxicam (INN)duloxetine (INN)ebselen (INN)ecastolol (INN)eciazolast (INN)edoxudine (INN)efaroxan (INN)efonidipine (INN)eigooipine (INN)elnadipme (INN)eltenac (INN)eltoprazine (INN)emakalim (INN)emorfazone (INN)enadoline (INN)enilospirone (INN)enocitabme (INN)enolicam (INN)epervudine (INN)epipropidine (INN)epitiostanol (INN)eprobemide (INN)eprovafen (!NN)erdosteine (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS»

16781-39-8441-61-2

64420-40-2

21715-46-8

7716-60-1

40054-69-1

41340-25-4

17692-35-2

82140-22-5

28189-85-7

127625-29-0

106100-65-6

65886-71-7

23271-74-1

1008-65-7

4378-36-3

5588-29-4

15302-16-6

21820-82-6

5053-06-5

22293-47-6

69123-90-6

69123-98-4

78168-92-0

34161-24-5

15301-69-6

98205-89-1

77590-96-6

53731-36-550-91-9

19888-56-3

21679-14-1

71923-29-0

7125-73-7

30914-89-7

61325-80-2720-76-3

60135-22-0

66934-18-7


etasulme (INN)ethylmethylthiambutene (INN)etibendazole (INN)etifoxine (INN)etisazole (INN)ehzolam (INN)etodoiac (INN)

etofuradme (INN)

etolotifen (INN)

etoxadrol (INN)

fanansenn (INN)

fasiplon (JNN)fazarabine (INN)fedrilate (INN)fenadiazole (INN)fenbutrazate (INN)fenmetramide (INN)fenozolone (INN)fenpipalone (INN)fenspiride (INN)feprosidnine (INN)

fiacitabrne (INN)fialundme (INN)

Slenadol (INN)

fipexide (INN)

fiavoxate (INN)

flesinoxan (INN)

flordipme (INN)

floredil (INN)

floxundine (INN)

fluazacort (!NN)fludarabine (INN)fludoxopone (INN)

flumetramide (INN)

flumexadol (INN)

flumezapine (INN)

flummorex (INN)

fiumoxonide (INN)

flunoxaprofen (INN)

Vol. 1867, 1-31874


HS6

293490

253490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS»

105182-45-4

2709-55-0

37717-21-8

27060-91-9

10202-40-1

52867-77-3

15687-22-6

18053-31-1

17692-39-6

22514-23-4

37132-72-2

60248-23-9556-12-7

139-91-3

1239-29-867-*5-8

5118-17-2

85666-24-6

2385-81-1

6281-26-1

138661-03-7

56119-96-1804-30-8

7761-75-3

64603-91-4

124012-42-6

95058-81-4

80763-86-6

59128-97-1

7247-57-6

3105-97-3611-53-0

130308-48-4

79944-58-4

54-42-2

3778-73-2

119719-11-8

137214-72-3

133454-47-4


fluparoxan (INN)

flupentixol (INN)

fiurocitabine (JNN)

flutazolam (INN)

nutizenot (1NN)

fluzopenne (INN)

fblescutol (INN)

fominoben (INN)

fomocaine (INN)

fopirtoline (INN)

fotretamme (INN)

fuprazote (INN)

furalazine (INN)

furaltadone (INN)

furazabol (INN)

furazolidone (INN)

furazotium chloride (INN)

furegrelate (INN)

furethidine (INN)

furmethoxaaone (INN)

fumidipine (INN)

furodazote (INN)

fursultiamine (INN)

furterene (INN)

gaboxadol (INN)

galocitabine (INN)

gemcitabme (INN)

glunicate (INN)

haloxazolam (INN)

heteronium Bromide (INN)

hycanthone (INN)

ibaatabme (INN)

icatibant(INN)

idazoxan (INN)

idoxundine (INN)

ifosfamide (INN)

ilatreotide (INN)

iliparcil (INN)

iiopendone (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

81167-16-0318-23-0

60929-23-9

39178-37-558-63-9

13445-12-0

51934-76-0

83656-38-61051-18-13-6

97682-44-5

57067-46-659-63-2

107320-86-5482-15-5

75949-60-9

34552-84-6

75695-93-1

84625-61-6

53003-81-9

27223-35-4

65277^12-1

34580-13-7

134678-17-4

101530-10-3

108736-35-2

75706-12-6

26513-90-6

14769-73-4

94535-50-9339-72-0

100986-85-4

3795-88-8

5666-11-5

4792-18-1

128620-82-675358-37-1

33876-97-0

72444-63-4

70374-39-9


imiloxan (INN)

imolamine (INN)

indeloxazîne (INN)

inicarone (INN)

inosrne (INN)

iobutoic acid (INN)

lomonmc acid (INN)

ipramidil (INN)

iprotiazem (INN)

innotecan (INN) 293990

isamoxole (INN)

isocarOoxazid (INN)

isomolpan (INN)

isothipendyl (INN)

isoxaprolol (INN)

isoxicam (INN)

isrodipine (INN)

straconazole (INN)

ivanmod (INN)

ketazolam (INN)

ketoconazole (INN)

ketotifen (INN)

iamivudine (INN)

lanoconazole (INN)

tanreotide (INN)

leflunomide (INN)

letimtde (INN)

levamisole (INN)

ievcromakalim (INN)

levcyclosenne (INN)

levofloxacm (INN)

ievofuraitadone (INN)

ievomoramide (INN)

levoxadrof (INN)

limazocic (INN)

Unoglinde (INN)

linsittomme (INN)

lodiperone(INN)

lomoxicam (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS»

.76612-20-9

1977-10-2

121288-39-9479-50-5

76743-10-7

85118-42-9

83903-06-4

88859-04-5

35846-53-8

59937-28-9

115550-35-1

65509-24-2

42024-98-653-31-6

13355-00-5494-79-1

83784-21-870-07-5

17854-59-0

4295-63-0

29053-27-8

34262-84-5135-58-0

1665-48-1493-78-7

91-80-5

721-19-7

5800-19-1

42110-58-7

20229-30-5

4969-02-2

17692-22-7

103980-45-6

22013-23-6

23707-33-7

31868-18-5

9414Q-41-4

37065-29-5

25905-77-5


lorteiâmine (INN) loxapme (INN)loxoribine (INN)lucanttione (INN)lueartamide (1NN)iufuradom (INN)luprtidine (!NN)

mafbsfamsde (INN)

martansine (INN)

malotiiate (INN)

martoofloxacin (INN)

maroxepin (INN)

mazatico! (INN)

medibazme (INN)

melarsonyl potassium (INN)

melarsoprol (INN)

menabitan (INN)

mephenoxalone (INN)

mepixanox (INN)

meprotixol (INN)

meseclazone (INN)

mesocarb (INN)

mesulfen (INN)

metaxalone (INN)

methaphenilene (INN)

methapynlene (INN)

methastyndone (INN)

metiapme (INN)

metioxate (INN)

metitepme (INN)

metixene (INN)

metizolme (INN)

metostitenol (INN)

metoxepin (INN)

metnfudil (INN)

mexazolam (INN)

midesteine (INN)

miloxacin (INN)

minapnne (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

.85118-44-1

117523-47-4

7696-00-6

50924-49-7

15518-84-0

71320-77-9

78967-07-4

54063-50-2

29936-79-6

5581-46-4

7416-34-4

94746-78-8

25717-80-0

132019-54-6

90243-66-6

75841-82-6

19395-58-5

20574-50-9

6536-18-1

31848-01-8

41152-17-4952-54-5

65847-85-0

35843-07-3

3731-59-7469-81-8

3780-72-1

112885-41-3

90697-57-7

17692-56-7

82239-52-9

52279-59-1

66203-94-9

58019-65-1

66556-74-953-84-9

84145-90-4

28820-28-2

101506-83-6


minocromil (INN)mirfentanil (INN)mitotenamine (INN)mizohbine (INN)mobecarb (INN)moclobemide (INN)mofezolac (INN)mofloverine (INN)mofoxime (INN)molinazone (INN)molmdone (INN)molracetam (INN)molsidomine (INN)monatepil (INN)montirelin (INN)

mopidralazme (INN)

moquizone (INN)

morantel (INN)

morazone (INN)

morclofbne (INN)

morforetx (INN)

morinamide (INN)

momiflumate (INN)

morocromen (INN)

moroxydine (INN)

morphendine (INN)

morsuximide (INN)

mosapride (INN)

motapizone (INN)

moxicoumone (INN)

moxirapnne(INN)

moxnidazole (INN)

murocainide (INN)

nabazenil (INN)

nabitan (INN)

nadide (INN)

nafoxadoi (INN)

naftoxate (INN)

namirotene (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS»

.22292-91-7

120819-70-7

88058-88-2

69049-73-6

86636-93-3

13669-70-0

99453-84-6

99803-72-2

90326-85-5

4397-91-5

95058-70-1555-84-0

4936^7-4

5036-03-3

3363-58-4

15179-96-1

26350-39-0

18857-59-5

57474-29-0

24632-47-1

13411-16-0

1614-20-6

5055-20-9

23256-30-6

1088-92-2

1900-13-6

39978-42-2

50435-25-1

6506-37-2

6363-02-667-20-9

110588-56-2

31430-18-9

16985-03-8

75963-52-9

36471-39-3

57726-65-5

129029-23-8

78410-57-8


narano! (INN)

naroparcil (INN)

naxagolide (INN)

nedocromil (INN)

nefiumozide (INN)

nefopam (INN)

neltenexme (INN)

nerbacadol (INN)

nesapidil (INN)

nicofurate (INN)

nictiazem (INN)

nifuradene (INN)

nifuratel (INN)

nifurdazil ((NN)

nifurfoline (INN)

nifunmide (INN)

nifurizone (INN)

nifurmazole (INN)

nifuroquine (!NN)

mfurpipone (INN)

nifurpinnol (INN)

nifurprazine (INN)

nifurquinazol (INN)

nifurtimox (INN)

nifurtoinol (INN)

nifurvidine (INN)

nifurzide (INN)

nimidane (INN)

nrmorazole (INN)

nitrarrosole (INN)

nitrofurantom (INN)

noberastine (INN)

nocodazole (INN)

nonabme (INN)

nuclomedone (INN)

nuclotixene (INN)

nufenoxole (INN)

ocapendone (INN)

ociltide (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

56391-55-0

131796-63-9

33380-47-6

132539-06-1

39567-20-9

64224-21-1

60175-95-3

78994-24-8

16509-11-8

16485-05-5

26629-87-8

56969-22-3

6577-41-9

21256-18-8

27591-42-0

24143-17-7

25392-50-1

17692-63-6

72830-39-8

90729-41-2959-14-8

14698-29-4

5585-93-3

124423-84-3115-67-3

26513-79-1

61400-59-7

61869-08-7

114716-16-4

2152-34-377-12-3

138661-02-6

81382-51-6

55694-83-2

53910-25-1

57083-89-3

62435-42-1

2055-44-9

467-84-5


octazamide (INN)odapipam (!NN)ofloxacin (INN)

olanzapine (INN)

olpimedone (INN)

oltipraz (INN)

omonasteine (INN)

ormeloxifene (INN)

otimerate sodium (INN)

oxadimedine (INN)

oxaflozane (INN)

oxapadol (INN)

oxapium iodide (INN)

oxaprozin (INN)

oxazidione (INN)

oxazolam (INN)

oxazorone (INN)

oxitefonium bromide (INN)

oxmetidine (INN)

oxodipine (INN)

oxolamine (INN)

oxolinic acid (INN)

oxypendyl (INN)

panadiplon (INN)

paramethadione (INN)

paraxazone (INN)

parconazole (INN)

paroxetine (INN)

pemedolac (tNN)

pemoline (INN)

pentacymum chloride (INN)

pentetreottde (INN)

pentiapine (INN)

pentizidone (INN)

pentostatin (INN)

peralopnde(INN)

perfosfamide (INN)

perisoxal (INN)

phenadoxone (INN)

Vol. 1867, 1-31874


KS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

634-03-7

134-49-6

115-55-9

76732-75-7

72467-44-8

39577-19-0

56208-01-6

27199-40-2

54341-02-5314-03-4

38955-22-5

53251-94-8

14008-66-3

2167-85-359-39-2

24886-52-0

23744-24-3

40680-87-3

30868-30-5

1043-21-6

3605-01-4

36322-90-4

132722-74-8

59840-71-0

15574-96-6

63394-05-8140-65-8

103177-37-3

52549-17-4

92623-83-1

19216-56-9

47543-65-7

30840-27-8

69425-13-4

70833-07-7

36505-82-5

34740-13-1

3615-74-5

33743-96-3


phendimetrazine (INN)phenmetrazine (INN)phenythilone (INN)picartamide (INN)picionidine (INN)picumast (INN)pifamine (INN)pifaxole (INN)piflutixol (INN)pimethixene (INN)pinadoline (INN)pinaverium bromide (INN)pmoxepin (INN)pipazetate (INN)piperoxan (INN)pipofezme (INN)pipoxolan (INN)piprofurol (INN)

pirazofunn (INN)

pirenoxine (INN)piribedil (INN)piroxicam (INN)pirsidomine (INN)prtenodii (INN)pizotifen (INN)

plafibnde (INN)

pramocaine (INN)

pranlukast(INN)

pranoprofen (INN)

pravadoline (INN)

prazosin (INN)

prenoxdiazme (INN)

pretiadil (INN)

prifelone(INN)

prifuroline (INN)

prodolic acid (INN)

profexalone (INN)

promolate (INN)

proroxan (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS»

303-69-5

2622-24-4

58416-00-5

5696-09-3

69815-38-9

15686-83-6

7035-04-3

86048-40-0

54340-59-9

62265-68-3545-59-5

84449-90-1

84071-15-8

30271-85-3

71620-89-8

76053-16-2

73080-51-0

36791-04-5

7724-76-7

72559-06-9

132014-21-2

54187-04-1

106266-06-2

87051-43-2

91833-77-1

119302-91-9

109543-76-2

38373-83-0

101363-10-4

126294-30-2

5578-73-4

110588-57-3

121617-11-6

79262-46-7

29050-11-1

5610-40-2

116476-13-2

99592-32-2

86487-64-1


prothipendyl (INN)

prothixene (INN)

protiofate (INN)

proxazole (INN)

proxorphan (INN)

pyrantel (INN)

pyridarone (INN)

quazolast (INN)

quincarbate (INN)

quinfamide (INN)

racemoramide (INN)

raloxifene (INN)

ramixotidine (INN)

razinodil (INN)

reboxetine (!NN)

reclazepam (INN)

repihnast (INN)

ribavirin (!NN)

riboprine (INN)

rifabutin (INN)

rilmakalim (INN)

riimenidine (INN)

risperidone (INN)ntansenn (INN)

rocastme (INN)

rocuronium bromide (INN)

romazarit (INN)

romifenone (INN)

ruftoxacin (INN)

sagandipine (INN)

sanguinanum chloride (INN)

saperconazole (INN)

saviprazole (INN)

savoxepin (INN)

seciazone (INN)

secunnine(INN)

semotiadil (INN)

sertaconazole (INN)

setoperone (INN)

Vol. 1867, 1-31874


Hse

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS»

138778-28-6

53123-88-9

3064-61-7

4448-96-8

68367-52-2

77181-69-2

95105-77-4

90243-97-3

87151-85-7

83647-97-6

83602-05-5

41992-23-8

1054-88-2

3056-17-5

72324-18-6

54340-66-8

56030-54-7

37753-1O-9

58095-31-1350-12-9

77590-92-2

40828-46-4

53813-83-5

104987-11-3

101626-70-4

67489-39-8

66898-62-2

21489-20-3

42408-80-0

106073-01-2

19388-87-5

124066-33-7

38668-01-8

79253-92-2

55837-23-5

17902-23-7

80880-90-6

111902-57-9

120210-48-2


siratiazem (INN)

sirolimus (INN)

sodium stibocaptate (INN)

solypertine (INN)

sorfainil (INN)

sorivudine (INN)

somidipine (INN)

spiclamine (INN)

sprradohne (INN)

spirapril (INN)

spiraprilat (INN)spirogermanium (INN)spiroxatrine (INN)stavudine (INN)stepronin (INN)

subendazote (INN)

sufentanil (INN)

sufosfamide (INN)

;Si3lbenox (WN)

sulbentine (INN)

suprocione (INN)

suprofen ;(INN)sunclone (INN)

tacrolimus (INN)

talipexole (INN)

talmetacm (INN)

talniflumate (INN)

talsupram (INN)

tandamme (INN)

tampion (INN)

tauroiidine (INN)

taurosteine (INN)

taurultam (INN)

tazipnnone (INN)

teflutixol (INN)

tegafur (INN)

telenzepme (INN)

temocapnl (INN)

tenidap (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

100599-27-7

82650-83-7

62473-79-4

86696-86-8

29767-20-2

21500-98-1

95232-68-1

129336-81-8

59804-37-4893-01-6

63590-64-7

67915-31-5

86433-40-1

121277-96-1

25683-71-0

119625-78-4

14636-12-5

59653-74-6

34784-64-0

5036-02-286-12-4

4304-40-991-79-2

7219-91-2

2240-21-3

115103-54-3

31428-61-2

51527-19-6

66981-73-5

57010-31-8

14785-50-3

33005-95-7

71116-82-0

5845-26-1

63996-84-9

97852-72-7

15686-72-370-10-0

55142-85-3


tenidap {INN)

îenilapine (INN)

teniloxazine (INN)

tenilsetam (INN)tenrposide (INN)

ienocyclidine (INN)

tenosal (INN)

îenosiprol (INN)

tenoxicam (INN)

tenytidone (INN)

terazosin (!NN)

terconazole (INN)

terflavoxate (INN)

terikalant (INN)

ierizidone (INN)

tertakiren (INN)

tertipressin (INN)

teroxirone (INN)

tertatolol (INN)

tetramisoie (INN)

thenalidine (INN)

thenium closilate (!NN)

thenyldiamine (INN)

thihexinol methylbromide (INN)

thiofuradene(INN)

tiagabine (!NN)

tiamenidine (INN)

tianafac (INN)

tianeptine (INN)

ttaparnil (INN)

tiapihnol (INN)

tiaprofenic acid (INN)

tiaprost (INN)

tiazesim (INN)

tibalosin (INN)

tibenelasî(INN)

tibrofan (INN)

ticlatone (INN)

ticlopidine (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

144-12-7

40180-04-9

75458-65-0

37967-98-9

90055-97-3

39754-64-8

81656-30-6

89875-86-5

14176-49-9

58433-11-7

42239-60-1

96306-34-2

35035-05-3

26839-75-8

50708-95-7

66788-41-8

24237-54-5

22619-35-8

65899-73-2

66969-81-1

38070-41-6

61220-69-7

87691-91-6

34976-39-1

40198-53-6

4991-65-5

95588-08-2

5169-78-8

54376-91-9

7489-66-9

83153-39-3

71731-58-3

35423-51-9

80680-05-3

2949-95-3

83573-53-9

51322-75-9

29218-27-7

123948-87-8


tiemonium iodide (INN)tienilic acid (INN)tienocarbine (INN)tienopramine (INN)tienoxolol (INN)tifemoxone (INN)tifluadom (INN)iifiucarbms (INN)tiletamine (INN)tilomisole (INN)tilozepine (INN)timelotem (INN)timepidium bromide (INN)timolol (INN)tinabinol (INN)tinofedrine (INN)tinoridine (INN)tioclomarol (INN)tioconazole (INN)tiodazosin (INN)tiodomum chloride (INN)tiopinae (INN)tiospirone (INN)tioxacin (INN)tioxaprofen (INN)tioxolone (INN)tipentosin (INN)tipepidine (INN)tipetropium bromide (INN)tipindole (INN)tipnnast (INN)tiquizium bromide (INN)

tisocromide (INN)

tivanidazole (INN)

tixadtl (INN)

tizabrin (INN)

feanidine (INN)

totoxatone (INN)

topotecan (INN)

Vol. 1867, 1-31874


HS6

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

293490

CAS*

655-05-0

103624-59-5

4047-34-1

58712-69-9

35943-35-270-00-8

68-91-7

127-48-0

635-41-6

35619-65-9

14504-73-5

47420-28-0

22089-22-1

27574-24-9

108001-60-1

84697-22-3

116289-53-3

118812-69-4

109683-61-6

109683-79-6

64860-67-9

17692-71-6

103222-11-3

5536-17-4

46817-91-8

89651-00-3

81801-12-9

14008-71-0

52832-91-4

7361-61-7

7481-89-2

109826-26-8

89482-00-8

127308-82-1

28810-23-3

30516-87-1

111406-87-2

84697-21-2

52867-74-0


lozalinone (INN)

traboxopine (INN)

trantelinium bromide (INN)

traxanox (INN)

triciribine (INN)

înflundine (INN)

trimetaphan camsilate (INN)

tnmethadione (INN)

trimetozine (INN)

tritiozine (INN)

tritoqualine (INN)

tnxolane (INN)

trofosfamide (INN)

îropatepine (INN)

troquidazole (INN)

tubulozole (INN)

îulopafant (!NN)

ulartitide (INN) 350400

utibapni (INN)

utibaprilat (INN)

valpehno! (INN)

vanitiolide (INN)

vapreotide (INN)

vidarabine (INN)

viloxazine (INN)

voxergolide (INN)

xamoterol (INN)

xanthiol (INN)

xinomiline (INN)

xylazrne (INN)

zalcrtabine (INN)

zaldaride (INN)

zattoprofen (INN)

zamifenacin (INN)

zepastine (INN)

zidovudine (INN)

zileuton (INN)

zinoconazole (INN)

zotoperone (INN)

Vol. 1867, 1-31874


HSS

293490

293490

293490

293490

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

CAS*

121929-20-2

26615-21^61-80-3

53772-83-159-66-5

968-81-0

3184-59-6

81982-32-3

5588-16-9

3754-19-6

1421-68-7

85320-68-9

51264-14-3

74863-84-6

133267-19-3

1150-20-5

27589-33-9

1824-52-873-48-3

91-33-8

104-22-3

90992-25-9

36148-38-6

28395-03-1

7007-88-7

2043-38-1339-43-5

42583-55-1138-41-0

58-94-6

94-20-2

77-36-1

68475-40-1671-95-4

636-54-4

2127-01-7

60200-06-8742-20-1

2259-96-3


zonielezole (INN)zotepine (INN)zoxazolamine (INN)

zuclopenthixol (INN)acetazolamide (INN)acetohexamide (INN)aiipamide (INN)alpiropride (INN)altizide (INN)ambuside (INN)amidefrine mes: late (INN)amosulalol (INN)amsacrine (INN)argatroban (INN)artilide (INN)azabon (INN)azosemide (INN)bemetizide (INN)bendroflumethiazide (INN)benzthiazide (INN)benzylsulfamide (INN)besulpamide (INN)besunide (INN)bumetanide (INN)butadiazamide (INN)butizide (INN)carbutamide (INN)carmetizide(INN)carzemde (INN)chlorothiazide(lNN)chlorpropamide (INN)chlortalidone(INN)ctpropnde (INN)clofenamide (INN)ctopamide (INN)clorexolone (INN)clorsulon (INN)cyciopenthiazide (INN)cyclothiazide (INN)

Vol. 1867, 1-31874


HS6

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

CAS*

79094-20-5

3436-11-1120-97-8

22736-85-2

7456-24-896-62-8

59032-40-5671-88-5

723-42-2

115256-11-6

120279-96-1

100981-43-9

1764-85-8

1213-06-5

1824-58-4

64795-23-9

103745-39-7

20287-37-0

80937-31-1

56488-61-0148-56-1

54-31-9

52157-91-2

51876-98-3

10238-21-8

26944-48-9

36980-34-4

24455-58-1

21187-98-4

52994-25-9

3074-35-9

35273-88-2

93479-97-1

37598-94-0

32797-92-5

29094-61-9

33342-05-1

52430-65-6

71010-45-2


daltroban (INN)

delfantrine (INN)

diclofenamide (INN)

diflumidone (INN)

dimetotiazine (INN)

dinsed (INN)

disulergine (INN)

disulfamide (INN)

ditolamide (INN)

dofetiiide (INN)

dorzolamide (INN)

ebrottdine (INN)

eprtizide (INN)

etebenecid (INN)

ethiazide (INN)

etisulergme (INN)

fasudil (INN)

fenquizone (INN)

flosulide (INN)

flubepnde (INN)

flumethiazide (INN)

furosemide (INN)

galosemide (INN)

gliamilide (INN)

glibenclamide (INN)

giibornuride (INN)

giicaramide (INN)

glicetanile (INN)

gliclazide (INN)

ghcondamide (INN)

ghdazamide (INN)

gliflumide (INN)

glimepmde (INN)

glipalamide (INN)

glipentide (INN)

glipizide (INN)

gliquidone (INN)

glisamunde (INN)

glisindamide (INN)

Vol. 1867, 1-31874


HS6

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

CAS*

.24477-37-0

25046-79-1

7007-76-3535-65-9

1492-02-0631-27-6

664-95-9

451-71-8

3459-20-9

1038-59-1

1228-19-980-34-2

3567-08-680-13-7

1034-82-8

13957-38-558-93-5

135-09-1

122647-31-8

26807-65-8

42792-26-7

23672-07-3

120824-08-0

68677-06-5138-39-6

515-57-1

3568-00-1

7195-27-9122-89-4

7541-30-2565-33-3

554-57-4

135-07-9

77989-60-7

1084-65-7

17560-51-9

61477-95-0

121679-13-8

51803-78-2


glisoiamide (INN)glisoxepide (INN)glucosulfamide (INN)glybuthiazol (INN)glybuzole (INN)glyctopyramide (INN)glycyclamide (INN)glyhexamide (INN)glymidine sodium (INN)glyoctamide (INN)glypinamide (INN)glyprothiazol (INN)glysobuzole (INN)halazone (INN)heptolamide (INN)hydrobentizide (INN)hydrochlorothiazide (INN)hydroflumethiazide (INN)

ibutilide (INN)

indapamide (INN)

isosulpnde (INN)

levosulpiride (INN)

hnotroban (INN)

lorapnde (INN)

mafenide (INN)

maleylsulfathiazole (INN)

mebutizide (INN)

mefruside (INN)

mesulfamide (INN)

mesupnne (INN)

metahexamide (INN)

methazolamide (INN)

methyclothiazrde (INN)

metibride (INN)

meticrane (INN)

metolazone (INN)

monalazone disodium (INN)

naratnptan (INN)

nimesulide (INN)

Vol. 1867, 1-31874


HS6

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

CAS»

473-42-7

1580-83-2

21132-59-2

1766-91-2485-24-5

85-73-4

39860-99-6

55837-27-9346-18-9

57-66-9

98-75-9

68556-59-273-49-4

64099-44-1

120688-08-6

111974-60-8

22933-72-8

2315-08^»139-56-0

515-58-2

56302-13-7

101526-83-4

123308-22-5

108894-39-9

3930-20-9

13642-52-9498-78-2

116-43-8

30279-49-3

34042-85-8

2455-92-7127-77-5

127-71-9

547-44-4

21662-79-3144-80-9

80-32-0

485-41-6

17784-12-2


nitrosulfathiazole (INN)

paraflutizide (INN)

pazoxide (INN)

penftutizide (INN)

phthalylsulfamethizole (INN)

phthalylsulfathiazole (INN)

pipotiazine (INN)

piretanide (INN)

polythiazide (INN)

probenecid (ÎNN)

propazolamide (INN)

prosuipride (INN)

quinethazone (INN)

quisultazme (INN)

risotilide (INN)

ritolukast (INN)

satazodine (INN)

salazosulfadimîdtne (INN)

salazosulfamide (INN)

salazosulfathiazole (INN)

satranidazole (INN)

sematilide (INN)

sezolamide (INN)

sitalidone (INN)

sotalol (INN)

soterenol (INN)

stearylsulfamide (INN)

succinylsuHathiazole (INN)

suclofenide (INN)

sudoxicam (INN)

sulclamide (INN)

sulfabenz (INN)

sulfabenzamide (INN)

sulfacarbamide (INN)

sulfacecole (INN)

suifacetamide (INN)

sulfachlorpyndazme (INN)

sulfachrysoidine (INN)

sulfacitrne (INN)

Vol. 1867, 1-31874


HS6

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

CAS*

4015-18-3

54063-55-7102-65-8

128-12-1

68-35-9

115-68-4

122-11-2

57-68-1

2447-57-694-19-9

127-69-5

57-67-0

27031-08-9152-47-6

14376-16-0

65761-24-2127-79-7

127-58-2

144-82-1

723-46-6

80-35-3

3772-76-7651-06-9

32909-92-5

1220-83-3729-99-7

122-16-7

599-88-2

526-08-9

116-42-7

852-19-7

144-83-2

59^0-5599-79-1

632-00-8

3563-14-2

1984-94-772-14-0

515-49-1


sulfaclomide (INN)sulfaclorazole (INN)sulfaclozine (INN)sulfadiasuifone sodium (INN)sulfadiazme (INN)sulfadicramide (INN)sulfadimethoxine (INN)sulfadimidine (INN)sulfadoxine (INN)sulfaethidole (INN)sulfafurazole (INN)sulfaguanidine (INN)sulfaguanole (INN)sulfalene (INN)sulfaloxic acid (INN)sulfamazone (INN)

suifamerazme (INN)

sulfamerazine sodium (INN)

sulfamethizole (INN)

sulfamethoxazole (INN)

sulfamethoxypyndazine (INN)

sulfametomidine (INN)

sulfametoxydiazme (INN)

sulfametrole (INN)

sulfamonomethoxine (INN)

sulfamoxole (INN)

sulfanitran (INN)

sulfapenn (INN)

sulfaphenazole (INN)

sulfaproxyhne (INN)

sutfapyrazole (INN)

sulfapyndine (INN)

sulfaqumoxaline (INN)

sulfasalazme (INN)

sulfasomizole (INN)

sulfasuccinamide (INN)

sulfasymazine (INN)

sutfathiazole (INN)

sulfathiourea (INN)

Vol. 1867, 1-31874


HS6

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

293500

CAS*

,1161-88-2

23256-23-7

13369-07-8515-64-0

90207-12-8

57479-88-6121-64-2

110311-27-8

82666-62-4

72131-33-0

15676-16-1

60325-46-461-56-3

73747-20-3

103628-46-2

32059-27-1

81428-04-8

106133-20-4

85977-49-7

4267-05-4

3692-44-2316-81-4

3688-85-5

69387-87-7

3313-26-6

56488-58-5

1156-19-064-77-7

1027-87-8

5588-38-5

56211-40-6

32295-18-4

87051-13-6127-65-1

133-67-5

24243-89-8

73803-48-2

52406-01-6119-85-7


sulfatolamide (INN)sulfatroxazole (INN)sulfatrozole (INN)sulfisomidine (INN)sulicrinat (INN)

sulmepride (INN)

sulocarbilate (INN)

sulofenur (INN)

sulosemide (INN)

sulotroban (INN)

sulpiride (INN)

sulprostone (INN)

sultiame (INN)

sulverapnde (INN)

sumatriptan (INN)

sumetizide(INN)

taltnmide (INN)

tamsulosin (INN)

tauromustine (INN)

teclothiazide (INN)

thiohexamide (INN)

thioproperazine (INN)

tiamizide (INN)

tlnisulphde (INN)

tiotixene (INN)

tizolemide (INN)

tolazamide (INN)

tolbutamide (INN)

tolpentamide (INN)

tolpyrramide (INN)

torasemide (INN)

tosifen (INN)

tosulur (INN)

îosylchloramide sodium (INN)

trichlormethiazide (INN)

thflumidate (INN)

tnpamide (INN)

uredofos (INN)

vanyldtsulfamide (INN)

Vol. 1867, 1-31874


HS6

293500

293500

293500

293500

293500

293810

293810

293810

293810

293810

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

293890

294000

294000

294000

294000

294000

294000

294000

294000

CAS»

66644-81-3

14293-44-8

75820-08-5

37000-20-7

68291-97-4520-27-4

30851-76-4

23869-24-1153-18-4

7085-55-4

1111-39-3

36983-69-4

17598-65-171-63-6

20830-75-5

14144-06-0

33419-42-0

1405-76-1

3261-53-8

10176-39-3

18719-76-1

17226-75^J

17575-22-3

33396-37-1

30685-43-9

131129-98-1

7242-04-8

8063-80-7466-06-8

100345-64-0

99759-19-0

10016-20-3

56824-20-5

7585-39-9-00-0

4618-18-2

15351-13-0

54182-58-0

57680-56-5


veraiipride (!NN)xipamide (INN)zidapamîde (INN)zinteral (INN)zonisamide (!NN)diosmin (!NN)ethoxazorutoside (INN)monoxerutin (INN)mtoside (iNN)troxerutin (INN)acetyldigtoxin (INN)actodigin (INN)deslanoside (INN)digitoxin (INN)digoxin (INN)disogluside (INN)etoposide (INN)gitalin, amorphous (INN)gitaioxin (INN)

gitoformate (INN)

keracyamn (INN)khelloside (INN)ianatoside C (INN)meprosciilann (INN)

metildigoxin (INN)

mipragoside (INN)

pengitoxin (INN)

polisaponin (INN)

proscillaridin (INN)

siagoside (INN)

tiqueside (INN)

alfadex (INN)

amiprilose (iNN)

betadex (INN)

lactalfate (INN)

lactulose (INN)

nicofuranose (INN)

sucralfate (INN)

sucrosofate (INN)

Vol. 1867, 1-31874


HS6

294200

294200

294200

310270

320300

320412

320412

320413

320413

320419

320490

340212

340213

340213

340213

340213

340213

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

CAS*

12182-48-8

16037-91-5

12040-73-2156-62-7

547-17-1

3861-73-2

15722-48-2548-62-9

92-31-9

7235-40-7

1461-15-0

8001-54-5

9004-95-9

9002-92-0

57821-32-6

9016-45-9

9002-93-1

143003-46-7

105857-23-6

9046-56-4

81669-57-0

9039-61-6

9000-99-1

9001-00-7

9001-09-6

9004-07-3

120608-46-0

9004-09-5

37326-33-3

9001-54-1

9001-01-8

99821-44-0

51899-01-5

9016-01-7

130167-69-09001-74-5-00-0

133652-38-7

9001-62-1


glucalox (INN)

sodium stibogluconate (INN)

sucralox (INN)

calcium carbimide (INN)

xantofyl palmitate (INN)

anazolene sodium (INN)

olsalazine (INN)

methylrosanilinium chloride (INN)

tolonium chloride (INN)

betacarotene (INN)

oftasceine (INN)

benzalkonium chloride (INN)

cetomacrogol 1000 (INN)

iauromacrogol 400 (INN)

menfegol (INN)

nonoxinol (INN)

octoxinol (INN)

alglucerase (INN)

alteplase (INN)

ancrod (INN)

anistrepiase (iNN)

batroxobin (INN)

bhnase (INN)

bromelains (INN)

chymopapain (INN)

chymotrypsin (INN)

duteplase (INN)

fibrinolysin (human) (INN)

hyalosidase (INN)

hyaluronidase (INN)

kailidmogenase (INN)

nasaruplase (!NN)

ocrase (INN)

orgotem (INN)

pegaspargase (INN)

pemciilmase (INN)

promelase (!NN)

reteplase (INN) 350400

rizohpase (INN)

Vol. 1867, 1-31874


HS6

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

350790

380840

382390

382390

382390

382390

382390

382390

382390

382390

390190

390290

390461

390590

390690

390690

390710

390720

390720

390720

390720

390720

390730

390760

390799

390810

390910

390940

391000

CAS*»

99149-95-8

37312-62-2

63551-77-9

131081-40-B

37340-82-2

9002-01-1

110294-55-8

12211-28-8

9002-04-4

9031-11-2

903S-53-6505-86-2

8063-24-9

87806-31-3

1338-39-2

1338-43-8

26266-57-9

8007-43-0

1338-41-6

26658-19-5

25053-27-4

71251-04-2

9002-84-0

9003-39-8

54182-57-9

9003-97-8

54531-52-1

25322-68-3-00-0

9003-11-6-00-0

25301-02-4

9003-23-0

25038-59-9

26009-03-025038-54-4

9011-05-6

101418-00-2

9006-65-9


saruplase (INN)

serrapeptase (INN)

sfericase (INN)

siiteplase (!NN)

streptodomase (INN)

streptokinase (INN)

sudismase (INN)

sutilains (INN)

thrombin (INN)

tiiactase (!NN)

urokinase (INN)

cetrimide (INN)

acrifiavinium chloride (INN)

porfimer sodium (INN)

sorbttan laurate (INN)

sorbitan oieate (INN)

sorbitan palmitate (INN)

sorbitan sesquioieate (INN)

sorbitan stéarate (INN)

sorbitan tristearate (INN)

sodium apolate (!NN)

surfomer (INN)

politef(INN)

poiyvidone (INN)

carbomer (INN)

potycarbophil (INN)

polybenzarsol (INN)

macrogol (INN)

macrogol ester (INN)

poloxalene (INN)

polysorbate (INN)

tyloxapol (INN)

poiyetadene (INN)

pegoterate (INN)

polyglycolic acid (INN)

policapram (INN)

polynoxyiin (INN)

policresulen (INN)

dtmeticone (INN)

Vol. 1867, 1-31874


HS6

391190

391190

391190

391190

391190

391190

391190

391190

391190

391190

391220

391231

391239

391239

391239

391290

391290

391390

391390

391390

391390

391390

391390

391390

391390

391390

391390

391390

391390

391390

391390

391390

391390

391400

391400

391400

391400

CAS»

82230-03-3

54063-44-4

56959-18-3

41385-14-2

29535-27-1

107667-60-7

75345-27-6

90409-78-2

41706-81^»

32289-58-0

9004-70-0

9000-11-7-00-0

8063-82-9

9004-67-5

9004-36-8

9004-38-0

110042-95-00-00-0

64440-87-5

9015-73-0-00-0

37209-31-7

9004-54-0

56087-11-7

8063-26-1-00-0

57680-55-4

53973-98-1

9012-76-4

9015-56-9

9050-67-3

57459-72-0

50925-79-6

11041-12-6

54182-62-6

56227-39-5


carbetimer (INN)

ferropolimaler (INN)

glusoferron (INN)

ieuciglumer (INN)

maletamer (INN)

polaprezinc (!NN) 300390

polidronium chloride (ÎNN)

polifeprosan (INN)

poliglecaprone (INN) 390799

polihexanide (INN)

pyroxylin (INN)

carmellose (INN)

celudoral (INN)

hypromellose (INN)

methylcellulose (INN)

cellaburate (INN)

cellacefate (INN)

acernannan (INN)

ardepann sodium (INN)

cideferron (INN)

colextran (INN)

daitepann sodium (INN)

detralfate (iNN)dextran (INN)

dextranomer (INN)

dextriferron (INN)

enoxapann sodium (INN)

gleptoferron (INN)

poligeenan (INN)

poliglusam (INN)

polygeline (INN)

sizofiran (INN)

suleparoid sodium (INN)

colestipol (!NN)

colestyramme (INN)

polacnlin (!NN)

polidexide sulfate (INN)

Vol. 1867, 1-31874


ANNEX H - Prefix» ami Suffixes for Saits, Esters and Hydrates of INNs

ACETATEACETQNIDE1-ACETOXYETHYLACETYLSALICYLATEADIPATEALLYLALLYL BROMIDEAU.YL IQDiDEALUMINIUMAMINOSAUCYLATEAMMONIUMAMMONIUM FUSIDATEANTIPYRATEARGININEASCORBATEAXtTiLBARBITURATE8ENZENESULFONATEBENZQACETATEBENZYLBENZYL BROMIDEBENZYL IODIDEBESILATE .BESYLATEBIQUINATEBIS (HYDROGEN) MALATEBIS (HYDROGEN) MALEATEBIS (HYDROGENS) MALONATEBIS (PHOSPHATE)BISMUTHBITARTRATEBORATEBROMIDEBUTYLt-BUTYLt-BUTYL ACETATEtert-SUTYL ACETATEtertiary BUTYL ACETATEtertiairy BUTYLAMINEt-BUTYL ESTERtert-BUTYL ESTERtertiary BUTYL ESTERBUTYLATEBUTYLBROMIDEBUTYRATECALCIUMCALCIUM CHLORIDECALCIUM OIHYDRATECAMPHOR-10-SUPHONATECAMPHORATECAMPHORSUFONATECAMSILATECAMSYLATECAPROATECARBAMATECARBONATECHLORIDES-CHLOROTHEOPHYLLINATECHOLINECINNAMATECITRATECYCLOHEXANPROPIONATE

CYCLOHEXYLAMMONIUMCYCLOHEXYLPROPIONATEDECANOATEDIACETATEDiAMMONiUMDIBENZOATEDIBUTYRATEDICHOLINEDICYCLOHEXYLAMMONIUMDfETHYLAMINEDIETHYLAMMONIUMDiFUROATEDIHYDRATEDIHYDROBROMIDEDiHYDROCHLOR IDEDIHYDROCHLORIDEPHOSPHATEDiHYOROGEN CITRATEDIHYDROGEN PHOSPHATEDIHYDROXYBENZOATEDIMALATEDIMALEA.TEDIMALONATEDIMESILATEDINITRATEDINITROBENZOATEDIOXIDEDiPHOSPHATEDIPRQPIQNATÊDISODIUMDÎSODIUM PHOSPHATEDÎSULFATEDiSULFIDEDIUNDECANOATEEDiS!U»,TEEMBONATEEHANTATEENANTHATEESILATEESTOLATEESYLATESTHANESULFONATE1,2-ETHANEDISULFONATEETHOBROMIDEETHYLETHYL ESTERETHYL IODIDEETHYLAMINEETHYLAMMONIUMETHYLENANTATEETHYLHEXANOATEETHYLSUCCINATEFERROUS CITRATEFLUORIDEFLUOROSULFONATEFORMATEFORMATE SODIUMFOSFATEXFUMARATEFUROATEGLUCARATEGLUCEPTATE

GLUCOHEPTONATEGLUCONATEGLUCOSiDEGLYCOLATEGLYOXYLATEGOLDHEWtiHYDRATEHEMISULFATEHEPTANOATEHEXAACETATEHEXAHYDRATEHEXANOATEH1PPURATEHYDRATEHYDROBROMIDEHYDROCHLORiDEHYDROCHLORÎDE DIHYDRATEHYDROCHLORIDEHEMIHYDRATEHYDROCHLORIDEMONOHYDRATEHYDROCHLORiDE PHOSPHATEHYDROGEN EDISILATEHYDROGEN FUMARATEHYDROGEN StSALATEHYDROGEN MALEATEHYDROGEN MALONATEHYDROGEN OXALATEHYDROGEN SUCCINATEHYDROGEN SULFATEHYDROGEN SULFITEHYDROGEN TARTRATEHYDROXIDEHYDROXYBENZOATE2-HYDROXYETHANESULFONATEHYDROXYNAPHTHOATEIODIDEIRON CHLORIDEISETHIONATEÎSETIONATEISOBUTYRATEISONICOTiNATEISOPHTHALATEISOPROPIONATEISOPROPYLLACTATELACTOBIONATELAURATELEVULINATELITHIUMLYSIf^TEMAGNESIUMMALATEMALEATEMALONATEMANDELATEMEGLUMINEMESILATEMESYLATEMETHANESULFONATEMETHILSULFATE

Vol. 1867, 1-31874


METHYL ESTERMETHYLBROMIDE4,4'-METHYLENEBlS(3-HYDROXY-2-NAPHTHOATE)METHYLENEDISALICYLATEN-METHYLGLUCAMINEMETHYUODIDEMETHYLSULFATEMETHYLSULPHATEMONOHYDRATEMONOHYDROCHLORIDEMONONITRATEN-CYCLOHEXYLSULPHAMATEN-OXIDE HYDROCHLORIDENAFATENAPADISILATENAPADISYLATE1.5-NAPHTHALENESULFONATE2-NAPHTHALENESULFONATENAPSILATENAPSYLATENICOTINATENITRATENITROBENZOATEOLEATEORTHOPHOSPHATEOROTATEOXALATEOXIDE4-OXOPENTANOATEPALMITATEPALMITATE HYDROCHLORIDEPAMOATEPANTOTHENATEPANTOTHENATE SULFATEPENTAHYDRATEPERCHLORATEPHENYLPROPIONATEPHOSPHATEPHOSPHITEPHTHALATEPICRATEPIVALATE(PIVALOYLOXY)METHYLPIVOXILPIVOXIL HYDROCHLORIDEPOTASSIUMPOTASSIUM SULFATEPROPIONATEPROPIONATEDODECYLSULPHATEPROPIONATE LAURYL SULFATEPROPYLPROPYL ESTERPYRIDYLACETATEQUINATERESINATESACCHARATESALICYLATESALICYLOYLACETATESODIUM 3-SULPHOBENZOATESODIUM HYDRATESODIUMHYDROGENPHOSPHATESODIUMMETHANESULPHONATESODIUM MONOHYDRATESODIUM PHOSPHATE

SODIUM SUCCINATESODIUM SULFATESODIUM SULFOBENZOATESODIUM SULPHATESTEARATESUCCINATESUCCINILSULFATESULFINATESULFITESULFOSALICYLATESULPHATESULPHOSALICYLATETANNATETARTRATETEBUTATETEOCLATETETRAHYDRATÊTETRAHYDROPHTHALATETETRASODIUMTHEOCLATETHIOCYANATEP-TOLUENESULFONATETOSILATETOSYLATETRIFLUOROACETATETRIHYDRATETRIIODIDETRIMETHYLACETATETRINITRATETRIPALMITATEUNDEC-10-ENOATEUNDECANOATEUNDECYLENATEVALERATEZINC

Vol. 1867, 1-31874


•JJ

5!

s « A

le, Si c

gt«4 *M JS S M O ,O M

« C.e -H H« -e

U

2

^t-

•ça c œ il .-i

h *>9 o•H Z-8 g

u: z

C O :3 i2 ë

X O

s 2l— 2]a—j- coia. £i =3!= 21 O

s 2 mO il 5 ~x 2 cr: CTC LJ ^- —*^ ™ ol >^

2 S 2 P * = 3 'aUJ ûd — —

cn cr.

Vol. 1867, 1-31874

ANNEX IV - ADDITIONAL PRODUCTS USED FOR THE MANUFACTURE OF FINISHED PHARMACEUTICAL PRODUCTS (INTERMEDIATES)2S-Mar-94

HS6 Cas No Description

2903.693312-04-7

620-20-2

2904.90121-17-5

2905.22505-32-8

2905.50920-68-1

54322-20-2

2906.Z91570-95-2

2909.305111-65-9

31264-51-4

2909.5083682-27-3

2910.9056718-70-B

2911.0094158-44-8

1.1'-(4-Ch!orobutylidene)btS(4-nuorobenzenel

m-Chtorobervyl chloride

4-Chlcro-3 ralrotiinuorom«thylbefi?«ie

lsoph>1ol

Hexaduofoisopropanol

Sodium 4-chloro-1 -hydroxy-1 -butane sulpnonate

2-Phenyl-1 3-propanediol

2-BFomo-6'methoxynaphthalene

3-Chloropropyl-2.S-Kylyl elhef

Monosodium sail of 3-Methoxy-4-hydroxy-phenyl acetone

Oxirane{[4-(2-methoxyelhyl)phenu>cy}methyl]-

t ,1-Olmelho>cy-2-(2-melhoxyelhoxy) elhane

a-Zfa

I

4V-

~a-


Description

ozsu

X

2-Nitrob«fizlld«hydt Dimethyl Aulal

Diisopropoxycycloheiiare

9.10 Elhanoanthfacene-9(lom-ac(0le'n

0 *-cô ^ ci1^ 10 _ Or- • CM 01C* CM M *CD CO ^Z OOCM l— ^J CO

^

SS(D

m

1~•i

1£

0 j-,A S

6-Methoxy-2-naphtMidehyd«

10.11-Oihydro-5H-dib«n2<)-[a;d|-eyclohepten-

5-H-Oiben20-[a.d]-cyck>heplen-5-one

Isobutyl acetophenone

Pregna- 1 ,4-diene-3.20-dione,1 1,17.21 -Inhydi

o •? T "? œ uS

Ok» °co «n e*1» o>^"

J5« S*" ™ CD S 00

«

!5.1 1sr)à

1rà

•̂EE

1é

9-beta.1 1-bela-Epoxy 17-alpha.21-dihydroxy-

o2S5 a

S Ss

?J

1s

0) t^"s tn "°

• m" -s« i à Si | r ° ? i }||| j 1 1

I I î i Htl 5 é è 1 ï f i * f I - "S "S v T 9 y <S -î -îrli 4 -4 4 — <N rj

O> CMM "? M "? T ô r;-

pfs^s*^ «Ssî?^ tf) CO f~- O ÎJlO-^-T^ Tr (^ ôï 00 CO A ^" **^ ^S^-r^ n TT cî^ ^" *"

Vol. 1867, 1-31874


I i2 ï-

i i

I

I i^ 2e ? i I« à.a l

<j6 T£T £

I Ic <6 A f.

I

Ii i

tlo

De

o• t

i i' 8-

g § §• )-6.9-

I £

o5

to 2T «

» S„<? •> " »>•

ex

3 9 ?g

g

»

S SS S

2918.9028416-82-2

Vol. 1867, 1-31874


Description

0zenen U

to m

J.

5 1 1 I | IV t 3 S

4-(Pnenylbuto>cy) benzoï Dielhyl ethonymelhylene lsobutyt-3 4-*pewybutan Methyl 5-8lyoxytyl-2-hyd

I . ? ii '? i Io r-- T- co <n as t- cv

i

fî|z ? i

| || |* ! t i it t « 1 ? ° !i « f I It i ifill 1 1 I 1 1 1 1i 1 ^ ! « !• Illî 1 *° 5 S £ ! « S||f ^ ,•! ï I t ! 1 î | f î 1 1! I ! t f f I I I ! i I« c w?<u5 ^ " * Z- E ^ 2 o z •§. ** S ««OS. < « £ tn ^™zz ^Ci-^-oj et Œ

§a»^

^ *fj o co co r-- ^

aï^j. *<o ''t'** *o (o * ^ uî 10 eo ^ *?• -2 *

gjin « "^ oï <B ^ o a> S» œ °° ^ ^ aï ° * ^ a»

Vol. 1867, 1-31874


II

!gf>r

o 1

- » t I

E Z

i tS |

<BU

CO

_ 6O ^^r-- S *r °* e»i T"

S <D OS p> •?.

(N T-

Ô -A

oo ^~eo ^>o CDin CDCO i— M ao

Vol. 1867, 1-31874


scripti

ohyd'

ragioe

!=;

-î s!y -Kfï

4-(4-chl

v S § o» •. ^- «

-: oo 2

œ 2 ° S «^ 10 m c$ i 1 l

« T- S ? £ s

Vol. 1867, 1-31874


ascription

0

oztnau(DtoX

i« E

i8ii?ï

3-Phenoxyph€ny1)prcpiononrtrile 5-T r imelhoxyphenylacetoniinte

:yana-N-(1 l-dimethyle1hytj-androsla-35^diei ha-lsopfopyl-3 4.5-tnmethoKybenzyl cyanide ha-lsopropyt-3 4-dimethoxy benzyicyinide

lyl ethoxymethylene c/anoacetat«

•—• w '— ' a. a. i: CN m r»> To 15 UJ

rj r- o "•;-

CO (D CO -fl- (*,(N oo r%i 0 in tn ro CM tft Sto n ^r co co "CN (O ^ to O •* CO *~ Z CO 04 O>

«

11

AminooKV)-2-methy1propanoic acid tnonohyc

rj

CO,1

2928.00 89766-9

1

|rtc.

=1 Î-

! 1

pare ChiMob*nzoyi-N pafa-fneltioxyphenyl-h

"JaphlhylchlorothlcfoftTiale

, 5-Fijoro-2-melhyi-1 (para-melhytthio-benzy ()-3 AcetyHhio-2-methyl propanoic acid (-)-3-acetylthio-2-me1hy(-pfopanyl chloride

Z r-4 û Û C

•«— co r\j co r^-f^- r*!- N- di CiO ~ <O C^ ^- COC3 O> <D N- CO Is-CP X o CM CM oa ro z: in to os -fl*s s e § £ s

i1

1 31 11 &O 09- 9-

(-)-Threo-2-ammo-3(4-methylsulfonylphenyl^ (-)-Threo-2-arrnno-3{4-methylsijlfonylphenyl)

O Q

r-00CM 00

m 21

» ^

El! !I i 1 1 1! I I ! ! 1i 1 t I 1 I i f 4 1 I f1 f Î i i €1 r | f | fi 2 E f S ~- >, "5L <N £ S ^~ ^ -^ ^ Q 2 è S ^ £ -4 c^ 5 .i Ji • z- -r ^Q Q S Z Z 2

co co QÏ O *nô ^ eg c<j N -1

•4- ^ -^j- to uS CNO> . » «D O CO !r- CO •«• CO CO OO

° m to oj CD CD

Vol. 1867, 1-31874


,3-dipheny1-

« ^L.1

0

a> o<? IDO TCD O>rf OO00 t-

i =O> 10

m CDgï sM i

« M T o, gi s g ^«co to r- 2 r~en œ en ^ n

Vol. 1867, 1-31874


gI

I

-melhyl

Wjph

•&osIT €E u*>

og.

^ri

—

6

1

l5ï

cô

tE

15"•j. ci•*

r>

1-^

O•^•

one 4-methylbenz<

11ÇcT3

yl)(4.pipec

fIU_

4

rtdinyl)-2H-benzirr

•?è"5L

1"S<ô m

à

Qm

CO

1XCN

îS &o.^6

J5f*3.

co

ine hydrochtoride

SS. Sfi5(NI

ts.O

I0si

°?

*nyl)-1H.benzlmii

c

iT

^_->,

1 t

}u_ 4,-T-

0)CT,

yl-5-chloro-

iIN

1

iT3

6X

01(0

il -g .y

CO (D« 3

°9 eô

O> CM

Vol. 1867, 1-31874


Desc

I IIi

ylma

_ 9° s

Quin

" 8« 0>in eo ^ ~«- o> o 5T- *- T- Z

•A <0 So>

^" CD O CO i- T-

Vol. 1867, 1-31874


Description

0z

uCDtaX

1•5Su

13£

Sta S

3 Isoqurnolinecarboxylk: acid S t .2 3 4-te(fahydro. benzyl este

CO

en

O)

'Ç

ro.y

«à •i

6,7-Dinuoro-H2,4-dinuofophefiyl) 1 4-dihydro-4-oxo-3-quinolcr

0*ô ai a> m o

TJ

my

Im

I£

1 o o•* g 1.s•*

b0

! iu

os

o03 Oï

7-Chloroquinaldlne

cô to

CDa>

•D

g4

Chloro-7-ethy1-1-fluoro-6-oxo-4-dihydfo-1 4-qulnoline-3-cafbox

CD

r- o oo<D

Vrô•5.

Ethyl. 1 -ethyt-6 7 6-tnFtuoro-4-dihydro-4-OKo3-quinoiine carbox

N-|(2-Qulnolinytcartony1)oxy| succmlmlde

o ^CN O>CD cr>•*- 10o toO CDo co

{1S)-2-Mçlhy|.2.5-diazabicyclo |2 2 1] heptane dthydrobromldï

2933.59

125224-62-6

:§

io

ïj16

fsà<Dto"

î1

(Z)-3-|2-|4-|(2 4-DtnuorophenytKhydroKyimlno)-methyl)-l-ptpef

co

0

o> ru co

—£ 10)

1 .3-PropanecJiol-2-|2-(2 amino 6-<:hlOfO-9H-pufin-9-y1)ethyl]-dii

ooô(D

co o>

1 -(2-Fufoyi)pipetazine

0inO» Ol

0

1 -(3-Chlorophenyl)-4-(3 chloropropyl) piperazine hydrochloride

1 -(Diphenylmethyl)piperazine

1 -[alpha, a lpha-bis(4-fluorophenyt)melhyl] -piperazine

1-Acelyl-4-(4-hydroxyphenyl) piperazine

S o 6 5ifl , <o (DuS t o> -4-O i <D •«-

w •* r- r^»O OO £M CD

1O

5*7

1I

1 -Amlno-4-methylpiperazine

1 -Ethyl-6,8-Difluoro-1 ,4-dlhydro-7-(3- methyl- 1 -piperaziny1)-4- 1

r-T -A uî moô r-CM O Oï 03 CD O>

S

i1CM"*-

sQ.

|

I

2,4-Oihydro-4-{4-j4-(4-hydfoxypneny))-1-ptperazinyl)p*ienyl}-2'

o

(O

to o

2,4-D!hydroxy-6,7-dimethoxyquinazo!ine

o

oo

rj

3-(2-Chloroe(hy1)-2-me1hy1-4H-pyTido [1 .2-a]pyrimldin-4-one

0ôor-0

|1J-^i0

è'Ë

I

3-(2-ChlOfo«thyl)-6.7.8,9-tetrahydfo-2-melhyl-4H-pytido |1 ,2-a

93076-03-0

Vol. 1867, 1-31874


)escriptlon

ozen w O

inX

i1H3Hi-qumazol

{o(->

f-.

COo

I(N

iac«

M

j

* 1 4 1

^ ï • § r

9 I | | J

i- ! 1 1 i * 1 f 1 'i < <o — 5e4 -w tri z —

O ^t ^ *~t^. •* T ci» o>O» CO if} CM <B <D«* ô T -A r- toT- CO O> O4 « *^>C35 tD f- 0 S 00r^- to o n- S *o <O CM in en J!| h*

«

f f4 « « si 1 * 81- ï 4L s *Ills 1 s 5 1 f ïri X i £ ç ri ™ ï S « ?

g i- s ê s 15

1 1 1 f 1 Ï ?1^ t t. | | S 2 *

? «j -a d. £ ^ ry

1 1 i ! M ! !«iî-Ssiïl S 1 I I 1 1 1 I 1Ciu^: *n oc> <JUJ * ^.^•fjci'rîiÔinuSS

Ol tO OJ f*"22«^«i'x <*':-ortr-fomio'OO»*

<D •*" -^- O9 (*) CO CO O CO

uiôooor^-rô•»-<D^— CMT-T— •r-r— i-

1 .C>J ^

§ § T •g N

t - i

! i i ! 1f i ! i 15 i S. "8 €

1 1 e 5 1° I I -: <?at S u. •>, •>. n û 4 fi £ csi r> s uj uj

•«- (D ^- Ol T- ^- rsi d> co CM

e co r^- <c o» *Ô> 1^- C» CO CO CD

• (O Q> <O ^- T-£; co o r- o i- 2 r^ w co o> (O g; CM « eo co CM

Vol. 1867, 1-31874


a._ç

ï i•B

I5" ï.

5 v

s i

jption

-o

'

Ë £n5 « T |<^ r* '5. <vi

m0

S.

CM CM O>

II)I cooo) --

Vol. 1867, 1-31874


... -o « T-- T-

CM £

cJ, ri *? -n0 °° o 5 *Tri in rt . oo«o «o ^ T- «o> -w 2 m nv T g <D CM o> M

illanic acid

y

!i+

to£m m

|11C.

^

•Ê

iaS0

1

iixyacetytjat

1o._<o

GO

29707-62-

IN

fI & £0>

«N

»t\î

??

1

iM£h

K

ir>«

•£

2,XÎ!i

(D-*

I1?M

a

¥|rï"

|

Itu^r

o>iA9r- «o•* '«•

£o?X

î

S15 5a

I

I

a «^b?S </)s

oo

28092-62-

4.2:0] oct-2-ene-2-cartx>xylic acid (and its salts and esters)

sS.O

i

S3,<

2

IV

É<N

8

Ïœ.ri.

I*7

?of(O.

ro

87932-78-

ne- 2-caitwxylic acld dlsolvate

f(M

i5" N2ôs.1i ?

!£ 1rt¥E ra

f

«f^ro"

ofœ.

^rOJo ^~ inr- o> n

nllrophenyl) methyl ester

I

1Ï ÇMiotN

S.

2

,

Sp3-chloro-8'

7-Amino-

£"

1

U)« «oî- O)o> « m

2ao

I1ftJ,

IiiN

g

5«.(5-methyl-i

1h|-

K

tf

30246-33-

?.Ç a.

cT

S^.

I1

5V

fi

fj fà fi

!ûyt£

53910-25-

Vol. 1867, 1-31874


Descriptio

T£

I S

I 3

S I I

-dihytiro-4-o«o-(t 3) dtoxol

-rrethanesulp

ydro-5-l

-Ac«tyi

,20-di

-dena-4-preg•3 « I I

xy-Z, s =

Q ci Ci Ci

OS

COC7>

CO ^»- u") 1-•<r -v CD r-•*- CM OO CMT- -r- OJ If)

i- O> —

^ œCO G) UJ

Vol. 1867, 1-31874


i !

ë "S.< ^cô ~

I 2f

§

E S

I IU- K K

CSJ OJ(D CV»^- Ol

OO O(D *-*- C\J

o>CO« ° S 2

3ri *? *9•^ Oï •*—-- —•V O O **ï 'r~ «- -«~to CNJ r- oj co ^- CDo T -fl- oj *~ o r*T- (N| (M P4 in r- (D

t*> OT- COtD CD

S 2r- œs so «VO <7>

ii ^- (O0> CD00 CM

Vol. 1867, 1-31874


I iI II £? 6o> c3 *

{ \ E I

Oia

yf}et

I 1I s.E 5

|

-,I ! f !

1-

I !IIu_ 5

_ (O f)O> ^i, J.

8 pr- CD

^- O O OJ CDoo •«— i— i— i—S 2 m o>n m

Vol. 1867, 1-31874


AGREEMENT ON AGRICULTURE

Members,

Having decided to establish a basis for initiating a process of reform of trade in agriculture in line with the objectives of the negotiations as set out in the Punta del Este Declaration;

Recalling that their long-term objective as agreed at the Mid-Term Review of the Uruguay Round "is to establish a fair and market-oriented agricultural trading system and that a reform process should be initiated through the negotiation of commitments on support and protection and through the establishment of strengthened and more operationally effective GATT rules and disciplines";

Recalling further that "the above-mentioned long-term objective is to provide for substantial progressive reductions in agricultural support and protection sustained over an agreed period of time, resulting in correcting and preventing restrictions and distortions in world agricultural markets";

Committed to achieving specific binding commitments in each of the following areas: market access; domestic support; export competition; and to reaching an agreement on sanitary and phytosanitary issues;

Having agreed that in implementing their commitments on market access, developed country Members would take fully into account the particular needs and conditions of developing country Members by providing for a greater improvement of opportunities and terms of access for agricultural products of particular interest to these Members, including the fullest liberalization of trade in tropical agricultural products as agreed at the Mid-Term Review, and for products of particular importance to the diversification of production from the growing of illicit narcotic crops;

Noting that commitments under the reform programme should be made in an equitable way among all Members, having regard to non-trade concerns, including food security and the need to protect the environment; having regard to the agreement that special and differential treatment for developing countries is an integral element of the negotiations, and taking into account the possible negative effects of the implementation of the reform programme on least-developed and net food-importing developing countries;


Pan I

Article 1

Definition of Terms

In this Agreement, unless the context otherwise requires:

(a) "Aggregate Measurement of Support" and "AMS" mean the annual level of support, expressed in monetary terms, provided for an agricultural product in favour of the producers of the basic agricultural product or non-product-specific support provided in favour of agricultural producers in general, other than support provided under programmes that qualify as exempt from reduction under Annex 2 to mis Agreement, which is:

Vol. 1867, 1-31874


(i) with respect to support provided during the base period, specified in the relevant tables of supporting material incorporated by reference in Part IV of a Member's Schedule; and

(ii) with respect to support provided during any year of the implementation period and thereafter, calculated in accordance with the provisions of Annex 3 of this Agreement and taking into account the constituent data and methodology used in the tables of supporting material incorporated by reference in Part IV of the Member's Schedule;

(b) "basic agricultural product" in relation to domestic support commitments is defined as the product as close as practicable to the point of first sale as specified in a Member's Schedule and in the related supporting material;

(c) "budgetary outlays" or "outlays" includes revenue foregone;

(d) "Equivalent Measurement of Support" means the annual level of support, expressed in monetary terms, provided to producers of a basic agricultural product through the application of one or more measures, the calculation of which in accordance with the AMS methodology is impracticable, other than support provided under programmes that qualify as exempt from reduction under Annex 2 to this Agreement, and which is:

(i) with respect to support provided during the base period, specified in the relevant tables of supporting material incorporated by reference in Part IV of a Member's Schedule; and

(ii) with respect to support provided during any year of the implementation period and thereafter, calculated in accordance with the provisions of Annex 4 of this Agreement and taking into account the constituent data and methodology used in the tables of supporting material incorporated by reference in Part IV of the Member's Schedule;

(e) "export subsidies" refers to subsidies contingent upon export performance, including the expert subsidies listed in Article 9 of this Agreement;

(f) "implementation period" means the six-year period commencing in the year 1995, except that, for the purposes of Article 13, it means the nine-year period commencing in 1995;

(g) "market access concessions" includes all market access commitments undertaken pursuant to this Agreement;

(h) "Total Aggregate Measurement of Support" and "Total AMS" mean the sum of all domestic support provided in favour of agricultural producers, calculated as the sum of all aggregate measurements of support for basic agricultural products, all non-product- specific aggregate measurements of support and all equivalent measurements of support for agricultural products, and which is:

(i) with respect to support provided during the base period (i.e. the "Base Total AMS") and the maximum support permitted to be provided during any year of the implementation period or thereafter (i.e. the "Annual and Final Bound Commitment Levels"), as specified in Part IV of a Member's Schedule; and

Vol. 1867, 1-31874


(ii) with respect to the level of support actually provided during any year of the implementation period and thereafter (i.e. the "Current Total AMS"), calculated in accordance with the provisions of this Agreement, including Article 6, and with the constituent data and methodology used in the tables of supporting material incorporated by reference in Part IV of the Member's Schedule;

(i) "year" in paragraph (f) above and in relation to the specific commitments of a Member refers to the calendar, financial or marketing year specified in the Schedule relating to that Member.

Article 2

Product Coverage

This Agreement applies to the products listed in Annex 1 to this Agreement, hereinafter referred to as agricultural products.

Pan II

Article 3

Incorporation of Concessions and Commitments

1. The domestic support and export subsidy commitments in Part IV of each Member's Schedule constitute commitments limiting subsidization and are hereby made an integral part of GATT 1994.

2. Subject to the provisions of Article 6, a Member shall not provide support in favour of domestic producers in excess of the commitment levels specified in Section I of Part IV of its Schedule.

3. Subject to the provisions of paragraphs 2(b) and 4 of Article 9, a Member shall not provide export subsidies listed in paragraph 1 of Article 9 in respect of the agricultural products or groups of products specified in Section II of Part IV of its Schedule in excess of the budgetary outlay and quantity commitment levels specified therein and shall not provide such subsidies in respect of any agricultural product not specified in that Section of its Schedule.

Part III

Article 4

Market Access

1. Market access concessions contained in Schedules relate to bindings and reductions of tariffs, and to other market access commitments as specified therein.

Vol. 1867, 1-31874


2. Members shall not maintain, resort to, or revert to any measures of the kind which have been required to be converted into ordinary customs duties', except as otherwise provided for in Article 5 and Annex 5.

Article 5

Special Safeguard Provisions

1. Notwithstanding the provisions of paragraph l(b) of Article II of GATT 1994, any Member may take recourse to the provisions of paragraphs 4 and 5 below in connection with the importation of an agricultural product, in respect of which measures referred to in paragraph 2 of Article 4 of this Agreement have been converted into an ordinary customs duty and which is designated in its Schedule with the symbol "SSG" as being the subject of a concession in respect of which the provisions of this Article may be invoked, if:

(a) the volume of imports of that product entering the customs territory of the Member granting the concession during any year exceeds a trigger level which relates to the existing market access opportunity as set out in paragraph 4; or, but not concurrently:

(b) the price at which imports of that product may enter the customs territory of the Member granting the concession, as determined on the basis of the c.i.f. import price of the shipment concerned expressed in terms of its domestic currency, falls below a trigger price equal to the average 1986 to 1988 reference price2 for the product concerned.

2. Imports under current and minimum access commitments established as part of a concession referred to in paragraph 1 above shall be counted for the purpose of determining the volume of imports required for invoking the provisions of subparagraph l(a) and paragraph 4, but imports under such commitments shall not be affected by any additional duty imposed under either subparagraph l(a) and paragraph 4 or subparagraph l(b) and paragraph 5 below.

3. Any supplies of the product in question which were en route on the basis of a contract settled before the additional duty is imposed under subparagraph l(a) and paragraph 4 shall be exempted from any such additional duty, provided that they may be counted in the volume of imports of the product in question during the following year for the purposes of triggering the provisions of subparagraph 1 (a) in mat year.

4. Any additional duty imposed under subparagraph l(a) shall only be maintained until the end of the year in which it has been imposed, and may only be levied at a level which shall not exceed one third of the level of the ordinary customs duty in effect in the year in which the action is taken. The trigger level shall be set according to the following schedule based on market access opportunities

'These measures include quantitative import restrictions, variable import levies, minimum import prices, discretionary import licensing, non-tariff measures maintained through state-trading enterprises, voluntary export restraints, and similar border measures other than ordinary customs duties, whether or not the measures are maintained under country-specific derogations from the provisions of GATT 1947, but not measures maintained under balance-of-payments provisions or under other general, non-agriculture-specific provisions of GATT 1994 or of the other Multilateral Trade Agreements in Annex 1A to the WTO Agreement.

*The reference price used to invoke the provisions of this subparagraph shall, in general, be the average c.i.f. unit value of the product concerned, or otherwise shall be an appropriate price in terms of the quality of the product and its stage of processing. It shall, following its initial use, be publicly specified and available to the extent necessary to allow other Members to assess the additional duty that may be levied.

Vol. 1867, 1-31874


defined as imports as a percentage of the corresponding domestic consumption3 during the three preceding years for which data are available:

(a) where such market access opportunities for a product are less than or equal to 10 per cent, the base trigger level shall equal 125 per cent;

(b) where such market access opportunities for a product are greater than 10 per cent but less than or equal to 30 per cent, the base trigger level shall equal 110 per cent;

(c) where such market access opportunities for a product are greater than 30 per cent, the base trigger level shall equal 105 per cent.

In all cases the additional duty may be imposed in any year where the absolute volume of imports of the product concerned entering the customs territory of the Member granting the concession exceeds the sum of (x) the base trigger level set out above multiplied by the average quantity of imports during the three preceding years for which data are available and (y) the absolute volume change in domestic consumption of the product concerned in the most recent year for which data are available compared to the preceding year, provided that the trigger level shall not be less than 105 per cent of the average quantity of imports in (x) above.

5. The additional duty imposed under subparagraph l(b) shall be set according to the following schedule:

(a) if the difference between the c.i.f. import price of the shipment expressed in terms of the domestic currency (hereinafter referred to as the "import price") and the trigger price as defined under that subparagraph is less than or equal to 10 per cent of the trigger price, no additional duty shall be imposed;

(b) if the difference between the import price and the trigger price (hereinafter referred to as the "difference") is greater than 10 per cent but less than or equal to 40 per cent of the trigger price, the additional duty shall equal 30 per cent of the amount by which the difference exceeds 10 per cent;

(c) if the difference is greater than 40 per cent but less than or equal to 60 per cent of the trigger price, the additional duty shall equal 50 per cent of the amount by which the difference exceeds 40 per cent, plus the additional duty allowed under (b);

(d) if the difference is greater than 60 per cent but less than or equal to 75 per cent, the additional duty shall equal 70 per cent of the amount by which the difference exceeds 60 per cent of the trigger price, plus the additional duties allowed under (b) and (c);

(e) if the difference is greater than 75 per cent of the trigger price, the additional duty shall equal 90 per cent of the amount by which the difference exceeds 75 per cent, plus the additional duties allowed under (b), (c) and (d).

6. For perishable and seasonal products, the conditions set out above shall be applied in such a manner as to take account of the specific characteristics of such products. In particular, shorter time periods under subparagraph 1 (a) and paragraph 4 may be used in reference to the corresponding periods in the base period and different reference prices for different periods may be used under subparagraph l(b).

'Where domestic consumption is not taken into account, the base trigger level under subparagraph 4(a) shall apply.

Vol. 1867, 1-31874


7. The operation of the special safeguard shall be carried out in a transparent manner. Any Member taking action under subparagraph l(a) above shall give notice in writing, including relevant data, to the Committee on Agriculture as far in advance as may be practicable and in any event within 10 days of the implementation of such action. In cases where changes in consumption volumes must be allocated to individual tariff lines subject to action under paragraph 4, relevant data shall include the information and methods used to allocate these changes. A Member taking action under paragraph 4 shall afford any interested Members the opportunity to consult with it in respect of the conditions of application of such action. Any Member taking action under subparagraph l(b) above shall give notice in writing, including relevant data, to the Committee on Agriculture within 10 days of the implementation of the first such action or, for perishable and seasonal products, the first action in any period. Members undertake, as far as practicable, not to take recourse to the provisions of subparagraph l(b) where the volume of imports of the products concerned are declining. In either case a Member taking such action shall afford any interested Members the opportunity to consult with it in respect of the conditions of application of such action.

8. Where measures are taken hi conformity with paragraphs 1 through 7 above, Members undertake not to have recourse, in respect of such measures, to the provisions of paragraphs 1 (a) and 3 of Article XIX of GATT 1994 or paragraph 2 of Article 8 of the Agreement on Safeguards.

9. The provisions of this Article shall remain in force for the duration of the reform process as determined under Article 20.

Pan IV

Article 6

Domestic Support Commitments

1. The domestic support reduction commitments of each Member contained in Part IV of its Schedule shall apply to all of its domestic support measures in favour of agricultural producers with the exception of domestic measures which are not subject to reduction in terms of the criteria set out in this Article and in Annex 2 to this Agreement. The commitments are expressed in terms of Total Aggregate Measurement of Support and "Annual and Final Bound Commitment Levels".

2. In accordance with the Mid-Term Review Agreement that government measures of assistance, whether direct or indirect, to encourage agricultural and rural development are an integral part of the development programmes of developing countries, investment subsidies which are generally available to agriculture in developing country Members and agricultural input subsidies generally available to low-income or resource-poor producers in developing country Members shall be exempt from domestic support reduction commitments that would otherwise be applicable to such measures, as shall domestic support to producers in developing country Members to encourage diversification from growing illicit narcotic crops. Domestic support meeting the criteria of this paragraph shall not be required to be included in a Member's calculation of its Current Total AMS.

3. A Member shall be considered to be in compliance with its domestic support reduction commitments in any year in which its domestic support in favour of agricultural producers expressed in terms of Current Total AMS does not exceed the corresponding annual or final bound commitment level specified in Part IV of the Member's Schedule.

4. (a) A Member shall not be required to include in the calculation of its Current Total AMS and shall not be required to reduce:

Vol. 1867, 1-31874


(i) product-specific domestic support which would otherwise be required to be included in a Member's calculation of its Current AMS where such support does not exceed 5 per cent of that Member's total value of production of a basic agricultural product during the relevant year; and

(ii) non-product-specific domestic support which would otherwise be required to be included in a Member's calculation of its Current AMS where such support does not exceed 5 per cent of the value of that Member's total agricultural production.

(b) For developing country Members, the de mnimispercentage under this paragraph shall be 10 per cent.

5. (a) Direct payments under production-limiting programmes shall not be subject to the commitment to reduce domestic support if:

(i) such payments are based on fixed area and yields; or

(ii) such payments are made on 85 per cent or less of the base level of production; or

(iii) livestock payments are made on a fixed number of head.

(b) The exemption from the reduction commitment for direct payments meeting the above criteria shall be reflected by the exclusion of the value of those direct payments in a Member's calculation of its Current Total AMS.

Article 7

General Disciplines on Domestic Support

1. Each Member shall ensure that any domestic support measures in favour of agricultural producers which are not subject to reduction commitments because they qualify under the criteria set out in Annex 2 to this Agreement are maintained in conformity therewith.

2. (a) Any domestic support measure in favour of agricultural producers, including any modification to such measure, and any measure that is subsequently introduced that cannot be shown to satisfy the criteria in Annex 2 to this Agreement or to be exempt from reduction by reason of any other provision of this Agreement shall be included in the Member's calculation of its Current Total AMS.

(b) Where no Total AMS commitment exists in Part IV of a Member's Schedule, the Member shall not provide support to agricultural producers in excess of the relevant de minimis level set out in paragraph 4 of Article 6.

Vol. 1867, 1-31874


PartV

Article 8

Export Competition Commitments

Each Member undertakes not to provide export subsidies otherwise than in conformity with this Agreement and with the commitments as specified in that Member's Schedule.

Article 9

Export Subsidy Commitments

1. The following export subsidies are subject to reduction commitments under this Agreement:

(a) the provision by governments or their agencies of direct subsidies, including payments- in-kind, to a firm, to an industry, to producers of an agricultural product, to a cooperative or other association of such producers, or to a marketing board, contingent on export performance;

(b) the sale or disposal for export by governments or their agencies of non-commercial stocks of agricultural products at a price lower than the comparable price charged for the like product to buyers in the domestic market;

(c) payments on the export of an agricultural product that are financed by virtue of governmental action, whether or not a charge on the public account is involved, including payments that are financed from the proceeds of a levy imposed on the agricultural product concerned or on an agricultural product from which the exported product is derived;

(d) the provision of subsidies to reduce the costs of marketing exports of agricultural products (other than widely available export promotion and advisory services) including handling, upgrading and other processing costs, and the costs of international transport and freight;

(e) internal transport and freight charges on export shipments, provided or mandated by governments, on terms more favourable than for domestic shipments;

(f) subsidies on agricultural products contingent on their incorporation in exported products.

2. (a) Except as provided in subparagraph (b), the export subsidy commitment levels for each year of the implementation period, as specified in a Member's Schedule, represent with respect to the export subsidies listed in paragraph 1 of this Article:

(i) in the case of budgetary outlay reduction commitments, the maximum level of expenditure for such subsidies that may be allocated or incurred in that year in respect of the agricultural product, or group of products, concerned; and

(ii) in the case of export quantity reduction commitments, the maximum quantity of an agricultural product, or group of products, in respect of which such export subsidies may be granted in that year.

Vol. 1867, 1-31874


(b) In any of the second through fifth years of the implementation period, a Member may provide export subsidies listed in paragraph 1 above in a given year in excess of the corresponding annual commitment levels in respect of the products or groups of products specified in Part IV of the Member's Schedule, provided that:

(i) the cumulative amounts of budgetary outlays for such subsidies, from the beginning of the implementation period through the year in question, does not exceed the cumulative amounts that would have resulted from full compliance with the relevant annual outlay commitment levels specified in the Member's Schedule by more than 3 per cent of the base period level of such budgetary outlays;

(ii) the cumulative quantities exported with the benefit of such export subsidies, from the beginning of the implementation period through the year in question, does not exceed the cumulative quantities that would have resulted from full compliance with the relevant annual quantity commitment levels specified in the Member's Schedule by more than 1.75 per cent of the base period quantities;

(iii) the total cumulative amounts of budgetary outlays for such export subsidies and the quantities benefiting from such export subsidies over the entire implementation period are no greater than the totals that would have resulted from full compliance with the relevant annual commitment levels specified in the Member's Schedule; and

(iv) the Member's budgetary outlays for export subsidies and the quantities benefiting from such subsidies, at the conclusion of the implementation period, are no greater than 64 per cent and 79 per cent of the 1986-1990 base period levels, respectively. For developing country Members these percentages shall be 76 and 86 per cent, respectively.

3. Commitments relating to limitations on the extension of the scope of export subsidization are as specified in Schedules.

4. During the implementation period, developing country Members shall not be required to undertake commitments in respect of the export subsidies listed in subparagraphs (d) and (e) of paragraph 1 above, provided that these are not applied in a manner that would circumvent reduction commitments.

Article 10

Prevention of Circumvention of Export Subsidy Commitments

1. Export subsidies not listed in paragraph 1 of Article 9 shall not be applied in a manner which results in, or which threatens to lead to, circumvention of export subsidy commitments; nor shall non commercial transactions be used to circumvent such commitments.

2. Members undertake to work toward the development of internationally agreed disciplines to govern the provision of export credits, export credit guarantees or insurance programmes and, after agreement on such disciplines, to provide export credits, export credit guarantees or insurance programmes only in conformity therewith.

3. Any Member which claims that any quantity exported in excess of a reduction commitment level is not subsidized must establish that no export subsidy, whether listed in Article 9 or not, has been granted in respect of the quantity of exports in question.

Vol. 1867, 1-31874


4. Members donors of international food aid shall ensure:

(a) thatthe provision of international food aid is not tied directly or indirectly to commercial exports of agricultural products to recipient countries;

(b) that international food aid transactions, including bilateral food aid which is monetized, shall be carried out in accordance with the FAO "Principles of Surplus Disposal and Consultative Obligations", including, where appropriate, the system of Usual Marketing Requirements (UMRs); and

(c) that such aid shall be provided to the extent possible in fully grant form or on terms no less concessional than those provided for in Article IV of the Food Aid Convention 1986.1

Article 11

Incorporated Products

In no case may the per-unit subsidy paid on an incorporated agricultural primary product exceed the per-unit export subsidy that would be payable on exports of the primary product as such.

Part VI

Article 12

Disciplines on Export Prohibitions and Restrictions

1. Where any Member institutes any new export prohibition or restriction on foodstuffs in accordance with paragraph 2(a) of Article XI of GATT 1994, the Member shall observe the following provisions:

(a) the Member instituting the export prohibition or restriction shall give due consideration to the effects of such prohibition or restriction on importing Members' food security;

(b) before any Member institutes an export prohibition or restriction, it shall give notice in writing, as far in advance as practicable, to the Committee on Agriculture comprising such information as the nature and the duration of such measure, and shall consult, upon request, with any other Member having a substantial interest as an importer with respect to any matter related to the measure in question. The Member instituting such export prohibition or restriction shall provide, upon request, such a Member with necessary information.

2. The provisions of this Article shall not apply to any developing country Member, unless the measure is taken by a developing country Member which is a net-food exporter of the specific foodstuff concerned.

1 United Nations, Treaty Series, vol. 1429, p. 71.

Vol. 1867, 1-31874


Pan VU

Article 13

Due Restraint

During the implementation period, notwithstanding the provisions of GATT 1994 and the Agreement on Subsidies and Countervailing Measures (referred to in this Article as the "Subsidies Agreement"):

(a) domestic support measures that conform fully to the provisions of Annex 2 to this Agreement shall be:

(i) non-actionable subsidies for purposes of countervailing duties4 ;

(ii) exempt from actions based on Article XVI of GATT I994 and Part III of the Subsidies Agreement; and

(iii) exempt from actions based on non-violation null ification or impairment of the benefits of tariff concessions accruing to another Member under Article II of GATT 1994, in the sense of paragraph i(b) of Article XXIII of GATT 1994;

(b) domestic support measures that conform fully to the provisions of Article 6 of this Agreement including direct payments that conform to the requirements of paragraph 5 thereof, as reflected in each Member's Schedule, as well as domestic support within de minimis levels and in conformity with paragraph 2 of Article 6, shall be:

(i) exempt from the imposition of countervailing duties unless a determination of injury or threat thereof is made in accordance with Article VI of GATT 1994 and Part V of the Subsidies Agreement, and due restraint shall be shown in initiating any countervailing duty investigations;

(ii) exempt from actions based on paragraph 1 of Article XVI of GATT 1994 or Articles 5 and 6 of the Subsidies Agreement, provided that such measures do not grant support to a specific commodity in excess of that decided during the 1992 marketing year; and

(iii) exempt from actions based on non-violation nullification or impairment of the benefits of tariff concessions accruing to another Member under Article II of GATT 1994, in the sense of paragraph l(b) of Article XXIII of GATT 1994, provided that such measures do not grant support to a specific commodity in excess of that decided during the 1992 marketing year;

(c) export subsidies that conform fully to the provisions of Part V of this Agreement, as reflected in each Member's Schedule, shall be:

(i) subject to countervailing duties only upon a determination of injury or threat thereof based on volume, effect on prices, or consequent impact in accordance with Article VI of GATT 1994 and Part V of the Subsidies Agreement, and

411 Countervailing duties" where referred to in this Article are those covered by Article V! of GATT 1994 and Part V of the Agreement on Subsidies and Countervailing Measures.

Vol. 1867, 1-31874


due restraint shall be shown in initiating any countervailing duty investigations; and

(ii) exempt from actions based on Article XVI of GATT 1994 or Articles 3, 5 and 6 of the Subsidies Agreement.

Pan VIII

Article 14

Sanitary and Phytosanitary Measures

Members agree to give effect to the Agreement on the Application of Sanitary and Phytosanitary Measures.

Part IX

Article 15

Special and Differential Treatment

1. In keeping with the recognition that differential and more favourable treatment for developing country Members is an integral part of the negotiation, special and differential treatment in respect of commitments shall be provided as set out in the relevant provisions of this Agreement and embodied in the Schedules of concessions and commitments.

2. Developing country Members shall have the flexibility to implement reduction commitments over a period of up to 10 years. Least-developed country Members shall not be required to undertake reduction commitments.

PartX

Article 16

Least-Developed and Net Food-Importing Developing Countries

1. Developed country Members shall take such action as is provided for within the framework of the Decision on Measures Concerning the Possible Negative Effects of the Reform Programme on Least-Developed and Net Food-Importing Developing Countries.

2. The Committee on Agriculture shall monitor, as appropriate, the follow-up to this Decision.

Part XI

Article 17

Committee on Agriculture

A Committee on Agriculture is hereby established.Vol. 1867, 1-31874


Article 18

Review of the Implementation of Commitments

1. Progress in the implementation of commitments negotiated under the Uruguay Round reform programme shall be reviewed by the Committee on Agriculture.

2. The review process shall be undertaken on the basis of notifications submitted by Members in relation to such matters and at such intervals as shall be determined, as well as on the basis of such documentation as the Secretariat may be requested to prepare in order to facilitate the review process.

3. In addition to the notifications to be submitted under paragraph 2, any new domestic support measure, or modification of an existing measure, for which exemption from reduction is claimed shall be notified promptly. This notification shall contain details of the new or modified measure and its conformity with the agreed criteria as set out either in Article 6 or in Annex 2.

4. In the review process Members shall give due consideration to the influence of excessive rates of inflation on the ability of any Member to abide by its domestic support commitments.

5. Members agree to consult annually in the Committee on Agriculture with respect to their participation in the normal growth of world trade in agricultural products within the framework of the commitments on export subsidies under this Agreement.

6. The review process shall provide an opportunity for Members to raise any matter relevant to the implementation of commitments under the reform programme as set out in this Agreement.

7. Any Member may bring to the attention of the Committee on Agriculture any measure which it considers ought to have been notified by another Member.

Article 19

Consultation and Dispute Settlement

The provisions of Articles XXII and XXIII of GATT 1994, as elaborated and applied by the Dispute Settlement Understanding, shall apply to consultations and the settlement of disputes under this Agreement.

Part XII

Article 20

Continuation of the Reform Process

Recognizing that the long-term objective of substantial progressive reductions in support and protection resulting in fundamental reform is an ongoing process, Members agree that negotiations for continuing the process will be initiated one year before the end of the implementation period, taking into account:

(a) the experience to that date from implementing the reduction commitments;

(b) the effects of the reduction commitments on world trade in agriculture;Vol. 1867, 1-31874


(c) non-trade concerns, special and differential treatment to developing country Members, and the objective to establish a fair and market-oriented agricultural trading system, and the other objectives and concerns mentioned in the preamble to this Agreement; and

(d) what further commitments are necessary to achieve the above mentioned long-term objectives.

Part XIII

Article 21

Final Provisions

1. The provisions of GATT 1994 and of other Multilateral Trade Agreements in Annex 1A to the WTO Agreement shall apply subject to the provisions of this Agreement.

2. The Annexes to this Agreement are hereby made an integral part of this Agreement.

Vol. 1867, 1-31874


ANNEX 1

PRODUCT COVERAGE

1. This Agreement shall cover the following products:

(i) HS Chapters 1

(ii) HS Code

HSCode

HS Heading

HS Headings

HS Code

HS Code

HS Headings

HS Heading

HS Headings

HS Headings

HS Headings

HS Heading

HS Heading

to 24 less fish and fish products,

2905.43

2905.44

33.01

35.01 to 35.05

3809.10

3823.60

41.01 to 41. 03

43.01

50.01 to 50.03

51.01 to 51.03

52.01 to 52.03

53.01

53.02

plus*

(mannitol)

(sorbitol)

(essential oils)

(albuminoidal substances, modified starches, glues)

(finishing agents)

(sorbitol n.e.p.)

(hides and skins)

(raw furskins)

(raw silk and silk waste)

(wool and animal hair)

(raw cotton, waste and cotton carded or combed)(raw flax)

(raw hemp)

2. The foregoing shall not limit the product coverage of the Agreement on the Application of Sanitary and Phytosanitary Measures.

*The product descriptions in round brackets are not necessarily exhaustive.

Vol. 1867, 1-31874


ANNEX 2

DOMESTIC SUPPORT: THE BASIS FOR EXEMPTION FROM THE REDUCTION COMMITMENTS

1. Domestic support measures for which exemption from the reduction commitments is claimed shall meet the fundamental requirement that they have no, or at most minimal, trade-distorting effects or effects on production. Accordingly, all measures for which exemption is claimed shall conform to the following basic criteria:

(a) the support in question shall be provided through a publicly-funded government programme (including government revenue foregone) not involving transfers from consumers; and,

(b) the support in question shall not have the effect of providing price support to producers;

plus policy-specific criteria and conditions as set out below.

Government Service Programmes

2. General services

Policies in this category involve expenditures (or revenue foregone) in relation to programmes which provide services or benefits to agriculture or the rural community. They shall not involve direct payments to producers or processors. Such programmes, which include but are not restricted to the following list, shall meet the general criteria in paragraph 1 above and policy-specific conditions where set out below:

(a) research, including general research, research in connection with environmental programmes, and research programmes relating to particular products;

(b) pest and disease control, including general and product-specific pest and disease control measures, such as early-warning systems, quarantine and eradication;

(c) training services, including both general and specialist training facilities;

(d) extension and advisory services, including the provision of means to facilitate the transfer of information and the results of research to producers and consumers;

(e) inspection services, including general inspection services and the inspection of particular products for health, safety, grading or standardization purposes;

(f) marketing and promotion services, including market information, advice and promotion relating to particular products but excluding expenditure for unspecified purposes that could be used by sellers to reduce their selling price or confer a direct economic benefit to purchasers; and

(g) infrastructural services, including: electricity reticulation, roads and other means of transport, market and port facilities, water supply facilities, dams and drainage schemes, and infrastructural works associated with environmental programmes. In all cases the expenditure shall be directed to the provision or construction of capital works only, and shall exclude the subsidized provision of on-farm facilities other than for the

Vol. 1867, 1-31874


reticulation of generally availablepublicutilities. It shall not include subsidies to inputs or operating costs, or preferential user charges.

3. Public stockholding for food security purposes5

Expenditures (or revenue foregone) in relation to the accumulation and holding of stocks of products which form an integral part of a food security programme identified in national legislation. This may include government aid to private storage of products as part of such a programme.

The volume and accumulation of such stocks shall correspond to predetermined targets related solely to food security. The process of stock accumulation and disposal shall be financially transparent. Food purchases by the government shall be made at current market prices and sales from food security stocks shall be made at no less than the current domestic market price for the product and quality in question.

4. Domestic food aid6

Expenditures (or revenue foregone) in relation to the provision of domestic food aid to sections of the population in need.

Eligibility to receive the food aid shall be subject to clearly-defined criteria related to nutritional objectives. Such aid shall be in the form of direct provision of food to those concerned or the provision of means to allow eligible recipients to buy food either at market or at subsidized prices. Food purchases by the government shall be made at current market prices and the financing and administration of the aid shall be transparent.

5. Direct payments to producers

Support provided through direct payments (or revenue foregone, including payments in kind) to producers for which exemption from reduction commitments is claimed shall meet the basic criteria set out in paragraph 1 above, plus specific criteria applying to individual types of direct payment as set out in paragraphs 6 through 13 below. Where exemption from reduction is claimed for any existing or new type of direct payment other than those specified in paragraphs 6 through 13, it shall conform to criteria (b) through (e) in paragraph 6, in addition to the general criteria set out in paragraph 1.

6. Decoupled income support

(a) Eligibility for such payments shall be determined by clearly-defined criteria such as income, status as a producer or landowner, factor use or production level in a defined and fixed base period.

sFor the purposes of paragraph 3 of this Annex, governmental stockholding programmes for food security purposes in developing countries whose operation is transparent and conducted in accordance with officially published objective criteria or guidelines shall be considered to be in conformity with the provisions of this paragraph, including programmes under which stocks of foodstuffs for food security purposes are acquired and released at administered prices, provided ihal the difference between the acquisition price and the external reference price is accounted for in the AMS.

5 *'For the purposes of paragraphs 3 and 4 of this Annex, the provision of foodstuffs at subsidized prices with the objective of meeting food requirements of urban and rural poor in developing countries on a regular basis at reasonable prices shall be considered to be in conformity with the provisions of this paragraph.

Vol. 1867, 1-31874


(b) The amount of such payments in any given year shall not be related to, or based on, the type or volume of production (including livestock units) undertaken by the producer in any year after the base period.

(c) The amount of such payments in any given year shall not be related to, or based on, the prices, domestic or international, applying to any production undertaken in any year after the base period.

(d) The amount of such payments in any given year shall not be related to, or based on, the factors of production employed in any year after the base period.

(e) No production shall be required in order to receive such payments.

7. Government financial participation in income insurance and income safety-net programmes

(a) Eligibility for such payments shall be determined by an income loss, taking into account only income derived from agriculture, which exceeds 30 per cent of average gross income or the equivalent in net income terms (excluding any payments from the same or similar schemes) in the preceding three-year period or a three-year average based on the preceding five-year period, excluding the highest and the lowest entry. Any producer meeting this condition shall be eligible to receive the payments.

(b) The amount of such payments shall compensate for less than 70 per 'cent of the producer's income loss in the year the producer becomes eligible to receive this assistance.

(c) The amount of any such payments shall relate solely to income; it shall not relate to the type or volume of production (including livestock units) undertaken by the producer; or to the prices, domestic or international, applying to such production; or to the factors of production employed.

(d) Where a producer receives in the same year payments under this paragraph and under paragraph 8 (relief from natural disasters), the total of such payments shall be less than 100 per cent of the producer's total loss.

8. Payments (made either directly or by way of government financial participation in crop insurance schemes) for relief from natural disasters

(a) Eligibility for such payments shall arise only following a formal recognition by government authorities that a natural or like disaster (including disease outbreaks, pest infestations, nuclear accidents, and war on the territory of the Member concerned) has occurred or is occurring; and shall be determined by a production loss which exceeds 30 per cent of the average of production in the preceding three-year period or a three-year average based on the preceding five-year period, excluding the highest and the lowest entry.

(b) Payments made following a disaster shall be applied only in respect of losses of income, livestock (including payments in connection with the veterinary treatment of animals), land or other production factors due to the natural disaster in question.

(c) Payments shall compensate for not more than the total cost of replacing such losses and shall not require or specify the type or quantity of future production.

Vol. 1867, 1-31874

428_______United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995

(d) Payments made during a disaster shal! not exceed the level required to prevent or alleviate further loss as defined in criterion (b) above.

(e) Where a producer receives in the same year payments under this paragraph and under paragraph 7 (income insurance and income safety-net programmes), the total of such payments shall be less than 100 per cent of the producer's total loss.

9. Structural adjustment assistance provided through producer retirement programmes

(a) Eligibility for such payments shall be determined by reference to clearly defined criteria in programmes designed to facilitate the retirement of persons engaged in marketable agricultural production, or their movement to non-agricultural activities.

(b) Payments shal! be conditional upon the total and permanent retirement of the recipients from marketable agricultural production.

10. Structural adjustment assistance provided through resource retirement programmes

(a) Eligibility for such payments shall be determined by reference to clearly defined criteria in programmes designed to remove land or other resources, including livestock, from marketable agricultural production.

(b) Payments shall be conditional upon the retirement of land from marketable agricultural production for a minimum of three years, and in the case of livestock on its slaughter or definitive permanent disposal.

(c) Payments shall not require or specify any alternative use for such land or other resources which involves the production of marketable agricultural products.

(d) Payments shall not be related to either the type or quantity of production or to the prices, domestic or international, applying to production undertaken using the land or other resources remaining in production.

11. Structural adjustment assistance provided through investment aids

(a) Eligibility for such payments shall bedetermined by reference to clearly-defined criteria in government programmes designed to assist the financial or physical restructuring of a producer's operations in response to objectively demonstrated structural disadvantages. Eligibility for such programmes may also be based on a clearly-defined government programme for the «privatization of agricultural land.

(b) The amount of such payments in any given year shall not be related to, or based on, the type or volume of production (including livestock units) undertaken by the producer in any year after the base period other than as provided for under criterion (e) below.


(d) The payments shall be given only for the period of time necessary for the realization of the investment in respect of which they are provided.

(e) The payments shall not mandate or in any way designate the agricultural products to be produced by the recipients except to require them not to produce a particular product.

Vol. 1867, 1-31874


(f) The payments shall be limited to the amount required to compensate for the structural disadvantage.

12. Payments under environmental programmes

(a) Eligibility for such payments shal! be determined as part of a clearly-defined government environmental or conservation programme and be dependent on the fulfilment of specific conditions under the government programme, including conditions related to production methods or inputs.

(b) The amount of payment shall be limited to the extra costs or loss of income involved in complying with the government programme.

13. Payments under regional assistance programmes

(a) Eligibility for such payments shall be limited to producers in disadvantaged regions. Each such region must be a clearly designated contiguous geographical area with a definable economic and administrative identity, considered as disadvantaged on the basis of neutral and objective criteria clearly spelt out in law or regulation and indicating that the region's difficulties arise out of more than temporary circumstances.

(b) The amount of such payments in any given year shall not be related to, or based on, the type or voiume of production (including livestock units) undertaken by the producer in any year after the base period other than to reduce that production.


(d) Payments shall be available only to producers in eligibîeregions, but generally available to all producers within such regions.

(e) Where related to production factors, payments shall be made at a degressive rate above a threshold level of the factor concerned.

(f) The payments shall be limited to the extra costs or loss of income involved in undertaking agricultural production in the prescribed area.

Vol. 1867, 1-31874


ANNEX 3

DOMESTIC SUPPORT: CALCULATION OF AGGREGATE MEASUREMENT OF SUPPORT

1. Subject to the provisions of Article 6, an Aggregate Measurement of Support (AMS) shall be calculated on a product-specific basis for each basic agricultural product receiving market price support, non-exempt direct payments, or any other subsidy not exempted from the reduction commitment ("other non-exempt policies"). Support which is non-product specific shall be totalled into one non-product- specific AMS in total monetary terms.

2. Subsidies under paragraph 1 shall include both budgetary outlays and revenue foregone by governments or their agents.

3. Support at both the national and sub-national level shall be included.

4. Specific agricultural levies or fees paid by producers shall be deducted from the AMS.

5. The AMS calculated as outlined below for the base period shall constitute the base level for the implementation of the reduction commitment on domestic support.

6. For each basic agricultural product, a specific AMS shall be established, expressed in total monetary value terms.

7. The AMS shall be calculated as close as practicable to the point of first sale of the basic agricultural product concerned. Measures directed at agricultural processors shall be included to the extent that such measures benefit the producers of the basic agricultural products.

8. Market price support: market price support shall be calculated using the gap between a fixed external reference price and the applied administered price multiplied by the quantity of production eligible to receive the applied administered price. Budgetary payments made to maintain this gap, such as buying-in or storage costs, shall not be included in the AMS.

9. The fixed external reference price shall be based on the years 1986 to 1988 and shall generally be the average f.o.b. unit value for the basic agricultural product concerned in a net exporting country and the average c.i.f. unit value for the basic agricultural product concerned in a net importing country in the base period. The fixed reference price may be adjusted for quality differences as necessary.

10. Non-exempt direct payments: non-exempt direct payments which are dependent on a price gap shall be calculated either using the gap between the fixed reference price and the applied administered price multiplied by the quantity of production eligible to receive the administered price, or using budgetary outlays.

11. The fixed reference price shall be based on the years 1986 to 1988 and shall generally be the actual price used for determining payment rates.

12. Non-exempt direct payments which are based on factors other than price shall be measured using budgetary outlays.

Vol. 1867, 1-31874


13. Other non-exempt measures, including input subsidies and other measures such as marketing-cost reduction measures: the value of such measures shall be measured using government budgetary outlays or, where the use of budgetary outlays does not reflect the full extent of the subsidy concerned, the basis for calculating the subsidy shall be the gap between the price of the subsidized good or service and a representative market price for a similar good or service multiplied by the quantity of the good or service.

Vol. 1867, 1-31874


ANNEX 4

DOMESTIC SUPPORT: CALCULATION OF EQUIVALENT MEASUREMENT OF SUPPORT

1. Subject to the provisions of Article 6, equivalent measurements of support shall be calculated in respect of all basic agricultural products where market price support as defined in Annex 3 exists but for which calculation of this component of the AMS is not practicable. For such products the base level for implementation of the domestic support reduction commitments shall consist of a market price support component expressed in terms of equivalent measurements of support under paragraph 2 below, as well as any non-exempt direct payments and other non-exempt support, which shall be evaluated as provided for under paragraph 3 below. Support at both national and sub-national level shall be included.

2. The equivalent measurements of support provided for in paragraph 1 shall be calculated on a product-specific basis for all basic agricultural products as close as practicable to the point of first sale receiving market price support and for which the calculation of the market price support component of the AMS is not practicable. Forthose basic agricultural products, equivalent measurements of market price support shall be made using the applied administered price and the quantity of production eligible to receive that price or, where this is not practicable, on budgetary outlays used to maintain the producer price.

3. Wherebasicagriculturalproductsfallingunderparagraph 1 arethesubjectofnon-exemptdirect payments or any other product-specific subsidy not exempted from the reduction commitment, the basis for equivalent measurements of support concerning these measures shall be calculations as for the corresponding AMS components (specified in paragraphs 10 through 13 of Annex 3).

4. Equivalent measurements of support shall be calculated on the amount of subsidy as close as practicable to the point of first sale of the basic agricultural product concerned. Measures directed at agricultural processors shall be included to the extent that such measures benefit the producers of the basic agricultural products. Specific agricultural levies or fees paid by producers shall reduce the equivalent measurements of support by a corresponding amount.

Vol. 1867, 1-31874


ANNEX 5

SPECIAL TREATMENT WITH RESPECT TO PARAGRAPH 2 OF ARTICLE 4

Section A

1. The provisions of paragraph 2 of Article 4 shall not apply with effect from the entry into force of the WTO Agreement to any primary agricultural product and its worked and/or prepared products ("designated products") in respect of which the following conditions are complied with (hereinafter referred to as "special treatment"):

(a) imports of the designated products comprised less than 3 per cent of corresponding domestic consumption in the base period 1986-1988 ("the base period");

(b) no export subsidies have been provided since the beginning of the base period for the designated products;

(c) effective production-restricting measures are applied to the primary agricultural product:

(d) such products are designated with the symbol "ST-Annex 5" in Section I-B of Part I of a Member's Schedule annexed to the Marrakesh Protocol, as being subject to special treatment reflecting factors of non-trade concerns, such as food security and environmental protection; and

(e) minimum access opportunities in respect of the designated products correspond, as specified in Section I-B of Part I of the Schedule of the Member concerned, to 4 per cent of base period domestic consumption of the designated products from the beginning of the first year of the implementation period and, thereafter, are increased by 0.8 per cent of corresponding domestic consumption in the base period per year for the remainder of the implementation period.

2. At the beginning of any year of the implementation period aMember may cease to apply special treatment in respect of the designated products by complying with the provisions of paragraph 6. In such a case, the Member concerned shall maintain the minimum access opportunities already in effect at such time and increase the minimum access opportunities by 0.4 per cent of corresponding domestic consumption in the base period per year for the remainder of the implementation period. Thereafter, the level of minimum access opportunities resulting from this formula in the final year of the implementation period shall be maintained in the Schedule of the Member concerned.

3. Any negotiation on the question of whether there can be a continuation of the special treatment as set out in paragraph 1 after the end of the implementation period shall be completed within the time- frame of the implementation period itself as a part of the negotiations set out in Article 20 of this Agreement, taking into account the factors of non-trade concerns.

4. If it is agreed as a result of the negotiation referred to in paragraph 3 that a Member may continue to apply the special treatment, such Member shall confer additional and acceptable concessions as determined in that negotiation.

5. Where the special treatment is not to be continued at the end of the implementation period, the Member concerned shall implement the provisions of paragraph 6. In such a case, after the end of the implementation period the minimum access opportunities for the designated products shall be maintained at the level of 8 per cent of corresponding domestic consumption in the base period in the Schedule of the Member concerned.

Vol. 1867, 1-31874


6. Border measures other than ordinary customs duties maintained in respect of the designated products shall become subject to the provisions of paragraph 2 of Article 4 with effect from the beginning of the year in which the special treatment ceases to apply. Such products shall be subject to ordinary customs duties, which shall be bound in the Schedule of the Member concerned and applied, from the beginning of the year in which special treatment ceases and thereafter, at such rates as would have been applicable had a reduction of at least 1 5 per cent been implemented over the implementation period in equal annual instalments. These duties shall be established on the basis of tariff equivalents to be calculated in accordance with the guidelines prescribed in the attachment hereto.

Section B

1. The provisions of paragraph 2 of Article 4 shall also not apply with effect from the entry into force of the WTO Agreement to a primary agricultural product that is the predominant staple in the traditional diet of a developing country Member and in respect of which the following conditions, in addition to those specified in paragraph l(a) through l(d), as they apply to the products concerned, are complied with:

(a) minimum access opportunities in respect of the products concerned, as specified in Section I-B of Part I of the Schedule of the developing country Member concerned, correspond to 1 per cent of base period domestic consumption of the products concerned from the beginning of the first year of the implementation period and are increased in equal annual instalments to 2 per cent of corresponding domestic consumption in the base period at the beginning of the fifth year of the implementation period. From the beginning of the sixth year of the implementation period, minimum access opportunities in respect of the products concerned correspond to 2 per cent of corresponding domestic consumption in the base period and are increased in equal annual instalments to 4 per cent of corresponding domestic consumption in the base period until the beginning of the 10th year. Thereafter, the level of minimum access opportunities resulting from this formula in the 10th year shall be maintained in the Schedule of the developing country Member concerned;

(b) appropriate market access opportunities have been provided for in other products under this Agreement.

8. Any negotiation on the question of whether there can be a continuation of the special treatment as set out in paragraph 7 after the end of the 10th year following the beginning of the implementation period shall be initiated and completed within the time-frame of the 10th year itself following the beginning of the implementation period.

9. If it is agreed as a result of the negotiation referred to in paragraph 8 that a Member may continue to apply the special treatment, such Member shall confer additional and acceptable concessions as determined in that negotiation.

10. In the event that special treatment under paragraph 7 is not to be continued beyond the 10th year following the beginning of the implementation period, the products concerned shall be subject to ordinary customs duties, established on the basis of a tariff equivalent to be calculated in accordance with the guidelines prescribed in the attachment hereto, which shall be bound in the Schedule of the Member concerned. In other respects, the provisions of paragraph 6 shall apply as modified by the relevant special and differential treatment accorded to developing country Members under this Agreement.

Vol. 1867, 1-31874


Attachment to Annex 5

Guidelines for the Calculation of TariffEquivalents for the Specific Purpose Specified in

Paragraphs 6 and 10 of this Annex

1. The calculation of the tariff equivalents, whether expressed as ad valorem or specific rates, shall be made using the actual difference between internal and external prices in a transparent manner. Data used shall be for the years 1986 to 1988. Tariff equivalents:

(a) shall primarily be established at the four-digit level of the HS;

(b) shall be established at the six-digit or a more detailed level of the HS wherever appropriate;

(c) shall generally be established for worked and/or prepared products by multiplying the specific tariff equivalent(s) for the primary agricultural product(s) by the proportion(s) in value terms or in physical terms as appropriate of the primary agricultural product(s) in the worked and/or prepared products, and take account, where necessary, of any additional elements currently providing protection to industry.

2. External prices shall be, in general, actual average c.i.f. unit values for the importing country. Where average c.i.f. unit values are not available or appropriate, external prices shall be either:

(a) appropriate average c.i.f. unit values of a near country; or

(b) estimated from average f.o.b. unit values of (an) appropriate major exporter(s) adjusted by adding an estimate of insurance, freight and other relevant costs to the importing country.

3. The external prices shall generally be converted to domestic currencies using the annual average market exchange rate for the same period as the price data.

4. The internal price shall generally be a representative wholesale price ruling in the domestic market or an estimate of that price where adequate data is not available.

5. The initial tariff equivalents may be adjusted, where necessary, to take account of differences in quality or variety using an appropriate coefficient.

6. Where a tariff equivalent resulting from these guidelines is negative or iower than the current bound rate, the initial tariff equivalent may be established at the current bound rate or on the basis of national offers for that product.

7. Where an adjustment is made to the level of a tariff equivalent which would have resulted from the above guidelines, the Member concerned shall afford, on request, full opportunities for consultation with a view to negotiating appropriate solutions.

Vol. 1867, 1-31874


AGREEMENT ON THE APPLICATION OF SANITARY AND PHYTOSANITARY MEASURES

Members,

Reaffirming that no Member should be prevented from adopting or enforcing measures necessary to protect human, animal or plant life or health, subject to the requirement that these measures are not applied in a manner which would constitute a means of arbitrary or unjustifiable discrimination between Members where the same conditions prevail or a disguised restriction on international trade;

Desiring to improve the human health, animal health andphytosanitary situation in all Members;

Noting that sanitary and phytosanitary measures are often applied on the basis of bilateral agreements or protocols;

Desiring the establishment of a multilateral framework of rules and disciplines to guide the development, adoption and enforcement of sanitary and phytosanitary measures in order to minimize their negative effects on trade;

Recognizing the important contribution that international standards, guidelines and recommendations can make in this regard;

Desiring to further the use of harmonized sanitary and phytosanitary measures between Members, on the basis of international standards, guidelines and recommendations developed by the relevant international organizations, including the Codex Alimentarius Commission, the International Office of Epizootics, and the relevant international and regional organizations operating within the framework of the International Plant Protection Convention? without requiring Members to change their appropriate level of protection of human, animal or plant life or health;

Recognizing that developing country Members may encounter special difficulties in complying with the sanitary or phytosanitary measures of importing Members, and as a consequence in access to markets, and also in the formulation and application of sanitary or phytosanitary measures in their own territories, and desiring to assist them in their endeavours in this regard;

Desiring therefore to elaborate rules for the application of the provisions of GATT 1994 which relate to the use of sanitary or phytosanitary measures, in particular the provisions of Article XX(b) ;'


* United Nations, Treaty Series, vol. 150, p. 67.

1 In this Agreement, reference to Article XX(b) includes also the chapeau of that Article.

Vol. 1867, 1-31874


Article 1

General Provisions

1. This Agreement applies to all sanitary and phytosanitary measures which may, directly or indirectly, affect international trade. Such measures shall be developed and applied in accordance with the provisions of this Agreement.

2. For the purposes of this Agreement, the definitions provided in Annex A shall apply.

3. The annexes are an integral part of this Agreement.

4. Nothing in this Agreement shall affect the rights of Members under the Agreement on Technical Barriers to Trade with respect to measures not within the scope of this Agreement.

Article 2

Basic Rights and Obligations

1. Members have the right to take sanitary and phytosanitary measures necessary for the protection of human, animal or plant life or health, provided that such measures are not inconsistent with the provisions of this Agreement.

2. Members shall ensure that any sanitary or phytosanitary measure is applied only to the extent necessary to protect human, animal or plant life or health, is based on scientific principles and is not maintained without sufficient scientific evidence, except as provided for in paragraph 7 of Article 5.

3. Members shall ensure that their sanitary and phytosanitary measures do not arbitrarily or unjustifiably discriminate between Members where identical or similar conditions prevail, including between their own territory and that of other Members. Sanitary and phytosanitary measures shall not be applied in a manner which would constitute a disguised restriction on international trade.

4. Sanitary or phytosanitary measures which conform to the relevant provisions of this Agreement shall be presumed to be in accordance with the obligations of the Members under the provisions of GATT 1994 which relate to the use of sanitary or phytosanitary measures, in particular the provisions of Article XX(b).

Article 3

Harmonization

1. To harmonize sanitary and phytosanitary measures on as wide a basis as possible, Members shall base their sanitary or phytosanitary measures on international standards, guidelines or recommendations, where they exist, except as otherwise provided for in this Agreement, and in particular in paragraph 3.

Vol. 1867, 1-31874


2. Sanitary or phytosanitary measures which conform to international standards, guidelines or recommendations shall be deemed to be necessary to protect human, animal or plant life or health, and presumed to be consistent with the relevant provisions of this Agreement and of GATT 1994.

3. Members may introduce or maintain sanitary or phytosanitary measures which result in a higher level of sanitary or phytosanitary protection than would be achieved by measures based on the relevant international standards, guidelines or recommendations, if there is a scientific justification, or as a consequence of the level of sanitary or phytosanitary protection a Member determines to be appropriate in accordance with the relevant provisions of paragraphs 1 through 8 of Article 5. 2 Notwithstanding the above, all measures which result in a level of sanitary or phytosanitary protection different from that which would be achieved by measures based on international standards, guidelines or recommendations shall not be inconsistent with any other provision of this Agreement.

4. Members shall play a full part, within the limits of their resources, in the relevant international organizations and their subsidiary bodies, in particular the Codex Alimentarius Commission, the International Office of Epizootics, and the international and regional organizations operating within the framework of the International Plant Protection Convention, to promote within these organizations the development and periodic review of standards, guidelines and recommendations with respect to all aspects of sanitary and phytosanitary measures.

5. The Committee on Sanitary and Phytosanitary Measures provided for in paragraphs 1 and 4 of Article 12 (referred to in this Agreement as the "Committee") shall develop a procedure to monitor the process of international harmonization and coordinate efforts in this regard with the relevant international organizations.

Article 4

Equivalence

1. Members shall accept the sanitary or phytosanitary measures of other Members as equivalent, even if these measures differ from their own or from those used by other Members trading in the same product, if the exporting Member objectively demonstrates to the importing Member that its measures achieve the importing Member's appropriate level of sanitary or phytosanitary protection. For this purpose, reasonable access shall be given, upon request, to the importing Member for inspection, testing and other relevant procedures.

2. Members shall, upon request, enter into consultations with the aim of achieving bilateral and multilateral agreements on recognition of the equivalence of specified sanitary or phytosanitary measures.

^or the purposes of paragraph 3 of Article 3, there is a scientific justification if, on the basis of an examination and evaluation of available scientific information in conformity with the relevant provisions of this Agreement, a Member détermina, that the relevant international standards, guidelines or recommendations are not sufficient to achieve its appropriate levd of sanitary or phytosanitary protection.

Vol. 1867, 1-31874


Article 5

Assessment of Risk and Determination of the Appropriate Level of Sanitary or Phytosanitary Protection

1. Members shall ensure that their sanitary or phytosanitary measures are based on an assessment, as appropriate to the circumstances, of the risks to human, animal or plant life or health, taking into account risk assessment techniques developed by the relevant international organizations.

2. In the assessment of risks, Members shall take into account available scientific evidence; relevant processes and production methods; relevant inspection, sampling and testing methods; prevalence of specific diseases or pests; existence of pest- or disease-free areas; relevant ecological and environmental conditions; and quarantine or other treatment.

3. In assessing the risk to animal or plant life or health and determining the measure to be applied for achieving the appropriate level of sanitary or phytosanitary protection from such risk, Members shall take into account as relevant economic factors: the potential damage in terms of loss of production or sales in the event of the entry, establishment or spread of a pest or disease; the costs of control or eradication in the territory of the importing Member; and the relative cost-effectiveness of alternative approaches to limiting risks.

4. Members should, when determining the appropriate level of sanitary or phytosanitary protection, take into account the objective of minimizing negative trade effects.

5. With the objective of achieving consistency in the application of the concept of appropriate level of sanitary or phytosanitary protection against risks to human life or health, or to animal and plant life or health, each Member shall avoid arbitrary or unjustifiable distinctions in the levels it considers to be appropriate in different situations, if such distinctions result in discrimination or a disguised restriction on international trade. Members shall cooperate in the Committee, in accordance with paragraphs 1, 2 and 3 of Article 12, to develop guidelines to further the practical implementation of this provision. In developing the guidelines, the Committee shall take into account all relevant factors, including the exceptional character of human health risks to which people voluntarily expose themselves.

6. Without prejudice to paragraph 2 of Article 3, when establishing or maintaining sanitary or phytosanitary measures to achieve the appropriate level of sanitary or phytosanitary protection, Members shall ensure that such measures are not more trade-restrictive than required to achieve their appropriate level of sanitary or phytosanitary protection, taking into account technical and economic feasibility. 3

7. In cases where relevant scientific evidence is insufficient, a Member may provisionally adopt sanitary or phytosanitary measures on the basis of available pertinent information, including that from the relevant international organizations as well as from sanitary or phytosanitary measures applied by other Members. In such circumstances, Members shall seek to obtain the additional information necessary for a more objective assessment of risk and review the sanitary or phytosanitary measure accordingly within a reasonable period of time.

8. When a Member has reason to believe that a specific sanitary or phytosanitary measure introduced or maintained by another Member is constraining, or has the potential to constrain, its exports and

'For purposes of paragraph 6 of Articles, a measure is not more trade-restrictive than required unless there is another measure, reasonably available taking into account technical and economic feasibility, that achieves the appropriate level of sanitary or phytosanitary protection and is significantly less restrictive to trade.

Vol. 1867, 1-31874


the measure is not based on the relevant international standards, guidelines or recommendations, or such standards, guidelines or recommendations do not exist, an explanation of the reasons for such sanitary or phytosanitary measure may be requested and shall be provided by the Member maintaining the measure.

Article 6

Adaptation to Regional Conditions, Including Pest- or Disease-Free Areas and Areas of Low Pest or Disease Prevalence

1. Members shall ensure that their sanitary or phytosanitary measures are adapted to the sanitary or phytosanitary characteristics of the area - whether all of a country, part of a country, or all or parts of several countries - from which the product originated and to which the product is destined. In assessing the sanitary or phytosanitary characteristics of a region, Members shall take into account, inter alia, the level of prevalence of specific diseases or pests, the existence of eradication or control programmes, and appropriate criteria or guidelines which may bedeveloped by the relevant international organizations.

2. Members shall, in particular, recognize the concepts of pest- or disease-free areas and areas of low pest or disease prevalence. Determination of such areas shall be based on factors such as geography, ecosystems, epidemiological surveillance, and the effectiveness of sanitary or phytosanitary controls.

3. Exporting Members claiming that areas within their territories are pest- or disease-free areas or areas of low pest or disease prevalence shall provide the necessary evidence thereof in order to objectively demonstrate to the importing Member that such areas are, and are likely to remain, pest- or disease-free areas or areas of low pest or disease prevalence, respectively. For this purpose, reasonable access shall be given, upon request, to the importing Member for inspection, testing and other relevant procedures.

Article 7

Transparency

Members shall notify changes in their sanitary or phytosanitary measures and shall provide information on their sanitary or phytosanitary measures in accordance with the provisions of Annex B.

Article 8

Control, Inspection and Approval Procedures

Members shall observe the provisions of Annex C in the operation of control, inspection and approval procedures, including national systems for approving the use of additives or for establishing tolerances for contaminants in foods, beverages or feedstuffs, and otherwise ensure that their procedures are not inconsistent with the provisions of this Agreement.

Vol. 1867, 1-31874


Anicle 9

Technical Assistance

1. Members agree to facilitate the provision of technical assistance to other Members, especially developing country Members, either bilaterally or through the appropriate international organizations. Such assistance may be, inter alia, in the areas of processing technologies, research and infrastructure, including in the establishment of national regulatory bodies, and may take the form of advice, credits, donations and grants, including for the purpose of seeking technical expertise, training and equipment to allow such countries to adjust to, and comply with, sanitary or phytosanitary measures necessary to achieve the appropriate level of sanitary or phytosanitary protection in their export markets.

2. Where substantial investments are required in order for an exporting developing country Member to fulfil the sanitary or phytosanitary requirements of an importing Member, the latter shall consider providing such technical assistance as will permit the developing country Member to maintain and expand its market access opportunities for the product involved.

Article 10

Special and Differential Treatment

1. In the preparation and application of sanitary or phytosanitary measures, Members shall take account of the special needs of developing country Members, and in particular of the least-developed country Members.

2. Where the appropriate level of sanitary or phytosanitary protection allows scope for the phased introduction of new sanitary or phytosanitary measures, longer time-frames for compliance should be accorded on products of interest to developing country Members so as to maintain opportunities for their exports.

3. With a view to ensuring that developing country Members are able to comply with the provisions of this Agreement, the Committee is enabled to grant to such countries, upon request, specified, time- limited exceptions in whole or in part from obligations under this Agreement, taking into account their financial, trade and development needs.

4. Members should encourage and facilitate the active participation of developing country Members in the relevant international organizations.

Article 11

Consultations and Dispute Settlement

1. The provisions of Articles XXII and XXIII of GATT 1994 as elaborated and applied by the Dispute Settlement Understanding shall apply to consultations and the settlement of disputes under this Agreement, except as otherwise specifically provided herein.

2. In a dispute under this Agreement involving scientific or technical issues, a panel should seek advice from experts chosen by the panel in consultation with the parties to the dispute. To this end, the panel may, when it deems it appropriate, establish an advisory technical experts group, or consult

Vol. 1867, 1-31874


the relevant international organizations, at the request of either party to the dispute or on its own initiative.

3. Nothing in this Agreement shall impair the rights of Members under other international agreements, including the right to resort to the good offices or dispute settlement mechanisms of other international organizations or established under any international agreement.

Article 12

Administration

1. A Committee on Sanitary and Phytosanitary Measures is hereby established to provide a regular forum for consultations. It shall carry out the functions necessary to implement the provisions of this Agreement and the furtherance of its objectives, in particular with respect to harmonization. The Committee shall reach its decisions by consensus.

2. The Committee shall encourage and facilitate ad hoc consultations or negotiations among Members on specific sanitary or phytosanitary issues. The Committee shall encourage the use of international standards, guidelines or recommendations by all Members and, in this regard, shall sponsor technical consultation and study with the objective of increasing coordination and integration between international and national systems and approaches for approving the use of food additives or for establishing tolerances for contaminants in foods, beverages or feedstuff's.

3. The Committee shall maintain close contact with the relevant international organizations in the field of sanitary and phytosanitary protection, especially with the Codex Alimentarius Commission, the International Office of Epizootics, and the Secretariat of the International Plant Protection Convention, with the objective of securing the best available scientific and technical advice for the administration of this Agreement and in order to ensure that unnecessary duplication of effort is avoided.

4. The Committee shall develop a procedure to monitor the process of international harmonization and the use of international standards, guidelines or recommendations. For this purpose, the Committee should, in conjunction with the relevant international organizations, establish a list of international standards, guidelines or recommendations relating to sanitary or phytosanitary measures which the Committee determines to have a major trade impact. The list should include an indication by Members of those international standards, guidelines or recommendations which they apply as conditions for import or on the basis of which imported products conforming to these standards can enjoy access to their markets. For those cases in which a Member does not apply an international standard, guideline or recommendation as a condition for import, the Member should provide an indication of the reason therefor, and, in particular, whether it considers that the standard is not stringent enough to provide the appropriate level of sanitary or phytosanitary protection. If a Member revises its position, following its indication of the use of a standard, guideline or recommendation as a condition for import, it should provide an explanation for its change and so inform the Secretariat as well as the relevant international organizations, unless such notification and explanation is given according to the procedures of Annex B.

5. In order to avoid unnecessary duplication, the Committee may decide, as appropriate, to use the information generated by the procedures, particularly for notification, which are in operation in the relevant international organizations.

6. The Committee may, on the basis of an initiative from one of the Members, through appropriate channels invite the relevant international organizations or their subsidiary bodies to examine specific

Vol. 1867, 1-31874


matters with respect to a particular standard, guideline or recommendation, including the basis of explanations for non-use given according to paragraph 4.

7. The Committee shall review the operation and implementation of this Agreement three years after the date of entry into force of the WTO Agreement, and thereafter as the need arises. Where appropriate, the Committee may submit to the Council for Trade in Goods proposals to amend the text of this Agreement having regard, inter alia, to the experience gained in its implementation.

Article 13

Implementation

Members are fully responsible under this Agreement for the observance of all obligations set forth herein. Members shall formulate and implement positive measures and mechanisms in support of the observance of the provisions of this Agreement by other than central government bodies. Members shall take such reasonable measures as may be available to them to ensure that non-governmental entities within their territories, as well as regional bodies in which relevant entities within their territories are members, comply with the relevant provisions of this Agreement. In addition, Members shall not take measures which have the effect of, directly or indirectly, requiring or encouraging such regional or non-governmental entities, or local governmental bodies, to act in a manner inconsistent with the provisions of this Agreement. Members shall ensure that they rely on the services of non-governmental entities for implementing sanitary or phytosanitary measures only if these entities comply with the provisions of this Agreement.

Article 14

Final Provisions

The least-developed country Members may delay application of theprovisions of this Agreement for a period of five years following the date of entry into force of the WTO Agreement with respect to their sanitary or phytosanitary measures affecting importation or imported products. Other developing country Members may delay application of the provisions of this Agreement, other than paragraph 8 of Article 5 and Article 7, for two years following the date of entry into force of the WTO Agreement with respect to their existing sanitary or phytosanitary measures affecting importation or imported products, where such application is prevented by a lack of technical expertise, technical infrastructure or resources.

Vol. 1867, 1-31874


ANNEX A

DEFINITIONS4

1. Sanitary or pfiytosanitary measure - Any measure applied:

(a) to protect animal or plant life or health within the territory of the Member from risks arising from the entry, establishment or spread of pests, diseases, disease-carrying organisms or disease-causing organisms;

(b) to protect human or animal life or health within the territory of the Member from risks arising from additives, contaminants, toxins or disease-causing organisms in foods, beverages or feedstuffs;

(c) to protect human life or health within the territory of the Member from risks arising from diseases carried by animals, plants or products thereof, or from the entry, establishment or spread of pests; or

(d) to prevent or limit other damage within the territory of the Member from the entry, establishment or spread of pests.

Sanitary or phytosanitary measures include all relevant laws, decrees, regulations, requirements and procedures including, inter alia, end product criteria; processes and production methods; testing, inspection, certification and approval procedures; quarantinetreatments including relevantrequirements associated with the transport of animals or plants, or with the materials necessary for their survival during transport; provisions on relevant statistical methods, sampling procedures and methods of risk assessment; and packaging and labelling requirements directly related to food safety.

2. Harmonization - The establishment, recognition and application of common sanitary and phytosanitary measures by different Members.

3. International standards, guidelines and recommendations

(a) for food safety, the standards, guidelines and recommendations established by the Codex Alimentarius Commission relating to food additives, veterinary drug and pesticide residues, contaminants, methods of analysis and sampling, and codes and guidelines of hygienic practice;

(b) for animal health and zoonoses, the standards, guidelines and recommendations developed under the auspices of the International Office of Epizootics;

(c) forplanthealth, the international standards, guidelines and recommendations developed under the auspices of the Secretariat of the International Plant Protection Convention in cooperation with regional organizations operating within the framework of the International Plant Protection Convention; and

'For the purpose of these definitions, "animal" includes fish and wild fauna; "plant" includes forests and wild flon "pests" include weeds; and "contaminants" include pesticide and veterinary drag residues and extraneous matter.

Vol. 1867, 1-31874


(d) for matters not covered by the above organizations, appropriate standards, guidelines and recommendations promulgated by other relevant international organizations open for membership to all Members, as identified by the Committee.

4. Risk assessment - The evaluation of the likelihood of entry, establishment or spread of a pest or disease within the territory of an importing Member according to the sanitary or phytosanitary measures which might be applied, and of the associated potential biological and economic consequences; or the evaluation of the potential for adverse effects on human or animal health arising from the presence of additives, contaminants, toxins or disease-causing organisms in food, beverages or feedstuffs.

5. Appropriate level of sanitary or phytosanitary protection - The level of protection deemed appropriate by the Member establishing a sanitary or phytosanitary measure to protect human, animal or plant life or health within its territory.

NOTE: Many Members otherwise refer to this concept as the "acceptable level of risk".

6. Pest- or disease-free area - An area, whether all of a country, part of a country, or all or parts of several countries, as identified by the competent authorities, in which a specific pest or disease does not occur.

NOTE: A pest- or disease-free area may surround, be surrounded by, or be adjacent to an area - whether within part of a country or in a geographic region which includes parts of or all of several countries - in which a specific pest or disease is known to occur but is subject to regional control measures such as the establishment of protection, surveillance and buffer zones which will confine or eradicate the pest or disease in question.

7. Area of low pest or disease prevalence - An area, whether all of a country, part of a country, or all or parts of several countries, as identified by the competent authorities, in which a specific pest or disease occurs at low levels and which is subject to effective surveillance, control or eradication measures.

Vol. 1867, 1-31874


ANNEX B

TRANSPARENCY OF SANITARY AND PHYTOSANITARY REGULATIONS

Publication of regulations

1. Members shall ensure that all sanitary and phytosanitary regulations5 which have been adopted are published promptly in such a manner as to enable interested Members to become acquainted with them.

2. Except in urgent circumstances, Members shall allow a reasonable interval between the publication of a sanitary or phytosanitary regulation and its entry into force in order to allow time for producers in exporting Members, and particularly in developing country Members, to adapt their products and methods of production to the requirements of the importing Member.

Enquiry points

3. Each Member shall ensure that one enquiry point exists which is responsible for the provision of answers to all reasonable questions from interested Members as well as for the provision of relevant documents regarding:

(a) any sanitary or phytosanitary regulations adopted or proposed within its territory;

(b) any control and inspection procedures, production and quarantine treatment, pesticide tolerance and food additive approval procedures, which are operated within its territory;

(c) risk assessment procedures, factors taken into consideration, as well as the determination of the appropriate level of sanitary or phytosanitary protection;

(d) the membership and participation of the Member, or of relevant bodies within its territory, in international and regional sanitary and phytosanitary organizations and systems, as well as in bilateral and multilateral agreements and arrangements within the scope of this Agreement, and the texts of such agreements and arrangements.

4. Members shall ensure that where copies of documents are requested by interested Members, they are supplied at the same price (if any), apart from the cost of delivery, as to the nationals6 of the Member concerned.

Notification procedures

5. Whenever an international standard, guidel ine or recommendation does not exist or the content of a proposed sanitary or phytosanitary regulation is not substantially the same as the content of an international standard, guideline or recommendation, and if the regulation may have a significant effect on trade of other Members, Members shall:

5Sanitary and phytosanitary measures such as laws, decrees or ordinances which are applicable generally

*When "nationals " are referred to in this Agreement, the term shall be deemed, in the case of a separate customs territory Member of the WTO, to mean persons, natural or legal, who are domiciled or who have a real and effective industrial or, commercial establishment in that customs territory.

Vol. 1867, 1-31874


(a) publish a notice at an early stage in such a manner as to enable interested Members to become acquainted with the proposal to introduce a particular regulation;

(b) notify other Members, through the Secretariat, of the products to be covered by the regulation together with a brief indication of the objective and rational e of the proposed regulation. Such notifications shall take place at an early stage, when amendments can still be introduced and comments taken into account;

(c) provide upon request to other Members copies of the proposed regulation and, whenever possible, identify the parts which in substance deviate from international standards, guidelines or recommendations;

(d) without discrimination, allow reasonable time for other Members to make comments in writing, discuss these comments upon request, and take the comments and the results of the discussions into account.

6. However, where urgent problems of health protection arise or threaten to arise for a Member, that Member may omit such of the steps enumerated in paragraph 5 of this Annex as it finds necessary, provided that the Member:

(a) immediately notifies other Members, through the Secretariat, of the particular regulation and the products covered, with a brief indication of the objective and the rationale of the regulation, including the nature of the urgent problem(s);

(b) provides, upon request, copies of the regulation to other Members;

(c) allows other Members to make comments in writing, discusses these comments upon request, and takes the comments and the results of the discussions into account.

7. Notifications to the Secretariat shall be in English, French or Spanish.

8. Developed country Members shall, if requested by other Members, provide copies of the documents or, in case of voluminous documents, summaries of the documents covered by a specific notification in English, French or Spanish.

9. The Secretariat shall promptly circulate copies of the notification to all Members and interested international organizations and draw the attention of developing country Members to any notifications relating to products of particular interest to them.

10. Members shall designate a single central government authority as responsible for the implementation, on the national level, of the provisions concerning notification procedures according to paragraphs 5, 6, 7 and 8 of this Annex.

General reservations

11. Nothing in this Agreement shall be construed as requiring:

(a) the provision of particulars or copies of drafts or the publication of texts other than in the language of the Member except as stated in paragraph 8 of this Annex; or

Vol. 1867, 1-31874

1995 United Nations — Treaty Series • Nations Unies — Recueil des Traités SOS

(b) Members to disclose confidential information which would impede enforcement of sanitary or phytosanitary legislation or which would prejudice the legitimate commercial interests of particular enterprises.

Vol. 1867, 1-31874


ANNEX C

CONTROL, INSPECTION AND APPROVAL PROCEDURES7

1. Members shall ensure, with respect to any procedure to check and ensure the fulfilment of sanitary or phytosanitary measures, that:

(a) such procedures are undertaken and completed without undue delay and in no less favourable manner for imported products than for like domestic products;

(b) the standard processing period of each procedure is published or that the anticipated processing period is communicated to the applicant upon request; when receiving an application, the competent body promptly examines the completeness of the documentation and informs the applicant in a precise and complete manner of all deficiencies; the competent body transmits as soon as possible the results of the procedure in a precise and complete manner to the applicant so that corrective action may be taken if necessary; even when the application has deficiencies, the competent body proceeds as far as practicable with the procedure if the applicant so requests; and that upon request, the applicant is informed of the stage of the procedure, with any delay being explained;

(c) information requirements are limited to what is necessary for appropriate control, inspection and approval procedures, including for approval of the use of additives or for the establishment of tolerances for contaminants in food, beverages or feedstuffs;

(d) the confidentiality of information about imported products arising from or supplied in connection with control, inspection and approval is respected in a way no less favourable than for domestic products and in such a manner that legitimate commercial interests are protected;

(e) any requirements for control, inspection and approval of individual specimens of a product are limited to what is reasonable and necessary;

(f) any fees imposed for the procedures on imported products are equitable in relation to any fees charged on like domestic products or products originating in any other Member and should be no higher than the actual cost of the service;

(g) the same criteria should be used in the siting of facilities used in the procedures and the selection of samples of imported products as for domestic products so as to minimize the inconvenience to applicants, importers, exporters or their agents;

(h) whenever specifications of a product are changed subsequent to its control and inspection in light of the applicable regulations, the procedure for the modified product is limited to what is necessary to determine whether adequate confidence exists that the product still meets the regulations concerned; and

'Control, inspection and approval procedures include, inter alia, procedures for sampling, testing and certification.

Vol. 1867, 1-31874


(i) a procedure exists to review complaints concerning the operation of such procedures and to take corrective action when a complaint is justified.

Where an importing Member operates a system for the approval of the use of food additives or for the establishment of tolerances for contaminants in food, beverages or feedstuffs which prohibits or restricts access to its domestic markets for products based on the absence of an approval, the importing Member shall consider the use of a relevant international standard as the basis for access until a final determination is made.

2. Where a sanitary or phytosanitary measure specifies control at the level of production, the Member in whose territory the production takes place shall provide the necessary assistance to facil itate such control and the work of the controlling authorities.

3. Nothing in this Agreement shall prevent Members from carrying out reasonable inspection within their own territories.

Vol. 1867, 1-31874